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FOREWORD – WOORD VOORAF  
5 years ago, in September 2013, I was ready to start my journey as a PhD fellow. The 5 years 
before, I had studied Bioscience Engineering: cell and gene biotechnology and I had 
completed my master’s thesis in the Cell Systems and Cellular Imaging (CSI) group of the 
fantastic – then dr., now prof. – Winnok De Vos, where I mimicked “Hutchinson-Gilford 
progeria”, a rapid aging disease, in healthy cell cultures. 
 
At that point, I had a decent knowledge about cellular biology and biochemistry, but I knew 
nothing about mass-spectrometry-based proteomics (the only thing I had learned about protein 
identification was one slide in our Biochemistry course about Edman degradation, a technique 
developed in 1950). Via courses like “Experimental design” and “Statistical genomics”, I had 
some basic statistical knowledge (e.g. about linear regression), but I had never heard about 
things like “generalized linear models”, “shrinkage estimation” or “Bayesian statistics”. 
 
The 5 years of my PhD have been a very long journey. Indeed, at the start of my PhD, I was 
affiliated with these institutions (IWT since January 2015): 
 
      
 
    
 
Now, after my five-year journey, all my affiliations have changed their logos: 
 
      
    
I feel proud of what I have achieved: I got thoroughly trained in both biostatistics and 
proteomics to the point that I developed my own software package “MSqRob” for quantification 





researchers who are interested in using MSqRob. This is the nicest feeling: to know that I have 
done something useful and that MSqRob will still be used after I leave Ghent. Indeed, on May 
15th, I will start a postdoctoral research in the lab of Johan Auwerx in Lausanne, Switzerland 
on a topic in which I have a quasi-lifelong interest: aging and longevity. 
 
I could have never gotten to the point where I am now without the help of many people. I 
immediately would like to apologize to you if I would have forgotten to mention your name here. 
If you have contributed to this work in one way or another, directly or indirectly, please do know 
that I am very grateful to you. 
 
First of all, I would like to express my gratitude to all members of the examination committee 
(prof. Jan De Neve, prof. Olivier This, prof. Laurent Gatto, prof. Dirk Valkenborg, dr. Maarten 
Dhaenens and dr. Gerben Menschaert) for thoroughly reading this thesis and for their valuable 
comments. They didn’t make it easy for me, but their input has truly improved the quality of 
this document. 
 
A special word of thanks goes of course my two amazing promotors: prof. Lieven Clement and 
prof. Kris Gevaert, who have always been very supportive. I would like to express my sincere 
gratitude to have been able to work with both of you. 
 
Lieven is a true genius. While many biologists tend to use suboptimal methods to analyze their 
data and many computer scientists do not always grasp the peculiarities of a biological 
problem, Lieven has the exceptional ability to translate almost every biological problem, no 
matter its complexity, into a suited and solid statistical solution. I noticed many times that when 
Lieven enthusiastically shares his ideas during informal conversations at congresses, other 
scientists, even the most experienced ones, are impressed, much more than Lieven himself 
sometimes realizes. Indeed, as a true West-Fleming, he is modesty itself. Lieven’s door is 
always open and hardly ever did I walk out of his office without having at least three possible 
solutions for a problem that seemed insurmountable to me at first. He is the kind of person that 
always makes time for his PhD students, sometimes with meetings in the Starbucks or even, 
e.g. during the visit of Terry Speed, in his own home in Bruges. Lieven, I am really happy to 
have had the chance to work for you and I sincerely hope that we can keep in touch for many 
years to come! 
 
Kris is an inspiring scientist: he is always on top of the latest developments in the proteomics 
field and he too is always approachable. Kris gives his researchers the freedom and trust they 
need to perform their research. He also has an exceptional talent for writing and proofreading 
and a very sharp eye for both smaller and larger mistakes in a text. His contributions and 
changes bring the quality of a text to a higher level. Moreover, with a simple question he can 
uncover fundamental weaknesses in a manuscript or research proposal, enabling me to 
address these issues before the text is externally evaluated This is, in my opinion, one of the 
reasons why the review process of all my research articles went so smooth. 
 
I also need to thank prof. Lennart Martens, who is a co-author on several of my manuscripts. 
Besides having invaluable expertise in protein bio-informatics, he has an excellent feeling for 
what is missing in the field and his strong network has helped us tremendously in getting 
accepted in the protein bio-informatics community. Moreover, he is one of the best speakers I 






Another big thanks goes to prof. Sven Eyckerman, who allowed me to investigate the 
proteomics signatures of BTF-3 (Nac-β) knockdowns in WI38 and BJ cells. I have learnt a lot 
by performing these experiments. Sven is also the first person to point me towards the very 
interesting aging-related work of prof. Johan Auwerx at EPFL, where I will do my postdoc 
starting on May 15th. 
 
I also want to thank prof. Klaas Vandepoele from VIB’s Center for Plant Systems Biology for 
the nice collaboration during the first year of my PhD. 
 
As a shared PhD student between Lieven and Kris, I divided my working time between two 
working environments: Sterre S9 and Rommelaere. At campus Sterre, I need to thank the 
following people: 
 
I want to thank all my present and former colleagues from the StatOmics group (Adriaan, Koen, 
Caroline, Jeroen, Gust, Elke (many thanks for proofreading my introduction, it really improved 
the quality of my thesis!), Lisa, Gwendolien and Bart Jacobs) for the amazing work environment 
and the nice collaborations while teaching statistics to undergraduate students. Thanks to 
Adriaan in particular for introducing me to Krav Maga. 
 
I’m also very grateful for the many fun office mates I have had over the years (Karel, Nele, 
Mushthofa, Bart Van Gasse, Sarah, Domien, Helena, Chris, Marko, Oliver Urs Lenz and 
Jeroen). A big thanks goes to Karel, my “godfather” at Ghent University, who introduced me to 
everyone and everything in the TWIST department. I also want to thank Bart Van Gasse and 
Sarah, as well as Christophe Ley, Benoît and Marnix for our participations in the yearly PRIME 
quiz. 
 
Further thanks go to all other members of the statistics group, in particular my “Ghent 
University godchild” Fatemeh, Vahe (also thanks for being such a nice roommate and for 
proofreading part of my introduction!), Holger (also thanks for being such a nice roommate!), 
Camila, Paula, Beatriz, Oliver Dukes, Sjouke, Machteld, Slađja, Charlotte, Thẳng, Christophe 
Ley, Chloe, Arnout, David, Hans, Stijn and Els for all the nice work- and non-work-related 
moments. Also thanks to Kasper, with who I followed a few Mastat courses, for the nice lunches 
together and your inspiring ideas. 
 
I would also like to thank the people from the TWIST secretariat: Herbert (thanks for all the IT 
help!), Wouter, Hilde, Katia and Ann, as well as all other TWIST members, especially those 
who frequently visit the coffee breaks: Robbert, Chamberlain, Hilmar, Kelly, Roy, Herman, 
Dieter, Bart Mesuere, Nico, Bart Van Rompaye, Charlotte, Michaël, Niels, Pieter, Veronique 
(thanks for driving me home from the VIB seminar!), Christophe Scholliers, Veerle, Michèle, 
Carmen, Annick, Tineke, Peter Dawyndt, Joris, Kris Coolsaet, Gunnar, Willy, Guido and Hans. 
Special thanks to Catherine for organizing the TWIST weekends and the after-work badminton. 
Also special thanks to Felix (for all your help with Git!) and Toon (for the help with Python!). 
 
At campus Rommelaere, I want to thank the following people:  
 
Special thanks to the MS operators (An, Evi, Delphi, Jarne, Pieter-Jan, Jonathan) for being the 
driving forces for the weekly Friday restaurant lunches, most of whom have also been my office 
mates. Thanks to Evi for introducing me to protein MS on my first day at Rommelaere and to 






Big thanks to my friends and colleagues Maša, Ursula, Daria and to Igor and Ignacio for all the 
fun moments and the nice trip to Slovenia. 
 
Also, many thanks to my Rommelaere office mates Giel, Eva (also for introducing me to the 
virus work), Noortje (also for explaining me how to make freeze stocks), Delphine (also for 
explaining me all the other protocols in the lab), Louis, Montse, Maarten, Sara, Esperanza, 
Michela, Elise, Arun, Jasmine, Sriram and Dai. Big thanks also to the other people from the 
proteomics group, many of whom also frequently joined for the Friday lunches and who also 
participated in after-work events (BBQs, watching the World Cup, etc.): Petra, Sven, Francis, 
Fabien, Lia, Rupert, Heidi, Sebastian, Annelies, Kevin, Bart Ruttens, Hans, Elisabeth, Jeff, Kim 
and Alan (also for explaining MaxQuant to me). 
 
Further thanks go to the people from prof. Lennart Marten’s CompOmics group, where I have 
also frequently stayed and who also invited me to their events: Andrea (for the nice 
collaboration on the integration of moFF with MSqRob), Pieter-Jan, Paola, Surya, Silvia, Niels 
and Ralf (both especially for the help with the coffee machine), Robbin, Pathmanaban, Tim, 
Demet, Şule, Elien (also thanks for proofreading my Marie Curie proposal!), Davy (also for the 
help with the PRIDE Archive API and Visual Basic programming) and Sven Degroeve. 
 
I also want to thank some people from prof. Mo Lamkanfi’s group (thank you for sending me 
an example of a former Marie Curie application, this has been tremendously helpful for me!):  
group: Anna, Daniel, Mike, Kevin, Pedro, Nathalia, Magda and Krzysztof. Thanks for the nice 
parties at countless VIB receptions and events. Many of you were also NeoDocs together with 
me. It has been a very nice experience to organize the NeoDoc party (also thanks to Slava 
and Hannes for that!). 
 
I also want to thank all members of the VIBes organizing committee: Marleen, Halina, Cecilia, 
Jolien, Evi, Jessica, Yessica, Marlies, Hermien, Rocco, Aleksandra, Yannick, Iryna, Maria and 
Nandita. It has been a huge effort to organize this conference all by ourselves, but it was a lot 
of fun and I am very proud of what we achieved together! Also special thanks to dr. Michelle 
Linterman for joining us to the afterparty and for her kind invitation to Cambridge and to prof. 
Ruedi Aebersold for referring me to prof. Johan Auwerx. 
 
Further thanks to prof. Nico Callewaert for his career advice, to my former thesis supervisor 
Winnok De Vos for his amazing letter of recommendation to prof. Johan Auwerx and to Peter 
Van den Hemel for all his IT-related help when I was at Rommelaere. 
 
From here one, the foreword continues in Dutch, as the remainder aims at thanking my friends 
and family. 
 
Verder wil ik ook graag Pieter bedanken om zo een toffe huisgenoot (en nadien overbuurman) 
te zijn en voor jouw advies en voor alle toffe momenten in de Goosedrive Condo en de feestjes 
in Gent! Om dezelfde redenen ook bedankt aan mijn voormalige huisgenoten Line, Serena, 
Holger, Vahe en Astrid! 
 
Ik ben ook mijn vrienden uit de bio-ingenieursgroep zeer dankbaar dat we jaren na het 





bedankt voor al die toffe momenten: Line, Margo, Yael, Michelle, Jeroen, Jorden, Niels, 
Andreia, Thomas, Kilian, Kevin en Harm! 
 
Ook heel erg bedankt aan al mijn vrienden uit Ternat voor al de toffe evenementen en feestjes 
die we samen gedaan hebben: Joren, Guido, Maarten (bedankt om mijn thesis toch niet na te 
lezen :p), Steven, Laetitia, Elout, Eowyn, Vincent, Matthias, Kristien, Karen Schets, Kelly, 
Benjamin, Tom, Wander, Karen Raets. 
 
Uiteraard ook bedankt aan mijn moeder en vader en aan Sigert, Sigien, Diederich, Boursin en 
Chaumes. Bedankt voor alles! Ik wil ook graag al mijn familieleden bedanken dat we zo een 
hechte groep zijn en voor de toffe momenten samen. In het bijzonder dank aan Pieter (zie 
eerder) en aan Ruth en Jarich en mijn andere mede-badmintonners! 
 
Als allerlaatste wil ik in het bijzonder mijn allerliefste Zühal Duran bedanken voor al onze mooie 
momenten samen. Ik ben je ook bijzonder dankbaar voor al jouw geduld en jouw steun terwijl 
ik uren en uren aan het schrijven was. Dat we nog veel mooie momenten mogen beleven 
samen in Lausanne en daarna! Seni çok çok çok seviyorum, tatlı civciv! 
 
Vanwege de grote hoeveelheid mensen die mij hebben geholpen, ben ik mogelijks in dit 
dankwoord nog een aantal mensen vergeten te vermelden. Ik wil mij bij hen op voorhand 
verontschuldigen: als u op de één of andere manier, direct of indirect, hebt bijgedragen aan 
het tot stand komen van deze thesis, weet dat ik u zeer erkentelijk ben. 
 
Deze thesis is opdragen aan mijn grootva, Longinus Verdoodt en mijn bompa, Jean Goeminne, 
die dit moment helaas niet meer kunnen meemaken. Jullie hebben mij mee gemaakt tot wie ik 
ben en ik ben er trots op zulke fantastische mensen te hebben gekend! 
 
Deze thesis is ook opgedragen aan Jelle Jacob, de allereerste vriend die ik ooit had en die 
recent veel en veel te vroeg van ons is weggerukt door een verkeersongeval. Woorden kunnen 
niet beschrijven hoe veel ik doorheen mijn leven aan jou gehad heb. Ik zal jouw enthousiasme 








Proteins are very diverse biomolecules that facilitate nearly all cellular processes of life. They 
interact with each other in complex networks in which disruption of a single protein can severely 
impact an organism. Therefore, quantitative information of a proteome (i.e. the entire set of 
proteins present in an organism) is extremely important to gain insights in the functioning of an 
organism in both healthy and diseased states. 
Mass spectrometry (MS)-based proteomics is the method of choice for the high-throughput 
identification and quantification of thousands of proteins in a single analysis. When deep 
proteome coverage on many samples is needed, the analysis is often performed without any 
stable isotope labels, label-free. Here, proteins are extracted and digested into peptides that 
are subsequently loaded onto a reverse-phase high-performance liquid chromatography 
column (HPLC) coupled to a mass spectrometer, by which they are separated, ionized and 
have their MS spectra recorded. The intensity peaks in these MS spectra are proxies for 
peptide abundance. Subsequently, (some) peptides are targeted for fragmentation and the 
resulting MS² spectra enable their identification. As a result, label-free proteomics data are 
hierarchical: the data are at the peptide ion level, while inference typically happens at the 
protein level. Important to note is that signal intensities are strongly peptide-dependent as 
some peptides ionize more efficiently than others. Furthermore, missing values are very 
common and a large fraction of this missingness is not at random. Indeed, intensities of low-
abundant and poorly ionizing peptides are more likely to go missing and competition for 
ionization makes missingness also context-dependent.  
Many ad hoc data analysis workflows for differential protein quantification do not handle label-
free proteomics data in a statistically rigorous way, which leads to suboptimal ranking of 
differentially abundant proteins. Consequently, many biologically relevant proteins remain 
unnoticed and valuable resources are wasted by needlessly trying to validate false positive 
hits. 
In chapter 8, we demonstrate the necessity of properly taking peptide-specific effects into 
account in differential protein quantification analyses. Peptide-based models, which naturally 
account for these effects, perform better than methods that summarize peptide intensities to 
the protein level prior to the statistical analysis. We further illustrate that controlling the false 
discovery rate becomes problematic when highly-abundant proteins are differentially abundant 
due to suppression of the intensity of the background proteome. Finally, we show that missing 
values should be handled with care as imputing these under wrong assumptions leads to worse 
results compared to not imputing missing values at all. 
Most peptide-based models suffer from overfitting, unstable estimations of residual variances 
and a disproportionate impact of outlying peptide intensities. To address these issues, I 
developed the versatile R package MSqRob, which adds three modular improvements to 
existing peptide-based models: ridge regression stabilizes fold change estimates, empirical 
Bayes variance estimations stabilize the variances of the test statistics and M-estimation with 
Huber weights reduces the impact of outliers. MSqRob’s algorithm has been described in detail 
in section 9.1 and it not only improves the fold change estimates in terms of precision and 
accuracy, but also the protein ranking, leading to a better discrimination between true and false 
positives. MSqRob is freely available on GitHub (https://github.com/statOmics/MSqRob) and 
has a user-friendly graphical interface that is made in "Shiny", an R package developed by 






In section 9.2, I pinpoint important aspects of both experimental design and data analysis. 
Furthermore, I provide a step-by-step guide on how to use the MSqRob graphical user 
interface for both simple as well as more complex experimental designs. I also provide well-
documented scripts to run analyses in bash mode, enabling the integration of MSqRob in 
automated pipelines on cluster environments. 
In my latest, unpublished work (chapter 10), I focus on the missing value problem. Indeed, 
missingness in label-free proteomics is a mix of missingness completely at random and 
missingness not at random. However, the exact contributions of both mechanisms are 
unknown and dataset-specific, and imputing under the wrong assumptions is detrimental for 
the downstream protein quantifications. Therefore, I developed a hurdle model that combines 
the power of MSqRob with the complementary information that is available in peptide counts 
without having to rely on undeterminable assumptions. This enables MSqRob to quantify 
proteins that are completely missing in one condition in a statistically rigorous manner. 
Moreover, it opens new possibilities to detect the sudden appearance of post-translationally 
modified peptides in addition to traditional protein fold change estimation. 
With the development of MSqRob, I have made an important contribution to enabling 
experimenters to get the most out of their proteomics data. And, even though MSqRob is 
already one of the most versatile differential proteomics quantification tools, there are ample 
opportunities to broaden MSqRob’s scope, both towards new types of (prote)omics data and 







Eiwitten (ook “proteïnen” genoemd) zijn heel diverse biomoleculen die bijna alle cellulaire 
processen van het leven faciliteren. Ze interageren met elkaar in complexe netwerken, waarbij 
verstoring van één enkel eiwit een ernstige impact kan hebben op het organisme. Daarom is 
kwantitatieve informatie over een proteoom (het geheel van eiwitten dat in een organisme 
aanwezig is) van groot belang om inzicht te krijgen in het functioneren van een organisme, 
zowel in zieke als in gezonde toestand. 
Massaspectrometrie (MS)-gebaseerde proteomics is de voorkeursmethode voor de 
identificatie en kwantificatie van duizenden eiwitten in één enkele analyse. Wanneer een diepe 
proteoomdekking op veel stalen vereist is, wordt de analyse vaak uitgevoerd zonder gebruik 
te maken van stabiele isotopen, zogenaamde labelvrije proteomics. Hierbij worden eiwitten 
geëxtraheerd en gekliefd in peptiden die vervolgens geladen worden op een reverse-phase 
high-performance liquid-chromatografiekolom (HPLC) gekoppeld aan een massaspectrometer 
(MS), waardoor ze worden gescheiden, geïoniseerd en hun MS-spectra worden geregistreerd. 
De intensiteitspieken in deze MS spectra zijn een soort surrogaat voor peptide-abundantie. 
Vervolgens worden (sommige) peptiden geselecteerd voor fragmentatie en de resulterende 
MS²-spectra laten toe om deze peptiden te identificeren. Labelvrije proteomics-data zijn 
bijgevolg hiërarchisch: de data bevinden zich op het niveau van de peptide-ionen, terwijl 
inferentie meestal op het eiwitniveau gebeurt. Belangrijk om op te merken is dat 
signaalintensiteiten sterk peptide-afhankelijk zijn omdat sommige peptiden efficiënter 
ioniseren dan andere. Ontbrekende waarden komen dus veelvuldig voor en zijn een groot deel 
niet willekeurig. Inderdaad, intensiteiten voor laag abundante en slecht ioniserende peptiden 
zullen gemakkelijker ontbreken en competitie voor ionisatie maakt zulke ontbrekende waarden 
ook contextafhankelijk. 
Veel ad hoc data-analyseworkflows voor differentiële eiwitkwantificering verwerken labelvrije 
proteomics-data niet op een statistisch rigoureuze manier, wat leidt tot een suboptimale 
rangschikking van differentieel abundante eiwitten. Bijgevolg blijven vele biologisch relevante 
eiwitten onopgemerkt en wordt waardevolle tijd en materiaal verspild door het onnodig 
proberen valideren van valse positieve hits. 
In hoofdstuk 8 tonen we de noodzaak van het correct rekening houden met peptide-specifieke 
effecten in differentiële eiwit-kwantificatieanalyses. Peptide-gebaseerde modellen, die deze 
effecten op natuurlijke wijze in rekening brengen, presteren beter dan methoden die, 
voorafgaand aan de statistische analyse, de peptide-intensiteiten samenvoegen naar het 
eiwitniveau. We illustreren dat het controleren van de false discovery rate problematisch wordt 
wanneer zeer abundante eiwitten differentieel abundant zijn vanwege de suppressie van de 
intensiteiten van het ongewijzigde deel van het proteoom. Ten slotte laten we ook zien dat er 
voorzichtig moet worden omgegaan met ontbrekende waarden omdat imputeren onder 
verkeerde aannames leidt tot slechtere resultaten in vergelijking met niet imputeren. 
De meeste peptide-gebaseerde modellen lijden onder overfitting, onstabiele schattingen van 
de residuele varianties en een buitenproportionele invloed van de uitschietende peptide-
intensiteiten. Om deze problemen aan te pakken, ontwikkelde ik het veelzijdige R-pakket 
MSqRob, dat drie modulaire verbeteringen toevoegt aan bestaande peptide-gebaseerde 
modellen: ridge-regressie stabiliseert de schattingen voor de differentiële-abundantieratio’s, 
empirical Bayes variantieschattingen stabiliseren de varianties van de teststatistieken en M-
estimation met Huber-gewichten vermindert de impact van uitschieters. Het algoritme van 





abundantieratio’s in termen van precisie en nauwkeurigheid, maar verbetert ook de 
rangschikking van de eiwitten, wat leidt tot een beter onderscheid tussen echte en valse 
positieven. MSqRob is gratis beschikbaar op GitHub (https://github.com/statOmics/MSqRob) 
en heeft een gebruiksvriendelijke grafische interface gemaakt in "Shiny", een R-pakket 
ontwikkeld door RStudio dat een soepele integratie toelaat van de R-programmeertaal met 
een html-interface. 
In sectie 9.2 identificeer ik belangrijke aspecten van zowel experimenteel ontwerp als van de 
data-analyse. Verder geef ik een stapsgewijze handleiding over het gebruik van MSqRob’s 
grafische interface voor zowel eenvoudige als meer complexe experimentele ontwerpen. Ik 
lever ook goed gedocumenteerde scripts om analyses uit te voeren in bash-modus, waardoor 
de integratie van MSqRob in geautomatiseerde analyses in clusteromgevingen mogelijk wordt. 
In mijn laatste, niet-gepubliceerde werk (hoofdstuk 10) focus ik op het probleem van de 
ontbrekende waarden. Ontbrekende waarden in labelvrije proteomics zijn immers een 
verzameling van volledig willekeurige ontbrekende waarden en ontbrekende waarden die niet 
willekeurig zijn. De exacte contributies van beiden zijn onbekend en dataset-specifiek, en 
imputeren onder verkeerde aannames is nadelig voor de eiwitkwantificaties in de 
daaropvolgende differentiële analyse. Daarom ontwikkelde ik een hurdle-model dat de kracht 
van MSqRob combineert met de complementaire informatie die beschikbaar is uit het aantal 
peptiden zonder te steunen op aannames die niet kunnen worden nagegaan. Hierdoor kan 
MSqRob toch eiwitten die volledig ontbreken in één conditie kwantificeren op een statistisch 
rigoureuze manier. Bovendien opent dit nieuwe mogelijkheden om het plotselinge opkomen 
van posttranslationeel gemodificeerde peptiden te detecteren, bovenop de gewone schatting 
van de eiwit-fold changes. 
Met de ontwikkeling van MSqRob heb ik een belangrijke bijdrage geleverd om onderzoekers 
in staat te stellen het maximale uit hun waardevolle proteomics-data te halen. En hoewel 
MSqRob al een van de meest veelzijdige differentiële proteomics kwantificeringsinstrumenten 
is, zijn er voldoende mogelijkheden om het bereik van MSqRob uit te breiden, zowel naar 








AUC   area under the curve 
CID   collision-induced dissociation 
CPTAC  Clinical Proteomic Technology Assessment for Cancer Network 
DA   differential abundance 
DE   differential expression 
DDA   data-dependent acquisition 
DIA   data-independent acquisition 
ESI   electrospray ionization 
ETD   electron-transfer dissociation 
FC   fold change 
FDR   false discovery rate 
FN   false negatives 
FP   false positives 
GFP   green fluorescent protein 
HCD   higher-energy collisional dissociation 
HILIC   hydrophilic interaction liquid chromatography 
HPLC   high-performance liquid chromatography 
IMAC   immobilized metal affinity chromatography 
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LC   liquid chromatography 
LFQ   label-free quantification 
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MALDI   matrix-assisted laser desorption 
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MCMC   Markov Chain Monte Carlo 
MDS   multidimensional scaling 
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ROC   receiver operating curve 
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SAX   strong anion exchange 
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UPS   Universal Proteomics Standard  
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During the five years of my PhD, I thoroughly investigated different statistical approaches to 
quantify proteins in label-free mass spectrometry (MS)-based shotgun proteomics. 
Furthermore, I developed MSqRob, an R package with graphical user interface for the 
statistically sound analysis of label-free proteomics data. Since I have worked on the interface 
of protein biology and statistics, it is important to understand both the biological and the 
statistical aspects of my work. 
Hence, in order to place my work in its proper context, this introduction is divided into four 
chapters. The first chapter aims to give an overview of the biology of proteins and the wide 
variety of applications of present-day mass spectrometry-based proteomics. In the second 
chapter, I will describe the technical context of bottom-up quantitative proteomics: the different 
quantification strategies and the specific peculiarities of the label-free proteomics workflow. In 
chapter three, I will explain how the spectra are processed into interpretable data. Finally, 






1. BIOLOGICAL CONTEXT 
Chapter 1 mainly aims at introducing proteomics to data analysists who are new to the field. 
In this chapter, I will first cover the very basics of protein biology (section 1.1). Then, I will give 
an overview of a generalized mass spectrometry-based proteomics workflow and the 
relationship of proteomics to other omics (section 1.2), followed by a more profound review of 
the possibilities of mass spectrometry-based proteomics in present-day life sciences research 
(section 1.3). 
1.1. Proteins as the central effectors of life 
Before discussing the need for proteomics, I will first introduce the biology of proteins. Proteins 
are an extremely diverse class of biomolecules that are essential for nearly all functions of life. 
In this section, I will give an overview of the molecular structure of proteins and how their 
structures are linked to the essential roles proteins play in health and disease. 
1.1.1. The molecular structure and origin of proteins 
Proteins are composed of amino acids and the general chemical structure of an amino acid 
and a protein is given in Fig. 1.1. 
 
 
Figure 1.1. Chemical structures of a proteinogenic1 amino acid (A) and a protein (B). All amino acids 
share the same base structure. They all contain an α-amino group (-NH2) and an α-carboxyl group (-
COOH) along with a rest group/side-chain (R). The part of the protein ending with the amino group is 
called the amino- or N-terminus, while the side ending in the carboxyl group is called the carboxyl- or C-
terminus. Amino acids differ only in their rest group. In proteins, amino acids are joined together by 
peptide bonds (-CO-NH-, indicated in red). 
                                               
1 Proteinogenic amino acids are amino acids that are translationally incorporated into proteins. All proteinogenic 
amino acids, except glycine, have an L-stereoisomeric configuration. This means that, when the amino acid is 
oriented from its N-terminus to its C-terminus as in (A), the rest group (R) will be in front of the plane while the 
hydrogen atom (H) will be behind the plane. Glycine has no chiral center because its rest group is a hydrogen 
atom, so the central carbon (α-carbon) is only linked to three different atoms. 
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There are only 20 different standard amino acids2 that can be incorporated in proteins. The 
actual sequence by which amino acids are joined together is encoded by the corresponding 
gene found in the genomic DNA (deoxyribonucleic acid). Indeed, in all living organisms, genes 
are transcribed to RNA (ribonucleic acid) molecules. RNA molecules are composed of only 
four different nucleotide building blocks holding the nucleobases guanine (G), uracil (U), 
adenine (A) or cytosine (C). In eukaryotic3 cells, protein-coding RNA, or messenger RNA 
(mRNA), is then transported from the nucleus (where the grand majority of the DNA resides) 
to the cytoplasm, where it can be translated into proteins by ribosomes (Fig. 1.2). This 
unidirectional transfer of information takes place in every living organism: from DNA to mRNA 
to proteins and has come to be known as the central dogma of molecular biology. Even though 
some viruses violate this dogma by directly replicating RNA using an RNA template4, or even 
generate DNA based on an RNA template5, the translation of mRNA to proteins remains a 
one-way process. RNA is however not always translated into protein. Indeed, RNA itself can 
have regulatory functions (e.g. micro RNA (miRNA) and long non-coding lncNRA6 can induce 
gene silencing [7, 8]), structural functions (e.g. ribosomal rNA (rRNA) is an important 
component of the ribosome [9]) and even catalytic functions (e.g. peptidyl transfer by rRNA, 
mRNA splicing, self-splicing [10, 11]). 
 
Figure 1.2. The grand majority of transcription occurs in the nucleus of a eukaryotic cell by a protein (or 
rather, enzyme) called RNA polymerase. Translation occurs in the cytoplasm where ribosomes, 
specialized cellular structures that are composed of ribosomal RNA and proteins, translate the mRNA 
into proteins. Both transcription and translation occur from the 5’ to the 3’ end of the oligonucleotides. 5’ 
                                               
2 There are two additional very rare non-standard amino acids that are translationally incorporated into proteins. 
Selenocysteine (Sec, U) is present in all domains of life [1], while pyrrolysine (Pyl, O) is only present in 9 
methanogenic Archaea of the Methanosarcina family and 15 Bacteria [2]. Both amino acids are present in only a 
few dozens of proteins. 
3 Eukaryotes are cells that, unlike Bacteria and Archaea, have a nucleus. All multicellular organisms (e.g. humans) 
are eukaryotic, though some eukaryotes are also unicellular. 
4 RNA viruses such as rhinoviruses (the most common causes of the common cold) and hepatitis C virus use a 
protein called RNA-dependent RNA polymerase to make new copies of their RNA genomes. 
5 HIV uses the protein reverse transcriptase to convert its RNA genome into DNA and subsequently integrates this 
DNA into its host’s genome. 
6 Note that some short open reading frames in long “non-coding” RNA were shown to generate very small proteins 
[3-6]. 
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and 3’ refer to the conventional chemical names of the carbon atoms in the (deoxy)ribose rings. Proteins 
are always synthesized from their N- to their C-termini. 
Transcription and translation are also unidirectional in space: they always occur from the 5’ to 
the 3’ terminus of the DNA and mRNA molecules respectively. Each group of three consecutive 
nucleotides (triplet) in the mRNA represents a codon and each codon represents one unique 
amino acid or encodes a stop codon. A general overview of the codons that translate into each 
of the 20 amino acids or are used as stop codons is given in Fig. 1.3. This genetic code is 
near-universal across the whole tree of life. Some minor exceptions include: yeasts from the 
CTG clade encode CUG partially or completely as serine instead of leucine [12] and UGA is 
sometimes translated into tryptophan or arginine instead of being used as a stop codon for 
some transcripts and some species [13, 14]. Note that all codons, except those for methionine 
and tryptophan, are redundant: e.g. UUA, UUG, CUU, CUC, CUA and CUG all code for 
leucine. This property is also called the “degeneracy” of the genetic code. 
 
 
Figure 1.3. The genetic code. The four mRNA ribonucleosides are guanosine (G), uridine (U), 
adenosine (A), and cytidine (C). The 20 amino acids are phenylalanine (Phe, F), leucine (Leu, L), 
isoleucine (Ile, I), methionine (Met, M), valine (Val, V), serine (Ser, S), proline (Pro, P), threonine (Thr, 
T), alanine (Ala, A), tyrosine (Tyr, Y), histidine (His, H), glutamine (Gln, Q), asparagine (Asn, N), lysine 
(Lys, K), aspartic acid (Asp, D), glutamic acid (Glu, E), cysteine (Cys, C), tryptophan (Trp, W), arginine 
(Arg, R) and glycine (Gly, G). Note that each amino acid has both a three-letter abbreviation and a one-
letter abbreviation. The AUG codon is the most common start codon and also codes for methionine. 
Hence, all nascent eukaryotic proteins start with a methionine at their N-terminus when being 
synthesized7. The three different stop codons (UAA, UAG and UGA) signal translation termination. 
However, knowing the mRNA sequence sometimes does not suffice to predict the protein 
sequence. Indeed, in all domains of life, besides AUG, which is used in more than 80% of the 
                                               
7 In Bacteria, the start codon codes for N-formylmethionine, but this formyl group is cotranslationally removed [15]. 
In all domains of life, the N-terminal methionine is often cleaved off, causing more than 50% of the proteins not to 
have a methionine at the N-terminus [16-18]. 
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cases, other codons are also used as start codons [19]. Such so-called near-cognate start 
codons include CUG, GUG, UUG, ACG, AUC, AUU, AAG, AUA and AGG [20]. In the bacterium 
Escherichia coli for example, up to 40 out of the 64 codons can be used as start codons, albeit 
in less than 0.1% of the cases [21]. Such alternative start codons also encode for methionine 
or N-formylmethionine (in the case of bacteria). If translation is initiated from a downstream8 
(near-cognate or canonical) start codon, a shorter protein is produced from the same mRNA 
template. Similarly, when translation is initiated from an upstream start codon, a longer protein 
is produced. More rarely, a stop codon can be replaced with another amino acid in a process 
called translational read-through [22]. 
Further, in both prokaryotes and eukaryotes, certain “slippery” mRNA sequences, such as 
AAAAAA, might, under certain circumstances, cause a frameshift, which means that 
translation continues in another reading frame [23] (Fig. 1.4). 
 
Figure 1.4. Example of a translational frameshift in the dnaX gene of the bacterium Escherichia coli. 
The dnaX gene encodes both the τ and the γ subunit of the DNA polymerase III protein. dnaX contains 
a slippery AAAAAA sequence (blue, italics). When the ribosome passes normally over this sequence 
(top), translation remains in frame and the τ subunit is produced. However, when the ribosome “slips” 
(bottom), a -1 frameshift occurs. Hereby, a premature stop codon (red, bold) is introduced resulting in 
the production of the shorter γ subunit. In the dnaX example, ribosome slipping is stimulated by the 
presence of a downstream stem loop structure in the mRNA that stalls the ribosome. An upstream 
Shine-Dalgarno like sequence helps repositioning the ribosome in its new reading frame. Example 
adapted from Dinman (2006) [24]. 
This ribosomal frameshift is rather rare in most organisms, but very common amongst viruses 
as it allows them to translate many proteins from a small genome that is limited by the size of 
the viral particles [24]. Similarly, slippage can already occur at the level of transcription, when 
the RNA polymerase introduces a variable number of nucleotides in long homopolymeric 
stretches [25]. Further, it is now also known that amino acids in bacterial proteins can be 
converted into their D-stereoisomeric form and recent work demonstrates that even a protein’s 
backbone can be changed by introducing an α-keto-β-amino acid [26, 27]. 
Besides these rather infrequent phenomena discussed above, alternative RNA splicing is very 
common as more than 95% of all mammalian genes express alternatively spliced transcripts 
[28]. Splicing involves the removal of certain parts of an RNA molecule and, dependent on 
which parts are being spliced out from an mRNA molecule, different protein products can be 
                                               
8 Downstream means “in the 3’ direction”, upstream is “in the 5’ direction”. 
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generated. Similarly, certain protein sequences, called inteins, are able to post-translationally 
cut themselves out of a protein [29]. Moreover, proteins are known to carry, often transiently, 
a plethora of modifications (see also 1.1.3). 
Because of these phenomena, many chemically different protein molecules can result from a 
single gene hence, the term “proteoform” was coined. Proteoforms are defined as “Highly 
related protein molecules arising from all combinatorial sources of variation giving rise to 
products arising from a single gene. These include products differing due to genetic variations, 
alternatively spliced RNA transcripts, and post-translational modifications” [30].  
The side-chain of an amino acid determines its physicochemical properties. The nature of a 
protein will thus not only be determined by the amino acids it contains, but also by the sequence 
in which they are connected to each other. The specific chemical structures for selected amino 
acids are given in Fig. 1.5. 
 
Figure 1.5. Examples of the diversity in chemical structures of amino acids: the structures of 6 different 
amino acids are given. The side-chains of lysine and arginine are long aliphatic chains that are positively 
charged at physiological pH9. Aspartic acid has a net negative charge at this pH. Tyrosine is a very bulky 
amino acid that is rather hydrophobic due to the benzene ring in its structure. It is however rather polar 
due to its hydroxyl (-OH) group. Glycine is the smallest amino acid and the only one that lacks a chiral 
center as its side-chain itself is a hydrogen atom. 
1.1.2. Protein folding 
Proteins arrange themselves into three dimensional structures. They are rather flexible, and it 
is mainly their sequence of amino acids that determines their final 3D structure. The complex 
interplay of the different chemical properties of the different amino acids will determine a 
protein’s thermodynamically most favorable 3D conformation. Known physicochemical forces 
that play a role in protein folding include the hydrophobic effect10, H-bridges, n→π* 
                                               
9 The average pH inside a cell, which is approximately 7.4 and thus close to the neutral pH 7. 
10 Since water is a polar solvent, apolar molecules do not mix well with water. Hence, apolar amino acid residues 
will often be found on the inside of a folded protein chain, away from the water that surrounds it. This property is 
called hydrophobicity (“being afraid of water”). 
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interactions, van der Waals forces, formation of disulfide bridges, the gain of conformational 
entropy of water on protein folding and electrostatic interactions [31]. Hydrophilic, polar amino 
acids will mainly be found on the surface of a folded protein, while hydrophobic, apolar amino 
acids will typically be present on the inside. So-called chaperones are proteins that often aid 
nascent proteins during the folding process11 to avoid aberrant folding [33]. Sometimes, 
multiple proteins cluster together to form a functional protein complex (Fig. 1.6). 
 
Figure 1.6. Three-dimensional structure of the protein hemoglobin. Hemoglobin consists of four folded 
proteins (two α subunits, red, and two β subunits, blue) that are held together by hydrogen bonds. Each 
subunit is folded such that it creates a pocket that strongly binds an iron-containing heme group (green). 
Image by Richard Wheeler (Zephyris) at the English language Wikipedia, CC BY-SA 3.0, 
https://commons.wikimedia.org/w/index.php?curid=2300973. 
1.1.3. The JAK-STAT pathway as an example of a protein network 
Cells are highly dynamic and thousands of biochemical processes are continuously going on 
in each cell. Proteins play a crucial role in nearly every one of these processes. The enormous 
diversity in 3D structures that are adopted by different proteins allows them to bind to other 
biomolecules with very high specificity. This in turn leads to an immense variety in protein 
functions. Well-known functions of proteins include, but are definitely not limited to, enzymatic 
reactions (e.g. trypsin, which digests other proteins in the stomach; kinases, proteins which 
add a phosphate group to protein substrates), DNA synthesis (DNA polymerases), DNA 
transcription (RNA polymerases, aided by different sorts of transcription factors), cellular 
structure (e.g. microtubules), muscle contraction (e.g. actin, myosin) and oxygen transport 
(hemoglobin). 
Therefore, proteins interact both with each other and with other biomolecules. Indeed, most 
changes inside the cell are triggered by cascades of both stable and transient protein-protein 
interactions, termed signaling pathways. The JAK-STAT pathway is just one of many 
intracellular pathways and constitutes a classic example of how a cell responds to a stimulus 
coming from its environment (Fig. 1.7). JAK-STAT signaling actually is a simple signaling 
                                               
11 Note that some chaperones also work after translation. Some chaperones aid in stabilizing protein structures in 
response to a cellular stressor, others aid in protein unfolding or revert protein aggregation [32].  
11 
cascade and, in reality, such cascades are highly branched, as most proteins have multiple 
interaction partners. 
 
Figure 1.7. Simplified view of the JAK-STAT pathway. Certain events in the human body can trigger the 
release of small proteins, called cytokines, in the blood. Some cells are programmed to respond to these 
cytokines and are therefore equipped with specific cytokine receptors. After binding to an extracellular 
cytokine, the cytokine receptors dimerize, bringing the JAK kinases in close proximity of each other. The 
JAKs will subsequently phosphorylate each other on a Tyr residue. The phosphorylated JAKs will then 
phosphorylate a Tyr residue on the cytoplasmic side of the cytokine receptors. This allows docking of 
STAT proteins. These STAT proteins will also be phosphorylated by the JAKs. Phosphorylated STATs 
will dimerize and translocate to the nucleus, where they allow transcription of mRNA molecules encoding 
for proteins that are needed for the response to the stimulus. Modified after Peter Znamenkiy [Public 
domain], from Wikimedia Commons. 
The JAK-STAT example involves phosphorylation as an illustration of a chemical group that is 
transferred by a protein (a kinase such as JAK) to another protein (a substrate, here the 
cytokine receptor, STAT, or JAK itself). In this example, phosphorylation on tyrosines occurs, 
though it can also occur on serine and threonine residues (as both contain a free hydroxyl (-
OH) group) and on the nitrogen atoms of the imidazole ring in histidine residues [34, 35]. 
Phosphorylation on arginine, lysine, aspartate and glutamate are also known to occur, but are 
very labile in an acid environment and were therefore proven difficult to study by means of 
mass spectrometry [36, 37]. Recent work published on BioRxiv proposes a workflow at near-
physiological pH that allows the identification of thousands of such non-canonical 
phosphorylation sites [38]. Moreover, next to phosphorylation, many more co- and post-
translational modifications exist, and it is not uncommon for proteins to carry modifications 
across different residues. These modifications are not only important in signaling cascades, 
but can also affect protein stability and degradation, alter enzymatic activity and target proteins 
to membranes [39]. Many diseases (e.g. infectious diseases, auto-immune diseases, 
neurodegenerative diseases, …) have been linked to aberrant protein modification states [40-
43]. A comprehensive overview of all possible protein modifications can be found in the UniMod 
database at: http://www.unimod.org/modifications_list.php [44]. 
1.1.4. Proteins in diseases 
The extremely complex web of interactions of proteins with each other and with other 
biomolecules makes that disruption of a single protein’s function often has severe outcomes 
[45]. Genetic diseases are often the result of a loss-of-function caused by the production of 
truncated or abnormally folded proteins. For instance, thalassemias are a family of genetic 
diseases in which an abnormal form of hemoglobin is produced that is less efficient in taking 
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up oxygen [46]. These diseases are caused by one or more mutations in the coding genes that 
lead to changes in hemoglobin’s amino acid sequence. Such changes can cause substitutions 
of one amino acid by another but can also result in shorter or longer proteins when stop codons 
are respectively introduced or erased. They might also impact on mRNA splicing. Large gene 
deletions or insertions and even fusions with other genes have been reported to cause 
thalassemia [47]. Such mutations inhibit the production of one or more hemoglobin chains or 
result in the production of abnormally folded hemoglobin. Mutations can also cause diseases 
by interfering with the normal modification status of a protein. For example, the severe but rare 
disease mandibuloacral dysplasia is caused by a single mutation in the gene encoding for the 
protease ZMPSTE24, which results in the accumulation of toxic farnesylated prelamin A (Fig. 
1.8). 
 
Figure 1.8. Left: overview of the maturation of the protein lamin A in healthy individuals. Normally, a 
hydrophobic farnesyl group is added to lamin A during its preprocessing. Lamin A’s C-terminal end 
containing the modification is then cleaved off by the ZMPSTE24 protease (here shown as a pair of 
scissors). Right: in mandibuloacral dysplasia a homozygous mutation12 in the ZMPSTE24 gene causes 
loss-of-function, which results in the accumulation of toxic farnesylated prelamin A. 
Conversely, for many diseases, genetics alone cannot fully explain disease onset. Late-onset 
Alzheimer’s disease, for instance, has no single genetic cause13. At the protein level, it is 
characterized by the aggregation of the amyloid-β protein in the brain. Other incurable brain 
diseases, like Creutzfeldt-Jakob, are caused by a prion, an incorrectly folded protein that 
causes other proteins of the same kind to take over its aberrant shape, leading to some sort 
of a chain reaction and massive accumulation of misfolded proteins [50]. 
                                               
12 Humans, like all mammals, have two copies of most genes [48]. ZMPSTE24 loss-of-function only occurs when 
both copies are affected. 
13 Many different genes influence susceptibility, and the overall genetic heritability is estimated between 60 and 
80% [49]. 
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1.1.5. Applications of protein research 
Proteins are so abundantly being applied throughout our daily lives, that it is nearly impossible 
to give a complete overview of all their applications. Moreover, researchers continuously strive 
to improve and broaden protein applications. 
In the medical field, proteins are used for diagnosis and disease monitoring. Examples of such 
biomarkers in blood and plasma approved by the US Federal Drug Administration (FDA) 
include HE4 for ovarian cancer, CA19-9 for pancreatic cancer and thyroglobulin for thyroid 
cancer, amongst many others [51], and researchers keep on developing novel biomarker 
assays. 
Determining the 3D structure of proteins is pivotal to their characterization. Indeed, not only do 
these models allow the prediction of a protein’s interactions with other proteins [52], they also 
aid in drug development. Nowadays, companies rationally design potential drug candidates by 
fitting them e.g. onto a protein’s docking site [53, 54]. However, determining a protein’s 
structure is a non-trivial task. Indeed, although the sequence of a protein will in the end 
determine its 3D structure, no algorithm exists that can accurately predict 3D structures solely 
based on amino acid sequences. X-ray crystallography and nuclear-magnetic resonance 
(NMR) are the most commonly used techniques to determine protein structures, although cryo-
electron microscopy is also becoming a viable option [55]. Alternatively, proteins with more 
than 30% sequence homology are often assumed to have a similar structure [56]. Indeed, such 
proteins often show an evolutionary relationship and therefore hold a similar structure and 
function. 
Proteins can also be used as therapeutics, with monoclonal antibodies forming the largest 
class of therapeutic proteins (48% of all FDA approvals in 2011 – 2016) [57]. Examples include 
antibodies against IL-5 for the treatment of asthma [58], anti-CD319 against relapsed multiple 
myeloma [59] and anti-VEGFR2 against gastric cancer [60]. New artificial (“recombinant”) 
proteins can also be produced by modifying the DNA sequence of existing proteins. Examples 
include ocriplasmin against vitreomacular adhesion [61], glucarpidase against kidney failure 
[62] and recombinant von Willebrand factor against von Willebrand disease [63]. Proteins are 
also extensively used in basic biomedical research. Examples include green fluorescent 
protein (GFP) and its derivatives to visualize proteins inside a cell [64] and the use of Crispr-
Cas9 to examine the function of genes by knocking them out or inducing targeted mutations 
[65]. 
However, the study of proteins is not only relevant for human diseases. Enzymes, proteins that 
catalyze biochemical reactions14, are used in sectors as diverse as the pharmaceutical sector, 
the food industry, paper production, detergent manufacturing and biofuel production [67]. For 
the production of pharmaceuticals, enzymes aid in the production of precursors or in chemically 
modifying the final compounds to increase their stability and/or bioavailability [68]. In the food 
industry, α-amylase is used to convert starch into sugars [69], pectinase to clarify fruit juices 
[70] and lactase to produce lactose-free milk [71], amongst many others. In the paper industry, 
xylanase is used to loosen the structure of cellulose fibers, which improves paper quality [72]. 
Proteases, amylases and lipases are used in laundry detergents to help break down stains of 
biological origin [73]. Lipases are used in biofuel production to convert free fatty acids to 
methyl/ethyl esters [74]. 
                                               
14 This acceleration often goes up to several trillions of orders of magnitude [66], allowing reactions that would 
naturally take millions of years to occur almost instantly. Previously mentioned proteins such as JAK and 
ZMPSTE24 are also enzymes: JAK catalyzes a phosphorylation reaction, ZMPSTE24 cleaves a peptide bond. 
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Finally, proteins are also extensively investigated in food crop research. The most well-known 
example is research on transgenic plants. Here, a DNA sequence coding for a protein with 
favorable properties is introduced into a commercial crop. This protein can for example 
promote crop yield or convey resistance against insects, pathogens or herbicides. A notorious 
example is the development of “golden rice”, a genetically engineered rice variant developed 
to combat vitamin A deficiency [75]. Indeed, per gram dry weight, the seeds of golden rice 
contain up to 37 μg β-carotene, a compound that is converted into vitamin A by the human 
body [76]. Although the rice genome can produce all enzymes needed for β-carotene 
production, four of these enzymes are not expressed in rice seeds. In golden rice, only two 
genes are introduced: the psy gene from maize, to produce the enzyme phytoene synthase 
and the crtI gene from the bacterium Erwinia uredovora to produce the enzyme carotene 
desaturase. Together, these enzymes restore the β-carotene pathway in the seeds, which 
results in a rice plant with the typical yellow seeds. Thanks to this simple genetic modification, 
golden rice holds the promise to save a substantial fraction of the 250,000 to 500,000 children 
that become blind every year due to vitamin A deficiency, half of which die within a year [77-
80]. This is especially the case in Asian countries, where rice is a dominant portion of the 
standard diet. 
Understanding how proteins interact with each other increases our understanding of a plant’s 
developmental pathways, which allows the breeding of high-yield variants as well as variants 
that produce stable yields under stress [81]. Indeed, various biotic and abiotic stresses can 
delay or even terminate plant growth, and even a relatively small, transient stress can markedly 
reduce crop yield [82]. Hence, researchers actively investigate protein networks involved in 
stress responses to explain why certain varieties are less stress-sensitive [83, 84]. This 
knowledge can then later be used for crop improvement through cross-breeding or genetic 
modification. The lab of my co-promoter is, amongst others, involved in research into protein 
signaling pathways during the germination of parasitic plants. This is expected to spur the 
development of germination inhibitors for these plagues [85]. 
1.2. The nature of mass spectrometry-based proteomics 
Researchers need to obtain information about the proteome to understand and act upon all 
these protein-related processes. Proteomics is the study of the proteome and today, MS-based 
proteomics is the most important proteomic technology. Here, I start by giving a very brief 
overview of the general principles of chromatography and MS, followed by a discussion of MS-
based proteomics workflows. Then, I will situate the proteomics field with respect to the other 
omics fields. 
1.2.1. General principles of liquid chromatography and mass spectrometry 
Like every other analytical technique, mass spectrometry has its limitations on the complexity 
it can efficiently cope with, both in terms of the number of distinct analytes and in terms of 
differences in the concentrations between these analytes. Separating analytes prior to further 
analysis is thus essential for reaching sufficient analytical depth. For MS-driven proteomics, 
the analytes – which are mainly peptides – are present in solution. Hence, liquid 
chromatography is the method-of-choice for separating peptides prior to analysis by means of 
mass spectrometry. In liquid chromatographic applications for proteomics, the peptides are 
first loaded onto a column (also called the stationary phase) in a buffered solution (also called 
the mobile phase). The composition of the column is such that most (if not all) of the peptides 
interact with and are thus withheld by this column. By now changing the composition of this 
mobile phase, the column-bound peptides will start to partition in the mobile phase and are 
thus eluted from the column at a given composition of this mobile phase. Liquid 
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chromatography can be used to separate peptides based on different physical characteristics 
such as size, charge and hydrophobicity. Separating peptides based on differences in 
hydrophobicity is the preferred chromatographic method that is linked to mass spectrometers. 
In the overall majority of applications, a hydrophobic stationary phase (e.g., chromatographic 
beads functionalized with C18-groups) is used to bind peptides via hydrophobic interactions. 
Here, the buffer used to load the peptides is an aqueous buffer. By now gradually increasing 
the concentration of a water-miscible organic solvent, peptides will start to favor being present 
in the increasingly organic mobile phase and elute from the stationary phase. 
To further analyze the eluted peptides, these peptides need first to be brought into the gas 
phase and need to get ionized. This process happens in the ionization part of a mass 
spectrometer. “Soft” ionization techniques, i.e. ionization techniques that transfer little residual 
energy onto the ions and therefore cause only minimal ion fragmentation have been extremely 
important for the measurement of intact ions. Indeed, John B. Fenn and Koichi Tanaka were 
awarded the 2002 Nobel Prize in Chemistry for the development of electrospray ionization 
(ESI) and soft laser desorption (SLD), respectively. Next to an ionization part, a mass 
spectrometer also consists of at least one analyzer and at least one detector. 
Different types of analyzers have been developed to separate and detect ions based on their 
mass-to-charge (m/z) ratio. In a time-of-flight (TOF) mass spectrometer, ions are accelerated 
by a fixed electric field into a vacuum tube. The time it takes for an ion to travel (or fly) through 
this tube and reach a detector depends on its mass and its charge. Indeed, given the formula 
of kinetic energy, the higher the mass of an ion, the lower its velocity and thus the later this ion 
will hit the detector. Conversely, the higher the charge of an ion, the higher its velocity and thus 
the faster it will hit the detector. The intensity of the signal recorded by this detector is used as 
a proxy for the initial abundance of the recorded peptide. These signals are recorded at 
discrete m/z-values at GHz resolution. 
A quadrupole mass analyzer is an example of a more complex analyzer that works as an m/z 
filter. Quadrupoles consist of four rods, which have an alternating radio frequency voltage with 
an offset direct current. The frequency voltage and the offset can be tuned in such a way that 
only ions with a specific m/z value follow a stable trajectory throughout the quadrupole, while 
all other ions are pushed out (Fig. 1.9). When the quadrupole is used to scan a beam of ions 
over a certain m/z range, a mass spectrum is recorded. 
 
Figure 1.9. Working principle of a quadrupole. The rods have an alternating radio frequency voltage 
with a direct current offset. Due to inertia, ions with very high m/z values will be relatively unaffected by 
the alternating current but will be pushed out of the quadrupole by the non-zero direct current offset. 
Contrary, ions with very low m/z values will be pushed out of the quadrupole as they are strongly affected 
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by the alternating current. By carefully tuning the alternating and direct currents, a quadrupole works as 
a very specific ion filter. Figure based on Vékey et al. (2008) [86]. 
1.2.2. The MS-based proteomics workflow 
Mass spectrometry-based proteomics is the method of choice for the high-throughput 
identification and quantification of peptides and proteins in a single analysis. Fig. 1.10 gives a 
general overview that encompasses the most frequently occurring steps in MS-based 
proteomics workflows. 
 
Figure 1.10. General overview of an MS-based proteomics workflow. The workflow starts with samples 
(a) from which proteins (b) are extracted. These proteins can e.g. be labeled and are, for most 
applications, digested into smaller fragments called peptides (c). The proteins/peptides are separated 
onto a high-performance liquid chromatography (HPLC) column and ionized (d). Then, an MS spectrum 
(e) is recorded. Some ions can be fragmented into smaller ions (f) after which the resulting spectrum is 
recorded (MS² spectrum, g). Some of these fragments can again be targeted for fragmentation (h), after 
which an MS³ spectrum can be recorded (i). Note that the presence or absence of some steps in this 
workflow depend on the type of analysis that is performed. 
Every MS-based proteomics workflow starts with one or more samples. The types of samples 
can vary widely, ranging from plant material over animal tissues, plasma samples, cell cultures 
or recombinantly produced proteins. If the sample is not a solution of (purified) proteins, the 
proteins will need to be extracted first. The techniques used for extraction and purification 
depend on the sample type. For mammalian cell cultures, for example, a rather simple lysis 
buffer will suffice [87]. For organisms with thick cell walls or for membrane proteins, (additional) 
mechanical disruption, e.g. sonication with glass or metal beads, might be necessary [88]. 
Techniques like ultracentrifugation or ammonium sulfate precipitation are then used to 
separate the proteome from other unwanted cellular components (e.g. DNA, RNA, lipids) and 
possible detergents that were used to disrupt cells. Solubilized intact proteins can be directly 
analyzed by MS (top-down proteomics) [89], but complex protein mixtures are generally 
enzymatically digested into smaller fragments, termed peptides, for so-called bottom-up 
proteomics or shotgun proteomics15. 
                                               
15 Note that the term “bottom-up proteomics” refers to any LC-MS proteomics technique that uses prior digestion of 
proteins to peptides, while the term “shotgun proteomics” specifically refers to LC-MS proteomics techniques 
whereby complex protein mixtures are digested into peptides. 
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Peptides have the advantage that they are more chemically tractable, more easily separated 
by liquid chromatography and more easily ionized and fragmented as compared to intact 
proteins [90-92]. To limit the number of possible peptides in bottom-up proteomics to a 
reasonable computational search space, the commonly-used protease is highly specific. 
Trypsin, for instance, is ideally suited, as it cleaves with high specificity after lysine and arginine 
residues. 
Alternative enzymes (e.g. pepsin, chymotrypsin, and the endoproteinases LysC, LysN, AspN, 
GluC and ArgC) have also been used, as they generate different sets of peptides and therefore 
reveal complementary parts of a proteome’s sequence space [93-99]. Parallel digestion of the 
same proteome with multiple proteases can also give a strong boost to the coverage of 
modification sites [100, 101]. Alternative proteases with more infrequent cleavage specificities 
will generate longer peptides that can be studied with middle-down proteomics [92, 102, 103]. 
Nonetheless, trypsin remains the dominant digestion enzyme in bottom-up proteomics. On 
November 2014, more than 96% of all raw files deposited in the PRIDE repository were using 
trypsin [102] and there is little reason to assume this percentage has drastically changed today. 
To facilitate proteolytic digestion, proteins are often first denatured with urea, which disrupts a 
protein’s hydrogen bonds causing the protein to denature and unfold. This results in a 
destruction of protein-protein interactions and a solubilization of hydrophobic lipid-bilayer 
bound proteins. Urea has the advantage that it can easily be removed by reverse-phase 
chromatography [104]. However, adding too much urea might also partially denature the 
protease and hence reduce the digestion efficiency. Further, at higher temperatures, urea 
partially decomposes into isocyanic acid which carbamylates primary amine groups and thus 
introduces artefactual amino acid modifications that also block enzymatic digestion [105, 106]. 
Note that detergents such as sodium dodecyl sulphate (SDS) that are commonly used to lyse 
cells or to denature proteins prior to polyacrylamide gel electrophoresis (SDS-PAGE), should 
generally be avoided as they are incompatible with liquid chromatography (LC)-MS [91]. 
Indeed, even though small amounts of SDS facilitate enzymatic digestion, this detergent 
suppresses ion signals even at very low concentrations (< 0.01%). SDS cannot be removed 
with a reverse-phase high-performance liquid chromatography (HPLC) separation step [106-
109], although the recently-introduced suspension trapping filter S-TrapTM includes a washing 
step that makes it compatible with SDS denaturation [110]. Nevertheless, most digestion 
protocols omit the use of denaturants [111]. Other contaminants may also adversely affect the 
analysis [112]. It is therefore strongly advised to discuss all preprocessing protocols with 
proteomics specialists prior to the experiment. 
If one is interested in only a subpart of the proteome, additional purification of certain proteins 
or peptides, e.g. by immunoprecipitation might be needed. Similarly, many protein 
modifications are transient, have low occupancies, are chemically unstable during standard 
sample preparation procedures and/or decrease a peptide’s ionization efficiency [113-116]. 
Therefore, detecting specific modifications requires optimized enrichment protocols [117]. 
Proteins or peptides are sometimes labeled to facilitate identification and quantification (see 
section 2.1). These labels can either be small chemical groups or heavy isotopes. They can 
either be incorporated during the growth of the organism (metabolic labeling, see 2.1.1) or after 
protein extraction (post-metabolic labeling, see 2.1.2). 
Sample pre-fractionation is an option when samples are very complicated and enough protein 
material is available [118]. Pre-fractionation can be done with a method that is orthogonal to 
the standard reverse-phase liquid chromatograph that is coupled to the mass spectrometer. 
Strong cation exchange (SCX) chromatography is a popular pre-fractionation strategy [119]. 
Although the complexity of each fraction will be reduced, separation is never perfect and many 
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proteins will be present in more than one fraction, which may complicate protein quantification 
[120]. Each of these samples (or fractions in the case of pre-fractionation) is subsequently 
analyzed by the mass spectrometer. If the samples are very simple (e.g. a single protein), the 
proteins/peptides can be directly analyzed by matrix-assisted laser desorption (MALDI) 
ionization coupled to a time-of-flight mass spectrometer, by which a mass spectrum for the 
entire sample is obtained [121]. If the samples are more complex, the proteins/peptides are 
first separated onto a reverse phase liquid chromatography column that is coupled to the mass 
spectrometer. Upon elution, the proteins/peptides are ionized, typically with electrospray 
ionization (ESI) [122]. Traditionally, positively charged ions are generated, while neutral 
molecules and negatively charged ions are filtered out [123]. At discrete time points, the mass 
spectrometer will measure the mass-to-charge ratios for all the ion species eluting from the 
column. In the commonly used Orbitrap analyzer, this is achieved by trapping the ions in an 
orbital motion around a spindle-like electrode, hence the name. The ions are moved back and 
forth and the fluctuations in charge caused by the movement of the ions are recorded by a 
detector. This wavelet signal is subsequently converted into a mass spectrum by Fourier 
transformation. The resulting spectrum is termed an MS or MS1 spectrum. It is important to 
note that due to the natural occurrence of heavy isotopes of all chemical elements in a fixed 
ratio, every ion species generates multiple isotopic peaks in the MS spectrum, resulting in a 
so-called isotopic envelope. Each ion’s charge state is then calculated from the m/z-distance 
between the peaks in such an isotopic envelope. The summed-up intensities of all ions in an 
MS spectrum is called the total ion current (TIC). The evolution of the TIC over time is used as 
a measure of quality control. 
In most workflows, an MS spectrum will be insufficient to identify the ion species. Therefore, a 
single peak in the isotopic envelope of the ions of interest will be selected by the mass 
spectrometer and targeted for fragmentation. Typically, high intensity peaks are targeted for 
fragmentation to avoid selecting noise, which would lead to significant losses in operating time. 
To avoid sequential fragmentations of the same ion during its elution, all previously targeted 
m/z values are often excluded from being targeted again for a certain amount of time (e.g. 20 
seconds). This setting is termed dynamic exclusion and substantially increases the coverage 
of the mass spectrometer by freeing MS time for the targeting and fragmentation of less intense 
MS peaks [124]. 
In shotgun proteomics, collision-induced dissociation (CID) [125] or higher-energy collisional 
dissociation (HCD) [126] are by far the most common fragmentation methods, while electron-
transfer dissociation (ETD) gains popularity for phosphoproteome studies (see 1.3.2) [127, 
128]. Negative electron-transfer dissociation (NETD) [123] and photo-dissociation [129-132] 
are examples of infrequently used fragmentation methods. With CID, ions are collided with 
noble gasses such as helium and argon that increase the ions’ internal vibrational energy and 
eventually lead to fragmentation [133]. With HCD fragmentation, the collision energies are 
higher than 1 keV [134]. Collision therefore occurs in a separate collision cell, typically with a 
heavier gas, such as dinitrogen [135]. If the peptide’s backbone is fragmented, six types of 
ions (a, b, c, x, y and z) can be formed, as shown in Fig. 1.11. The mass spectrum of the 
fragment ions is termed an MS/MS or MS² spectrum. 
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Figure 1.11. Left: overview of the different types of ions that can be formed after fragmentation of a 
peptide ion’s backbone. a-, b- and c-ions are formed if the charge is retained on the N-terminal peptide 
fragment. Conversely, x- y- and z- ions are formed if the charge is retained on the C-terminal fragment. 
Breaking the peptide bond (red) is by far the most energetically favorable fragmentation pattern. 
Therefore, b- and y-ions will be the most abundant ion species in every MS² spectrum generated by CID 
or HCD. n is the total number of amino acids in the protein. Modified after Steen and Mann (2004) [136]. 
Right: example fragmentation pattern for the peptide LDGER. b-ions are indicated in purple, y-ions are 
indicated in blue. Fragments LDG and ER have the same average mass and therefore form a single 
peak in the MS² spectrum. 
With CID and HCD, b- and y-ions will be far more intense than the other types of ions (a-, c-, 
x- and z-ions) [137]. For tryptic peptides, CID fragmentation generates both b- and y-ions, 
while y-ions are much more prominent with HCD fragmentation [137-139]. 
When the intensities of certain fragment ions are to be used for quantification, MS² fragment 
ions can optionally be isolated and subjected to mass spectrometry (MS³ spectrum) to prevent 
interference of other fragment ions with the intensity of the fragment ion of interest. Such MS³ 
workflows are mainly useful for isobaric labeling (see 2.1.2). Identification of an ion species is 
typically achieved by searching the fragment ion spectra against a database (see section 3.1). 
Note that MS instrumentation is evolving extremely rapidly. Only a few years ago, 20 MS² 
spectra per second was considered state-of-the-art [140], but the most recent machines now 
exceed a scanning speed of over 40 spectra per second [141]. This implies that if one MS 
spectrum is recorded per second, more than 40 peaks in this MS spectrum can be fragmented 
and thus potentially identified. 
1.2.3. Proteomics in relation to other omics 
Many omics techniques can provide some information about the state of the proteome, but 
proteomics is the most suited for this purpose. The fields of genomics, epigenomics, 
transcriptomics and ribosome profiling largely rely on the analysis of DNA and RNA molecules. 
RNA can easily be reverse transcribed to DNA and even a single molecule can be readily 
amplified to billions of copies with a routine polymerase chain reaction (PCR). Moreover, 
advanced techniques have been devised to sequence and characterize even single RNA and 
DNA molecules. These possibilities are currently lacking for other types of biomolecules, 
including proteins. Present-day proteomics relies heavily on mass spectrometry and with the 
ever-increasing resolutions and operating speeds of contemporary mass spectrometers, the 
proteomics field has evolved rapidly over the past few years [142, 143]. Other mass 
spectrometry-based omics fields, such as lipidomics and glycomics, are considered to be still 
in their infancies. 
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Since the completion of the Human Genome Project, we have an adequate view on most of 
the protein-coding genes16 and the genomes of more and more organisms are almost routinely 
being added to the ever expanding genome databases [145-149]. However, the genome only 
provides a view on which proteins can potentially be expressed. Indeed, a retina cell is very 
different from a muscle cell, despite sharing the same genomes. Similarly, a caterpillar is very 
different from a butterfly because they both activate different genetic programs. Thus, the 
genome alone provides little information about the current proteomic state of a cell. 
Epigenomics is the study of the modifications (e.g. methylation, acetylation) of the DNA and 
its associated proteins (histones amongst others) [150]. These chemical markers change the 
chromatin’s structure and dictate the accessibility of each gene for the transcription machinery. 
Within the same species, different cell types have different epigenetic patterns. However, 
epigenomics only provides an overview of how easily genes can be accessed, but it does not 
provide answers to how much of each proteoform is actually being produced.  
Transcriptomics is a routine technique to quantify the amounts of (m)RNA molecules derived 
from each gene [151]. It can therefore be used as a rough estimate for protein production. 
However, a substantial amount of mRNA is not translated and there is a variety of mechanisms 
that modulate protein synthesis at the translation step17. The ribosome profiling technique 
provides a quantitative snapshot of which mRNA is getting translated. Therefore, ribosome 
profiling provides a much better estimate of protein translation than mRNA sequencing [153]. 
Metabolomics and lipidomics, the large-scale analyses of metabolites and lipids respectively, 
can elucidate complex metabolic processes related to health and disease [154]. Metabolic 
conversions are not only catalyzed by enzymes, but also closely regulated by various protein 
signaling cascades. Therefore, metabolomics and lipidomics can provide additional indirect 
information on the state of the proteome [155]. 
However, none of these omics’ techniques are able to determine which proteoforms will be 
produced, nor can they provide any information about protein degradation, the other side of 
the balance that governs protein steady-state. They are also not well-suited to assess protein 
localization and are unable to provide information about a protein’s interaction partners. The 
only technique that is able to assess with high-throughput the properties of a protein within a 
proteome is MS-based proteomics. 
1.3. Applications of mass spectrometry-based proteomics 
MS-based proteomics is the preferred method for solving numerous biological questions from 
the “proteome angle”. Identifying and later also quantifying proteins were and are still the main 
initial applications of MS-based proteomics. Over the last decade, the application of proteomics 
for the identification and quantification of protein modifications has also gained significant 
attention. The proteomics field has also been expanded to study amongst others, protein-
protein interactions [156-159], protein-compound interactions [160-163], cellular protein 
localization [164-167] and protein structure determination [89, 160, 168-173]. However, the 
identification and quantification of proteins remains the most important application of MS-
based proteomics and many of these applications rely on the quantitative ability of the mass 
spectrometer. Since my thesis focuses on protein quantification, I will elaborate here on protein 
quantification and the quantification of protein modifications. 
                                               
16 Although the detection of many small “hidden” proteins remains challenging [144]. 
17 These include, amongst others, RNA splicing, reading frame shifts, translational read-through, sequestration of 
mRNA and mRNA degradation [152]. 
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1.3.1. The analysis of protein and peptide abundance 
After a peptide or protein is identified, quantification is the next logical step. Typically, peptides 
from different biological conditions are labeled either isotopically or chemically in order to 
induce a mass shift in the MS, MS² or MS³ spectrum. Alternatively, if labeling is omitted (label-
free proteomics), mass spectra from different runs should be compared. The peak intensities 
are a proxy for peptide (and hence a protein) abundance. The peak intensities registered 
during the elution of a peptide therefore allow for protein quantification in each biological 
condition. Alternatively, quantification can be done by the less accurate, but simpler spectral 
or peptide counting. Relating intensities to protein concentrations is challenging because 
peptides can have very different ionization efficiencies, which are difficult to predict. 
Nonetheless, there were some attempts at absolute protein quantification [174, 175]. Since the 
analysis of protein abundance is the focus of my work, I have kept this section intentionally 
brief since more details about quantitative proteomics are given in chapters 2-4.  
1.3.2. The analysis of protein modifications 
Both bottom-up and top-down proteomics can be employed to study protein modifications as 
these cause shifts in the masses of affected peptides that can readily be detected.  
As mentioned earlier under 1.1.3, proteins can carry a plethora of modifications. Most of these 
modifications occur too infrequently to be detected or prove to be very chemically labile. Other 
modifications, such as the frequently occurring, but often labile phosphorylation, are also 
difficult to detect because of the poor ionization of the phosphoryl group, which carries a 
negative charge. Therefore, when the main research goal is to study a certain protein 
modification, specific enrichment procedures are often required [117]. 
Phosphorylation is both the most common and the most intensively studied protein 
modification [176]. Indeed, phosphorylation is a key modification in many signaling cascades 
and phosphoproteomics has contributed enormously to our understanding of these pathways 
[177-179]. However, the negative charge of the phosphoryl group and the default usage of 
positive electrospray ionization makes it difficult to generate and therefore detect positively-
charged phosphorpeptides. Thus, phosphopeptides are enriched via pre-fractionation with 
hydrophilic interaction liquid chromatography (HILIC), Strong cation exchange (SCX) 
chromatography or strong anion exchange (SAX) chromatography, as well as 
immunoprecipitation, immobilized metal affinity chromatography (IMAC), metal-oxide affinity 
chromatography (MOAC), Phos-Tag chromatography, polymer-based metal ion affinity 
capture (PolyMAC), hydroxyapatite chromatography, enrichment by chemical modification, 
and/or phosphopeptide precipitation [180]. Negative electron-transfer dissociation (NETD) can 
also increase the MS intensities of phosphopeptides [123]. 
Acetylation and methylation are modifications that were first discovered on histones, proteins 
that are associated with the DNA and package it into structural units called nucleosomes [181, 
182]. Histone acetylation is generally associated with open chromatin [183], while histone 
methylation, dependent on the location of the methylation site, can both be associated with 
open and closed chromatin [184]. Acetylation can occur both on protein N-termini and on lysine 
residues [183], while methylation can also occur on arginine residues [184]. 
Acetylation is important for protein localization [185-188], protein folding [189], protein stability 
[190] and interactions with other proteins [191]. Methylation is a major factor in important cell 
signaling pathways such as JAK-STAT, MAPK, WNT, Hippo and BMP [192] and overall protein 
methylation seems to be strongly intertwined with the organism’s metabolic state [193]. 
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Again, enrichment procedures by e.g. (immuno)affinity purification or chromatography are 
preferable when assessing acetylation or methylation on a proteome-wide scale [194-196]. 
Glycosylation is another very important post-translational protein modification as over 50% of 
all mammalian proteins are glycosylated [197]18. Glycosylation plays an important role in 
protein structure and stability [199-201]. The presence of a glycan structure can block other 
modifications such as phosphorylation [202]. Glycan structures can be sensed by other 
proteins (leptins) and play an important role in e.g. cancer and immunity [203, 204]. They are 
also intensively studied in the context of therapeutic proteins, as many of these proteins carry 
glycan structures [200, 205]. The enormous complexity of many glycan structures has spurred 
the development of a new field called glyco(proteo)mics [206]. 
Ubiquitin is a small 8.6 kDa protein that can be covalently linked to lysine residues of other 
proteins. However, non-canonical ubiquitination can also occur at Ser, Thr and Cys residues 
and at a protein’s N-terminal amine group [207]. The earliest known function of K48-linked19 
polyubiquitination is the degradation of the modified proteins in the proteasome. This discovery 
resulted in the 2004 Nobel Prize in Chemistry for Avram Hershko, Aaron Ciechanover, and 
Irwin A. Rose [208]. Although K11-linked polyubiquitination can also result in proteasomal 
degradation [209], ubiquitin is also an important scaffold that allows recruitment of other 
proteins and plays an important role in cellular processes as diverse as e.g. protein trafficking, 
mitophagy and cell cycle control. Next to K48 and K11; K6, K27, K29, K33 and K63 linkages 
have also been described. Many proteins are mono-ubiquitinated, but ubiquitin chains can also 
be linear and branched and even combined with other small ubiquitin-like modifiers such as 
SUMO and NEDD-8 [210]. 
Detection of ubiquitination by MS is challenging because ubiquitin is often either quickly 
degraded by the proteasome or part of very dynamic signaling pathways [211]. Moreover, 
ubiquitin is much bigger than most other small modifications. Being a protein, ubiquitin is also 
degraded by trypsin, leaving only a small GG or LRGG tag behind [212, 213]. Finally, 
ubiquitination does not seem to occur on well-defined amino acid sequence motifs [214-216]. 
Nonetheless, protocols for proteome-wide detection of ubiquitination are now readily available 
thanks to innovative purification and chemical tagging strategies [211, 217]. Similarly, protocols 
have also been developed for the proteomic analysis of other less characterized small 
ubiquitin-like modifiers like SUMO [218, 219], NEDD-8 [220, 221] and ISG [222, 223]. 
  
                                               
18 Note that not only proteins, but also lipids can be glycosylated [198]. 
19 K48-linkage means that each ubiquitin in the chain is linked to the previous ubiquitin via the lysine (K) residue at 
position 48 (starting from the N-terminus). 
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2. TECHNICAL CONTEXT 
As amply demonstrated in the previous chapter, mass spectrometry-based proteomics has 
become an invaluable tool for protein researchers. In chapter 2, I will discuss the different 
flavors of mass spectrometry-based proteomics with a focus on their technicalities. I will 
specifically emphasize label-free shotgun proteomics, as all my PhD work revolves around this 
particular technique. This technical overview will provide a handle for chapter 3, where I will 
link the statistical challenges to the technology. 
2.1. Label-based mass spectrometry-based proteomics 
Traditionally, quantitative proteomics has made use of stable-isotope coded labels. This used 
to be a necessity, as the peptides that were identified often differed strongly between LC-
MS/MS runs. Indeed, even minor differences in electrospray voltages and/or chromatographic 
flow rates increase the run-to-run variability in signal intensities and hence reduce the precision 
of label-free quantification [224, 225]. By metabolically labeling proteins from different samples 
and subsequently pooling these together for a single analysis, it became possible to identify 
the peptides in each sample analyzed and remove the inter-sample variability. In fact, one 
distinguishes two categories of label-based proteomics: metabolic and post-metabolic labeling. 
In metabolic labeling, labels are incorporated during cell or organism expansion. By contrast, 
in post-metabolic labeling, a label is added after protein extraction or even after protein 
digestion, typically by means of a chemical reaction that targets specific reactive groups in 
proteins or peptides. The main advantage of metabolic labeling is that the labeled proteins can 
immediately be pooled together, thus any random or systematic experimental errors that occur 
after pooling will affect all samples equally [226]. Thereby, this unwanted variability can be 
factored out from the analysis, which increases the overall precision. Post-metabolic labeling, 
by contrast, does not affect the biology of the organism under study (see below), as labeling 
only occurs after protein extraction. And, although post-metabolic labeling requires more 
protein material, it is more broadly applicable [227]. Fig. 2.1 gives an overview of the 






Figure 2.1. Schematic overview of the labeling workflow for two experimental conditions (blue and 
yellow). Horizontal lines indicate when samples are combined, dashed lines indicate the protocol steps 
where experimental variation unequally affects both samples. Reprinted with permission from 
Bantscheff et al. (2012) [228], copyright © 2012, Springer-Verlag. 
2.1.1. Metabolic labeling 
In metabolic labeling, a cell culture or even an entire organism is expanded in a medium that 
contains nutrients composed of heavy isotopes. Metabolic incorporation of radioactive isotopes 
was first used to quantify proteins in gels [229], whereas 15N labeling was the first MS-based 
quantitative proteomics approach [230]. Here, cells were grown in a medium with nutrients 
containing the stable 15N isotope, which allows this isotope to be incorporated into the 
biomolecules of the cell. The heavy-labeled proteins have higher masses compared to proteins 
from cells expanded in a medium containing the natural 14N isotope. This results in a mass 
shift for each peptide that is detected in the mass spectra. 15N labeling is thus well-suited to 
compare the levels of all identified proteins between two conditions: one grown in normal 
(“light” or “unlabeled”) medium and the other in heavy medium. Indeed, peptides originating 
from digesting both proteomes are pooled and analyzed by mass spectrometry. The intensities 
of the 14N and 15N peptides are compared to infer differences in protein abundances. This 
approach assumes that cellular metabolism remains unaffected by the heavy isotopes. 
Nonetheless, several studies indicate that there might be biological effects of heavy isotopes 
given differential preferences of enzymes for certain isotopes [231-234]. To guard against 
statistical confounding due to these kinetic isotopic effects and unavoidable differences in 
quality20 between the light- and the heavy-labeled medium, the heavy and light conditions are 
routinely swapped in experimental repeats. 15N labeling was originally used to quantify baker’s 
yeast (Saccharomyces cerevisiae) proteins and was later also applied on bacterial and 
mammalian cell cultures [235], and even on whole organisms [236-238]. 
                                               
20 E.g. small deviations from the stated isotopic content might bias quantifications. Also, since the heavy and light 
media are stored in separate bottles, there might be small differences in biological effects since fetal bovine serum, 
an essential serum supplement for most cell cultures, is often added separately to each bottle. Moreover, the 
quality of both media might also diverge over time. 
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Incomplete labeling is a major disadvantage of all metabolic labeling strategies. Indeed, natural 
medium still contains a non-negligible albeit very low amount of heavy isotopes (e.g., 1% 13C 
and 0.4% 15N ) [239]. Similarly, medium highly enriched in heavy isotopes still contains a 
fraction of lighter isotopes. As peptides differ in their number of amino acids and different amino 
acids have different numbers of atoms, isotopic labeling will generate a plethora of different 
partially unlabeled variants for every peptide analyzed [240]. Therefore, the mass shift of a 
peptide after labeling depends on its composition, which complicates downstream peptide 
identification and quantification. 
Stable Isotope Labeling by Amino acids in Cell culture (SILAC) is a metabolic labeling 
approach where amino acids, typically essential amino acids, containing one or more stable 
heavy isotopes are used for differential protein quantification [241, 242]. The use of amino 
acids as opposed to isotopically labeled nutrients has greatly simplified data analysis for MS-
based protein quantification, and this because the labeled amino acids are incorporated into 
proteins, implying that a peptide’s mass shift can be directly derived from its amino acid 
composition. An important point is that the organism in the heavy condition needs to be 
exposed to the heavy-labeled amino acids for long enough to allow the complete replacement 
of the organism’s natural (unlabeled) amino acids by the supplied heavy amino acids. For cell 
cultures, seven doubling times seems to be sufficient to allow full incorporation, even for 
proteins with very slow turnover rates [240]. By contrasting light (e.g. 12C614N4-arginine), 
medium (e.g. 13C614N4-arginine) and heavy (e.g. 13C615N4-arginine) SILAC labeling, three 
different conditions can be directly compared [243]. In 2010, the introduction of 5-plex SILAC 
allowed the comparison of up to five different conditions in a single MS run [244]. When more 
than five conditions need to be compared with SILAC, a heavy-labeled standard proteome can 
be spiked into every condition and be used as a reference to allow calculation of the protein 
ratios for every comparison (super-SILAC) [245] [246]. SILAC-labeling was initially confined to 
cell cultures, but over time, it has been expanded to organisms such as the worm 
Caenorhabditis elegans [247], the fruit fly Drosophila melanogaster [248], mice [249] and 
plants [250]. Fig. 2.2 gives an overview of a typical SILAC workflow. 
 
Figure 2.2. Overview of a SILAC workflow where three experimental conditions need to be compared. 
The proteomes from the light, medium-labeled and heavy-labeled conditions can be pooled together 
and analyzed in a single MS run. The intensity ratios of the triplets for each peptide ion species can then 
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be directly calculated from its corresponding MS spectrum. Reprinted with permission from Geiger et al. 
(2011) [251], copyright © 2011, Springer-Verlag. 
Also, the isotopic purity of the SILAC medium is of utmost importance. When the fraction of 
“heavy” amino acids is insufficiently high, the hence-labeled proteome contains a substantial 
fraction of “light” amino acids, leading to quantification biases in the direction of the “light” 
condition [240]. Further, when using trypsin to digest an arginine-SILAC labeled proteome, a 
possible caveat is introduced by the metabolic conversion of arginine into proline and 
glutamate [252], which introduces extra stable isotopes in proline-containing peptides, thereby 
obstructing accurate quantification. This can be prevented by adding an excess of unlabeled 
proline [253, 254] and/or by reducing the arginine concentration [255]. 
SILAC requires dialyzed fetal bovine serum as no other variants of the selected essential 
amino acids other than the labeled variants must be present in the medium. Dialysis however 
results in the loss of growth factors, which will cause a cellular stress response that might bias 
the response to the treatment of interest or even completely prevent cell or organism growth 
altogether [227, 256]. 
Despite its main advantage of factoring out run-to-run variability from each comparison, SILAC 
seems to be slowly getting out of favor for high-throughput protein quantification. The main 
reason is that the quantification depth (i.e. the number of proteins identified) of SILAC is 
reported to be ~30 to 60% lower than the quantification depth of label-free quantification (see 
2.2.1) [257, 258], although this difference also depends on sample complexity and instrument 
resolution. Indeed, as multiple SILAC-labeled samples are jointly analyzed in a single MS run, 
the amount of protein analyzed per experimental condition is two to five (for 5-plex SILAC) 
times lower, while the number of peaks in each MS spectrum increases with the same factor 
[258, 259]21. In such complex spectra, the peptide ion signals will be lower and might even 
become indiscernible from the background noise. Also, the more peaks, the higher the chances 
of co-fragmentation: i.e. two (or more) peptide ions with overlapping isotopic envelopes are 
fragmented together, increasing the risk of unidentifiable spectra [260]. Moreover, as all 
isotopic variants of the same peptide can be targeted for identification, less MS peaks might 
be identified due to limitations on the MS² sampling rate [261]. Another disadvantage of 
metabolic labeling is that its dynamic range is generally smaller than those of label-free and 
isobaric quantification approaches (see 2.1.2 and 2.2.1) [262-265]. Also, isobaric labeling 
appears to have a higher precision [265].  
Recently, neutron-encoded (NeuCode) labeling has been proposed as a promising new 
metabolic labeling approach that relies on the ability of modern high-resolution MS to 
distinguish extremely small mass differences (in the orders of mDa) [261, 266]. However, 
NeuCode did not gain a lot of traction yet because of the extremely high cost of its reagents, 
which seriously limits its throughput. 
2.1.2. Post-metabolic labeling 
In post-metabolic labeling, a different chemical label is added to each sample after protein 
extraction or digestion. Post-metabolic labeling strategies are often used for large experiments 
in which many samples need to be compared because of their superior opportunities to 
simultaneously measure multiple experimental conditions in a single MS run (“multiplexing”). 
In the context of high-throughput protein quantification, labels are added after digestion 
                                               
21 The reason is that the total amount of peptides (in µg) that is spiked onto the mass spectrometer is a fixed 
constraint. Under-spiking will result in low signal intensities and hence low proteome coverage, while over-spiking 
will result in signal saturation. 
27 
because this allows labeling of peptides that are buried within a protein’s 3D structure, resulting 
in a higher peptide coverage. 
Dimethylation is one of the oldest post-metabolic labeling strategies, though still widely used 
as it is easy to multiplex and fairly cheap [267]. Indeed, dimethylation requires relatively cheap 
reagents such as isotopically labeled formaldehyde and cyanoborohydride [268]. Here, all 
lysine side chains and peptide N-termini are dimethylated, except if the N-terminus starts with 
proline, in which case it will be monomethylated [269]. Originally performed in duplex [270], 
dimethylation was expanded to 3- [271], 4- [272] and 5-plex labeling [273]. By combining 
dimethylation with SILAC, 6-plex labeling has been achieved [274].  Compared to SILAC, 
dimethylation has a similar dynamic range and accuracy [265, 275]. Thus, the additional 
experimental variability introduced by post-metabolic labeling as compared to metabolic 
labeling seems to be limited in practice. Deuterium was used in the dimethylation approaches 
described above. However, compared to hydrogen-1, deuterium binds less strongly to the 
hydrophobic stationary phase due to the lower amplitude of its vibrational frequencies [276]. 
This results in a chromatographic shift as deuterium-labeled peptides elute somewhat earlier 
than their hydrogenated counterparts, which increases the uncertainty on the ratios of their 
peak intensities [277, 278]. Therefore, most contemporary isotopic labeling strategies avoid 
deuterium and favor e.g. 13C, which does not induce a noticeable chromatographic shift [279]. 
18O labeling is an enzymatic post-metabolic labeling approach that was originally used to 
improve peptide identification [280-282]. Soon after, 18O labeling also became a tool for protein 
quantification [283-286]. Here, protein digestion is performed either in normal water or in 18O-
rich water. Two 18O-atoms are incorporated at the peptides’ C-termini, resulting in 4 Da mass 
shifts. Nowadays, 18O labeling is not very common anymore as 18O incorporation efficiency is 
variable and the technique cannot be multiplexed [287]. 
Isobaric labeling relies on mass differences in the fragment ions of isotopologic tags to quantify 
peptide ions via their MS² spectra. Indeed, the isobaric labels in each condition have the same 
total nominal mass, but a specific fragment ion, the reporter ion, has different masses for each 
label. Differentially labeled peptides thus coincide in the MS spectrum, but the reporter ions 
allow for quantification in the MS² spectrum. iTRAQ [288] and TMT [227] are the most well-
known and frequently used reagents for isobaric labeling (Fig. 2.3). 
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Figure 2.3. Left: chemical structures of 4-plex iTRAQ- (top) and 6-plex TMT- (bottom) labeled peptides. 
In isobaric labeling, peptide mixtures from different conditions are labeled with different isobaric labels 
that have the same total nominal masses but differ in the distributions of heavy isotopes within their 
structures (i.e. the isobaric labels are isotopologues of each other). Indeed, the reporter groups of the 
different isobaric labels all have different nominal masses (due to differential usage of heavy isotopes). 
This mass difference is balanced out by the balance group to ensure equal total nominal masses. The 
reporter group is constructed so that it detaches easily during fragmentation. It also has a strong 
preference to carry the positive charge after fragmentation so that it can be readily detected. Right: the 
monoisotopic22 forms of differentially labeled peptide ions with identical amino acid sequences and 
charges will generate a single peak in the MS spectrum (top, red). However, after fragmentation of the 
isobaric labels, the mass difference of the reporter fragment ions will allow differential quantification in 
the MS² spectrum (bottom, red). 
The main advantage of isobaric labeling is that it does not increase the complexity of the MS 
spectra and is therefore highly suitable for multiplexing [289]. Indeed, TMT readily allows 6-
plex quantification [290], while iTRAQ goes up to 8-plex [291]. By making use of isotopologues, 
TMT-labeling has now even reached 11-plex [292, 293]. However, despite the market 
dominance of iTRAQ and TMT, some recent isobaric labeling alternatives such as DiArt [294] 
and DiLeu [295] labeling are gaining attention due to their easy synthesis, low cost, labeling 
efficiency and improved fragmentation efficiency. With DiLeu, up to 12 samples [296] can be 
compared in a single run. Isobaric labeling has also been combined with SILAC which 
increases its multiplexing potential even further [297]. 
However, in isobaric labeling, distortion of the reporter ion intensities in the MS² spectra is a 
major issue. Furthermore, isotopic impurities in the isobaric labeling reagents lead to isotopic 
                                               
22 The monoisotopic form is the isotopic variant wherein all atoms of a molecule are in their most abundant isotopic 
form. 
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overlaps in neighboring reporter ion intensities. Prior to data analysis, each reporter ion peak 
should therefore be corrected for isotopic overlap using correction factors supplied by the 
reagent manufacturer [298]. Another issue is that co-eluting near-isobaric peptide ions are 
isolated and co-fragmented with the target peptide ion, skewing the ratios of the reporter ion 
intensities towards the median value over all proteins, which is usually very close to one23. For 
this reason, this phenomenon is also called ratio compression [298-300]. 
Several technical solutions have been developed to reduce ratio compression. Gas-phase 
purification [301] and ion mobility separation [302] remove interfering ion species prior to 
fragmentation. MS³ prevents co-fragmentation by isolating an MS² peptide fragment ion and 
fragmenting it again to produce an MS³ spectrum. This additional step massively reduces the 
chance that the selected fragment ion will again be co-isolated with a fragment ion from another 
peptide species. As this MS² fragment ion contains all the isobaric labels, the reporter ions in 
the MS³ spectrum enable more accurate and more reproducible protein quantification [303]. 
Even with these improvements, around 8% of the MS³ spectra remain affected by co-
fragmentation [265]. The introduction of synchronous precursor selection MS³ (SPS-MS³), in 
which multiple MS² fragment ions of a precursor peptide are co-isolated, strongly boosts MS³’s 
sensitivity [304]. However, despite clear progress, MS³ still requires complex instrumentation 
and has a slower duty cycle, resulting in a lower identification depth compared to MS² 
quantification [289]. TMTc and EASI tag are new strategies whereby the complement ions (i.e. 
peptide fragments that remain attached to the balance group) are quantified in the MS² 
spectrum [289, 305, 306]. These approaches avoid both the complexities of MS³ and the 
unwanted ratio compression because they examine the isotopic envelope of a particular 
labeled MS² peptide ion fragment. 
Disadvantages of isobaric labeling include the loss of quantification depth and the poor 
accuracy for quantifying low-intensity peaks due to the lower signal-to-noise ratio in MS² 
spectra compared to MS spectra [265, 307]. The former can be partially alleviated by pre-
fractionation. However, this results in longer run times and a more complicated data analysis 
[308, 309]. MS²-based quantification also implies that only those peptides that are selected for 
fragmentation can be used for quantification [266]. Hence, for the many proteins that are 
identified with few peptides, it is difficult to assess the precision on their differential abundance 
estimates. Finally, iTRAQ and TMT labeling are relatively costly [275]. 
2.2. Label-free mass spectrometry-based proteomics 
My PhD work is centered around the quantification of data-dependent label-free discovery-
based shotgun proteomics data. Therefore, I will here give an extensive overview of the label-
free shotgun proteomics workflow. 
2.2.1. The label-free proteomics workflow 
An overview of a generalized proteomics workflow has already been given in 1.2.2. In this 
section, I will focus on the aspects that are specific to label-free proteomics, and more 
specifically on those aspects that pose challenges to the ensuing data analysis. 
A label-free proteomic workflow consists of the following steps: (1) proteins are extracted from 
the sample, (2) these proteins are digested into peptides, (3) the peptides are separated by 
reverse phase HPLC (RP-HPLC), (4) eluting peptides are ionized, (5) an MS spectrum is taken, 
(6) a precursor ion is selected, (7) this precursor ion is fragmented and (8) an MS² spectrum 
                                               
23 The total amounts of peptides loaded and analyzed are usually equal for all samples. 
30 
of its fragments is taken. Steps 6-8 are typically repeated several times for different precursor 
ions before a new MS spectrum is recorded. The peak intensity in the MS spectrum is used as 
a proxy for a peptide ion’s abundance, while its corresponding MS² spectrum is used to identify 
the precursor. An overview of this procedure for a quadrupole Orbitrap instrument is given in 
Fig. 2.4. 
 
Figure 2.4. Overview of a typical label-free mass-spectrometry-based proteomics workflow on a 
quadrupole Orbitrap instrument. First, proteins are extracted from a sample. Then, the extracted proteins 
are digested into peptides, using a protease with a strong cleavage specificity (typically trypsin). This 
peptide mixture is loaded onto the instrument. A high-performance liquid chromatography column allows 
separation of the peptides by their hydrophobicity (RP-HPLC). The eluate from the column is ionized by 
electrospray ionization (ESI). The quadrupole ensures that only positively charged ions pass through. 
In the Orbitrap, an MS spectrum is taken. Each peak in the spectrum corresponds to a peptide ion. In a 
next step, the quadrupole will select a peptide ion with a sufficiently high peak in the MS spectrum. This 
peptide is fragmented and an MS² spectrum of its fragments is taken. This process is repeated for other 
peptides with high enough MS intensities. 
Several of these steps create particular issues that are important to consider when analyzing 
the data. Table 2.1 presents a non-exhaustive overview of common issues in label-free 
proteomics workflows that have an important impact on the ensuing data. In what follows, I will 





Table 2.1. Non-exhaustive list of issues that arise during a label-free shotgun proteomics workflow and 
their impact on the data. 
Analysis step Issues Consequences 
Protein extraction Differences in extraction 
efficiencies 
Variable protein concentrations 
over different samples 
Protein digestion Unequal enzymatic cleavage 
efficiencies, non-canonical 
cleavage, peptide ragging  
Unequal concentrations of 
peptides originating from the 
same protein 
RP-HPLC separation Technical variability in elution 
times 
Difficulties in matching 
unidentified peptides to 
identified peptides across 
different runs 
 Peptide carry-over due to 
peptides from previous runs that 
did not elute from the column 
Detection of peptides that were 
not present (worst case), 
peptide intensities influenced 
(increased) by the order in 
which the samples were run 
ESI ionization Strong differences in peptide 
ionization efficiencies 
Strong differences in MS 
intensities for peptides 
originating from the same 
protein 
 ESI saturation: peptides 
compete for ionization 
Ionization suppression: a 
peptide’s MS intensity (partially) 
depends on the nature and 
amount of other co-eluting 
peptides 
  Suppression of high MS 
intensities resulting in an upper 
limit of quantification 
 Peptides ionize in different 
charge states 
Intensities for different charge 
states need to be taken into 
account when quantifying a 
peptide 
 Gas-phase peptide ions 
undergo chemical reactions 
Artificial peptide modifications, 
which are possibly not 
accounted for, resulting in 
unidentifiable spectra and 
missing values 
 Changes in electrospray 
voltage during and across 
different runs 
Increased variability in peptide 
ionization efficiencies 
MS recording Discrete MS spectrum 
recording 
MS intensity not recorded at the 
elution peak 
 MS detector saturation Suppression of high MS 
intensities resulting in an upper 
limit of quantification 
MS² recording Limited amount of MS peaks 
targeted for fragmentation 
Different peaks fragmented 
across different runs: missing 
values 
 Preferential targeting of high-
intensity MS peaks 
Intensity-dependent missing 
values 
 Loss of unexpected peptide 
fragments 
Difficulties in MS² spectrum 
identifications and thus missing 
values 
 Co-fragmentation of peptide 
ions with similar m/z values 
Unidentifiable chimeric MS² 
spectra and thus missing values 
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The first step in the protocol, protein extraction, was shown to be responsible for 72% of all 
technical variability [310]. However, small differences in protein extraction efficiencies 
generally should not pose too much problems as an equal amount of total peptides is loaded 
onto the instrument for every sample. As noted in 1.2.2, it is imperative that all sample 
preprocessing is compatible with RP-HPLC-MS. It is therefore important to limit or avoid the 
use of urea [105, 106] and to avoid the use of SDS [91, 106-109] as well as other contaminants 
[112]. 
The digestion step is also critical. If the digestion efficiencies differ between samples, certain 
peptides might be formed to different extents. Consider for example the proteolytic cleavage 
of the following protein: 
SESNAHFSFPKEEEKEFLESYPQNCPPDALPGTPGNLDSAQELEGFQIPTNLDWAGTSQAR 
The most commonly used protease, trypsin, cleaves at the C-terminus of lysine (K) and 
arginine (R) (indicated in red) [311]. Depending on the digestion efficiency, varying amounts 
of the peptides SESNAHFSFPK and SESNAHFSFPKEEEK can be identified. Both the very 
short EEEK peptide and the very long EFLESYPQN…R peptide are barely or not detected by 
the mass spectrometer. Peptide SESNAHFSFPKEEEK is said to have one missed cleavage 
site, but peptides can have multiple missed cleavages. The presence of missed cleavages not 
only depends on the duration of the digestion, but also on the quality of the enzyme [312]. 
However, peptides can also be formed at non-canonical cleavage sites (i.e. not at lysine’s or 
arginine’s C-terminus) and modifications (either of biological origin or artifacts formed during 
sample preprocessing) may affect enzymatic digestion efficiency [311]. Next to these 
elements, the amino acids adjacent to a possible cleavage site, the location of a peptide in a 
protein’s 3D structure and chemical degradation also play a role in the kinetics of the 
generation and degradation of different peptide species. Moreover, unwanted chemical 
reactions during sample preprocessing and/or the activities of exopeptidases that might be 
present in the sample or as contaminants in the commercial protease batch may cause N-
terminal or C-terminal peptide degradation (“peptide ragging”) [313]. For these reasons, the 
concentrations of most peptides are not equal to the initial protein concentration [314]. This 
stresses the importance of uniformity in the digestion conditions over the different samples. 
Since the RP-HPLC column is typically packaged with porous silica beads coated with apolar 
alkyl chains (e.g. C18), peptides will be separated by their differences in hydrophobicity [315]. 
Protein modifications can however influence the column retention of an affected peptide [316]. 
Further, there is inherent variability in the chromatographic retention of a given peptide over 
different MS runs. This is an important factor to bear in mind when matching an identified peak 
in one MS run to an unidentified peak in another run; so-called matching between runs [317]. 
Comparing retention times over different runs is routinely done by algorithms for retention time 
alignment [318]. Retention times are often monitored as a general quality control measure by 
spiking in a known peptide or peptide mix [319, 320] and several algorithms have been 
developed to predict the retention times of known peptides [315, 321-323]. In order to maximize 
the mass spectrometer’s operation time, HPLC columns are generally not replaced between 
analyses. Therefore, peptides from a previous injection might partially remain retained on the 
column and elute during a subsequent run, thus leading to the detection of peptides that were 
not present in that last sample and/or biased quantifications. Little has been published in the 
literature about sample carry-over, even though this is a non-negligible problem [324]. 
Peptide elution happens continuously, while the mass spectrometer only generates mass 
spectra at discrete time points. As peptide elution takes around 5 – 25 seconds [325, 326] and 
modern mass spectrometers typically tend to record an MS spectrum every second, the 
intensity peak for a single peptide ion will be recorded in sequential MS spectra. To allow for 
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an accurate quantification, it is important to record at least one MS peak at or near each 
peptide’s elution apex. High-resolution RP-HPLC separation concentrates peptides in 
narrower elution peaks and is highly beneficial for different reasons [141]. First, repeated 
fragmentations of the same peptide ion over its elution window are highly reduced, thus 
winning MS analysis time. Next, highly focused peptide elution increases ion intensities and 
the ability to target monoisotopic peaks, which facilitates identification. Finally, an improved 
separation reduces co-elution of peptides, preventing ion suppression and co-fragmentation 
(see below). 
The quality of ionization is of utmost importance as poor ionization leads to lower quality 
spectra (lower signal-to-noise ratio), making it more difficult to identify and quantify peptides. 
The electrospray voltage should also be kept as constant as possible over different runs as 
even small voltage deviations aggravate the variability in ionization efficiencies of peptides 
over different runs, which reduces the precision of label-free quantification [225]. 
During electrospray ionization (ESI), peptides are endowed with a positive charge (when 
working in positive ionization mode) [122]. However, the ionization efficiency of peptides 
differs. For example, highly acidic peptides and phosphopeptides ionize more poorly [123]. 
Such different ionization efficiencies leads to different MS intensities across different peptides, 
even if their concentrations are equal. In addition, the ionization efficiency of a peptide is also 
influenced by the nature and the amount of co-eluting peptides as these may suppress each 
other’s ionization, a phenomenon known as ionization competition or ionization suppression 
[122, 327]. For these reasons, peptide ionization efficiencies are still difficult to predict [328]. 
Finally, the total amount of peptides that can be ionized simultaneously is also limited due to 
saturation effects during ionization [329, 330], which results in a suppression of high MS 
intensities and therefore an upper limit on the amount of peptides that can be quantified.  
Ionization also generates different ion species from a single peptide, which differ in charge 
state. Indeed, ESI typically generates multiple ions with different charge states from the same 
peptide. For tryptic peptides, a double positive (+2) charge state is the by far most common 
after ESI ionization (around 75 - 90% of all ions), followed by triple positive (+3, around 10 - 
20% of all ions) and single positive (+1, around 5% of all ions) [331]. The ionization step might 
also affect the chemical composition, and hence the mass, of an ion. Examples include in-
source peptide oxidation and the loss of water or ammonia from N-terminal glutamate or 
glutamine residues, respectively, to form pyroglutamate [332, 333]. 
In the MS spectrum, the intensity of every ion that eluted from the HPLC column at that 
particular point in time is recorded in function of its mass-to-charge (m/z) ratio. Ion intensities 
can be seen as proxies for abundance, with the caveat that the ionization efficiencies differ 
strongly between different ion species. The detector of the mass spectrometer is also sensitive 
to saturation, which might also result in suppression of high MS intensities [329, 330]. 
After the generation of the MS spectrum24, a high-intensity ion species is isolated with the 
quadrupole and targeted for fragmentation, a process that is repeated several times before a 
new MS spectrum is recorded. High-intensity MS peaks are intentionally targeted for 
fragmentation to avoid the targeting of noise peaks and hence increase the depth of the 
analysis. However, the fact that not all peaks in an MS spectrum can be targeted for 
fragmentation and the fact that high-intensity peaks are preferentially selected, results in 
intensity-dependent missing values. Dynamic exclusion, whereby previously-targeted m/z 
                                               
24 Or sometimes during the generation of the MS spectrum, if the machine has two mass analyzers. 
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values are temporarily excluded from fragmentation increases the quantification depth but 
does not alleviate the issue of intensity-dependent missingness.  
Fragmentation also commonly results in neutral losses of water and ammonia, or even partial 
or complete amino acid side chains [137]. Such losses need to be taken into account when 
identifying a peptide ion based on its MS² spectrum. To facilitate identification, it is also 
preferable that the monoisotopic peak is correctly determined. For short peptides, the 
monoisotopic peak is often the highest one, but for longer peptides, this peak might be 
considerably smaller. This sometimes leads to determination of the wrong peak in the isotopic 
envelope and hence a wrong selection of candidate peptides during database filtering. Finally, 
when one or more peptides of about the same m/z elute together with a target peptide ion, 
such neighboring ions can be isolated as well, resulting in a mixed MS² spectrum [334]. Such 
a mixed fragmentation spectrum will also cause problems regarding identification and 
quantification. 
2.2.2. Advantages and disadvantages of label-free MS-based proteomics 
An obvious advantage of label-free MS-based proteomics is that the laborious and often costly 
labeling is omitted altogether [226]. Moreover, label-free analyses have a deeper coverage 
compared to label-based strategies. Indeed, compared to label-based quantification at the MS 
level, a significantly deeper coverage in label-free proteomics is caused by the decrease in 
spectral complexity [257, 258]. Compared to isobaric labeling strategies, the increase in 
coverage mainly results from the higher signal-to-noise ratios in MS spectra compared to MS² 
spectra [265, 307]. As noted before, label-free approaches also have a higher coverage and a 
higher dynamic range than label-based approaches [263, 308]. Another major advantage of 
label-free quantification is that there are no restrictions on the sample type. Indeed, metabolic 
labeling cannot be applied to every type of sample (e.g. patient blood samples), and, although 
the use of a labeled reference standard (e.g. super-SILAC) might be an option in certain cases, 
this application is destined to fail when the samples in an experiment are too different from 
each other. Isobaric labeling can be applied on any sample type and has reached multiplexing 
capacities up to 12 [296]. However, when more samples need to be compared, between-run 
comparisons will need to be made [335]. Moreover, for any label-based strategy, all samples 
should be generated prior to the MS analysis of the first sample. Label-free quantification 
allows for the analysis of an unlimited number of samples, even retroactively, as long as the 
machine’s working conditions have not been changed dramatically [317, 336]. 
Since labeling is omitted, each sample is analyzed separately. This results in longer overall 
run times and thus a lower throughput [306, 336]. Inevitably, precision will also be lower 
compared to label-based approaches because random run-to-run variability cannot be factored 
out. Thus, robustness of the instrumentation and the analytical conditions is imperative for 
successful label-free analyses [336]. However, after balancing the pros and the cons, most 
research publications that compared label-based quantification to label-free quantification 
seem to express a general preference for the latter [257, 258, 308, 309], although the 
preference of individual researchers is often driven by their own experience, i.e. the 
instrumentation and quantitation technology they are most comfortable with. 
2.2.3. Other label-free approaches 
Next to label-free discovery-based data-dependent shotgun proteomics, there are two other 
major label-free proteomic techniques: targeted proteomics and data-independent proteomics. 
For the sake of completeness, and because I briefly refer to them in my future perspectives, I 
will here outline their major points. 
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All techniques outlined so far in this chapter aim to identify and quantify as many proteins as 
possible. However, none of these techniques guarantees that a particular protein of interest 
will be identified, especially if this protein is very low abundant (e.g. many transcription factors) 
[337] or is difficult to solubilize (e.g. membrane-inserted proteins) [338]. In fact, some proteins 
or protein regions have never even been identified by mass spectrometry, the so-called 
“hidden” or “dark” proteome [337, 339, 340]. Moreover, even if a protein of interest is identified 
in a certain run, it is not guaranteed to be identified in another run due to inherent run-to-run 
variability. 
Targeted proteomics aims to reproducibly monitor and precisely quantify one or more selected 
proteins [341]. Indeed, if the retention times and m/z values from peptide ions of interest are 
known, a mass spectrometer can be programmed to detect, fragment and record MS² spectra 
only for those peptide ions. This technique is called selected reaction monitoring (SRM) and is 
typically performed on a triple quadrupole instrument (QQQ) instrument. In this instrument, the 
first quadrupole is used to isolate the peptide ion, the second quadrupole serves as a collision 
cell to fragment this ion and the third quadrupole is used to isolate selected fragment ions. 
Since the QQQ only isolates selected fragment ions, SRM on a QQQ instrument has a high 
dynamic range and is very selective and sensitive [342]. Note that it is also possible to operate 
other machines in SRM mode [343]. In parallel reaction monitoring (PRM), the third quadrupole 
is substituted with a highly accurate mass analyzer to record all fragment ions [344]. PRM 
recently gained a lot of traction as PRM assays have a similar performance compared to SRM 
assays, but are easier to develop and possibly even more specific [345]. 
In data-independent acquisition (DIA), the intensity of the MS peak does not determine which 
ions are being fragmented. Shotgun CID, MSE and All-ion Fragmentation are DIA methods in 
which the complete m/z range of the MS spectrum is targeted for fragmentation [135, 346, 
347]. Other approaches divide the m/z range of the MS spectrum into predetermined m/z 
isolation windows and sequentially co-fragment all ions within such windows before going on 
to record the next MS spectrum [120, 348, 349]. DIA methods are immensely promising 
because they record all fragment ion spectra. Theoretically, it is thus possible to record every 
possible peptide in a sample as long as its fragment ions can be identified. Moreover, DIA data 
can be retroactively queried for new peptides of interest (e.g. modified forms of peptides). DDA 
search engines have been modified to unravel the very complicated MS² spectra that result 
from DIA [346, 348]. However, deconvoluting such multiplexed spectra remains challenging 
[350]. 
Out of all DIA methods, Sequential Windowed Acquisition of all Theoretical fragment ion mass 
spectra (SWATH-MS) is the most popular [351-353]. In SWATH-MS, specific MS² fragment 
ion peaks are tracked over time without deconvoluting the spectra [351]. On the new Q 
Exactive HF-X, a single SWATH-MS run identifies on average more than twice the number of 
peptides of a DDA run [354]. Moreover, in a benchmark experiment where 12 human proteins 
were spiked in a HEK-293 background, SWATH-MS analysis had only 1.6% missing values 
compared to 51% missing values in the DDA analysis of the same sample [355]. SWATH-MS 
is also highly reproducible across different labs [356]. Compared to targeted proteomics, it has 
a much higher coverage, but remains slightly less sensitive [351, 357-359]. 
The major disadvantage of DIA is that knowledge on the chromatographic and mass 
spectrometric behavior of peptides of interest is required to build a spectral library needed to 
identify the peptides [359]. This often implies that a DDA analysis is performed prior to the DIA 





3. FROM SPECTRA TO DATA 
In the previous chapter, I described the bottom-up shotgun proteomics workflow up to the 
generation of MS and MS² spectra. Given the continuous elution of peptides from the HPLC 
column, most peptide ions will be recorded in multiple, consecutive MS spectra. The peaks in 
these spectra must be converted into meaningful qualitative and quantitative information about 
the peptides in the samples. In this chapter, I will describe how MS and MS² spectra are used 
to identify peptides in label-free DDA MS-based proteomics. Then, I will show how peptides 
are assigned to proteins and I will describe how a single intensity value is assigned to each 
peptide followed by a description of the nature of the MS data. I will conclude this chapter with 
an explanation for the need for benchmarking and the description of the CPTAC Study 6 
benchmark dataset. 
3.1. Peptide ion identification 
In MS-based proteomics, peptide ions (also called “features”) are identified based on 
information present in both the MS and the MS² spectrum and only features that are deemed 
to be reliably identified are typically passed on to the quantification stage. Do note that a 
feature’s identification is actually not required for its quantification. Indeed, some workflows, 
such as those proposed by Sieve (Thermo Fisher Scientific) and Progenesis (Nonlinear 
Dynamics) adopt a feature-based quantification whereby identification efforts are primarily 
focused on features that are flagged as differentially abundant after the quantification stage. 
However, my thesis primarily focuses on the protein quantification, for which prior identification 
of features is required. Therefore, the remainder of this thesis describes the identification-
based workflow. 
The charge state and the mass of a feature can be readily determined from its MS spectrum. 
Indeed, charge state variants elute simultaneously and are thus present in the same MS 
spectra. As mass-to-charge ratios (m/z values) are recorded in MS spectra, an ion with, say, 
charge state +3 will have a peak at an m/z value exactly equal to 2/3 times the m/z value of 
the same ion with charge state +2. As mentioned in 1.2.2, the natural occurrence of stable 
heavier isotopes generates an isotopic envelope for each charge state of an ion. Since 
isotopes differ in mass by a natural number of neutrons, the minimal difference in mass 
between two isotopic variants is approximately 1 Dalton. This knowledge is used to infer the 
charge state of an ion: a difference of m/z = 1/2 Th between the peaks of an isotopic envelope 
denotes a +2 charge state, whereas a difference of m/z = 1/3 Th points to a triply positively 
charged ion. From this charge state, the monoisotopic mass of a peptide ion can be readily 
calculated by multiplying its corresponding monoisotopic m/z value by its charge state. 
However, knowing the mass of a peptide is not enough to identify it. Indeed, not only do all 
permutations of a particular amino acid sequence have exactly the same masses25, some 
entirely different combinations of amino acids also have the same nominal masses26. Also note 
that modifications change a peptide’s mass and that modified peptides often do not co-elute 
with their unmodified counterparts [333]. For these reasons, an MS² spectrum of a peptide is 
required to identify the amino acid sequence corresponding to a peptide’s MS peak. 
An MS² spectrum contains the m/z values for all the fragment ions obtained by fragmenting a 
single peptide ion. To enable identification, the selected peptide ion should by preference be 
the monoisotopic peptide ion. Indeed, any other peak in the isotopic envelope is in fact a 
                                               
25 E.g. the amino acid sequences LDGER, DGERL, GERLD, etc. all have a 588 Da mass. 
26 E.g. the amino acid sequences LGD and ER both have a nominal mass of 303 Da. 
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mixture of numerous isotopic variants. For example, the m+1 peak represents a mixture of ions 
that consist of a single heavy isotope together with only light isotopes. However, this heavy 
isotope can be for example a heavy carbon in the first amino acid, or a heavy carbon in the 
second amino acid, or a heavy nitrogen in the third amino acid, and so on. 
As described in 1.2.2, the type of fragmentation determines the main type of fragment ions that 
will be found in the MS² spectrum (both y- and b-ions for CID, mainly y-ions for HCD [137-
139]). In the early days, when mass spectrometers only generated a few 100 MS² spectra, 
peptide identification was often done manually by printing out the MS² spectra and measuring 
the distances between the fragment ion peaks. The sequence could then be inferred through 
some sort of “ladder sequencing” as demonstrated in Fig. 3.1. 
 
Figure 3.1. Theoretical demonstration on the inference of a peptide sequence based on some sort of 
ladder sequencing if all b- and y-ions are present (shown in purple and blue, respectively). The mass 
differences between the peaks give information about the amino acid sequence of the peptide. Since 
leucine (L) and isoleucine (I) have the same empirical chemical formula and thus the same masses, no 
direct distinction can be made between both. y-ions are often somewhat more abundant than b-ions, 
especially in HCD fragment spectra. Therefore, peptide sequencing based on y-ions is shown. The 
presence of the b-ions complicates the analysis somewhat but can also provide supporting evidence. 
Note that this representation is somewhat simplistic. In reality, a-, c-, x- and z-ions might also be present 
in the fragmentation spectrum. Moreover, some b- and y-ions might not exceed noise levels, while noise 
peaks (either true noise or fragments from co-isolated peptides) might obfuscate the analysis. 
Modifications will also influence the masses of those fragments that carry the modified amino acid. 
Nowadays, manual inspection of the sheer number of MS² spectra is impossible as high-quality 
experiments typically generate well over 5,000 MS spectra and over 50,000 MS² spectra in a 
single run. 
Because of the sheer amount of data, bioinformatics software is now indispensable for feature 
identification. One example is PeptideProphet [360], which makes use of the SEQUEST 
algorithm [361]. The idea behind SEQUEST is rather simple. First, a database with protein 
sequences is provided to the algorithm. This database clearly depends on the sample: when 
the sample is e.g. a human cell culture, one uses the human proteome from the UniProt 
Knowledgebase, whereas for an Arabidopsis sample, the TAIR database is often used [362]. 
All proteins in the database are then in silico digested according to the cleavage rules of the 
protease used. For trypsin, all protein sequences are thus split at lysine (K) or arginine (R) 
residues. Next, only those peptides are selected from the database which lie within a narrow 
mass tolerance range around the observed mass value of the MS peak. Then, all possible b- 
and y-ions are calculated for each of these peptides and a score is calculated. This score 
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increases for each theoretical b- or y-ion that, again within a certain mass tolerance, can be 
matched to an observed MS² peak. Similarly, the score decreases for each theoretical peak 
that cannot be matched to an observed peak and for any observed peak that cannot be 
matched to a theoretical one. All theoretical peptide candidates are then ranked according to 
their scores and the highest-ranking peptide is assumed to be the correct one if it scores 
significantly higher than the second-highest ranking peptide. This coupling of a peptide ion 
species to a certain MS² spectrum (and hence the corresponding MS peak) is termed a 
peptide-to-spectrum match (PSM) [363]. The simple idea of calculating a score based on 
theoretical spectra from in silico digested proteins still remains the basis of all other database 
search algorithms today. 
In reality, the SEQUEST algorithm is more complicated than described above as it also takes 
neutral losses such as water, ammonia and carbon dioxide into account. In its earliest version, 
modifications could only be considered if they were assumed to be present at every occurrence 
of the modification site. This was achieved by simply shifting the masses of the in silico 
peptides. Later on, variable modifications were also introduced. This means that the algorithm 
searches both for the presence and the absence of certain modifications on certain amino 
acids in certain peptides. Phosphorylation of serine, threonine and tyrosine residues is an 
example of a variable modification that is often included in a search. One problem with 
searching for variable modifications is that they massively inflate the computational search 
space, especially if peptides are allowed to carry multiple modifications at multiple amino acids. 
For example, a variable search for phosphorylation alone may lead to a 67-fold increase in the 
search space [364]. Such inflations do not only drastically increase computational search 
times, but also increase the uncertainty on PSMs that map to unmodified peptides because of 
the increased probability that an in silico spectrum of an unrelated modified peptide matches 
against the spectrum of an unmodified peptide. Researchers are therefore often advised to not 
search for more than two or three variable modifications. Nonetheless, search space inflation 
can be largely fended off with some clever optimizations because the masses of modifications 
rarely coincide with amino acid masses, a property that can be exploited in high-resolution MS 
data [365]. Other optimizations include performing a two-pass search in which the second 
search only probes for modifications of peptides for which an unmodified counterpart was 
already identified in the first search [366]. Alternatively, one could limit the search to those 
modifications and modification sites that have previously been confirmed and are stored in a 
curated database [364]. Interestingly, it has been shown that unaccounted modifications are 
responsible for about 20–50% of all false positive identifications [367]. Therefore, open 
modification search engines have been developed that allow users to search for mass 
differences [365]. That way, much more modifications and even peptides that differ by a single 
amino acid from the canonical sequence in the database can be detected. 
The Mascot search engine was the first to introduce probability-based scoring, whereby the 
probability of an identification was weighted against the probability that a match between the 
theoretical and the observed spectrum occurred by random chance [368]. This was later on 
improved by incorporating the concept of target-decoy matching [369, 370]. In target-decoy 
matching, a set of nonsensical peptides (decoys) of the same size as the theoretical database 
peptide set (targets) is added to the search space. This nonsensical set can be obtained in 
multiple ways, e.g. by random scrambling of the original protein sequences, but is mostly 
obtained by simply reversing the protein sequences followed by in silico digestion. In case of 
palindromic sequences, forward and reverse sequences would overlap, but palindromes are 
extremely rare in practice because the protease’s specificity typically requires peptides to end 
in very few specific amino acids (e.g. arginine (R) or lysine (K) in the case of trypsin). Therefore, 
a palindromic sequence should already display a missed cleavage after the first amino acid, 
which is rather uncommon. Next, the observed peaks are matched against the combined 
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database as described before. Then, an identification false discovery rate (FDR) threshold is 
calculated for each target-PSM. This FDR is simply calculated by dividing the number of 
equally- or higher-scoring decoy-PSMs by the number of equally- or higher-scoring target-
PSMs. Finally, an FDR threshold is set (typically at 1%, rarely at 5%) and all PSMs under this 
threshold are passed on to the quantification stage, while the PSMs that exceed the threshold 
are removed from the data as these are deemed not certain enough. Note that for two-pass 
searches, this FDR calculation is way too liberal because the enrichment of targets in the first 
pass makes it more likely for the spectra to match to targets in the second pass. This 
constitutes a violation of the assumption that false matches should be equally likely to match 
a target or a decoy. Therefore, two-pass searches require an adjusted target-decoy database 
[371]. 
Nowadays, there are many different algorithms that enable peptide identifications from MS² 
spectra. These include Tide, a fast implementation of the SEQUEST algorithm [372],  
X!Tandem [373], MS-GF+ [374], MS Amanda [375], MyriMatch [376], Comet [377], Andromeda 
[378], OMSSA [379], Novor [380] and DirecTag [381]. A tool like SearchGUI [382], developed 
by the compOmics lab, unites all these algorithms in a graphical user interface. Furthermore, 
tools such as PeptideShaker [383] can be used to combine results of different search engines 
to boost identifications. The MaxQuant software package, which uses the Andromeda search 
engine, is very popular nowadays thanks to its integrated pipeline from identification to 
quantification and its user-friendly graphical user interface [384]. 
3.2. Protein inference 
In a typical shotgun proteomics workflow, the aim is to identify and quantify as many proteins 
as possible, but the data used for this are at the PSM level. Therefore, PSMs should be first 
assigned to one (or more) protein(s). Protein inference is straightforward for peptides that can 
be uniquely mapped to a protein sequence stored in a database. However, this becomes more 
complicated when a peptide can be mapped to several protein sequences [385], which 
frequently occurs for different protein isoforms that result from alternative splicing and for 
proteins that originate from paralogous  genes27. Such peptides are called “shared peptides”, 
“degenerate peptides” or “razor peptides”. 
PeptideProphet was the first algorithm to propose a solution to this problem [386]. Here, protein 
identification probabilities are first calculated under the assumption that all peptide matches 
are independent. Then, peptide identification probabilities are updated based on the protein 
identification probabilities. This updating of peptide and protein identification probabilities is 
then repeated until convergence. Others statistical models have also been proposed in an 
attempt to more reliably assign shared peptides [387, 388]. A conceptually simple way to deal 
with shared peptides is Occam’s razor approach. Here, each shared peptide is simply assigned 
to the protein which already has the highest number of identified unique peptides assigned to 
it. This is the approach currently implemented in MaxQuant [384]. MaxQuant also groups 
proteins that share a large fraction of their peptides in so-called “protein groups”. As the 
abundance of a shared peptide might reflect the combined abundance of multiple proteins, 
shared peptides are almost always removed from the dataset prior to quantification. 
Another issue in protein inference is the occurrence of so-called “one hit wonders”: proteins 
that are identified by a single peptide. It is generally considered unreliable to infer a protein 
                                               
27 Paralogous genes are genes that descend from the same ancestral gene within a species and therefore often 
have a high sequence homology. Their resulting protein products often execute similar functions. 
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based on a single peptide because if this identification is incorrect28, a protein is quantified that 
might not even be present in the sample. Therefore, such proteins are often removed from the 
dataset after using the so-called “two-peptide rule” [385], which however has also been 
criticized. It was indeed shown that it is more likely to find a protein with two mediocre-scoring 
peptides in the decoy database than it is to find a protein with a single high-scoring peptide in 
the decoy database [389, 390]. It was therefore proposed to abandon this two-peptide rule in 
favor of an approach in which the protein identification FDR is the sole criterion to accept a 
protein as being identified. Indeed, although in the past, all PSMs that passed a certain FDR 
threshold were passed on to the quantification stage, it was soon shown that if the PSM FDR 
is controlled at the 1% level, the protein FDR is much higher and should therefore also be 
taken into account [391, 392]. This is because the chance that a false positive PSM maps to a 
protein in the database is in theory random and therefore only dependent on that protein’s 
number of theoretical (tryptic) peptides. However, a protein that is truly present in a sample will 
typically generate multiple PSMs that will correctly map to that protein. Therefore, a fraction of 
the proteins in the dataset (i.e. the true positives) will be enriched in true positive PSMs, while 
a relatively large fraction of false positive proteins will have very little PSMs assigned to them 
[393]. 
Many different methods have been developed to estimate protein identification FDRs [386, 
394-396]. However, when calculating a protein FDR, it is important to clearly define how this 
value is to be interpreted. As noted by The et al. (2016), a distinction should be made between 
defining a false discovery as a protein that is inferred from an incorrect PSM versus defining a 
false discovery as the incorrect identification of a protein that is in reality not present in the 
sample [397]. These are not the same, as many proteins might be present in the sample that 
are not assigned any correct PSM but can be assigned to one or more incorrect PSMs by 
random chance. These authors noted that protein FDRs can strongly differ depending on the 
definition.  
The protein inference problem is reviewed more in depth in Huang et al. (2012) [398] and 
Serang and Noble (2012) [399]. 
3.3. Peptide quantification 
A first step in the quantification procedure is the determination of the abundance of all identified 
peptides. This can be done in two ways. The first way, summing up MS² intensities, is now 
largely deprecated for label-free DDA data. The second and by far the most common way is 
by using the MS intensities. 
The reason why label-free approaches in which MS² fragment ion intensities are summed to 
determine a peptide ion’s intensity perform worse than MS peak-based methods in terms of 
reproducibility, missing data, quantitative dynamic range and quantitative accuracy [307] is 
because MS² intensities are highly data-dependent. Due to dynamic exclusion, a particular 
peptide ion can be targeted for fragmentation when it is relatively far from its elution apex. This 
makes summed-up MS² intensities much more variable from run to run and hence less suited 
for reliable quantification. 
When quantifying peptides based on MS intensities, it is important to realize that peptides elute 
continuously from the RP-HPLC column, while MS spectra are recorded at discrete time points. 
Indeed, if an MS spectrum is recorded every second and peptide elution typically ranges from 
5-25 seconds [325, 326], most peptide ion peaks will be recorded in multiple, sequential MS 
                                               
28 At a 1% PSM identification FDR, on average 1% of all PSMs is expected to be wrong, but for each specific PSM, 
this probability might be significantly higher or lower. 
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spectra (see also 2.2.2). Here, every peptide ion is recorded in each MS spectrum as an 
isotopic envelope due to the natural isotopic occurrence. A simple way to determine an 
identified peptide ion’s intensity would be to sum the intensities of the isotopic envelopes in 
each MS spectrum and select the MS spectrum in which this summed intensity is the highest 
(i.e. near the peptide’s elution peak). However, this results in rather imprecise quantifications 
because for one peptide ion, an MS spectrum might be recorded very close to its elution peak, 
while for another ion, the MS spectrum with the ion’s highest intensity peak might be recorded 
up to 0.5 seconds29 before or after its elution peak. As shown in Fig. 3.2, the elution profile of 
a peptide can be fairly easily reconstructed based on the sampled MS intensities of this 
peptide. Indeed, by fitting a curve to these summed intensities over time, a peptide’s elution 
profile can be reconstructed, which results in a much more reproducible quantification [400, 
401]. 
 
Figure 3.2. Theoretical example demonstrating the challenges in MS1 and MS² peptide quantification. 
A. Illustration of the elution profile of three peptides (blue, red and green). Arrows denote the discrete 
time points at which an MS spectrum is taken. Crosses on the elution profile indicate when that specific 
peptide is selected for fragmentation, which results in an MS² spectrum. MS spectra at time points a, b 
and c are shown in B; MS² spectra are shown in C. Due to its high abundance, the blue peptide was 
selected for fragmentation early in its elution profile (MS² spectrum d: dark blue). Because of dynamic 
exclusion, this peptide was not re-selected for fragmentation again until far beyond its elution peak (MS² 
spectrum f: light blue). Reprinted with permission from Krey et al. (2014) [402], © 2014 American 
Chemical Society. 
Some methods are even more sophisticated in trying to increase the quantitative accuracy. 
For example, the Andromeda search engine, incorporated in MaxQuant, integrates the peak 
intensities of each ion’s isotopic envelope during peptide elution. More specifically, Andromeda 
fits a Gaussian peak to the three most central data points in each isotopic envelope. These 2D 
peaks are then smoothed to 3D peaks in the retention time dimension and the total intensity 
for a particular ion is then set equal to the volume of its corresponding 3D peak [384]. Fig. 3.3 
gives a 3D visualization of the increase in intensities in the isotopic envelope at the start of the 
elution of a peptide ion. 
                                               
29 This is, given that an MS spectrum is recorded every second, a typical user-defined setting. 
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Figure 3.3. 3D view of the isotopic peaks during the elution of the doubly charged peptide ion 
CCSDVFNQVVK in sequential MS spectra in the MaxQuant Viewer tab. Image adapted from Tyanova 
et al. (2015) [403]. Proteomics. Published by Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim, CC BY-
NC-ND 4.0. 
A disadvantage of Andromeda’s algorithm is that it is computationally intensive. Moreover, until 
very recently, MaxQuant was only available on Windows, which impeded its inclusion in 
automated Linux server pipelines [404]. These were the main motivations for the development 
of moFF, a platform-independent quantification algorithm that only quantifies the apex of the 
elution profile, making it fast, but without compromising on quality [405, 406]. Do note that 
many other algorithms have been developed to calculate peptide ion intensities, some of which 
are reviewed in Sandin et al. (2014) [407]. 
3.4. The nature of the data 
The previously described workflow results in specific data properties that are typical for MS-
based proteomics and that are important to bear in mind when evaluating protein levels.  
In bottom-up proteomics, PSMs do not correspond to peptides, but to peptide ions, whereby 
multiple peptide ions can map to the same peptide sequence. Indeed, the same peptide can 
often be identified under different charge states and/or with different modifications. Sometimes, 
a given modification can be detected at more than one location within the same peptide. As 
the (unmodified) backbone amino acid sequences of such PSMs are identical, these ion 
species are expected to behave more alike compared to unrelated ion species. Therefore, the 
intensities of these species are correlated with each other. Similarly, ion species of the same 
charge states will also be correlated. On a higher level, there is correlation between all peptides 
that are mapped to the same protein. The highest level in the hierarchy is the correlation 
between proteins. Indeed, since proteins interact with each other in numerous pathways, 
proteins that closely interact with each other, that are part of the same signaling pathway or 
even reside in the same subcellular location tend to behave more similarly than totally 
unrelated proteins. Orthogonal to the correlations between peptides and proteins, there is a 
strong within-run correlation due to the relatively large run-to-run variability in label-free 
proteomics. To keep this run-to-run variability minimal, it is necessary to tightly control the 
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instrumentation. This makes raw label-free proteomics data hierarchical with correlations on 
many levels in the data. Moreover, it is possible that for the same protein in the same MS run, 
e.g. two peptides are observed with only one PSM, three peptides with two PSMs and one 
peptide with three PSMs. 
Even for peptides originating from the same protein, differences in intensities are often 
substantial. One reason for this is that differences in proteolytic cleavage efficiency cause 
some peptides to be generated more efficiently than others, rendering individual peptide levels 
not equal to protein levels. Moreover, intensities of different peptide ions also strongly differ 
because of large differences in ionization efficiency. Finally, the latter is context-dependent as 
the nature and the amount of co-eluting peptides also drive the efficiency by which a peptide 
is ionized (see chapter 8). Such ionization competition can be a more important driver of a 
peptide’s intensity than its actual abundance [408]. As noted in section 3.2, the intensities of 
shared peptide sequences arise from an unknown combination of peptide ions coming from 
different proteins. Therefore, shared peptides are often removed from the dataset prior to 
quantification. 
While the raw data is at the PSM-level, quantification is typically done at the protein level. PSM-
level data thus needs to be summarized to the protein level. It is possible to summarize the 
PSMs directly to the protein level. However, this might be suboptimal because of the 
hierarchical nature of the data and the missing values that make the data unbalanced. Indeed, 
if the PSMs would be summarized as if they were independent observations, a bias will be 
introduced because some peptides will be “overrepresented” in the protein’s abundance 
estimate, while other peptides will be “underrepresented”. Therefore, summarization is 
sometimes done in two steps: in a first step, the data are summarized to the peptide level (i.e. 
each peptide sequence is the summary of all its potential charge states and peptideforms). 
MaxQuant, for example, outputs peptide-level summaries as summed raw PSM intensities. In 
a second step, the peptide-level data are summarized to the protein level (discussed in detail 
in 4.1.5). Contrary to protein summarization based on peptide-level values, PSM to peptide 
summarization has not been studied in detail, and commonly-used data analysis pipelines 
such as the MaxLFQ algorithm in MaxQuant [317] and MSstats [409] calculate protein-level 
summaries based on PSM intensities, ignoring possible correlation between PSMs that map 
to the same peptide sequence. From here on, I will assume that all data are summarized to 
the peptide level, unless specifically mentioned otherwise. However, note that all of the 
criticisms regarding peptide-to-protein summarization outlined in 4.1.5 can also be applied to 
PSM to peptide summarization. 
The linear dynamic range of the mass spectrometer also affects the data. Indeed, within a 
certain concentration range, an increase in peptide concentration will result in a multiplication 
of the MS signal with more or less the same factor. This range is termed the linear dynamic 
range. Above this range, the ESI spray ionization and/or the MS detector becomes saturated, 
leading to a plateau in the ion’s MS intensity signal. Below the linear dynamic range, a peptide 
ion will not be observed. Note that the linear dynamic range will be different from peptide to 
peptide due to their different ionization efficiencies. Fig. 3.4 gives a graphical representation 
of the linear dynamic range. 
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Figure 3.4. The concept of linear dynamic range in proteomics. (a) Peptide ion intensities for three 
theoretical proteins: a low abundant, middle abundant and highly abundant protein. For the low abundant 
protein, many of its peptides will fall below the limit of detection (LOD) and will therefore not be identified. 
Its abundance will only be estimated based on the identified peptides and might therefore be over-
estimated. For the middle abundant protein, most of its peptides are observed and the protein’s 
estimated abundance will be close to its true abundance. For the highly abundant protein, some of its 
peptides will be more abundant than the upper limit of quantification (ULOQ), and their ion signals will 
be lowered. Hence, the highly abundant protein’s abundance might be under-estimated. (b) The 
dynamic range in practice. In this experiment, different known amounts of proteins were compared to 
each other. When the differences in concentration become large, the difference between the estimated 
protein abundances and the true protein abundances also increase. Such deviations from linearity are 
substantial for large differences in abundance. Image (a) modified after Jarnuczak et al. (2016) [330], © 
2016 by American Chemical Society (“ACS”), CC BY 4.0 and image (b) adapted from Arsova et al. 
(2012) [410] © 2012 by The American Society for Biochemistry and Molecular Biology, Inc. 
The large amount of missing values in the data is a major issue in label-free DDA shotgun 
proteomics. Upon searching the public repository PRIDE [411] for MaxQuant datasets that 
applied shotgun proteomics to full or partial proteomes, we found 16 to 82% missing values at 
the peptide level (see chapter 10). There are multiple reasons for this missingness. A first 
reason is that a protein might simply not be present in certain samples. A second reason is 
that experimental reasons (e.g. different tissues with different protein abundance profiles are 
compared), biological reasons (e.g. downregulation or degradation of a protein) or technical 
reasons (e.g. inferior quality of a certain run) might cause the MS intensity of a peptide that is 
truly present to fall below the background noise level. For label-free shotgun proteomics, the 
limit of detection was estimated to lie around 1 fmol [412]. A third important reason is in the 
data-dependent nature of the sampling: a peak that was selected in one run, might not be 
selected for fragmentation in a next run. Indeed, the height of the peak mainly dictates if a peak 
is targeted for fragmentation or not [413]. This type of missingness is thus largely intensity-
dependent, although ionization also renders this type of missingness context-dependent. A 
fourth reason for missing values in label-free shotgun proteomics is that on average around 
75% of all MS² spectra is not identified [414]. This happens when an MS² spectrum’s highest-
scoring PSM falls below the pre-set identification FDR threshold or when no distinction can be 
made between two or more high-scoring alternatives. Alternatively, the PSM could pass the 
FDR threshold but might in reality be misidentified. Poorly ionizing peptides are particularly at 
risk for failed or incorrect identifications. Peptides carrying a phosphate-modification, for 
example, ionize notoriously poorly because of the phosphoryl group’s default double negative 
charge state. Moreover, CID fragmentation of peptides with a phosphorylated serine residue 
often results in a dominant neutral loss of phosphoric acid, leaving too little energy for the 
efficient fragmentation of the precursor’s peptide bonds [415]. Furthermore, most peptide 
modifications with a biological or an artefactual origin are often unsearched for due to the 
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strong inflation in computational search space when allowing for too much modifications to 
occur on the peptides. It has been estimated that at least one third of all spectra cannot be 
assigned to a peptide due to the presence of sub-stoichiometric post-translational 
modifications [416]. Another cause for failed MS² identification is co-fragmentation [334]. The 
chimeric MS² spectra that result from co-fragmented peptide ions are either not identified, or 
misidentified, resulting in a missing value, or mapped onto only one of the precursor ions. As 
the corresponding MS peak is a mixture of more than one ion, the abundance of this ion will 
be estimated higher than it actually is. 
All of this stresses the importance of MS² fragmentation. Indeed, all MS peaks that were not 
targeted for fragmentation or for which no peptide could be matched to the MS² spectrum 
remain unidentified. One way to alleviate such cases of missing values is by applying a feature 
alignment or “match-between-runs” algorithm [400, 417, 418]. Here, unidentified MS peaks in 
one MS run are matched, based on their masses, charges and retention times, to identified 
peaks of another run in which a similar sample was analyzed. Important for these algorithms 
is that they should be able to accurately align retention times over different runs and keep their 
retention time windows (i.e. the deviations in retention time to allow a match between two MS 
peaks) narrow enough to prevent incorrect matches. This again stresses the importance of a 
stable analysis workflow and sufficient quality control [419]. A match-between-runs algorithm 
is also frequently applied in MaxQuant searches [420]. 
3.5. The need for benchmarking 
As explained above, peptide intensities are used for differential analysis of protein 
abundances. However, there is an enormous variety in differential protein abundance analysis 
workflows, and each step in these workflows has its impact on the result. Hence, the 
performances of the different workflows might also differ considerably. This difference in 
performance is an important point. Indeed, if suboptimal workflows are used, biologically 
relevant proteins might remain under the radar. Therefore, I will here explain the need for 
benchmarking to allow comparison of the performances of different workflows. 
To evaluate the sensitivities and specificities of different quantitative pipelines, a dataset is 
needed in which the true relative amounts of proteins in all samples (“the ground truth”) are 
known. Such a dataset can either be generated by simulation or by spiking in proteins of a 
certain organism into another organism’s proteome. Simulations have the advantage that they 
are very simple to generate: one only needs a computer. However, simulated datasets often 
do not reliably capture the complex data structures of true biological experiments. In a spike-
in experiment, a set of proteins from one organism is spiked into a complex protein background 
from another organism at different concentrations. Hence, when two different spike-in 
conditions are compared, only the spiked-in proteins are differentially abundant. Generating a 
spike-in dataset requires setting up a wet-lab experiment. Here, it is important to pick two 
organisms that are genetically very distinct to avoid a large number of shared peptides between 
both organisms. 
In what follows, I will use the CPTAC study 6 dataset to demonstrate the effect of each 
preprocessing step. In the 6th study of the National Cancer Institute's Clinical Proteomic Tumor 
Analysis Consortium (CPTAC), a trypsin-digested mix of 48 human proteins (Universal Protein 
Standard 1, UPS1) was spiked in 5 different concentrations into a mix of trypsin-digested 
Saccharomyces cerevisiae proteins. These concentrations were: 0.25 fmol/µL (sample 6A), 
0.74 fmol/µL (sample 6B), 2.2 fmol/µL (sample 6C), 6.7 fmol/µL (sample 6D) and 20 fmol/µL 
(sample 6E). These samples were sent to five different labs and analyzed on six different mass 
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spectrometers30. For convenience, I only used the data from the LTQ-orbitraps at sites 56, 65 
and 86. The study was conceived to provide a benchmark dataset to compare the power of 
different approaches to detect differential abundance and it is the most well-known 
quantification benchmark dataset. Indeed, Paulovich et al. were cited 121 times in Scopus on 
February 7th, 2019. 
This dataset is ideal to demonstrate the statistical concept of blocking. Indeed, a typical 
proteomics experiment is often restricted by spatiotemporal constraints that prevent the 
generation of all samples simultaneously, with the same equipment, etc. Such variation causes 
unwanted technical variability (noise) and makes it harder to detect the effect of interest. 
Blocking is the experimental design choice to assign the experimental units (e.g. MS runs) to 
different “blocks” (e.g. batches, periods in time) in such a way that the treatments that need to 
be compared are present within each block. This enables to estimate the treatment effect within 
each block, in which the noise is lower. Blocking is therefore a way of removing unwanted 
variability and thus increases the power of a statistical analysis. In the CPTAC dataset, we 
retained the data from three different laboratories. Since the between-lab variability is not of 
interest, “lab” can be considered as a blocking factor, which allows to remove the between-lab 
variability from the analysis.  
Note that there are issues with ionization competition in the CPTAC dataset [421]. Due to the 
relatively high spike-in concentrations of the UPS1 mix, ionization of UPS1 peptides will 
partially suppress the intensities of the yeast peptides. This might lead to the false positive 
calling of yeast proteins as DA. We indeed noticed that most quantification methods could not 
control their quantification false discovery rates at the 5% level when large differences in spike-
in concentrations were compared [422]. Fig. 3.5 gives an overview of CPTAC Study 6, which 
was used in all my first-author manuscripts. 
 
Figure 3.5. Overview of the subset of the CPTAC Study 6 that will be used throughout this thesis. 
Digested human UPS1 proteins were spiked in five different concentrations (6A – 6E) into digested 
                                               
30 “Lab 65” analyzed the samples on two different machines 
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yeast (Saccharomyces cerevisiae) proteome. These samples were sent to three different laboratories. 
Each laboratory analyzed the samples in technical triplicates. 
Other, more recent spike-in datasets were published in Ramus et al. (2016) [423] and 
Jarnuczak et al. (2016) [330]. 
There might be some confusion on the usage of the term “sample”. In this section, I denoted 
the different spike-in conditions as “samples”, which were repeatedly analyzed. However, in a 
biological experiment, multiple samples will be taken for each treatment condition of interest 
and each of these samples will be analyzed in one or more technical replicates on the mass 
spectrometer. Because of the ever-increasing sequencing depth, technical replication is often 
omitted in modern experiments, which causes each “sample” to correspond to a single MS run. 
In the literature, indicators referring to “sample” or “MS run” are therefore almost always used 
interchangeably. To avoid confusion, I will use the terms “condition” or “treatment” to refer to 
the spike-in conditions from now on. 
  
49 
4. DIFFERENTIAL PROTEIN ABUNDANCE ANALYSIS 
Once peptides are identified, linked to a protein and assigned an intensity value, the data can 
be used for the analysis of differential protein abundance. In this chapter, I will go deeper into 
the different steps in a typical differential protein abundance analysis workflow. I will start with 
data preprocessing, followed by a demonstration of the most important methods to use the 
preprocessed data for differential protein abundance analysis. 
4.1. Preprocessing 
Because of the nature of the peptide-level data described in section 3.4, preprocessing is 
required before proteins can be quantified. There is a plethora of preprocessing workflows and 
many of these are often constructed ad hoc. Nonetheless, in most workflows, the data typically 
undergo some kind of (log-)transformation, filtering, normalization, imputation and 
summarization. Note that the order in which each of these preprocessing steps are executed 
impacts on the final results. Transformation, in principle can be executed at any stage in the 
preprocessing workflow, but typically occurs early because it makes the data easier to handle. 
Similarly, filtering is done early in the workflow to remove those observations that are deemed 
unreliable and/or unwanted for various reasons. Furthermore, Karpievitch et al. (2012) showed 
that normalization followed by imputation generally outperforms imputation followed by 
normalization [424]. The rationale behind this is that imputing missing values obscures 
possible bias trends and therefore renders normalization less efficient. Moreover, imputing 
missing values does not make sense when unaccounted systematic bias is still present in the 
data. Finally, data summarization is best done after imputation as it is much more difficult to 
summarize data that contains missing values [425]. Nonetheless, some workflows, such as 
the default MaxQuant-Perseus workflow impute the data only after summarization (see 4.1.4). 
In this section, I discuss each of the preprocessing steps in more detail. 
4.1.1. Transformation 
The distributional properties of raw intensity measurements are often unfavorable for direct 
statistical modeling. Therefore, nearly every quantitative proteomics workflow involves a 
transformation of the raw intensity values. Log-transformation is a logical choice because raw 
intensity and concentration measurements are often more or less log-normally distributed: their 
values are always positive, they are skewed to the right and their variances increase with the 
mean. The strong right-skewness of the raw intensities is shown in Fig. 4.1: there are many 
relatively low intensities and only a few very high intensities. After log-transformation, the 
distributions become much more symmetrical. 
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Figure 4.1. Impact of log2 transformation on the raw peptide intensities in the CPTAC dataset [426]. 
Left: the densities of the raw peptide intensities are strongly skewed to the right. Right: the densities of 
the log2-transformed peptide intensities are much more symmetrical. The densities are colored 
according to lab: red corresponds to the orbitrap at site 56, yellow to the orbitrap at site 65 and blue to 
the orbitrap at site 86. 
Moreover, the variance structure of the raw intensities is often multiplicative: the variability in 
the data tends to be higher for higher intensities than for lower intensities (Fig. 4.2). Log-
transformation will stabilize the variances by transforming a multiplicative error structure into 
an additive error structure [263]. In an additive error structure, the variability in the data is 
independent of the mean. The statistical property of equal variances is called homoscedasticity 
(as opposed to heteroscedasticity: unequal variances). The assumption of homoscedasticity 
opens the way to use the standard toolbox for statistical inference, such as linear regression. 
Such classic inference methods often provide closed-form solutions for their estimators, which 
makes the estimation procedures much simpler and faster. In practice, there sometimes 
remains a mildly positive mean-variance correlation in the log2-transformed intensities. 
 
Figure 4.2. Raw intensities (left) and log2-transformed intensities (left) of peptide NVNPVALPR, which 
is part of the human UPS1 protein P08311 (cathepsin G) in the CPTAC dataset [426]. The variability in 
the peptide’s raw intensities increases with higher spike-in concentrations but remains constant for the 
log2-transformed intensities. 
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A final argument in favor of the log-transformation is that by modeling PSM intensities at the 
log-scale, one models proportional differences at the biological scale, which is also more 
relevant from a biological point of view. Most researchers choose a log-transformation with a 
base of 2. A one-unit increase in log2-abundance will then be equivalent with a factor 2 increase 
in protein abundance. 
4.1.2. Filtering 
The data are filtered prior to differential analysis to remove peptides and proteins that are a 
priori uninformative from a biological or statistical perspective. Removing uninformative 
peptides increases the power to detect differential abundance in their corresponding proteins. 
Removing uninformative proteins reduces the number of proteins that needs to be tested for 
differential abundance. This will result in a less severe multiple testing correction and thus in a 
higher statistical power [427]. 
Examples of peptides or proteins that are typically filtered out include:  
- decoy peptides  
- typical contaminants such as keratin, which originate from the operator’s skin amongst 
others 
- other highly abundant and possibly less informative proteins (e.g. RuBisCo in plant 
samples) 
- shared peptides, being peptides that map to more than one protein. Sometimes, these 
shared peptides are assigned to a protein (group) with the most unique peptides, but 
this practice should be discouraged because a shared peptide’s intensity could very 
well represent the combined intensity of multiple proteins. 
- proteins or peptides identified in only a few samples 
- proteins identified with only one or a few unique peptides (e.g. the two-peptide rule) 
- proteins for which no peptides without a modification site are identified. The rationale 
here is that the identification FDR is more difficult to calculate for a peptide carrying a 
modified site or amino acid mutation. Some search engines, such as MaxQuant, are 
less certain about the identification of a peptide with a modification and prefer to filter 
out proteins that are identified with only modified peptides, rather than doing inference 
on a protein of which they are less certain that it is really present in the data. 
- peptides with very variable retention times over different runs, as this might be an 
indication for misidentification [428]. 
According to the vignette of the R package genefilter [429], a good filtering criterion should 
adhere to three criteria: 
1. It should be statistically independent from the test statistic under the null hypothesis 
(i.e. the protein is not differentially abundant). 
2. It is correlated with the test statistic under the alternative hypothesis (i.e. the protein is 
differentially abundant). 
3. Filtering based on the criterion does not notably change the dependence structure (if it 
exists) of the joint test statistics. 
The second property provides a benefit for filtering as it enriches for differentially abundant 
proteins after filtering. The first and the third criterion are necessary to keep control over the 
false discovery rate of the subsequent analysis at the pre-specified level (see 4.2.5). Indeed, 
as long as these criteria are fulfilled, filtering will not result in a biased analysis. The 
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aforementioned filtering procedures all fulfill the first criterion31. However, filtering on a criterion 
such as fold change estimates would induce a biased downstream quantification, as the fold 
change is an integral part of almost every test statistic and hence strongly correlates with it, 
also under the null hypothesis. The effect of filtering on different quantification methods has 
been studied in Belouah et al. (2019) [430]. 
4.1.3. Normalization 
Even in a very clean, synthetic dataset as CPTAC, where there is no biological variability and 
only the spiked 48 UPS1 proteins are differentially abundant, the marginal peptide distributions 
are quite distinct. Considering all proteins in the dataset, there are considerable effects 
between samples with different spike-in concentrations, even within the same lab (Fig. 4.3, 
left). Moreover, for replicate measurements of the same samples, there is considerable lab-to-
lab variability, and even the within-lab variability is non-negligible (Fig. 4.3, right). 
 
Figure 4.3. Left: density plot of the log2 peptide intensities for the orbitrap at site 65 in the CPTAC 
dataset [426]. The densities are colored according to spike-in condition (black: spike-in condition 6A, 
dark red: spike-in condition 6B and green: spike-in condition 6C). Right: density plot of the log2 peptide 
intensities for spike-in condition 6A. The densities are colored according to lab (red: orbitrap at site 56, 
yellow: orbitrap at site 65 and blue: orbitrap at site 86). 
Normalization aims to remove, or at least dampen, this potentially large, unwanted variability.  
Center mean and center median normalization subtract the respective means or medians from 
each distribution (Fig. 4.4). These simple normalization approaches aim to remove non-
biological variability by centering the peptide intensity distributions and do not impact on their 
shapes [431]. However, it is clear from Fig. 4.4 that the shapes of the distributions are also 
affected by technical variability. Hence, more advanced normalization procedures are needed. 
A method that has proven to work well for microarray data is quantile normalization [432, 433]. 
Quantile normalization will impose the same density distribution upon each MS-run. Here, the 
peptide intensities are sorted from low to high. The lowest peptide intensity for each run is then 
set equal to the mean of the lowest peptide intensities over these runs. Similarly, the second-
lowest peptide intensity in each run will be equal to the mean of the second-lowest peptide 
                                               
31 In practice, criterion 3 is rarely problematic, as most filtering procedures do not noticeably change the correlation 
structure of the tests [429]. 
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intensities in each run, and so on. Missing values are handled based on the assumption that 
the data are missing at random. 
Linear regression is a versatile statistical framework that can also be used to normalize the 
data (more about linear regression in section 4.2) [424, 434, 435]. VSN normalization is an 
example of a regression-based normalization approach that simultaneously executes 
transformation and normalization [436]. In brief, VSN normalization assumes that the different 
raw intensities from the different MS runs can be brought onto the same scale through linear 
mappings. VSN normalization assumes that the variance of the raw intensities 𝜐𝑝 depends on 
the mean 𝜇𝑝 as follows: 
𝜐𝑝 = 𝜐(𝜇𝑝) = (𝑐1𝜇𝑝 + 𝑐2)
2 + 𝑐3,                                                                                                            (Eq. 4.1) 
with 𝑐3 > 0. Based on these assumptions, a transformation ℎ is proposed such that the 
variance is approximately independent of the mean. Then, the following statistical model is 
proposed: 
ℎ𝑟(𝑌𝑝𝑟) = 𝜇𝑝 + 𝜀𝑝𝑟,                                                                                                                                    (Eq. 4.2) 
for all 𝑝 ∈ 𝑝null. Here, 𝑌𝑝𝑟 is the raw intensity for peptide 𝑝 in MS run 𝑟, and 𝑝null is the set of 
non-differentially abundant peptides. The parameters of the model are estimated with a least 
trimmed sum of squares regression under the assumptions that E[𝜀𝑝𝑟] = 0 and that the 
variance of the error term is constant: Var[𝜀𝑝𝑟] = 𝜎2. A more detailed explanation of the VSN 
algorithm can be found in Huber et al. (2002) [436]. Both older and more recent publications 
that compared the performance of different normalization methods seem to indicate that linear 
regression-based methods, such as VSN, generally outperform other normalization methods 
[435, 437, 438], although the relative performance of different normalization methods is also 
strongly dataset-dependent [439]. 
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Figure 4.4. Overview of the effects of different types of normalization on the peptide intensity 
distributions in the CPTAC dataset [426]. 
The MaxLFQ summarization algorithm described in 4.1.5 combines summarization with 
normalization, although MaxLFQ summaries are sometimes still normalized afterwards. 
An important assumption of all these normalization approaches is that the abundance of the 
large majority of the peptides remains unchanged over the different treatments. This 
assumption is often reasonable because researchers are mostly interested in biological 
perturbations that affect very specific pathways in the cell, thus affecting a minority of proteins. 
Moreover, most normalization methods can tolerate quite large fractions of differentially 
abundant peptides, as long as there is a more or less equal number of up- and downregulated 
peptides. This premise is also quite reasonable since the total amounts of peptides (in µg) 
analyzed in each run are as equal as possible. 
The assumption of no major changes in the bulk of the proteome is however problematic for 
specific studies. For example, in AP-MS studies, proteins are purified that specifically interact 
with a protein of interest (bait). The control group contains only “background proteins”, i.e. 
proteins that non-specifically interact with the bait. Therefore, a large fraction of the identified 
proteins is more abundant in the samples with the bait, while the background proteins are, in 
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theory, equally abundant between control and bait samples. In such kinds of experiments, 
normalization should be performed with extreme caution [407]. 
Note that even though normalization intends to remove the overall run-to-run variability, 
considerable block effects can persist at the level of the individual peptides. Fig. 4.5 shows a 
multidimensional scaling (MDS) plot after quantile normalization for the CPTAC dataset. Even 
with a radical normalization method like quantile normalization, which literally forces the log2-
transformed intensity distributions to be equal in each MS run, the runs clearly cluster together 
per lab. This demonstrates that it will be necessary to also correct for blocking effects further 
down the analysis pipeline. 
 
Figure 4.5. Multidimensional Scaling (MDS) plot after quantile normalization for the CPTAC dataset 
[426]. The MDS plot shows each MS run in such a way that the distance between each pair of runs is 
equal to the root-mean-square deviation for the top 500 peptides that are the most distinct between the 
pairs of runs. 
4.1.4. Imputation 
To demonstrate the important aspects of missingness, we investigated the amount of missing 
values at the peptide level in 73 recent label-free shotgun proteomics datasets. We showed 
that on average 44% of all values at the peptide level are missing (see chapter 10). To cope 
with such large amounts of missing values, they are often replaced with substitute values in a 
process called imputation. 
Classically, three types of missingness can be defined: missingness completely at random 
(MCAR), missingness at random (MAR) and missingness not at random (MNAR) [440]. MCAR 
assumes that the missing values cannot be explained by the nature of their underlying true 
values, nor by any known covariate: every value in the data matrix has an equal probability of 
being missing. MAR is a type of missingness whereby the probability of an observation to be 
missing is dependent on one or more observed covariates, but independent of the nature of 
the underlying values themselves. MNAR are all cases where the missingness is dependent 
on the underlying values (and optionally also on one or more known covariates): some values 
(e.g. very low values, very high values) have a higher probability of being missing than others. 
Missingness in label-free shotgun proteomics datasets is a combination of missingness 
completely at random (MCAR) (e.g. an enzymatic modification in one experimental condition 
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might cause a peptide to be unidentified if that modification was not accounted for during the 
search), missingness at random (MAR) (e.g. certain peptide sequences ionize more easily 
than others; therefore, missingness is much more likely for poorly-ionizing peptides) and 
missingness not at random (MNAR) (e.g. more abundant peptides simply have a higher chance 
of getting fragmented and thus being identified).  Note that this MNAR is exacerbated as the 
probability for a peptide to be identified is also context-dependent: when co-eluting with many 
other highly abundant peptides, a peptide will have a smaller chance of getting identified than 
if these other peptides would be absent or lower in abundance.  
When choosing an imputation strategy, it is important to keep in mind the assumptions of that 
imputation strategy as most imputation strategies make use of either a MCAR or a MNAR 
assumption, but not both. 
k-nearest neighbors (kNN) imputation is an example of an MCAR imputation strategy. In kNN, 
a Euclidean distance metric is calculated on all peptide intensities. Based on this distance 
matrix, the k most similar peptides (neighbors) are identified for each peptide that has at least 
one missing value. All missing values for that peptide are then imputed with the average of the 
corresponding (non-missing) values from the k neighbors [441, 442]. 
Quantile Regression Imputation of Left Censored data (QRILC) imputation is an example of 
an MNAR-based imputation strategy [443]. In QRILC, missing values are imputed with random 
draws from a truncated distribution with parameters that are estimated using quantile 
regression. QRILC has been implemented in the MSnbase R/Bioconductor package for 
manipulation, processing and visualization of proteomics data [444]. 
The popular proteomics computational platform Perseus also makes use of an MNAR-based 
imputation strategy. In Perseus, imputation is achieved by imputing the data with random 
draws from a rescaled, down-shifted normal distribution [445]. The characteristics of this 
distribution are calculated based on the data. More specifically, its mean is equal to the 
average of all the observed data minus d times the standard deviation of the observed data.  
Its standard deviation is equal to w times the standard deviation of the observed data. The 
default values for w and d are 0.3 and 1.8, respectively. 
The current version of the popular Bioconductor package MSstats (version 3.12.2) [446] uses 
a more advanced, model-based approach to impute missing values under a MNAR 
assumption. Their accelerated failure time (AFT) model (see 4.2.3) does not incorporate a 
random missingness component as the authors argue that due to the improved technology, 
the proportion of random missing values has become negligible.  
Choosing for no imputation, MCAR-based imputation or MNAR imputation can have a big 
impact on the downstream analysis. For example, the MCAR-based kNN is more suited when 
the majority of the missing values is not intensity-dependent [447]. Contrary, MNAR-based 
methods like QRILC, Perseus and AFT model imputation, perform better in a context with 
relatively more intensity-dependent missing values. These MNAR-based methods might 
however perform poorly in detecting special cases, e.g. where a long isoform of a certain 
protein is absent, but a smaller isoform is strongly upregulated (Fig. 4.6). In such cases, 
imputation with low-intensity values might dilute the signal and obscure the classification of the 




Figure 4.6. Imputation with low-intensity values can dilute signals present in the data. In this theoretical 
example, a protein consisting of 6 tryptic peptides is present in the left condition, while only a short 
isoform of the same protein giving rise to tryptic peptides 1 and 2 is 4 times more abundant in the right 
condition. When assessing peptides 1 and 2, the protein log2 fold change is equal to 2. However, 
imputing the missing values (“not assigned”, NA) with either MCAR or MNAR methods will dilute this 
signal. 
Indeed, although imputing missing peptide values was suggested in the proteomics literature, 
imputation should always be used with caution. When nothing is known about the nature of the 
missing values, it has been suggested to use MCAR imputation approaches based on local 
similarity, as these perform well on average [424]. It has to be noted however, that the 
performance of an imputation approach is highly dataset-dependent [422, 447-449]. In reality, 
missing values are often caused by an unknown mix of intensity-dependent and -independent 
mechanisms, which is strongly dataset-specific [424, 447] and choosing the wrong imputation 
method for the dataset at hand can result in a severe backlash in performance [422]. 
Some imputation methods try to combine MCAR and MNAR imputation. For example, one of 
the imputation strategies in the DEP Bioconductor package by Smits and Huber suggests an 
imputation method whereby proteins for which the values are completely missing in one or 
more experimental conditions are imputed with a MNAR method, while the other missing 
values are imputed with a MCAR method [450]. However, this distinction is rather arbitrary, 
since for some proteins, all values in an experimental condition might also be missing due to 
random chance. Conversely, some missing values for proteins which are detected in all 
experimental conditions might still be due to low intensities. 
A final issue with imputation is that, even if the true mechanism of missingness would be 
known, the uncertainty caused by replacing a missing value by a fixed value from a certain 
distribution is essentially ignored. A correct data analysis strategy should take this uncertainty 
into account. This problem might be solved by using a multiple imputation strategy [451, 452] 
in which the dataset is imputed multiple times and each of these imputed datasets is 
subsequently analyzed. The variability in the outcomes gives a good idea of the impact of the 
imputation on the analysis. Unfortunately, multiple imputation has not yet been widely adopted 
in the field. Note that it is also possible to model mechanisms of missingness explicitly (see 
section 4.2.3) [440]. 
4.1.5. Summarization 
As noted in section 3.4, differential analysis mostly takes place at the protein level, but the data 
are at the peptide level. Therefore, most workflows involve some kind of summarization. In this 
section, I will focus on peptide- to protein-level summarization to show the effects of different 
summarization techniques. A simple way to summarize is by summing up all raw peptide 
intensities that correspond to each protein in each MS run [453]. Alternatively, mean 
summarization involves taking the mean of the peptide intensities to obtain a protein-level 
summary. Median summarization is also very common as a median is insensitive to outlying 
peptide intensities [384]. For the same reason, weighted means [454, 455] or medians [456], 
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whereby the outlying peptides are given less weight, or trimmed means [299] have also been 
proposed. 
Although these techniques are very simple to apply, one needs to consider a few things. The 
first one is the intensity-dependent missingness. Indeed, in samples with a high concentration 
of a particular protein, more of its poorly ionizing peptides are expected to be found compared 
to samples with a lower concentration of that protein. However, such poorly ionizing peptides 
reduce the protein concentration estimates in the samples where the protein is highly 
abundant. Therefore, a naive mean or median summary that does not correct for peptide 
ionization efficiency produces fold change estimates that are biased towards 0. This fold 
change bias is demonstrated in Fig. 4.7. 
 
Figure 4.7. Effect of intensity-dependent missingness on mean and median summarization. The figure 
shows the log2-transformed intensities for all identified peptide sequences of a UPS1 protein in the 
CPTAC dataset [426] in the low spike-in condition 6A (black) and the higher spike-in condition 6C (green 
and blue). Symbols denote different labs (plus: site 56, triangle: site 65, circle: site 86). All peptides 
identified in condition 6A were also identified in condition 6C. Blue are the peptides which are exclusively 
identified in condition 6C. Full lines denote the mean summaries, dashed lines the median summaries. 
The black lines are the summaries for condition 6A, the blue lines the summaries for condition 6C. The 
green lines are the summaries for condition 6C when the peptides exclusively identified in condition 6C 
(blue) are omitted. Omitting those peptides increases both the mean and median summaries for 
condition 6C. 
To avoid this issue, it is of course possible to base the protein summaries only on the 
overlapping peptides. However, when many different conditions are compared, the number of 
peptides that is identified in every condition tends to be very low, which makes it impossible to 
obtain such a protein-level summary for many proteins in the dataset. 
MaxLFQ, the algorithm that is used to summarize proteins in MaxQuant, addresses this issue 
by making use of only those PSMs that overlap between each pair-wise MS run comparison. 
[317]. A schematic overview of the MaxLFQ algorithm is given in Fig. 4.8. 
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Figure 4.8. (A) Example of a protein of which five peptide sequences (indicated in magenta) are 
detected. (B) These five peptides were identified as seven different PSMs (“peptide species”). (C) 
Occurrence of each of the seven PSMs in 6 exemplary samples A – F, each of which was run once on 
the mass spectrometer. (D) Matrix with the pairwise protein ratios. Protein ratios are calculated by taking 
the median of all valid normalized pair-wise PSM ratios. Valid protein ratios are ratios for which two or 
more PSMs are in common between both runs (green). Protein ratios for which less than two PSMs are 
in common are considered invalid (red). (E) System of equations that needs to be solved to obtain the 
MaxLFQ protein intensities per run. MaxLFQ intensities for runs for which no valid protein ratios exist 
(e.g. run F) will be set to zero (i.e. a missing value on the log-scale). (F) Run-wise MaxLFQ protein 
intensities for the given protein. MaxLFQ intensities are calculated by solving the equations in (E) 
through least squares and rescaling the result to maintain the total summed intensity over all runs. Image 
adapted from Cox et al. (2014) [317], © 2014 by The American Society for Biochemistry and Molecular 
Biology, Inc., CC BY 4.0. 
The rationale behind MaxLFQ is the following: 
The intensity for each PSM is calculated as the area under the isotopic envelope at the 
maximum intensity over the retention time profile multiplied by a run-wise normalization factor. 
These normalization factors are calculated by least-squares minimization of the overall pair-
wise log fold changes for all PSMs between all runs. As with most normalization methods, the 
assumption is made that the large majority of the proteome is not differentially abundant. 
Then, the common PSM intensities between each run pair 𝑞 and 𝑟 are used to calculate PSM 
ratios. The pair-wise protein ratio 𝜚𝑞𝑟 between runs 𝑞 and 𝑟 is then equal to the median of all 
pair-wise PSM ratios between runs 𝑞 and 𝑟. 
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Based on all pair-wise protein ratios, it is then possible to calculate log-transformed protein-
level intensities 𝑦𝑞 for each run 𝑞. This is done by performing the following protein-wise least-
squares analyses for each “valid” pair of runs 𝑞 and 𝑟: 
log 𝜚𝑞𝑟 = 𝑦𝑟 − 𝑦𝑞 + 𝜀𝑞𝑟                                                                                                                              (Eq. 4.3) 
Herein, 𝜚𝑞𝑟 is the pair-wise protein ratio between runs 𝑞 and 𝑟, 𝑦𝑞 the log-transformed protein 
intensity in run 𝑞 and 𝑦𝑟 the log-transformed protein intensity in run 𝑟.  𝜀𝑞𝑟 is a random error 
term. Pairs are considered valid if they have at least two PSMs in common. Finally, the whole 
profile of the estimated run intensities ?̂?𝑞 is rescaled to maintain the total summed intensity for 
a protein over all runs. Important to note is that in this procedure, summaries are calculated 
solely based on the PSMs that are common between each pair of runs. Therefore, MaxLFQ 
does not suffer from a downwards bias in its summary estimates. 
It is also possible to reformulate the summarization problem as follows: 
𝑦𝑓𝑟 = 𝛽0 + 𝛽𝑓feature + 𝛽𝑟run + 𝜀𝑓𝑟,                                                                                                           (Eq. 4.4) 
Herein, 𝑦𝑓𝑟 is the log-transformed intensity for PSM (feature) 𝑓 in run 𝑟, 𝛽0 is the intercept, 
which corresponds to the average log-transformed intensity of a certain reference PSM in a 
certain reference run. 𝛽𝑓feature is the effect of PSM 𝑓 relative to the intercept and 𝛽𝑟run is the 
effect of run 𝑟 relative to the intercept. 𝜀𝑓𝑟 is a random error term. The MaxLFQ procedure is 
in fact an ad hoc procedure to fit such a model for the ratio 𝑦𝑓𝑟/𝑦𝑓𝑞, conditional on all PSMs 𝑓 
that are in common between runs 𝑞 and 𝑟. The disadvantage of the MaxLFQ procedure is that 
if the PSM overlap between runs 𝑞 and 𝑟 is very limited, the MaxLFQ estimates become very 
imprecise. This is the reason that MaxLFQ requires an overlap of at least two PSMs before 
allowing a ratio to be valid. 
It is however more efficient to fit model (Eq. 4.4) as it is, as this model uses the information in 
all the PSMs, not only those that overlap, and still corrects for peptide-specific effects thanks 
to the 𝛽𝑓feature effect. 𝛽0 + 𝛽𝑟run can then be interpreted as the average protein intensity in run 
𝑟 for the reference PSM. 
Median polish [457, 458] is a robust way of fitting model (Eq. 4.4) that is also implemented in 
the current version of MSstats, but still seems show a slightly downwards bias. MaxLFQ, 
conversely,  produces nearly unbiased protein-level estimates (Fig. 4.9). 
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Figure 4.9. Overview of the log2 fold change estimates between condition 6C and 6A for the 36 UPS1 
proteins for which these estimates could be calculated based on log2-transformed PSM-level intensities 
with four different summarization methods: mean summarization, median summarization, median polish 
and MaxLFQ. The red line denotes the true log2 fold change based on the known spike-in concentrations 
(2.2 fmol/µL for 6C, 0.35 fmol/µL for 6A). Mean and mean summarization strongly underestimate the 
true fold change. Median polish shows a smaller downwards bias, while MaxLFQ is nearly unbiased. 
To avoid the downwards bias introduced by intensity-dependent missingness, MSstats 
imputes the data under a missing-by-low-intensity assumption prior to median polish 
summarization. However, such an assumption is not always valid, as already discussed in 
4.1.4. 
Note that both MaxLFQ and MSstats start from PSM-level intensities without taking into 
account the fact that PSMs mapping to the same peptide sequence are correlated. 
4.2. Methods for differential protein abundance analysis 
Differential analysis here aims at identifying those proteins that are differentially abundant. In 
proteomics, there are three main methods to perform differential analysis: summarization-
based methods, counting-based methods and peptide-based methods. However, differential 
analysis is only meaningful if the design of the study allows for it. Therefore, I will start this 
section with a note on the importance of the study design. 
4.2.1. The importance of study design 
In its early days, mass spectrometry was tedious, time-consuming and costly. The main reason 
for this was the low duty cycle of the mass spectrometers, implying that, within a given time 
frame, very few peptides got selected for fragmentation and could thus be identified. Intelligent 
approaches such as MudPIT [119] and ICAT [459], countered this by peptide pre-fractionation 
or by selecting for so-called protein-representative peptides respectively. The former increased 
the overall analysis time, whereas the latter relied on expensive reagents that also tended to 
interfere with peptide fragmentation and peptide identification. Hence, samples were often 
analyzed only once on mass spectrometers. Proteins were then declared “significant” solely 
based on a fold change threshold [241, 243]. Publications using this approach are sometimes 
still accepted in high-impact journals [460]. Alternatively, a normal distribution was fitted to all 
fold change estimates and fold changes for proteins in the upper and lower 2.5% quantiles 
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were declared “significant” [455, 461]. Some authors even developed advanced empirical 
Bayes methods to deal with single-run experiments [462]. However, these methods provide 
little to no evidence about which proteins are truly differentially abundant. Indeed, with no 
information on the biological variability between biological repeats, it is impossible to assess 
how an estimator varies from experiment to experiment. For all we know, a protein with a very 
high fold change estimate can be in fact a protein whose abundance is highly variable, but 
unrelated to the studied treatment [463]. Hence, experiments without biological repeats make 
it impossible to infer the results towards the population. It is thus of utmost importance to design 
a study in such a way that samples are included from multiple, independent subjects from the 
population on which one aspires to do inference. For instance, if properly conceived, a study 
containing only BALB/c mice should provide results that are valid for all BALB/c mice. However, 
if a researcher wants to extrapolate these results towards other mice strains, he or she should 
have included at least a few different mouse strains in his/her experimental design. Fig. 4.10 
demonstrates how different levels of replication contribute to the total variability in the system. 
  
Figure 4.10. Different levels of replication do not contribute equally and independently to the total 
variability in the system. In the given example, there are two biological levels of replication (animal and 
cell) and one technical level of replication (measurement). Although the average expression of all 
animals in the population is equal to 10, each of these replication levels contributes to the total 
measurement variability by introducing, in this example, a random error that follows a normal distribution 
with variances 1, 2 and 0.5 respectively (the corresponding standard deviations are shown as horizontal 
lines). Note that in proteomics data, these levels of replication hold for every single protein. Moreover, 
proteomics data has multiple levels of technical replication: MS run, peptide and PSM, as discussed in 
section 3.4. Reprinted with permission from Blainey et al. (2014) [464], copyright © 2014, Springer-
Verlag. 
Still too often, researchers limit themselves to conducting a few “biological” replicates on the 
same cell line, often from the same vial, or worse, they run only one sample in a few technical 
replicates on the mass spectrometer. In the first case, the results can only be extrapolated to 
that specific cell line in that specific lab, but at least, the experimental variability was taken into 
account (i.e. difference due to slightly different handling of the cells, a slightly different 
temperature because the repeats were performed on a different day, etc.). In case only 
technical replicates are used, the results can only be extrapolated to that specific sample. 
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These types of improper study designs are, in my opinion, one of the reasons for the replication 
crisis that plagues the biological sciences. An extensive overview of the statistical 
considerations to bear in mind when designing an MS-based proteomics experiment can be 
found in Oberg and Vitek (2009) [465]. 
4.2.2. Summarization-based methods 
Summarization-based methods for differential analysis start from protein-level summaries. In 
this section, I will explain a few of the most commonly used methods. 
Perseus is one of the most popular software packages amongst mass spectrometrists to 
perform differential analysis [445]. It seamlessly imports MaxQuant output and is equipped 
with a user-friendly GUI that allows for a variety of data manipulations, statistical analyses and 
visualizations. 
Perseus’ default way to perform differential analysis between two groups is via t-tests on 
MaxLFQ-summarized, log2-transformed and preprocessed protein intensities. A t-test relies on 
three assumptions: 
1. Independence. The information about any of the observations does not provide 
additional information about any of the other observations after correction for the 
treatment. This implies that all observations should be at the same level of hierarchy 
and that no pair of observations can be assumed (by design) to be more similar to each 
other than any other pair of observations (after correction for the treatment). 
2. Normality. The normality assumption demands that the observations in both conditions 
are realizations of a normally distributed population. 
3. Homoscedasticity. Homoscedasticity or equality of the variances means that the 
population variances in both conditions are equal. When the homoscedasticity 
assumption is not met, it is however still possible to use the Welch two-sample t-test 
(see below). 
If the rigid assumptions of the t-test are not met, there is no guarantee that the inference will 
be correct. In practice, however, researchers seldom assess these assumptions, especially in 
high-throughput omics contexts. The rationale behind a t-test is to weigh the fold change of a 
protein by its natural variability in abundance. Indeed, as explained above, a high fold change 





Figure 4.11. Illustration of signal and noise. If the signal increases, the confidence that a protein is 
differentially abundant between the green and the black condition will also increase. However, if for a 
constant signal, the noise increases, the confidence that a protein is differentially abundant will 
decrease. Hence, the signal-to-noise ratio is an ideal statistic to assess differential abundance. 
The t-test will wrap the ratio of signal (fold change estimate) to noise (estimate of the variability 
in protein intensities) in a single test statistic 𝑡 that estimates the signal-to-noise ratio. The t-
test statistic performs superior compared to the use of simple fold change cut-offs because it 





                                                                                                                                             (Eq. 4.5) 
Here, ?̅?1 is the average protein-level log2 intensity in the first treatment group, ?̅?2 the average 
log2 intensity in the second treatment group, 𝑅1 the number of observations (MS runs) 
corresponding to the first treatment and 𝑅2 the number of MS runs corresponding to the second 
treatment. 𝑠 is the pooled variance estimate. It is calculated as follows: 
𝑠 =
1






                                                                                                        (Eq. 4.6) 
Here, 𝑡 = 1,2 is the indicator for each treatment and 𝑟 = 1,… , 𝑅𝑡 the indicator for each MS run 
in a treatment. If the assumptions are correct, the test statistic follows a t-distribution with 𝑅1 +
𝑅2 − 2 degrees of freedom under the null hypothesis. If only the homoscedasticity assumption 
is not met, it is possible to use the Welch two-sample t-test instead. This option is also foreseen 
in Perseus. A Welch two-sample t-test omits the pooled variance estimator and instead 









                                                                                                                                                (Eq. 4.7) 
With 𝑠12 and 𝑠22 the sample variances in both treatments. This test statistic no longer follows a 
t-distribution under the null hypothesis, but it can be approximated as a t-distribution with an 
adjusted number of degrees of freedom through the Welch-Satterthwaite approximation. 
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The null hypothesis of a two-sample t-test states that there is, in reality, no difference in the 
average log2 intensities between both treatments. Next, the calculated test statistic 𝑡 is 
confronted with the t-distribution (Fig. 4.12). 
 
Figure 4.12. Illustration of the determination of p-values based on the t-test statistic. The p-value 
corresponds to the area under the t-distribution for which the t-statistic is as extreme as or more extreme 
than the observed t-statistic. The regions for which a t-statistic would be accepted and rejected at the 
5% significance level given a t-distribution with three degrees of freedom are also given. 
The percentile corresponding to the calculated test statistic can be easily converted into a p-
value. This p-value denotes the probability that a new test statistic, calculated based on an 
independent repeat of the given experiment would be as extreme as, or more extreme than 
the observed test statistic, given that the null hypothesis is true. If this p-value is very small, it 
is not very likely to observe the given result under the null hypothesis. One then chooses to 
reject the null hypothesis and accept the alternative hypothesis, i.e. there is a real difference 
in the average log2 intensities between both treatments. The p-value threshold below which 
one chooses to reject the null hypothesis is called the significance level. Traditionally, this 
significance level is often set at 5%, but in fact, the choice of the significance level is up to the 
researcher. Other thresholds (e.g. 1%, 10%) can also be set, depending on the relative impact 
of falsely reporting non-differentially abundant proteins versus not reporting truly differentially 
abundant proteins. 




,                                                                                                                                                  (Eq. 4.8) 
with: 






                                                                                                                                   (Eq. 4.9) 
Hence, an offset 𝑠0 is provided to the numerator of the t-test statistic. Providing a small offset 
reduces the impact of a protein’s variance estimate 𝑠. Indeed, sometimes it happens that, due 
to random chance, the protein level estimates in the dataset are not very variable. This will 
66 
result in a small pooled variance estimate 𝑠, and hence a high test statistic 𝑡 and a small p-
value, even if a protein’s fold change is rather small. Such proteins, with very small fold 
changes, but significant p-values due to small variance estimates are often not of interest to 
the researcher. Adding the offset 𝑠0 stabilizes the test statistic. This procedure is known as 
significance analysis of microarrays (SAM) [466]. By adding the offset, the test statistic no 
longer follows a t-distribution and p-values are calculated by permuting the log2 protein 
intensities across all proteins over both treatments. The widespread use of the SAM procedure 
in the proteomics community, whereby 𝑠0 is arbitrarily chosen by the experimenter has been 
criticized as it may lead to biased quantifications [467]. 
The use of t-tests and SAM limits Perseus analyses only to two-group comparisons. Consider 
the CPTAC dataset as an illustration. When comparing condition 6C to condition 6A for 
example, the independence assumption of the t-test is violated. Indeed, samples that were 
analyzed in the same lab are more similar than samples that were analyzed in different labs. 
Therefore, each sample contains some information about the other samples from the same 
lab, thereby invalidating the independence assumption. Summarizing the data from the 
sample- to the lab-level seems like a solution, but besides the loss of information, this does 
not solve the problem that data from the same lab over different conditions are more similar 
than data from different labs over different conditions. 
Therefore, the t-test should be expanded towards a more general framework: linear regression. 
In the linear regression framework, every observed outcome variable 𝑦𝑟 (with index 𝑟 = 1,… , 𝑅 
denoting the MS run) is assumed to originate from a linear combination of covariates 𝑥𝑟𝑚 and 
regression coefficients (also termed “parameters” or “effects”) 𝛽0 and 𝛽𝑚 (with index 𝑚 =
1,… ,𝑀 denoting the model parameters) summed with a random error term 𝜀𝑟 that covers the 
deviation of each observation 𝑦𝑟 from its expected value under the model: 
𝑦𝑟 = 𝛽0 + ∑ 𝑥𝑟𝑚𝛽𝑚
𝑀
𝑚=1
+ 𝜀𝑟                                                                                                                    (Eq. 4.10) 
The linear regression model has four assumptions: 
1. Independence: Independence again denotes that none of the observations holds 
additional information about any of the other observations after correction for the 
covariates 𝑥𝑟1 to 𝑥𝑟𝑀. 
2. Linearity: Linearity between the response and predictors means that the outcome 
variable varies linearly in function of the predictors 𝑥𝑟𝑚 and that there are thus no 
higher-order trends that cannot be accounted for. Linearity implies that the residuals 
(i.e. fraction of the data that cannot be explained by the predictors) have a mean of 0 
and that they are orthogonal on the predictors. 
3. Normality: The errors are assumed to be normally distributed, i.e. ε𝑟~N(0, 𝜎2). 
4. Homoscedasticity: Homoscedasticity requires that the variance of the residuals is equal 
for each covariate pattern. This also implicates that are no trends in the spread of the 
residuals when the residuals are plotted in function of the fitted outcome values. 
At a first glance, the linearity assumption seems to be rather restrictive for linear regression 
modeling. However, linear regression models can be easily adapted to capture higher-order 
(e.g. quadratic effects) or even non-parametric trends (e.g. splines).  
Linear regression models are often written in a compact matrix notation: 
𝒚 = 𝑿𝜷 + 𝜺                                                                                                                                                 (Eq. 4.11) 
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For the CPTAC dataset, our aim is to compare the different conditions to each other. Therefore, 
separate linear regression models can be proposed for every protein 𝑖, whereby the protein-
level log2 intensities are modeled in function of the spike-in conditions. By including lab effects, 
we also account for the blocked experimental design. As the peptide-level intensities are 
summarized to protein-level intensities in each run, we opt here to write an indicator 𝑟 for run 
instead of 𝑗 and we call 𝑅 the number of runs for which a protein-level summary could be 
determined for protein 𝑖. Ultimately, the matrices can be specified as follows for each protein 𝑖 








































































]                                                                                                                                                      (Eq. 4.15) 
Here, 𝒚 is a vector containing all log2-transformed protein-level intensities 𝑦𝑟. The vector 𝜷 
contains the effect sizes: 𝛽0 is a constant intercept, which refers to the average log2-
transformed protein intensity in a certain reference condition 1 (e.g. spike-in condition 6A) in a 
reference lab 1 (e.g. LTQ-orbitrap at site 86). 𝛽2condition and 𝛽3condition are the effects of the 
second and the third spike-in conditions relative to the reference condition after correction for 
lab-effects. They can be directly interpreted in terms of log2 fold changes between their 
corresponding spike-in condition and the condition that was chosen as a reference condition. 
Given a certain spike-in condition, 𝛽2lab and 𝛽3lab denote the effects on the log2 protein intensity 
of the second and the third labs, respectively, relative to the reference lab. To model the 
discrete, non-linear effects of spike-in condition and lab, we make use of so-called “dummy” 
variables whereby e.g. 𝑥𝑟2condition is equal to 1 if run 𝑟 corresponds to the second spike-in 
condition and 0 otherwise. Idem for the other dummies. 𝜺, finally, is a vector that contains the 
random error terms 𝜀𝑟. For the CPTAC dataset, the regression model can then be written as 
follows: 






+ 𝜀𝑟                                                                  (Eq. 4.16) 
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Regression models that contain only categorical variables32 are often presented in the more 
condense ANOVA notation whereby the predictor variables 𝒙𝒓 are not written explicitly, but 
indices are used instead to denote different levels of the categorical variable. For the CPTAC 
dataset, the ANOVA notation of the model can be written as follows:  
𝑦𝑡𝑏𝑟 =  𝛽0 + 𝛽𝑡condition + 𝛽𝑏lab + 𝜀𝑟                                                                                                     (Eq. 4.17) 
Here, 𝑦𝑡𝑏𝑟 is the log2-transformed protein-level intensity for protein 𝑖 in MS run 𝑟, which 
corresponds to condition (treatment) 𝑡 = 2,3 and lab (block) 𝑏 = 2,3. 𝛽0 is the constant 
intercept. 𝛽𝑡condition is the effect of condition 𝑡 relative to the reference condition, 𝛽𝑏lab the effect 
of lab 𝑏 relative to the reference lab and 𝜀𝑟 the random error term. The estimated condition 
effects ?̂?𝑡condition are the effects of interest.  
The most common way to estimate the parameters is by least squares, i.e. by minimizing the 
sum of the squared distances of the observations to the model fit: 
‖𝒚 − 𝑿𝜷‖2 = (𝒚 − 𝑿𝜷)T(𝒚 − 𝑿𝜷)                                                                                                      (Eq. 4.18) 
This results in the following estimator for 𝜷: 
?̂? = (𝑿𝐓𝑿)−𝟏𝑿𝐓𝒚                                                                                                                                     (Eq. 4.19) 
In the least-squares context, the estimator for the variance of ?̂? is given by: 
Var̂(?̂?) = ?̂?2(𝑿𝐓𝑿)−1                                                                                                                              (Eq. 4.20) 





,                                                                                                                                      (Eq. 4.21) 
with 𝑅 the number of runs and 𝑀 the number of estimated parameters in the mean model. The 
estimator for the standard error on the 𝑚th parameter estimator ?̂?𝑚 can also be written as: 
?̂??̂?𝑚 = ?̂?√𝜐𝑚,                                                                                                                                              (Eq. 4.22) 
with 𝜐𝑚 = (𝑿𝐓𝑿)𝑚,𝑚
−1  the 𝑚th diagonal element of (𝑿𝐓𝑿)−1. Under the null hypothesis of no 




~𝑡𝑅−𝑀                                                                                                                                             (Eq. 4.23) 
Here, ?̂?𝑚 is the estimated value for the 𝑚th model parameter 𝛽𝑚 (typically the effect of a certain 
treatment; in the case of the CPTAC study: the spike-in condition), 𝑎 the value of 𝛽𝑚 under the 
null hypothesis (typically zero) and ?̂??̂?𝑚 the estimated variance on the estimate of 𝛽𝑚. Given 
the null distribution, a p-value can be calculated for each parameter, denoting its statistical 
significance. Note that some research questions (e.g. the difference in protein abundance 
between two non-reference conditions) require statistical inference on a linear combination of 
                                               
32 Categorical variables are variables that do not correspond to any measurable quantities. Examples include 
gender, different compounds, different treatments, etc. This is opposed to numerical variables that correspond to 
measurable quantities (e.g. doses of a certain compound, time after treatment, blood pressure,). 
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multiple model parameters, so-called statistical contrasts. Just as for single parameters, t-
statistics and p-values can also be calculated for contrasts. 
The current version (3.12.2) of the popular Bioconductor package MSstats makes use of linear 
regression at the protein level. These protein-level summaries are obtained after imputation at 
the PSM-level data under a MNAR assumption followed by a median polish summarization 
[446]. 
The popular Bioconductor package limma was originally developed for the analysis of 
microarray data [468], but has also become popular for differential proteomics analyses [469]. 
Limma makes use of the huge amounts of data in high-throughput omics datasets to borrow 
strength across proteins. More specifically, limma assumes that the residual variances from 
each regression model are composed of a common variance shared by all proteins (models) 
and a protein-specific variance. This allows to obtain a more stable estimate of the error 
variance, which is especially beneficial for proteins identified by only a few peptides. Indeed, 
their variances are stabilized by relying on the variances estimated for proteins with much more 
data. 
Limma uses an empirical Bayes framework to provide a statistically sound alternative to SAM 
for linear regression models. More specifically, limma proposes a Bayesian model which 







2                                                                                                                                               (Eq. 4.24) 
In this formula, 𝜎02 is a prior variance and 𝜒𝑑0
2 denotes a 𝜒2 distribution with 𝑑0 degrees of 
freedom. In limma, the user does not define the value of the prior variance 𝜎02 and the prior 
degrees of freedom 𝑑0, but estimates 𝜎02 and 𝑑0 based on all protein error variance estimates 
?̂?𝑖2 and the degrees of freedom 𝑑𝑖 = 𝑀 − 𝑅 of all proteins in the dataset. Statistical inference 
methods whereby the priors are estimated based on the data are termed empirical Bayesian 
methods. 
Limma’s empirical Bayes estimators for the prior variance 𝜎02 and the prior degrees of freedom 
𝑑0 have closed-form solutions that are computationally very fast. Furthermore, instead of 
estimating full posterior distributions, limma calculates a maximum a posteriori point estimate 




                                                                                                                                  (Eq. 4.25) 
Herein, ?̂?𝑖 is the residual standard error for protein 𝑖 and ?̂?02 the estimated common variance 
over all proteins. Substituting the residual standard deviation by its maximum a posteriori 




                                                                                                                                            (Eq. 4.26) 
It can be shown that the moderated t-test statistic ?̃?𝑖𝑚 follows a t-distribution with 𝑑𝑖 + 𝑑0 
degrees of freedom, with 𝑑𝑖 equal to 𝑅 − 𝑀, as indicated before. Hence, not only are the 
variances being stabilized as in SAM, but, contrary to SAM, the null distribution follows an 
analytical t-distribution. Note that the degrees of freedom of this t-distribution are augmented 
with 𝑑0 as compared to the degrees of freedom of the null distribution of the ordinary t-test. 
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This reflects the increased power of the moderated t-test due to the borrowing of strength 
across proteins. 
4.2.3. Peptide-based models 
Summarization-based approaches, especially the naive ones such as those based on mean 
and median summarization, use summary values that are based on different peptides and 
different numbers of peptides. When such summaries are compared to each other, a bias will 
be introduced due to the comparison of different peptides with non-negligible differences in 
ionization efficiency. Also, differences in precision due to the different numbers of peptides for 
each summary are ignored. Instead of summarizing PSMs directly to the protein level, it is 
however also possible to keep the data at the PSM or peptide-level and to include the 
hierarchical nature of the data directly into the statistical model. We call these models peptide-
based models (see chapter 8). They have the advantage that they correct for differences in 
ionization efficiencies between different peptides and for differences in precision due to 
different numbers of identified peptides in each MS run. Compared to summarization-based 
methods, two additional parameters need to be added to the model. A peptide-based linear 
regression model for each protein 𝑖 in the CPTAC experiment then looks as follows (whereby 
the indicator 𝑖 is again suppressed for notational convenience): 
𝑦𝑝𝑟 =  𝛽0 + 𝛽𝑡condition + 𝛽𝑏lab + 𝛽𝑝
peptide + 𝑢𝑟run + 𝜀𝑝𝑟                                                                  (Eq. 4.27) 
The response variable 𝑦𝑝𝑟 is now the log2-transformed intensity of peptide 𝑝 in run 𝑟. 𝛽𝑝
peptide 
is added to account for the effect of the 𝑝th peptide. The effect for MS run, 𝑢𝑟run, is added 
because for protein 𝑖, there can be multiple peptides identified in the same run. This is an 
important point: the run effect needs to be included because peptide intensities within the same 
run are expected to be positively correlated. Indeed, due to the run-specific effects described 
in 3.4, peptide intensities from a protein within the same run will behave more similar compared 
to peptide intensities that were measured across different runs. However, if the run effect were 
modeled as a standard fixed effect, statistical inference would only be valid for within-run 
comparisons because the run-to-run variability would be removed from the model. When the 
run effect is modeled as a random effect, whereby it is assumed that 𝑢𝑟run~N(0, 𝜎𝑢2), both 
within- and between-run variability are taken into account. This is important in label-free 
proteomics experiments because the treatment will vary between runs, but not within runs. The 
run effect thus both accounts for the correlation of all peptides of protein 𝑖 identified within run 
𝑟 and enables a correct statistical inference for between-run comparisons. Statistical models 
that contain both fixed and random effects are referred to as mixed models and allow to model 
correlation structures in the data.  This mixed model structure for peptide-level data was first 
proposed by Daly et al. (2008) [470]. 
Clough et al. (2009) [471] propose a specific parameterization for protein-wise mixed models: 
𝑦𝑓𝑟 =  𝛽0+𝛽𝑓feature + 𝛽𝑡condition+𝛽𝑓𝑡feature:condition + 𝛽𝑏
biorep + 𝜀𝑓𝑟                                            (Eq. 4.28) 
These authors later implemented this model in the proteomics quantification package MSstats 
prior to version 3, in which MSstats used to model the data directly at the feature (PSM) level 
[409, 472]. 
Herein, 𝛽𝑓feature is the effect of the 𝑓th feature (PSM). 𝛽𝑓𝑡feature:condition is an interaction effect 
between feature and condition. Such an interaction allows the effect of interest (condition) to 
affect each feature differently. 𝛽𝑏
biorep is then the effect of the 𝑏th biological repeat. In MSstats, 
the experimenter can opt to encode 𝛽𝑏
biorep either as a fixed effect, which is useful when 𝛽𝑏
biorep 
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is a blocking factor, or as a random effect, which is useful in the case of biological replication. 
Indeed, biological replication caused by e.g. multiple measurements on the same animals also 
leads to correlation in the data and should therefore be modeled as random. The disadvantage 
of the former MSstats framework is that it does not allow to correctly model the within-sample 
correlation unless the samples coincide with the biological repeats. Moreover, just like the 
present MSstats implementation, it only allows to model experiments that fit into this specific 
model framework. 
It has to be noted that, if the summarization step is performed correctly, the estimated 
differences in ionization efficiencies can in fact be removed from the data. Hence, the only 
clear advantage of peptide-based models is that they account for difference in precision due 
to different numbers in peptides. However, this advantage seems to be rather small in practice, 
which may be one of the reasons why MSstats in their most recent version, reverted to a faster, 
summarization-based workflow. 
The very first peptide-based model for label-free shotgun proteomics was proposed in 2008, 
when Bukhman et al. proposed the following model [473]: 
𝑦𝑝𝑟 = 𝛾𝑝 + 𝜓𝑝 ∑𝛿𝑖𝑝𝜃𝑖𝑟 + 𝜀𝑝𝑟
𝑖
                                                                                                             (Eq. 4.29) 
Herein, 𝑦𝑝𝑟 is the log-transformed intensity of peptide 𝑝 in sample (or MS run, assuming each 
sample was only run once) 𝑟, 𝛾𝑝 the background log-transformed intensity of peptide 𝑝, 𝜓𝑝 the 
peptide-specific effect of peptide 𝑝, 𝛿𝑖𝑝 an indicator whether peptide 𝑝 maps to protein 𝑖 (1 if 
the peptide maps and 0 if the peptide does not map), 𝜃𝑖𝑟 the abundance of protein 𝑖 in sample 
𝑟 and 𝜀𝑝𝑟 a random error term. The inclusion of the 𝜓𝑝 term allows the sample effect 𝜃𝑖𝑟 to be 
different from peptide to peptide. Note that in this model, all proteins are modeled together and 
that this model allows to use shared peptides, although the authors exclude peptides that are 
shared by three or more proteins. 
Another peptide-based model was proposed by Henao et al. (2012) [474]: 
𝑦𝑝𝑠𝑏 = 𝑚𝑝𝑏 + ∑𝑎𝑙𝑝𝑧𝑙𝑠 + ∑𝑏𝑖𝑝𝑤𝑖𝑠 + 𝜀𝑝𝑠                                                                                       (Eq. 4.30)
𝑖𝑙
 
Herein, 𝑦𝑝𝑠𝑏 is the average log-transformed intensity of peptide 𝑝 in sample 𝑠 in batch 𝑏. 𝑚𝑝𝑏 
is the average intensity of peptide 𝑝 in batch 𝑏. This model also accounts for the correlation of 
certain peptides within the same sample (e.g. peptides that behave similarly due to 
physicochemical similarities). To capture this correlation,  𝑧𝑙𝑠 represents the 𝑙th intra-sample 
effect for sample 𝑠, while 𝑎𝑙𝑝 are the peptide-specific effects that correspond to each of these 
intra-sample effects. 𝑤𝑖𝑠 represents the effect of interest: the effect of protein 𝑖 in sample 𝑠, 
while 𝑏𝑖𝑝 models the impact of peptide 𝑝 on the effect of protein 𝑖. 𝜀𝑝𝑠 is a random error term. 
From the model specification, it is clear that this model will be strongly over-parameterized for 
most, if not all proteins. These authors, however, tried to tackle the quantification problem from 
a Bayesian perspective. In classic frequentist statistics, the aim is to estimate the true value of 
one or more unknown population parameters and provide estimates on the uncertainty of these 
parameter estimates. Contrary, in Bayesian statistics, the population parameters are believed 
upfront to follow certain distributions, the prior distributions. When experiments are performed, 
evidence (data) is collected that might confirm or challenge this prior belief. The prior 
distributions are then updated based on the data by making use of Bayes’ theorem and result 
in posterior distributions that reflect the statistician’s new beliefs after confronting his beliefs 
with the data. 
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The idea of including a researcher’s beliefs into a statistical method is very sensible because 
experiments are rarely, if ever, performed without any prior knowledge. Indeed, even if nothing 
is known about a protein in the literature, a protein’s true log2 fold change will either be 0 
(unregulated), or a positive or negative value rather close to zero (up- or downregulated). Very 
extreme log2 fold changes such as +1000 or -1000 are highly unlikely and can therefore be 
given a very low prior probability. And, even if absolutely nothing is known or can be assumed 
about an experiment and all values are equally likely, a so-called uninformative prior can be 
used. In this respect, the framework of Bayesian statistics is very elegant because it allows the 
posterior distribution of a previous experiment to be used as a prior distribution in a follow-up 
experiment and thus to organically update our beliefs based on the data. 
Henao et al. (2012) indeed place Gaussian (normal) priors on the average abundance 𝜇𝑖𝑚 and 
the noise component 𝜀𝑖𝑛 [474]. Gaussian priors are also assigned to 𝑎𝑖𝑙, while a Laplace prior 
is set on 𝑧𝑙𝑛 to allow these intra-sample effects to shrink to 0 if necessary. 𝑏𝑖𝑘 is also given a 
normal prior, but hyperpriors are set in such a way that proteins can also be correlated with 
each other in a hierarchical tree structure. Bayesian models have also been proposed to 
include the effects of shared peptides [475]. 
Disadvantages of the Bayesian framework are that the choice of the prior is always somewhat 
arbitrary and based on the beliefs of the researcher. Moreover, Bayesian inference models 
mostly do not have a closed-form expression for the posterior distributions. Therefore, the 
posterior distributions need to be approximated by repeated sampling, e.g. by making use of 
Markov Chain Monte Carlo (MCMC) methods, which are computationally very intensive. 
Another persistent issue in the proteomics field are missing values, hence the usual custom of 
including an imputation step in a typical workflow. Instead of imputing missing values, it is also 
possible to handle missing values within the framework of the statistical model. For shotgun 
proteomics data, this approach was pioneered by Karpievitch et al. (2009) [425]. In their 
censored regression model, peptide intensities are assumed to be either missing completely 
at random, or missing not at random if a peptide’s intensity falls below a certain censoring 
threshold 𝑐𝑖𝑝 for each peptide 𝑝 corresponding to protein 𝑖. These authors model all proteins 
together in one model. It is assumed that all log2-transformed intensities originate from a 
normal distribution with mean 𝜇𝑖𝑝𝑡 and standard deviation 𝜎𝑖𝑝. The expected intensity for a 
peptide 𝑝 of a protein 𝑖 in treatment condition 𝑡 can then be described as follows: 
𝜇𝑖𝑝𝑡 = 𝛽0 + 𝛽𝑖
protein + 𝛽𝑖𝑝
peptide + 𝛽𝑖𝑡condition                                                                                     (Eq. 4.31) 
In each MS run 𝑟, the probability of a peak to be missing at random is assumed to be equal to 
𝜋𝑟. If 𝑊𝑖𝑝𝑡𝑟 is the probability that a log2-transformed intensity 𝑦𝑖𝑝𝑡𝑟 is observed (0 if observed 
and 1 if unobserved), the probability that intensity 𝑦𝑖𝑝𝑡𝑟 will be missing can be written as follows: 
𝑃(𝑊𝑖𝑝𝑡𝑟 = 1) = 𝜋𝑟 + (1 − 𝜋𝑟)Φ(
𝑐𝑖𝑝 − 𝜇𝑖𝑝𝑡
𝜎𝑖𝑝
)                                                                                 (Eq. 4.32) 
In this expression, Φ is the cumulative distribution of the normal distribution with mean equal 
to 0 and standard deviation equal to 1. This expression shows that peptides are missing at 
random (MAR, conditionally on run 𝑟) with a probability 𝜋𝑟. Any peptide that is not MAR will be 
MNAR if its log2-transformed intensity is lower than the peptide-specific censoring threshold 
𝑐𝑖𝑝. The current implementation of MSstats uses a very similar model to impute missing values 
prior to summarization to the protein level, albeit without the random missingness component 
[446]. In 2012, Koopmans et al. proposed an empirical Bayesian random censoring threshold 
model to cope with missing values in a summarization-based context, but just like most 
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Bayesian inference models, the posterior does not have a closed-form solution and needs to 
be constructed by repeated MCMC sampling, which makes it computationally intensive [476]. 
4.2.4. Ridge regression 
Due to low protein abundances, limited numbers of tryptic peptides per protein and the data-
dependent nature of the acquisition, the number of observed peptides is relatively small for 
most of the proteins in a typical label-free shotgun proteomics dataset. This makes protein-
wise statistical modeling challenging because even relatively simple models are prone to over-
fitting for such proteins. Over-fitting occurs when a model is too complex with respect to the 
amount of data that is available: the model is fit too closely to the observed data but will not 
generalize towards new data. 
Ridge regression is a way to reduce over-fitting. Recall that for ordinary least squares, the 
following loss function is minimized: 
‖𝒚 − 𝑿𝜷‖2 = (𝒚 − 𝑿𝜷)T(𝒚 − 𝑿𝜷)                                                                                                      (Eq. 4.33) 
Ridge regression adds a penalty term to this loss function (indicated in red): 





]                                                                                                            (Eq. 4.35) 
Herein, 𝟎 is a matrix with only zeros and 𝑰 is the unit matrix33. Matrix D allows certain 
parameters to be unpenalized by setting their corresponding diagonal elements to 0. In the 
given example, only the intercept 𝛽0 remains unpenalized. The penalty term increases if the 
absolute values of the parameters 𝜷 increase. This prevents over-fitting by shrinking model 
parameters towards 0 (Fig. 4.14). 
 
Figure 4.14. Graphical representation of the ridge estimate and the ordinary least squares (OLS) 
estimate in an example case where two model parameters 𝛽1 and 𝛽2 need to be estimated. The OLS 
                                               
33 The unit matrix is a matrix with 1 on its diagonal elements and 0 on its off-diagonal elements. The model thus 
implies equal variances for all covariates and no correlation between the covariates. 
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estimate minimizes the residual sum of squares (RSS), while the ridge estimates are shrunken towards 
0. 
When fitting this regression model, the aim is to minimize the mean squared error (MSE): 
MSE(?̂?) ≝ E [(?̂? − 𝜷)
2
]                                                                                                                        (Eq. 4.36) 
It can be shown that the MSE can also be written as [477]: 
MSE(?̂?) = E [(?̂? − E[?̂?])
𝟐
] + E[(E[?̂?] − 𝜷)]
2                                                                                 (Eq. 4.37) 
= Var(?̂?) + Bias(?̂?)
2                                                                                                                              (Eq. 4.38) 
In 1956, Stein showed that for models with 3 or more parameters, certain shrinkage estimators 
outperform the least-squares estimator in terms of MSE [478]. Shrinkage estimators introduce 
a small bias but reduce the overall MSE due to a strong reduction in the variance of the 
estimator. Therefore, such shrinkage estimators are more stable overall. Leave-one-out cross-
validation is one way to tune the penalty parameter. Cross-validation enables to assess how 
accurate a model is on new, unobserved data. In leave-one-out cross-validation, the data is 
fitted to the dataset from which one observation 𝑗 is removed. This allows to estimate the MSE: 
the model’s estimate ?̂?𝑗 for observation 𝑗 can be seen as a “new” data point. With cross-









                                                                                                             (Eq. 4.39) 
Herein ?̂?(𝑗)(𝜆) is a vector of ridge parameter estimates based on the data from which the 𝑗th 
observation is removed and [𝑿?̂?(𝑗)(𝜆)]𝑗 the leave-one-out model estimate for the 𝑗th 
observation 𝑦𝑗. Leave-one-out cross validation requires iteratively fitting ridge models without 
the 𝑗th observation until convergence. It is also possible to repeatedly leave out 𝐾 observations 
and reduce the squared distances of the leave-𝐾-out model fit to the 𝐾 observations that were 
left out. 
As explained in 4.2.3, peptide-based models require the inclusion of a random sample effect 
to allow correct statistical inference. Leave-one-out cross-validation would require iterative 
fitting of a mixed model. There is however a link between mixed models and ridge regression, 
which is tempting to exploit when introducing ridge regression in a mixed model context as this 
would give a big computational advantage. As a demonstration of this link, assume the 
following mixed model: 
𝒚 = 𝑿𝜷 + 𝒁𝒖 + 𝜺                                                                                                                                      (Eq. 4.40) 

















, 𝒁 the design matrix for the random 





] with 𝒖~MVN(𝟎, 𝜎𝑢2𝑰). Herein, MVN denotes the multivariate normal 
75 
distribution, 𝟎 a 1 × 𝑁 column vector with zeros, 𝜎𝑢2 the variance on the random effects and 𝑰 
the unit matrix. 𝜺~MVN(𝟎, 𝜎2𝑰) denotes the random error terms. We maximize the joint 
likelihood of y, 𝜷 and 𝒖 towards 𝜷 and 𝒖: 







𝑒−(−𝒖)T(−𝒖) 2𝜎𝑢2⁄                                                       (Eq. 4.42) 
Log-transformation results in: 



















                                                                                                          (Eq. 4.43) 
With 𝑁 the number or random effect parameters. After replacing 𝜎𝑢2 by 𝜎2 𝜆⁄  and multiplying 
by -2, this is equivalent with minimizing the following expression: 
𝐽 log(2𝜋) + 𝐽 log(𝜎2) +
(𝒚 − 𝑿𝜷 − 𝒁𝒖)T(𝒚 − 𝑿𝜷 − 𝒁𝒖)
𝜎2







                                                                                                                                                                        (Eq. 4.44) 
Set 𝜽 = [𝜷𝒖] and 𝑪 =
[𝑿 𝒁]. Minimization to 𝜽 only involves: 
(𝒚 − 𝑪𝜽)T(𝒚 − 𝑪𝜽) + 𝜆𝜽T𝑫𝜽,                                                                                                              (Eq. 4.45) 
which is exactly the ridge regression loss function. Hence, parameters with a ridge penalty can 
be estimated by parameterizing them as random effects in a mixed model. In peptide-based 
models, where a random run effect needs to be included to account for within-run correlation, 
this link between mixed models and ridge regression can be exploited to estimate parameters 
with a ridge penalty, as we will see in Chapter 9.1. After optimizing the loss function, we obtain 
the following estimator: 
?̂? = [?̂?
?̂?
] = (𝑪T𝑪 + ?̂?𝑫)
−1𝑪T𝒚                                                                                                               (Eq. 4.46) 
This estimator for ?̂? is termed the best linear unbiased predictor (BLUP). An estimate for 𝜎2 
can be obtained by plugging in the estimates ?̂? into the log likelihood and solving this profile 
log-likelihood towards 𝜎2. In practice, we make use of the restricted maximum likelihood 
(REML) criterion that also accounts for the degrees of freedom due to the fixed effects in the 
model. Conditional on 𝒖, the variance on ?̂? can be estimated as follows: 
Var̂ ([ ?̂?
?̂? − 𝒖
] |𝒖) = ?̂?2(𝑪T𝑪 + ?̂?𝑫)
−1𝑪T𝑪(𝑪T𝑪 + ?̂?𝑫)
−1                                                             (Eq. 4.47) 
This variance estimator, however, does not account for the bias in the estimator ?̂?. Hence, 
inference based on this estimator will only be correct when the bias is negligible. However, 
since E(𝒖) = 0, the BLUP estimator ?̂? is unbiased on average over the distribution of u. 
Unconditional on 𝒖, the variance estimator on ?̂? is given by: 
Var̂ ([ ?̂?
?̂? − 𝒖
]) = ?̂?2(𝑪T𝑪 + ?̂?𝑫)
−1                                                                                                      (Eq. 4.48) 
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The estimator also accounts for the bias introduced by the penalized regression and is 
therefore somewhat larger than the conditional variance estimator. Ridge regression has been 
used in other omics fields to predict the effects of various molecular markers on organismal 
phenotypes [480, 481]. 
4.2.5. Robust regression with M estimation 
Outliers are observations with extreme response values. If such observations also have a 
strong leverage (i.e. if they have a large distance to the average predictor values), the 
observation will have a strong influence on the model fit: the model will be fit close to the 
influential observation due to a lack of neighboring observations. Outliers are more likely to 
correspond to less reliable measurements. Indeed, an extremely high intensity value could for 
example have originated from a spike in electrospray voltage, while a very low intensity value 
is very likely to be missing in a repeated run due to intensity-dependent missingness. 
Moreover, even if the outlier is a valid measurement, it is often undesirable that a single 
observation has a very strong impact on the model.  
Robust regression with M estimation aims to minimize the maximal bias of the estimators. With 
robust regression, statistical tests are only asymptotically valid. However, if the errors are 
normally distributed, M estimators have a high efficiency. Recall the OLS loss function: 
‖𝒚 − 𝑿𝜷‖2 = (𝒚 − 𝑿𝜷)T(𝒚 − 𝑿𝜷)                                                                                                      (Eq. 4.49) 
This function is also called the L2 loss function since it minimizes the L2 norm of 𝒚 − 𝑿𝜷. With 
M estimation, the following loss function is minimized: 
Ω(𝒚 − 𝑿𝜷)                                                                                                                                                   (Eq. 4.50) 
The function Ω(𝑥) should have the following characteristics: 
• Ω(𝑥) is symmetric 
• Ω(𝑥) has a minimum at Ω(0) = 0 
• Ω(𝑥) is positive for all 𝑥 ≠ 0 
• Ω(𝑥) increases as 𝑥 increases 
Given these conditions, the estimator ?̂? is the solution to the equation: 
ω(𝒚 − 𝑿𝜷) = 0                                                                                                                                          (Eq. 4.51) 
Where ω is the derivative of Ω. For ?̂? to possess the robustness property, ω should be bounded 
(i.e. there exists a real number 𝑀 such that |𝜔(𝑥)| ≤ 𝑀 for all values of 𝑥). However, robust ω 
functions are non-linear in 𝜷 and typically do not have a closed-form solution. We will therefore 
recast the problem. 










) = 0                                                                                                                                        (Eq. 4.53) 
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Define 𝜼 = 𝒚−𝑿𝜷
𝜎
 and weight function 𝑤(𝜼) = ω(𝜼) 𝜼⁄ . The last estimation equation can then be 
rewritten as: 
𝑤(𝜼)𝜼 = 0                                                                                                                                                   (Eq. 4.54) 
This expression can be solved as an iteratively reweighted least-squares (IRWLS) problem. 
Herein, the weights 𝑤(𝜼) are kept constant in 𝜼 and the expression is solved to 𝜷. Then, the 
weights are recalculated based on the new ?̂? and the procedure is repeated until convergence. 
Examples of robust loss functions Ω include: 
• Huber: ΩHuber = {x
2 2⁄                  if |𝑥| ≤ 𝑘
𝑘(|𝑥| − 𝑘/2)   if |𝑥| > 𝑘,                                                                      (Eq. 4.55) 
with 𝑘 = 1.345 the default tuning constant 
• “Fair”: ΩFair = 𝑐2 (|𝑥|
𝑐
− log (1 + |𝑥|
𝑐
)),                                                                                (Eq. 4.56) 
with 𝑐 = 1.3998 the default tuning constant 
• Cauchy: ΩCauchy = 𝑐
2
2
(1 + (𝑥 𝑐⁄ )2),                                                                                    (Eq. 4.57) 
with 𝑐 = 1.3849 the default tuning constant 
The default tuning constants are chosen in such a way that the methods have a 95% 
asymptotic efficiency when applied to standard normal data. Fig. 4.15 demonstrates the impact 
of robust regression with M estimation with Huber weights. 
 
Figure 4.15. Plot of the residuals 𝑦𝑗 − ?̂?𝑗 in function of the model-fitted values for all log2-tranformed 
peptide intensities ?̂?𝑗 (𝑗 = 1,… , 637) of yeast protein SYKC in the CPTAC dataset after fitting regression 
model (Eq. 4.27) robustly with Huber weights. The sizes of the datapoints are proportional to the Huber 
weights in the IRWLS procedure. Note that observations with large residuals have small weights, which 
is indicative of the robustness property. 
Examples of common loss functions and their corresponding weight functions are plotted in 
Fig. 4.16 and 4.17, respectively. An extensive overview of robust loss functions can be found 
in Bolstad (2004) [482].  
78 
 
Figure 4.16. The default L2 loss function and examples of loss functions Ω that are commonly used in 
robust M estimation. Figure adapted from Bolstad (2004) [482].  
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Figure 4.17. Examples of the weight functions 𝑤 that are used in the IRWL procedure to obtain the 
corresponding loss functions in Fig. 4.15. Figure adapted from Bolstad (2004) [482]. 
4.2.6. Counting-based methods 
To quantify proteins with any of the above-described methods, it is necessary to extract ion 
intensities, which generally requires, as shown in section 3.3, rather advanced algorithms that 
are implemented in specialized software. Moreover, reliable protein quantification with these 
methods requires, depending on the study design, basic to advanced statistical knowledge. It 
was soon noticed that simply counting the number of MS² spectra that map to a certain protein 
provides a reasonably good approximation of a protein’s abundance [483, 484]. This makes 
sense because the more abundant a protein, the more of its peptide ions that can be expected 
to be detectable above noise levels. Moreover, the more abundant a peptide, the longer its 
elution time and hence the higher the chance that it will be targeted for fragmentation more 
than once, thus generating more MS² spectra. Spectral counting also deals more naturally with 
missing values: as a zero count [90]. Spectral counting became very appealing to many 
researchers, not because of its reliability, but mainly because of its ease-of-use. Indeed, 
researchers could now simply count the number of MS² spectra mapping to a protein and 
directly divide these numbers in order to obtain a fold change estimate. However, when the 
significance of such fold changes needs to be assessed, statistics are again needed. A natural 
framework for handling count data is Poisson regression. Poisson regression assumes that 
the spectral counts 𝑥𝑖𝑟 for each protein 𝑖 in each run 𝑟 follow a Poisson distribution: 
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𝑥𝑖𝑟~Poisson(𝜇𝑖𝑡𝑏)                                                                                                                                     (Eq. 4.58) 
This makes sense because a Poisson distribution is typically used to model the number of 
times an event occurs (detecting a spectrum that maps to protein 𝑖) during a fixed time interval 
(an MS run). For the CPTAC example, we can make use of the generalized linear model 
framework, to model the first two moments (mean and variance) of the spectral counts. As 
counts always have a lower bound of 0 and negative means are not meaningful for count data, 
we make use of a log-link function to allow unbounded estimation of the model parameters. 
For the CPTAC dataset, the model can be specified as follows: 
log(𝜇𝑖𝑡𝑏) = 𝛽𝑖0 + 𝛽𝑖𝑡condition + 𝛽𝑖𝑏lab                                                                                                       (Eq. 4.59) 
Note that for a Poisson distribution the mean 𝜇𝑖𝑡𝑏 and the variance 𝜐𝑖𝑡𝑏 are equal. 
Here, 𝛽𝑖0 is the intercept, 𝛽𝑖𝑡condition is the effect of spike-in condition 𝑡 and 𝛽𝑖𝑏lab is the effect of 
lab 𝑏. By using a Poisson distribution, it is implied that the variance in the data 𝜐𝑖𝑡𝑏 is equal to 
the mean 𝜇𝑖𝑡𝑏. Such a mean-variance relationship is very restrictive. In reality, the residual 
variance is often larger (over-dispersion) or sometimes even smaller (under-dispersion) than 
what would be expected under the Poisson distribution. The mean-variance relationship can 
however be relaxed by making use of a quasi-Poisson regression model [485].  
Note that quasi-Poisson regression does not model the full distribution, but only the first two 
moments of the distribution: the mean 𝜇𝑖𝑡𝑏 and the variance 𝜐𝑖𝑡𝑏. The specification of the 
mean model is identical to Poisson regression. However, the variance is more flexible: 
𝜐𝑖𝑡𝑏 = 𝜑𝑖𝜇𝑖𝑡𝑏                                                                                                                                               (Eq. 4.60) 
The factor 𝜑𝑖 allows to to correct for over- or under-dispersion. Count data can also be 
proposed to follow a negative binomial distribution, which assumes a quadratic mean-variance 
relationship: 
𝜐𝑖𝑡𝑏 = 𝜇𝑖𝑡𝑏 + 𝜑𝑖𝜇𝑖𝑡𝑏2                                                                                                                                   (Eq. 4.61) 
A negative binomial distribution reduces to a Poisson distribution if 𝜑𝑖 is zero. Negative 
binomial generalized linear models are implemented in the popular RNA sequencing 
quantification packages EdgeR [486, 487] and DESeq2 [488], which have also been applied 
in proteomics contexts [489]. 
Other statistical models have been proposed as well to deal with count data in proteomics, 
including a generalized linear mixed effects Poisson regression model in which all proteins are 
modeled together [490], a beta-binomial model [491] and Bayesian models [492]. 
Peptide counting is an alternative to spectral counting. In peptide counting, the number of 
unique peptides instead of the number of unique PSMs that match to each protein are counted. 
Some authors reported that spectral counting is more accurate and more reproducible than 
peptide counting which is in turn more reproducible than sequence coverage-based 
approaches [483, 493, 494]. This is probably because spectral counting is more fine-grained 
than peptide counting (there at least as much PSMs as peptides per protein), which might 
make it more feasible to quantify smaller differences in abundance. 
A very simple peptide counting method is the Exponentially Modified Protein Abundance Index 
(emPAI). For each protein 𝑖, the emPAI is calculated as follows [174]: 
emPAI𝑖 = 10𝑛𝑖
pep 𝑛𝑖
predpep⁄ − 1                                                                                                               (Eq. 4.62) 
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Hereby, 𝑛𝑖
pep is the number of observed unique peptides mapping to protein 𝑖 and 𝑛𝑖
predpep is 
the number of tryptic peptides that can theoretically map to protein 𝑖. emPAI is an example of 
so-called “absolute protein quantification” method. By normalizing the peptide count of each 
protein by its number of predicted unique tryptic peptides 𝑛𝑖
predpep, emPAI claims to be able to 
compare the abundances of different proteins to each other (as opposed to comparing the 
abundances of the same proteins over different conditions, so-called “relative quantification”). 
The content of protein 𝑖 in mol % is then calculated as follows: 





,                                                                               (Eq. 4.63) 
with 𝑛protein the total number of proteins in the dataset. Of course, for quantitative protein 
inference, peptide counting methods also require some statistical modeling. The models for 
peptide counting are very similar to those of spectral counting and many statistical models for 
spectral counting and peptide counting can be used interchangeably. 
Absolute Protein Expression (APEX) is an example of an absolute quantification method based 
on spectral counting that has gained quite some traction [175, 495]. An APEX score for protein 










,                                                                                                (Eq. 4.64) 
with 𝑛𝑖MS2 the total number of MS² spectra mapping to protein 𝑖, 𝜋𝑖ID the probability that protein 𝑖 
is correctly identified,  𝑛𝑖
predPSM the number of computationally predicted PSMs for protein 𝑖 
and 𝐶 an estimate of the total concentration of protein molecules in the cell. 
Do note that although absolute quantification methods might give some indication about a 
protein’s abundance, these estimates remain generally very crude because normalizing 
protein abundances to each other based on e.g. the theoretical number of tryptic peptides they 
can generate is quite inaccurate. Also, count-based approaches have become largely obsolete 
in present-day proteomics given that quantification based on continuous intensity-based 
signals is clearly superior over discrete counts [317]. It has indeed been shown that count-
based methods have a lower linear response to various protein loading amounts, a lower 
reproducibility, a lower quantitative accuracy, a lower precision, lower sensitivity, and a higher 
ratio of false positives to false negatives compared to MS intensity-based quantification [307]. 
This is because peptide counting disregards the inherent abundance-intensity relationship 
(within a certain dynamic range [496]) for each peptide. Dynamic exclusion, during which 
identified ions are excluded from being re-targeted for fragmentation for a certain amount of 
time, further obscures the relationship between spectral counts and protein abundances [497]. 
Counting-based approaches perform especially poorly for low-abundant proteins [228, 483, 
498]. Indeed, it is not possible to calculate an accurate protein ratio between two conditions if 
only one or two spectra per condition are mapped to the protein of interest [497]. And, at higher 
levels of protein abundances, saturation effects come into play for relatively low total protein 
concentrations when all peptides that can theoretically be detected are in fact detected [228]. 
Spectral counting is reviewed extensively in Lundgren et al. (2010) [494]. 
4.2.7. Controlling the false discovery rate 
Whether statistical inference is done with t-tests, linear regression models, or other statistical 
approaches, the fact that statistical inference is done for each protein in the dataset creates a 
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huge multiple testing problem. Imagine testing 1,000 proteins, all of which are not differentially 
abundant (i.e. the null hypothesis is true). When using the traditional 5% cut-off at the p-value 
level, on average 5%, i.e. 50 proteins, will be erroneously declared differentially abundant 
(false positives). Therefore, it is clear that, in the case of multiple testing, a significance 
threshold based on p-values will be way too liberal. 
Solutions to this problem have been proposed in the form of controlling the family-wise error 
rate (FWER). The aim of FWER procedures is to control the probability of detecting at least a 
single false positive at a given level, typically 5%. An example of an FWER procedure is the 
simple, but somewhat conservative Bonferroni correction [499]. Here, a protein is only declared 
significantly differentially abundant if its p-value is smaller than 𝛼 𝑛protein⁄ , with 𝛼 the significant 
threshold (e.g. 5%) and 𝑛protein the number of proteins that are being tested. It turns out that 
FWER procedures are often too conservative for high-throughput applications. Indeed, the 
number of biological replicates in such a context is often rather low, which limits the statistical 
power of each individual test. 
To cope with the specific context of high-throughput experiments, false discovery rate (FDR) 
procedures were developed. The false discovery rate aims to control the expected fraction of 
false positive proteins in a list of differentially abundant proteins at a certain level, again, 
typically 5% [500]. In practice, FDR-controlled lists are much more interesting for practitioners: 
a researcher will prefer a list of 20 significant proteins of which on average 1 is a false positive 
(i.e. the FDR is controlled at 5%) over a list of maybe 2 or 3 proteins that are not in error 
according to the FWER criterion. The most well-known and most widely used FDR procedure 
is the Benjamini-Hochberg FDR [501]. The procedure works as follows: 
In a first step, the p-values are sorted from large to small. If 𝐼 p-values need to be FDR 
corrected, let 𝑖 = 1,… , 𝐼 be the rank of the 𝑖th p-value. Then, the q-value 𝑞𝑖 for the 𝑖th p-value 
is calculated as follows: 
𝑞𝑖 = min𝑘 (1,
𝐼𝑝𝑘
𝐼 − 𝑘 + 1
) ,                                                                                                                        (Eq. 4.65) 
for 1 ≤ 𝑘 ≤ 𝑖. All proteins with a q-value smaller than the proposed threshold, e.g. 5%, are then 
considered statistically significant. 
  
83 
5. RESEARCH HYPOTHESIS 
5.1. Setting the stage 
Many biological processes strongly depend on balanced levels of protein expression and the 
perturbation of a single protein can already lead to organismal malfunctioning (e.g. abnormal 
hemoglobin production in thalassemia [47] or extensive cellular remodeling towards a 
cancerous phenotype [502]). In this respect, quantitative knowledge of a proteome is very 
important for the unraveling of the development and progression of diseases and the 
identification of biomarkers, amongst others. It is fair to state that the transcriptome and the 
translatome only reflect the proteins that can be or are being expressed, but largely fail to 
provide information on a protein’s activity, function, interaction partners, localization and 
modification state (see 1.2.3). As proteins and their modified variants are expressed over a 
large concentration range, accurate quantitative information is a must to distinguish different 
cellular and organismal conditions [503]. 
Label-free shotgun proteomics leads to the identification and quantification of thousands of 
peptides and proteins in a single experiment. Here, analysis of differential abundance of 
proteins is based on ratios derived from reconstructed elution profiles based on MS intensities 
for all PSMs pointing to the same protein or the same protein group in a sample (see section 
3.2). However, the data are highly hierarchical, and intensities can be strongly influenced by 
variations of peptide-specific properties. In addition, the number of peptides identified in all 
samples is usually limited, which leads to large numbers of missing values (Fig. 5.1), which do 
not occur at random. Some peptides are better detected than others and high-abundant 
peptide ions are more likely to yield higher numbers of fragmentation spectra. "Match between 
runs" algorithms can only partly compensate for this effect by reducing the number of missing 
values (see section 3.4). 
 
Figure 5.12. The missing value problem. Left: the number of unique peptides identified per protein in 
the CPTAC dataset [426]. Right: the number of samples in which each protein in the CPTAT dataset is 
identified. The number of proteins identified in 9, 18 and all 27 samples are markedly elevated (cyan 
bars). This is because of the higher numbers of proteins that are exclusively identified in all MS runs 
from 1, 2 or 3 labs respectively. 
Researchers have used a plethora of pipelines for the analysis of label-free shotgun 
proteomics data (see chapter 4). Indeed, since most mass spectrometry researchers do not 
have a background in statistics, different preprocessing and differential analysis methods are 
often combined ad hoc without a proper motivation. Many methods analyze the data protein 
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by protein by (a) filtering out proteins as soon as they are missing in a specified number of 
samples (see 4.1.2), (b) summarize the peptides for each protein in a sample and ignore 
missing values (see 4.1.5) or (c) impute missing values based on the observed peptides for 
the corresponding protein in other samples (see 4.1.4). Filtering out all proteins (a) leads to 
substantial information loss. Indeed, as demonstrated in Fig. 5.1, removing proteins that are 
only identified with more than a given number of peptides or requiring proteins to be identified 
in all of the samples would remove a substantial amount of proteins from the dataset. 
Summarization (b) needs to be executed such that it correctly takes the peptide-specific effects 
into account. A particular challenge here are the limited numbers of peptides that are identified 
across different samples. If summarization does not correctly take the differences in ionization 
efficiencies into account, it will introduce a bias because the final data will be based on different 
peptides. Moreover, summarization will always ignore differences in accuracy due to the 
different numbers of peptides on which each summary is based. Imputation (c) is even more 
tedious because missing values in proteomics are a combination of missing completely at 
random and intensity- and even context-dependent missingness. Since it is impossible to know 
the exact contributions of these different types of missingness, imputation according to 
incorrect assumptions will lead to biased quantifications. However, if missing values are simply 
ignored, low-abundant proteins will be over-estimated due to the limited linear dynamic range, 
which will reduce the power to detect differential abundance. 
In addition, a proteomics experiment typically consists of a relatively small number of biological 
repeats compared to the large number of proteins analyzed. This gives rise to unstable 
variance estimates for certain proteins, especially if these proteins are identified with only a 
few peptides. Indeed, a small sample drawn from a given population might display a variance 
that is much smaller (or much bigger) than the true population variance just by random chance. 
Therefore, some observations might be flagged as differentially abundant solely because of 
their low observed variances while other truly differentially abundant proteins might be missed 
due to their large observed variances. This data sparsity also leads to unstable fold change 
estimates: one or two outlying intensities, which can for example be caused by 
misidentifications or co-eluting peptides, can strongly influence a protein’s fold change. 
These unstable fold change and variance estimates may cause a significant increase in the 
number of false positives and false negatives (see e.g. the supplementary material of Doll et 
al. (2017) [504], where SERINC3 and PNMA1 were declared significantly altered with very 
weak evidence based on only a single peptide). It is therefore not surprising that a recent power 
calculation study on four biological repeats of Arabidopsis thaliana Col-0 samples analyzed in 
technical triplicate estimated that for MaxLFQ summaries, a minimal fold change of 1.4 is 
required to detect a statistically significant difference with 95% confidence and a power of 
80%[463]. 
State-of-the-art proteomics quantification methods only focus on some of the sub-problems 
mentioned above. They generally remain fairly sensitive to outliers and correct for missing 
observations only to a limited extent. In addition, they usually prune the number of potential 
hits by filtering out proteins which have few peptides in common across the majority of the 
samples. Methods that model peptide-level data are often more sensitive because they 
naturally correct for the correlation present within the same samples, as well as for the peptide 
effects and the number of detected peptides for a given protein in each sample [425, 471]. 
Like summarization-based methods, many peptide-based models still produce unstable 
estimates of differential abundance and variance components due to over-parameterization. 
This especially occurs when few peptides are identified per protein: many low-abundant 
proteins are then falsely labeled as differentially abundant. Filtering on the basis of the number 
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of identified peptide spectra can provide a solution, but there is a risk that real hits will also be 
filtered out. Moreover, most peptide-based models remain very sensitive to outliers. 
In addition, many methods are only suitable to analyze specific types of experimental designs. 
For example, in Perseus, it is possible to compare multiple groups to each other, but it is not 
possible to accurately analyze blocked designs, such as CPTAC. In MSstats, the user should 
annotate each experiment with a “Run”, “Condition” and “BioReplicate”. Hereby, “Run” refers 
to the MS run, “Condition” to the treatment of interest and “BioReplicate” to a grouping factor 
that is encoded as a random effect. While this set-up allows most simple experimental designs 
to be analyzed in a correct way, it is insufficiently flexible to correctly analyze more complicated 
designs with multiple confounding effects. 
Finally, state-of-the-art data analysis methods, such as published models at the peptide level, 
do not always find their way to proteomic labs [474, 475]. This is a non-negligible problem! 
Indeed, many groups only demonstrated proof-of-concept, but never developed their method 
into a usable software package. And, those who did often lack a convenient graphical user 
interface that is appealing to less-experienced users. Availability, user-friendliness, 
documentation, support and maintenance of software tools are very important for new methods 
to be effective for end users. 
5.2. Aims of my PhD work 
Based on the previous section, it is clear that state-of-the-art proteomics quantification 
methods do not yet make optimal use of the data, resulting in suboptimal protein 
quantifications. The development of robust data analysis tools for quantitative proteomics is 
therefore essential for the further development of the proteomics research field because, with 
the current data-analytical methods, many proteins remain under the radar [505]. The overall 
aim of my work was to develop a more robust, easy-to use proteomics quantification method 
that is also usable for the analysis of proteins with a limited overlap in identified peptides.  
More specifically, this method should: 
- account for the hierarchical nature of the data,  
- handle missing peptides in a more correct way,  
- derive strength from the massive parallel availability of peptides to estimate variance 
components more correctly, 
- be robust to outliers, 
- and be able to handle complex experimental designs. 
In such a method, it is important that a random effect for run is included in order to allow to 
correct for within-run correlation. In this respect, it is tempting to build upon the link between 
mixed models and ridge regression, to make use of robust regression with M estimation and 
to allow for empirical Bayes variance estimation. Implementing this method is expected to 
increase the number of truly differentially abundant proteins identified in screening 
experiments. The method should also be implemented and distributed in a user-friendly 
software tool for differential proteomics with the possibility of a graphical user interface to 
maximize the impact of the research. 
To develop such a method, it is first necessary to thoroughly benchmark the most promising 
and most commonly used quantification methods. This will shed light on how preprocessing, 
standardization and differential analysis in a label-free proteomics quantification workflow 







The remainder of my thesis is constructed as follows: first, I will present each of my published 
papers. In my first paper, I demonstrate how I compared different data analysis methods for 
differential quantification in label-free shotgun proteomics. My second paper presents the 
rationale behind MSqRob, the algorithm I developed to improve quantification in label-free 
shotgun proteomics. In my third paper, I provide a tutorial on experimental design and data 
analysis with MSqRob. In my fourth, unpublished paper, I make use of the additional 
information of peptide counts to boost MSqRob’s power and to indicate whether a protein’s 
significance is mainly driven by differential abundance, differential detection or both. 
In the discussion, I explore the significance of my work and place it in a broader context. In the 
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8. SUMMARIZATION VS PEPTIDE-BASED MODELS IN 
LABEL-FREE QUANTITATIVE PROTEOMICS: 
PERFORMANCE, PITFALLS, AND DATA ANALYSIS 
GUIDELINES 
In chapter 8, we show that peptide-based models outperform summarization-based pipelines 
for the analysis of quantitative proteomics data. We also demonstrate that the predefined false 
discovery rate cut-offs for the detection of differentially regulated proteins can become 
problematic when differentially abundant (DA) proteins are highly abundant in one or more 
samples. We also show that care should be taken when data are interpreted from samples 
with spiked-in internal controls and from samples that contain a few very highly abundant 
proteins. For this work, I performed most of the data analysis and wrote the manuscript 
together with my co-authors. 
Goeminne L.J.E.*, Argentini A.*, Martens L. and Clement L. (2015). Summarization vs 
Peptide-Based Models in Label-Free Quantitative Proteomics: Performance, Pitfalls, 
and Data Analysis Guidelines. Journal of Proteome Research. 14(6), 2457-2465 




Quantitative label-free mass spectrometry is increasingly used to analyze the proteomes of 
complex biological samples. However, the choice of appropriate data analysis methods 
remains a major challenge. We therefore provide a rigorous comparison between peptide-
based models and peptide-summarization-based pipelines. We show that peptide-based 
models outperform summarization-based pipelines in terms of sensitivity, specificity, accuracy, 
and precision. We also demonstrate that the predefined FDR cutoffs for the detection of 
differentially regulated proteins can become problematic when differentially expressed (DE) 
proteins are highly abundant in one or more samples. Care should therefore be taken when 
data are interpreted from samples with spiked-in internal controls and from samples that 
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contain a few very highly abundant proteins. We do, however, show that specific diagnostic 
plots can be used for assessing differentially expressed proteins and the overall quality of the 
obtained fold change estimates. Finally, our study also illustrates that imputation under the 
“missing by low abundance” assumption is beneficial for the detection of differential expression 
in proteins with low abundance, but it negatively affects moderately to highly abundant 
proteins. Hence, imputation strategies that are commonly implemented in standard proteomics 
software should be used with care. 
8.2. Keywords 
data analysis; differential proteomics; linear model 
8.3. Introduction 
Current high throughput mass spectrometry (MS) experiments enable the simultaneous 
identification and quantification of thousands of peptides and proteins in biological samples 
under various experimental conditions. These methods allow us to extend our understanding 
of biological processes and are important for the identification of biomarkers for the early 
detection, diagnosis, and prognosis of disease. Quantitative proteomics workflows broadly fall 
into two categories: labeled approaches and label-free approaches.(1) Labeled workflows rely 
on the labeling of proteins or peptides with isobaric or isotopic mass tags and are currently 
more commonly used. Label-free proteomics workflows, however, do not require these 
additional labor intensive and expensive sample processing steps.(2) Label-free approaches 
can perform quantitative proteome comparisons among an unlimited number of samples and 
can also be applied retroactively to previously acquired data.(3) Although label-free 
quantifications tend to have slightly higher coefficients of variation compared to SILAC labeling, 
label-free quantifications are more reproducible and can identify up to 60% more proteins than 
labeled quantifications.(4, 5) 
A typical label-free shotgun MS-based proteomics workflow consists of (a) a protein extraction 
step followed by enzymatic digestion, (b) reverse phase high performance liquid 
chromatography (HPLC) separation, (c) mass spectrometry (MS), (d) a data analysis step 
involving the identification and quantification of peptides and proteins, and (e) a statistical 
analysis for assessing differential protein abundance.(6, 7) In a typical data-dependent 
analysis, selected peptides are isolated and fragmented, generating a fragmentation spectrum 
that is then used for peptide identification.(8) Technological constraints, however, limit the 
number of peptides in each fraction that can be selected for fragmentation. As the selection 
criteria typically involve the MS peak intensities in a particular time window, the identifications 
in MS-based experiments are inherently associated with the abundance of ionized peptides. 
Moreover, the steric effects of digestion enzymes(9) and differences in ionization efficiency 
favor particular peptides. Coeluting peptides heavily influence the observed MS intensities.(10) 
Hence, proteomics data suffer from nonrandom missing values and a large variability, 
rendering the development of reliable data analysis pipelines for quantitative proteomics a 
challenging task.(11) 
The current data analysis strategies for label-free quantitative proteomics are typically based 
on spectral counting or peak intensities.(1) In the former approach, the number of peptide-to-
spectrum matches (PSMs) for a given peptide are counted, and these are then accumulated 
over all peptides from a given protein.(12) Even though these methods are very intuitive and 
easy to apply, they remain controversial.(13, 14) Moreover, these methods necessarily ignore 
a large part of the information available in high precision mass spectra and are not very efficient 
in detecting low fold changes.(15) Peak-intensity-based methods, however, use the maximum 
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intensity or the area under the peak as a proxy for peptide abundance and tend to produce 
more precise protein abundance estimates.(15) We therefore focus on these latter 
approaches. 
Many peak-based data analysis methods for the preprocessing and differential analysis of 
quantitative label-free proteomics data have been described in the literature. Modular 
approaches consisting of a separate normalization, summarization, and data analysis step are 
commonly used.(16, 17) Peptides originating from the same protein can indeed be considered 
technical replicates and theoretically should lead to similar abundance estimates. However, 
the summarization of the peptide intensities into protein expression values is cumbersome, 
and most summarization-based methods do not correct for differences in peptide 
characteristics or for the between-sample differences in the number of peptides that are 
identified per protein. This might introduce bias and differences in uncertainty between the 
aggregated protein expression values, which are typically ignored in downstream data analysis 
steps. The aforementioned nonrandom character of missing peptides further exacerbates 
these issues. 
In response, linear regression approaches have been developed that immediately estimate the 
differential abundance between the proteins from observed peptide intensities, and their 
authors have made bold claims on their performance.(18, 19) Objective comparisons and 
general guidelines for the practitioner are, however, still lacking, which impedes the 
dissemination of more efficient data analysis pipelines into the proteomics community. 
In this paper, we therefore present a rigorous comparison among modular and peptide-based 
regression methods for analyzing label-free quantitative proteomics data. We exploit the 
availability of the benchmark data sets to provide insight into the performance differences and 
technological artifacts that often arise in label-free proteomics experiments. It should also be 
noted that the benchmark data used here present a range of concentration differences, which 
enables us to analyze the suitability of different methods for different situations (e.g., small 
abundance differences versus large abundance differences or few missing peptides versus 
many missing peptides across analyses). In section 2 we present the benchmark data, the 
different data analysis methods, and the performance criteria that will be used in our 
comparison. The results are presented and discussed in sections 3 and 4. 
8.4. Materials and methods 
We used the publicly available data set from Study 6 of the Clinical Proteomic Technology 
Assessment for Cancer (CPTAC) Network(20) for assessing the performance of different data 
analytic workflows for quantitative label-free proteomics. In the CPTAC study, a mixture of 48 
human proteins from the Sigma-Aldrich Universal Proteomics Standard 1 (UPS) was spiked 
into a 60 ng of protein/μL resuspended yeast lysate of Saccharomyces cerevisiae strain 
BY4741 (MATa, leu2Δ0, met15Δ0, ura3Δ0, and his3Δ1). Spike-ins were performed at five 
different concentrations: 0.25 fmol of UPS protein/μL (A), 0.74 fmol of UPS protein/μL (B), 2.22 
fmol of UPS protein/μL (C), 6.67 fmol of UPS protein/μL (D), and 20 fmol of UPS protein/μL 
(E). The prepared samples were then sent to five different laboratories and analyzed on four 
different mass spectrometry platforms. 
We identified peptides by searching the data using MaxQuant v1.5 against the yeast 
UniprotKB/Swiss-Prot protein database (v 15.14) to which the 48 UPS protein sequences were 
added. Detailed search settings can be found in the Supporting Information. A general 
overview of the number of identified peptides and proteins in our search can be found in Table 
S1, Supporting Information. Statistical analyses were implemented in RStudio version 
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0.98.978 (RStudio, Boston, MA) interfacing R 3.1.0 (“Spring Dance”). Standard Perseus 
analysis workflows were executed in Perseus version 1.5. We introduce two Perseus 
workflows in section 8.4.1, two different modular pipelines that aggregate peptide intensities 
into protein expression values in section 8.4.2, and three different peptide-based regression 
methods in section 8.4.3. The performance criteria used to compare the different methods can 
be found in section 8.4.4. 
8.4.1. Perseus-based workflows 
We used a typical workflow implemented in the software package Perseus. The analysis starts 
from (a) the LFQ intensities given in the MaxQuant’s proteinGroups.txt file, which consist of 
normalized and summarized intensities at protein level. The MaxLFQ procedure then proceeds 
as follows: for all pairwise comparisons of a protein between samples, the median ratio for the 
common peptides in both samples is calculated. Next, the abundance protein profile that 
optimally satisfies these protein ratios is reconstructed with a least-squares regression model. 
The whole profile is then rescaled to the cumulative intensity across the samples with 
preservation of the total summed intensity for a protein across the samples. As the resulting 
LFQ intensities are already normalized by the MaxLFQ procedure,(21) no additional 
normalization step is required. In (b), the LFQ protein intensities are read into Perseus. The 
proteins that are only identified by a modification site, the contaminants, and the reversed 
sequences are removed from the data set, and the remaining intensities are log2-transformed. 
Next, (c) involves the imputation of missing values using Perseus’ standard settings.(22) 
Finally, (d) consists of inference by pairwise two-sample t tests. The multiple testing problem 
is addressed using the Benjamini–Hochberg False Discovery Rate (FDR) procedure.(23) The 
(a)–(d) pipeline is referred to as perseusImp. We also consider a second variant, 
perseusNoImp, in which the imputation step (c) is omitted. 
8.4.2. Summarization-based workflows 
A typical modular workflow for quantitative proteomics consists of a normalization, 
summarization, and statistical analysis step.(6, 7) In our contribution, we assess two 
customized pipelines that build upon popular mean and median summarization strategies for 
the summarization of peptide intensities into protein expression values. The following steps 
are considered in the analysis pipelines: (a) the intensities from MaxQuant’s peptides.txt output 
file are log2-transformed and normalized using quantile normalization (with the peptides 
mapping to reversed sequences or mapping to multiple proteins being removed from the data), 
(b) peptide intensities are aggregated into protein expression values using mean or median 
summarization, and (c) summarized protein expression values are further analyzed using 
empirical Bayes moderated t tests implemented in the R/Bioconductor package “limma”.(24) 
The Benjamini–Hochberg FDR procedure is used to correct for multiple testing. The two 
resulting methods are referred to as limmaMean and limmaMedian. 
In the limma analysis, the following model is considered for each protein i: 
𝑦𝑖𝑘𝑙 = 𝑡𝑟𝑒𝑎𝑡𝑖𝑘 + 𝑒𝑥𝑝𝑖𝑙 + 𝜀𝑖𝑘𝑙, (1) 
with 𝑦𝑖𝑘𝑙 being the aggregated protein intensity for the k-th treatment (treat) and the l-th 
experiment (exp) correcting for (lab × instrument × repeat) batch effects. εikl is a random error 
term that is assumed to be normally distributed with mean 0 and variance 𝜎𝑖2. Note that the 
treat effect is the effect of interest. Contrasts between treat parameters can be interpreted as 
log2 fold changes for protein i. For instance, k = A indicates condition A (spike-in concentration 
of 0.25 fmol of UPS protein/μL) and k = E indicates condition E (spike-in concentration of 20 
119 
 
fmol of UPS protein/μL). If so, then 𝑡𝑟𝑒𝑎𝑡𝑖𝐸 − 𝑡𝑟𝑒𝑎𝑡𝑖𝐴 indicates the expected log2 difference in 
concentration for protein i between group E and group A. The statistical significance of the 
contrasts can be addressed by using t tests. The limma analysis exploits the massively parallel 
nature of quantitative proteomics experiments and allows for the borrowing of strength across 
proteins to estimate the error variance, i.e., makes use of a moderated empirical Bayes 





with 𝑠𝑖 and 𝑑𝑖 being the standard deviation and the residual degrees of freedom for protein i, 
respectively, 𝑠0 the estimated prior standard deviation, and 𝑑0 the prior degrees of freedom. 
Both the prior standard deviation and the prior degrees of freedom are estimated using 
empirical Bayes by pooling information across all proteins. Hence, the protein-based variance 
𝑠𝑖2 is shrunk toward a common variance 𝑠02, leading to more stable variance estimates (?̃?𝑖2). 
Note that the degrees of freedom from the moderated t test also increase to d0 + di. Detailed 
information can be found in the work of Smyth.(24) 
8.4.3. Peptide-based models 
Peptide-based models use the MaxQuant peptides.txt file as input. In (a), the extracted peptide 
intensities are log2-transformed and quantile normalized (Figures S8 and S9, Supporting 
Information), and peptides mapping to reversed sequences or mapping to multiple proteins are 
removed from the data. In (b), the peptide data are modeled with three different candidate 
models. In (c), inference is done by pairwise contrast testing. Multiple testing is addressed 
using the Benjamini–Hochberg FDR. 
Linear Model without Sample Effect 
For each protein i, the following model is proposed: 
𝑦𝑖𝑗𝑘𝑙𝑚 = 𝑝𝑒𝑝𝑖𝑗 + 𝑡𝑟𝑒𝑎𝑡𝑖𝑘 + 𝑒𝑥𝑝𝑖𝑙 + 𝜀𝑖𝑗𝑘𝑙𝑚, (2) 
with 𝑦𝑖𝑗𝑘𝑙𝑚 being the log2-transformed intensity for the j-th peptide sequence 𝑝𝑒𝑝𝑖𝑗 of the k-th 
treatment 𝑡𝑟𝑒𝑎𝑡𝑖𝑘 and the l-th experiment 𝑒𝑥𝑝𝑖𝑙. 𝜀𝑖𝑗𝑘𝑙𝑚 is a normally distributed error term with 
mean 0 and variance σi2. The index m refers to multiple spectra that are identified for the same 
peptide in the same experiment and the same treatment. Contrasts in 𝑡𝑟𝑒𝑎𝑡𝑖𝑘 parameters can 
again be interpreted as log2 fold changes for protein i. The model also incorporates a 𝑝𝑒𝑝𝑖𝑗 
effect to account for peptide-specific fluctuations around the mean protein intensity, which 
originate from differences in digestion and ionization efficiency, among others.(9) 
Linear Model with Sample Effect 
Model 2 is extended by incorporating an additional sample effect, 𝑠𝑎𝑚𝑝𝑙𝑒𝑖𝑘𝑙, to capture 
deviations specific to each MS run (lab × instrument × treatment × repeat): 
𝑦𝑖𝑗𝑘𝑙𝑚 = 𝑝𝑒𝑝𝑖𝑗 + 𝑡𝑟𝑒𝑎𝑡𝑖𝑘 + 𝑒𝑥𝑝𝑖𝑙 + 𝑠𝑎𝑚𝑝𝑙𝑒𝑖𝑘𝑙 + 𝜀𝑖𝑗𝑘𝑙𝑚. (3) 
Note that all remaining effects are similar to those of model 2. 
Mixed Model with Random Sample Effect 
The mixed model extends the linear model 3 by putting a normal prior on the sample effect, 
𝑠𝑎𝑚𝑝𝑙𝑒𝑖𝑘𝑙 ∼ 𝑁(0, 𝜎𝑠𝑎𝑚𝑝𝑙𝑒,𝑖2 ). This model accounts for the correlation within samples and 
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incorporates both within- and between-sample variability when inference is performed on 
contrasts in the 𝑡𝑟𝑒𝑎𝑡𝑖𝑘 effects. The degrees of freedom of the t tests are approximated using 
the Satterthwaite approximation,(25) and the Benjamini–Hochberg FDR procedure is used to 
account for multiple testing.(23) 
8.4.4. Performance 
For each method, p values are converted to q values using the Benjamini–Hochberg FDR 
procedure,(23) and a cutoff is set at 5% FDR. At this level, the number of false positives (FP), 
true positives (TP), false negatives (FN), and true negatives (TN) are recorded, and the 
nominal FDR level is compared to the observed false discovery rate FDR̅̅ ̅̅ ̅̅  = FP/(FP + TP). Note 
that the observed FDR equals 1 minus the positive predictive value, PPV = TP/(FP + TP). 
The ROC curves are constructed on the basis of the ordering of the p values. Bias (Figures S4 
and S5, Supporting Information), standard deviation (sd), median absolute deviation (mad), 
and root mean squared error (RMSE) (Figures S6 and S7, Supporting Information) are 
calculated both for yeast and for UPS proteins. We also calculated the F1 score, which is 
defined as the harmonic mean of the PPV and the sensitivity. Higher F1 scores indicate that a 
method provides a good balance between the PPV and the recall (Figures S1 and S2, 
Supporting Information). 
8.5. Results 
We investigated the sensitivity, specificity, and F1 score of the test procedure as well as the 
accuracy and the precision of the fold change (FC) estimates for three peptide-based methods 
and four summarization-based data analysis pipelines using the CPTAC Study 6 data set.(20) 
This data set consists of samples with a uniform yeast proteome background in which human 
UPS peptides are spiked at five different concentrations (0.25, 0.74, 2.22, 6.67, and 20 
fmol/μL). All 10 pairwise comparisons are assessed in each analysis. The following peptide-
based methods are considered: a linear model without sample effect (lmNoSamp), a linear 
model with sample effect (lmSamp), and a mixed model with a random sample effect 
(mixedSamp). The summarization-based approaches consist of mean and median 
summarizations of peptides into protein expression values followed by limma analyses 
(limmaMean and limmaMedian) as well as the more advanced MaxLFQ summarization(21) 
followed by a standard Perseus workflow with and without imputation (perseusImp and 
perseusNoImp). All peptide identifications and intensities were based on MaxQuant so as to 
avoid biases due to the search engine or peak intensity calculation algorithm. 
Receiver operating characteristic (ROC) curves for the four comparisons with the smallest 
differences in spiked-in protein abundance (B–A, C–B, D–C, and E–D) are shown in Figure 1. 
Detecting the differential abundance of UPS proteins is most challenging in these comparisons 
as they only involve fold changes (FCs) very close to 3. ROC curves for the six remaining 
comparisons can be found in Figure S1 in the Supporting Information. Figure 1 shows that the 
lmNoSamp and mixedSamp models clearly outperform the other methods. The lmNoSamp, 
mixedSamp, and perseusImp workflows do control the FDR at 5% for comparisons B–A, C–A, 
and C–B, but perseusNoImp could only control the FDR for comparisons B–A and C–B, and 
both limmaMean and limmaMedian could only control the FDR for comparison B–A (see 
Tables S2–S8 and S12 in the Supporting Information). The lmSamp method is unable to 
control the FDR. When differences in spiked-in concentrations increase, however, none of the 
methods are able to control the FDR correctly (Tables S2–S8 and S12 in the Supporting 
Information). lmSamp is more conservative but cannot control its FDR at 5%, either. The ROC 
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curves also show that the mean summarization outperforms the more robust but less efficient 
median summarization. 
 
Figure 8.1. Receiver operating characteristic (ROC) curves for the seven analysis methods in 
comparisons B–A, C–B, D–C, and E–D. The UPS proteins in these comparisons were spiked in at a 
ratio close to 3:1. Dots denote the estimated cutoff for each method at 5% FDR. The termination of the 
curve before the point (1, 1) indicates either that proteins are prematurely removed from the analysis 
(e.g., for the Perseus workflows) or that there is an inability of the models to fit a protein with too few 
observations (e.g., for peptide-based models). 
As only a part of the ROC curve is relevant in practice, i.e., that experimenters typically want 
to restrict the number of candidate proteins for validation in follow-up experiments, we also 
compared the relative partial areas under the curve (rpAUC) for FPR <0.1. Relative pAUCs 
(Table 8.1) are obtained by dividing pAUC values (Table S13, Supporting Information) by the 
maximum pAUC value of 0.1. Table 8.1 also demonstrates that the lmNoSamp and 
mixedSamp models are superior to the competing pipelines in terms of pAUC. Their power is 
higher in spite of the fact that no information is borrowed across proteins for estimating the 
variance (as compared to the limma workflows) and that there is an absence of imputation (as 
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compared to the standard Perseus method). perseusImp outperforms limmaMean and 
limmaMedian in terms of pAUC when differential expression in very-low-abundance proteins 
needs to be detected (e.g., comparison B–A). In these situations, imputation under the 
assumption of low abundance strongly boosts the performance of the method. The perseusImp 
workflow outperforms the perseusNoImp workflow for all comparisons involving A, i.e., when 
very-low-abundance differentially expressed (DE) proteins are involved in the comparison. But 
in comparisons with more abundant UPS spikes, the opposite is observed, and perseusImp 
shows a suboptimal performance compared to that of perseusNoImp. 
Table 8.1. Relative Partial Area under the Curve (rpAUC) for FPR <0.1 for All Seven Models for Each 













B-A 83.01% 12.41% 83.93% 69.65% 55.70% 68.14% 56.21% 
C-A 98.33% 49.31% 98.60% 85.93% 59.76% 87.22% 77.26% 
D-A 99.20% 72.65% 99.26% 86.31% 63.42% 96.79% 95.18% 
E-A 99.72% 89.06% 99.72% 89.62% 63.79% 97.92% 95.93% 
C-B 95.10% 77.81% 94.60% 52.45% 70.08% 61.79% 50.54% 
D-B 97.05% 89.60% 96.72% 71.00% 72.06% 89.21% 83.54% 
E-B 96.98% 93.50% 95.90% 77.68% 72.41% 90.94% 87.69% 
D-C 96.51% 84.85% 96.01% 64.48% 67.09% 59.77% 54.25% 
E-C 97.34% 94.48% 96.21% 72.92% 74.85% 81.94% 79.23% 
E-D 94.06% 79.45% 92.76% 71.13% 78.02% 74.16% 71.21% 
Mean 95.73% 74.31% 95.37% 74.12% 67.72% 80.79% 75.11% 
 
When the F1 score is examined, the lmNoSamp and mixedSamp models show very 
comparable patterns (Figure S2, Supporting Information). In comparisons E–A, E–B, E–C, and 
D–B, the lmSamp is superior to the other peptide-based models. This is most likely due to its 
more conservative nature. lmNoSamp and mixedSamp suffer from many false positives for 
these comparisons. For the summarization-based models (Figure S3, Supporting Information), 
we notice that perseusNoImp outperforms the other summarization-based methods for most 
comparisons. In comparisons D–A, D–B, E–A, E–B, and E–C, perseusImp shows a higher F1 
score than Perseus without imputation. Again, the mean summarization method almost 
consistently outperforms the median summarization in terms of F1 score, although the 
differences are generally not very large. 
The accuracy and precision of the pipelines are assessed by comparing the differential 
expression estimates to the true log2 fold changes of the spiked UPS peptides [log2 FC ≈ 
log2(3), log2(9), log2(27), and log2(80)] and the yeast peptides (log2 FC = 0). Figures 8.2 and 
8.3 show boxplots of the different DE estimates of the different methods for UPS and yeast 
proteins, respectively. The actual log2 FC is also indicated in the plot. 
                                               




Figure 8.2. Boxplots showing the distributions of the DE estimates of the UPS proteins for each of the 
seven methods in each of the 10 comparisons. Outliers are not shown. The actual fold changes of the 
spikes are indicated with the yellow horizontal lines. 
 
Figure 8.3. Boxplots showing the distributions of the DE estimates of the yeast proteins for each of the 
seven methods in each of the 10 comparisons. Outliers are not shown. All samples consisted of the 
same yeast background. Hence, no differential expression should occur for these proteins. 
Figure 8.2 illustrates that the lmNoSamp and mixedSamp models are superior to the other 
methods in terms of both the accuracy and the precision of the FC estimates for the 
differentially abundant UPS proteins. The mean and median summarization methods 
systematically show a downward bias (Figure S4, Supporting Information). The bias is more 
pronounced in comparisons involving condition A. In condition A, the lowest concentration UPS 
(0.25 fmol/μL) is spiked in and, consequently, fewer UPS peptides are identified. Missingness, 
however, can be expected to involve peptides with a lower ionization efficiency, which typically 
display lower peak intensities than other peptides of the same protein. The simple mean and 
median summarization methods do not correct for differences in peptide characteristics, 
leading to an overestimation of the expression value for UPS proteins in condition A. This leads 
to moderation of the log2 fold change estimates involving condition A. Peptide-based pipelines 
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correcting for peptide effects also suffer from a slight negative bias in comparisons that involve 
condition A. Note that imputation has a severe impact on the precision. Figure S7 in the 
Supporting Information also shows that summarization-based limmaMean and limmaMedian 
methods give the highest root mean squared error (RMSE = [bias2/variance]1/2) among all 
methods that were evaluated. 
Figure 8.3 confirms that the lmNoSamp and the mixedSamp models are favorable in terms of 
accuracy and precision. For the yeast proteins (non-DE), the median and mean summarization 
methods show a bias similar to that of competing methods. An increasing downward bias of 
the log2 FC estimates can be observed for the null proteins (yeast) in comparisons involving 
increasing UPS concentrations. This becomes very apparent for comparisons that involve 
condition E. In this condition, a very high fraction of the total protein mass in the sample 
consists of UPS proteins. Hence, yeast peptides are likely to be masked by UPS, leading to 
an underestimation of the abundance of yeast peptides in the D and E mix. Most false positive 
yeast proteins had negative log2 FC estimates as opposed to the spiked UPS proteins, which 
show positive log2 FC estimates in each comparison. Therefore, issues involving the FDR are 
likely to be linked to the extreme sample composition under conditions D and E, which invokes 
an MS bias.(10) The F1 score masks this artifact, as it combines PPV and sensitivity. The 
same trend is also visible in MA plots for the linear model without sample effect (Figures S10 
and S11, Supporting Information). In these graphs, the average FC is plotted in function of the 
average protein expression for a particular comparison. These graphs are therefore very 
helpful for screening for artifacts induced by the technical and data analysis workflows. Figure 
8.3 also illustrates that the precision reduces with increasing FC, i.e., for comparisons involving 
conditions D and E. Finally, the lmSamp method shows a dramatic decrease in precision for 
comparison B–A. This is a data analysis artifact; the model is overidentified for many proteins, 
leading to the aliasing of sample and treatment effects. Due to the specific model 
parametrization, the overidentification has a larger impact on comparisons involving condition 
A. 
We also investigated alternative data analysis strategies to alleviate this problem. For the 
peptide-based lmNoSamp method, we assessed the impact of testing against the median log2 
FC of all proteins instead of testing against 0. This slightly improves the observed FDR except 
for comparisons C–A and D–B and improves the rpAUC except for comparisons D–A, D–B, 
D–C, and E–C (Table S14, Supporting Information). However, the method still returns too 
many false positives for the comparisons involving high concentrations (Table S9, Supporting 
Information). For the summarization-based methods, we assessed the impact of switching the 
order of the normalization and summarization steps. When the quantile normalization is 
performed after summarization, the observed FDR improved for comparisons involving D and 
E, but the performance decreased dramatically for comparisons B–A and C–A (Tables S10–
S12. Supporting Information). The ROC curves also suggest that switching the order of the 
normalization and summarization steps deteriorates the performance of the limmaMean and 
limmaMedian workflows (Figure S12, Supporting Information). 
8.6. Discussion 
Our analysis showed that peptide-based models perspicuously outperform summarization-
based methods. Both the linear model without sample effect and the mixed model outperform 
the other methods in terms of accuracy, precision, sensitivity, and specificity. The ROC curves 
clearly indicate that these methods produce a more reliable ordering of DE proteins than the 
competing methods. The linear model with sample effect has a suboptimal performance but 
still outperforms the other methods in comparisons that do not involve A. Due to selective and 
periodic sampling in both MS stages, not all peptides are being observed or identified in all 
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samples. Moreover, intensities from different peptides of the same protein vary considerably 
due to differences in cleavage and ionization efficiency among others.(26, 27) Summarization 
thus typically involves different peptides and a different number of peptides in each sample. 
This leads to protein expression values with distinct characteristics, which induces bias and 
incorrect precision of the fold change estimates. 
Peptide-based models are superior in correcting for individual peptide effects, which are 
typically quite strong(18, 19) and accounting for the different number of peptides in each 
sample. Thus, bias is reduced and improved precision estimates are provided, leading to 
higher sensitivity and specificity. The mixed model can also account for the correlation that is 
present in peptides from the same protein within a sample. The peptide-based models with a 
fixed sample effect suffer from the unstable estimation of fold changes and variance 
components due to the overfitting of sparse proteins identified by a few peptides. Moreover, 
the inclusion of a fixed sample effect eliminates the between-sample variability from the 
analysis. Inference between the samples will be based on an underestimated variance, leading 
to a higher number of false positives in a top list. In the linear model without sample effect, 
fewer parameters have to be estimated, and the variances within and between samples are 
combined in the error term. Hence, the method is less prone to overfitting and incorporates 
both within- and between-sample variability in the test statistics, leading to a better control of 
the number of false positives. However, the method does not account for the correlation 
between peptides from a particular protein within a sample. The mixed modeling approach with 
a random sample effect does incorporate within- and between-sample variances as well as the 
within-sample correlation between peptides of the same protein. The mixed model and the 
linear model without sample effect are more or less on par in terms of all assessed 
performance criteria. Hence, the increased computational complexity of the mixed model 
cannot be justified for this particular application. However, in real experiments, more 
correlation can be expected due to the additional biological variation among samples. 
We also showed that the use of FDR thresholds might be flawed under certain experimental 
conditions. This was observed for comparisons involving conditions D and E, i.e., the samples 
with the highest spiked-in UPS concentrations. Under these conditions, the UPS proteins 
correspond to a considerable fraction of the total protein mass in the sample. The ROC curves 
show that peptide-based methods still produce reliable top lists with a superb ordering, but the 
use of a 5% FDR threshold was too liberal. Hence, long protein lists are produced with many 
false positives. The majority of these false positives, however, had FC estimates in the 
opposite direction as those of spiked UPS proteins. This was due to a systematic downward 
bias in the FC estimates of nondifferentially expressed yeast proteins. Competitive ionization 
makes the identification and quantification of yeast peptides cumbersome in samples with 
highly concentrated UPS spikes. Thus, the majority of false positives originate from 
technological artifacts rather than from flaws in the data analysis pipeline. We therefore 
recommend that researchers who are planning to use internal controls in their MS experiments 
avoid overspiking, as this can have detrimental effects on the quantification of the proteins of 
interest. Moreover, artifacts similar to those from spiked UPS proteins are bound to occur in 
certain experimental setups (e.g., undepleted blood plasma proteomic samples are known to 
be dominated by a few highly abundant proteins, and undepleted green tissue samples from 
plants will suffer from the omnipresence of RuBisCo). Our analysis showed that experimenters 
should interpret proteins further down the DE list with care. We therefore advise data analysts 
to use diagnostic plots based on all fold change estimates for assessing the quality of the FC 
estimates and for detecting potential artifacts. MA plots and boxplots were shown to be well 
suited for evaluating candidate DE proteins, to flag critical experimental conditions as well as 
flaws in the data analysis pipeline. 
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The myriad missing values in quantitative proteomic experiments present severe challenges 
to the data analysis. The standard MaxQuant pipeline therefore utilizes the match-between 
runs option to boost the number of peptide intensities that different samples have in common. 
Moreover, Perseus also incorporates imputation-based routines to deal with missing protein 
expression values. We showed that imputation is beneficial for detecting differentially 
expressed proteins with low abundance but performs suboptimally for moderately to highly 
abundant proteins. Perseus’ standard imputation algorithm assumes that missing values 
originate from lower intensity values. Hence, the imputation can lead to a downward bias for 
more abundant proteins. Moreover, experimenters should also be aware that imputation 
comes at the cost of a decreased precision for the FC estimates. 
In general, the current peptide-based methods are prone to overfitting and rely on protein-by-
protein variance estimates. Hence, the development of robust methods that can borrow 
information across peptides and proteins would enable proteomics researchers to further 
deploy label-free quantitative proteomics. 
In summary, we have shown that issues inherent to the methodology create challenges in 
quantitative proteomics, even in highly controlled and standardized samples such as the 
CPTAC ones. We then go on to show that downstream statistical data analysis approaches 
differ in their ability to cope with these different issues, and that the importance of these issues 
depends on the characteristics of the sample under study (e.g., the dominance of a few highly 
abundant proteins or large protein concentration ratio differences between two samples). 
Crucial, perhaps, is the fact that although peptide-based approaches fare better than 
summarization methods, no single method currently exists that can easily tackle all possible 
issues in quantitative proteomics data. Hence, more sophisticated data processing approaches 
that recognize these various issues are needed and can compensate for such issues more 
successfully across the board. 
8.7. Conclusion 
In this paper, we compared the performance of peptide-based linear models, mean and median 
summarization followed by limma analysis, and the standard MaxQuant/Perseus workflow for 
assessing differential abundance in label-free quantitative proteomics experiments. The 
evaluation of the performance was assessed using the CPTAC benchmark data set. Peptide-
based models outperformed the competing data analysis pipelines in terms of sensitivity, 
specificity, accuracy, and precision. Modeling quantitative proteomics data at the peptide level 
allows for the correction of strong peptide-specific effects, which avoids the bias associated 
with summarization-based methods that aggregate different types of peptide intensities into a 
single value. Moreover, peptide-based models also improve the precision estimates by 
accounting for the different numbers of peptides that are identified in a sample. We have also 
shown that the FDR cutoffs used to determine the length of lists with significant differentially 
expressed (DE) proteins could become problematic in experimental setups with samples that 
are dominated by a few very abundant proteins. Technological artifacts might induce bias in 
the non-DE proteins, which can inflate the number of false positives that are returned at a 
particular FDR level. However, the ordering of the top DE proteins in the lists was shown to 
remain valid. We therefore advise proteomics researchers to be careful when spiking internal 
controls, to deplete the highly abundant proteins, and to use diagnostic plots for assessing the 
candidate DE proteins as well as the overall quality of the obtained fold change estimates. 
Finally, standard proteomics software provides experimenters with the ability to impute missing 
values. Perseus’ imputation strategy was shown to be beneficial for detecting DE proteins with 
low abundance but at the cost of reduced precision as well as a suboptimal performance for 
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moderately to highly abundant DE proteins. Hence, we advise proteomics data analysts to use 
imputation strategies with care. 
8.8. Supporting information 
Figures showing the receiver operating characteristic (ROC) curves for the seven analysis 
methods in comparisons, F1 scores for the studied models, comparison of the bias terms for 
yeast and UPS proteins, comparisons of the root mean squared error for yeast and UPS 
proteins, boxplots showing log2 peptide intensities, MA plots for linear models, and ROC curves 
for normalization on the peptide and protein level with mean and median aggregation. Tables 
showing a general overview per spike-in conditions for UPS and yeast proteins, characteristics 
for various models and workflows, an explanation of the outlined characteristics, partial areas 
under the curves for a false positive rate, and relative partial areas under the curves for a false 
positive rate. The Supporting Information is available free of charge on the ACS Publications 
website at DOI: 10.1021/pr501223t. 
pr501223t_si_001.pdf (1.38 MB) 
8.9. Acknowledgement 
Part of this research was supported by IAP research network “StUDyS” grant no. P7/06 of the 
Belgian government (Belgian Science Policy) and the Multidisciplinary Research Partnership 
“Bioinformatics: From Nucleotides to Networks” of Ghent University. A.A. is supported by the 
IWT SBO grant “INSPECTOR” (120025). L.J.E.G. is supported by the IWT SBO grant 
“Differential Proteomics at Peptide, Protein, and Module Level” (141573). L.M. acknowledges 
the PRIME-XS project, grant agreement no. 262067, funded by the European Union Seventh 
Framework Program. 
8.10. References 
This article references 27 other publications. 
1. Vaudel, M.; Sickmann, A.; Martens, L. Peptide and protein quantification: A map of the 
minefield Proteomics 2010, 10 (4) 650– 670  
2. Bluemlein, K.; Ralser, M. Monitoring protein expression in whole-cell extracts by targeted 
label- and standard-free LC-MS/MS Nat. Protoc. 2011, 6 (6) 859– 869 
3. Cox, J.; Hein, M. Y.; Luber, C. A.; Paron, I.; Nagaraj, N.; Mann, M. Accurate proteome-wide 
label-free quantification by delayed normalization and maximal peptide ratio extraction, termed 
MaxLFQ Mol. Cell. Proteomics 2014, 13 (9) 2513– 2526 
4. Liu, N. Q.; Dekker, L. J. M.; Stingl, C.; Güzel, C.; De Marchi, T.; Martens, J. W. M.; Foekens, 
J. A.; Luider, T. M.; Umar, A. Quantitative Proteomic Analysis of Microdissected Breast Cancer 
Tissues: Comparison of Label-Free and SILAC-based Quantification with Shotgun, Directed, 
and Targeted MS Approaches J. Proteome Res. 2013, 12 (10) 4627– 4641 
5. Mosley, A. L.; Sardiu, M. E.; Pattenden, S. G.; Workman, J. L.; Florens, L.; Washburn, M. 
P. Highly Reproducible Label Free Quantitative Proteomic Analysis of RNA Polymerase 
Complexes Mol. Cell. Proteomics 2011, DOI: 10.1074/mcp.M110.000687  
6. Wang, G.; Wu, W. W.; Zeng, W.; Chou, C.-L.; Shen, R.-F. Label-Free Protein Quantification 
Using LC-Coupled Ion Trap or FT Mass Spectrometry: Reproducibility, Linearity, and 
Application with Complex Proteomes J. Proteome Res. 2006, 5 (5) 1214– 1223 
128 
 
7. Silva, J. C.; Gorenstein, M. V.; Li, G.-Z.; Vissers, J. P. C.; Geromanos, S. J. Absolute 
Quantification of Proteins by LCMSE: A Virtue of Parallel ms Acquisition Mol. Cell. Proteomics 
2006, 5 (1) 144– 156 
8. Vaudel, M.; Sickmann, A.; Martens, L. Current methods for global proteome identification 
Expert Rev. Proteomics 2012, 9 (5) 519– 532 
9. Peng, M.; Taouatas, N.; Cappadona, S.; van Breukelen, B.; Mohammed, S.; Scholten, A.; 
Heck, A. J. R. Protease bias in absolute protein quantitation Nat. Methods 2012, 9 (6) 524– 
525 
10. Schliekelman, P.; Liu, S. Quantifying the Effect of Competition for Detection between 
Coeluting Peptides on Detection Probabilities in Mass-Spectrometry-Based Proteomics J. 
Proteome Res. 2013, 13 (2) 348– 361 
11. Kumar, C.; Mann, M. Bioinformatics analysis of mass spectrometry-based proteomics data 
sets FEBS Lett. 2009, 583 (11) 1703– 1712 
12. Liu, H.; Sadygov, R. G.; Yates, J. R. A Model for Random Sampling and Estimation of 
Relative Protein Abundance in Shotgun Proteomics Anal. Chem. 2004, 76 (14) 4193– 4201 
13. Bantscheff, M.; Schirle, M.; Sweetman, G.; Rick, J.; Kuster, B. Quantitative mass 
spectrometry in proteomics: a critical review Anal. Bioanal. Chem. 2007, 389 (4) 1017– 31 
14. Mueller, L. N.; Brusniak, M.-Y.; Mani, D. R.; Aebersold, R. An Assessment of Software 
Solutions for the Analysis of Mass Spectrometry Based Quantitative Proteomics Data J. 
Proteome Res. 2008, 7 (1) 51– 61 
15. Old, W. M.; Meyer-Arendt, K.; Aveline-Wolf, L.; Pierce, K. G.; Mendoza, A.; Sevinsky, J. 
R.; Resing, K. A.; Ahn, N. G. Comparison of Label-free Methods for Quantifying Human 
Proteins by Shotgun Proteomics Mol. Cell. Proteomics 2005, 4 (10) 1487– 1502 
16. Théron, L.; Gueugneau, M.; Coudy, C.; Viala, D.; Bijlsma, A.; Butler-Browne, G.; Maier, A.; 
Béchet, D.; Chambon, C. Label-free Quantitative Protein Profiling of vastus lateralis Muscle 
During Human Aging Mol. Cell. Proteomics 2014, 13 (1) 283– 294 
17. Hubner, N. C.; Bird, A. W.; Cox, J.; Splettstoesser, B.; Bandilla, P.; Poser, I.; Hyman, A.; 
Mann, M. Quantitative proteomics combined with BAC TransgeneOmics reveals in vivo protein 
interactions J. Cell Biol. 2010, 189 (4) 739– 754 
18. Clough, T.; Key, M.; Ott, I.; Ragg, S.; Schadow, G.; Vitek, O. Protein Quantification in Label-
Free LC-MS Experiments J. Proteome Res. 2009, 8 (11) 5275– 5284 
19. Karpievitch, Y.; Stanley, J.; Taverner, T.; Huang, J.; Adkins, J. N.; Ansong, C.; Heffron, F.; 
Metz, T. O.; Qian, W.-J.; Yoon, H.; Smith, R. D.; Dabney, A. R. A statistical framework for 
protein quantitation in bottom-up MS-based proteomics Bioinformatics 2009, 25 (16) 2028– 
2034 
20. Paulovich, A. G.; Billheimer, D.; Ham, A.-J. L.; Vega-Montoto, L.; Rudnick, P. A.; Tabb, D. 
L.; Wang, P.; Blackman, R. K.; Bunk, D. M.; Cardasis, H. L.; Clauser, K. R.; Kinsinger, C. R.; 
Schilling, B.; Tegeler, T. J.; Variyath, A. M.; Wang, M.; Whiteaker, J. R.; Zimmerman, L. J.; 
Fenyo, D.; Carr, S. A.; Fisher, S. J.; Gibson, B. W.; Mesri, M.; Neubert, T. A.; Regnier, F. E.; 
Rodriguez, H.; Spiegelman, C.; Stein, S. E.; Tempst, P.; Liebler, D. C. Interlaboratory Study 
Characterizing a Yeast Performance Standard for Benchmarking LC-MS Platform 
Performance Mol. Cell. Proteomics 2010, 9 (2) 242– 254 
129 
 
21. Cox, J.; Hein, M. Y.; Luber, C. A.; Paron, I.; Nagaraj, N.; Mann, M. Accurate Proteome-
wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio 
Extraction, Termed MaxLFQ Mol. Cell. Proteomics 2014, 13 (9) 2513– 2526 
22. Cox, J.; Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-
range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 2008, 26 
(12) 1367– 1372 
23. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple Testing J. R. Stat. Soc.: Series B 1995, 57 (1) 289– 300 
24. Smyth, G. K., Linear models and empirical bayes methods for assessing differential 
expression in microarray experiments. Stat Appl. Genet. Mol. Biol. 2004, 3, Article 3. 
25. Satterthwaite, F. E. An approximate distribution of estimates of variance components 
Biometrics 1946, 2 (6) 110– 4 
26. Rodriguez, J.; Gupta, N.; Smith, R. D.; Pevzner, P. A. Does Trypsin Cut Before Proline? J. 
Proteome Res. 2008, 7 (1) 300– 305 
27. Abaye, D. A.; Pullen, F. S.; Nielsen, B. V. Peptide polarity and the position of arginine as 
sources of selectivity during positive electrospray ionisation mass spectrometry Rapid 







9. ROBUST QUANTIFICATION FOR LABEL-FREE  
MASS SPECTROMETRY-BASED PROTEOMICS 
Chapter 9 describes MSqRob, our R software package for improved differential protein 
abundance analysis in label-free MS-based proteomics. MSqRob is freely available on GitHub 
(https://github.com/statOmics/MSqRob) and is implemented in a "Shiny" user-friendly 
graphical interface. 
In section 9.1, I introduce MSqRob as a new algorithm for the analysis of quantitative 
proteomics data that improves protein quantification by combining three innovative statistical 
approaches: ridge regression, empirical Bayes variance estimation, and M-estimation with 
Huber weights. MSqRob is both more precise and more accurate than state-of-the-art tools. I 
developed and implemented MSqRob as an R package and wrote the manuscript together 
with my supervisors. 
Section 9.2 is published as an invited tutorial paper in which I outline key statistical concepts 
to help researchers to design proteomics experiments and showcases of quantitative 
proteomics data analysis with MSqRob. For this manuscript, I designed and performed 
analyses, set up the GitHub repository and wrote the paper together with my supervisors. 
9.1. Peptide-level Robust Ridge Regression Improves Estimation, 
Sensitivity, and Specificity in Data-dependent Quantitative Label-free 
Shotgun Proteomics 
Goeminne L.J.E., Gevaert K. and Clement L. (2016). Peptide-level Robust Ridge 
Regression Improves Estimation, Sensitivity, and Specificity in Data-dependent 
Quantitative Label-free Shotgun Proteomics. Molecular & Cellular Proteomics. 15(2), 657-
668 
 
9.1.1. Associated data 
Supplementary Materials 












Peptide intensities from mass spectra are increasingly used for relative quantitation of proteins 
in complex samples. However, numerous issues inherent to the mass spectrometry workflow 
turn quantitative proteomic data analysis into a crucial challenge. We and others have shown 
that modeling at the peptide level outperforms classical summarization-based approaches, 
which typically also discard a lot of proteins at the data preprocessing step. Peptide-based 
linear regression models, however, still suffer from unbalanced datasets due to missing 
peptide intensities, outlying peptide intensities and overfitting. Here, we further improve upon 
peptide-based models by three modular extensions: ridge regression, improved variance 
estimation by borrowing information across proteins with empirical Bayes and M-estimation 
with Huber weights. We illustrate our method on the CPTAC spike-in study and on a study 
comparing wild-type and ArgP knock-out Francisella tularensis proteomes. We show that the 
fold change estimates of our robust approach are more precise and more accurate than those 
from state-of-the-art summarization-based methods and peptide-based regression models, 
which leads to an improved sensitivity and specificity. We also demonstrate that ionization 
competition effects come already into play at very low spike-in concentrations and confirm that 
analyses with peptide-based regression methods on peptide intensity values aggregated by 
charge state and modification status (e.g. MaxQuant's peptides.txt file) are slightly superior to 
analyses on raw peptide intensity values (e.g. MaxQuant's evidence.txt file). 
9.1.3. Introduction 
High-throughput LC-MS-based proteomic workflows are widely used to quantify differential 
protein abundance between samples. Relative protein quantification can be achieved by stable 
isotope labeling workflows such as metabolic (1, 2) and postmetabolic labeling (3–6). These 
types of experiments generally avoid run-to-run differences in the measured peptide (and thus 
protein) content by pooling and analyzing differentially labeled samples in a single run. Label-
free quantitative (LFQ)1 workflows become increasingly popular as the often expensive and 
time-consuming labeling protocols are omitted. Moreover, LFQ proteomics allows for more 
flexibility in comparing samples and tends to cover a larger area of the proteome at a higher 
dynamic range (7, 8). Nevertheless, the nature of the LFQ protocol makes shotgun proteomic 
data analysis a challenging task. Missing values are omnipresent in proteomic data generated 
by data-dependent acquisition workflows, for instance because of low-abundant peptides that 
are not always fragmented in complex peptide mixtures and a limited number of modifications 
and mutations that can be accounted for in the feature search. Moreover, the overall 
abundance of a peptide is determined by the surroundings of its corresponding cleavage sites 
as these influence protease cleavage efficiency (9). Similarly, some peptides are more easily 
ionized than others (10). These issues not only lead to missing peptides, but also increase 
variability in individual peptide intensities. The discrete nature of MS1 sampling following 
continuous elution of peptides from the LC column leads to increased variability in peptide 
quantifications. Finally, competition for ionization and co-elution of other peptides with similar 
m/z values may cause biased quantifications (11). However, note that in this respect, using 
data-independent acquisition (DIA), all peptide ions (or all peptide ions within a certain m/z 
range, depending on the method used) are fragmented simultaneously, resulting in multiplexed 
MS/MS spectra (12, 13). Hence, issues of missing fragment spectra are less a problem with 
DIA, however, some of its challenges lie in deconvoluting MS/MS spectra and mapping their 
features to their corresponding peptides (14). 
Standard data analysis pipelines for DDA-LFQ proteomics can be divided into two groups: 
spectral counting techniques, which are based on counting the number of peptide features as 
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a proxy for protein abundance (15), and intensity-based methods that quantify peptide features 
by measuring their corresponding spectral intensities or areas under the peaks in either MS or 
MS/MS spectra. Spectral counting is intuitive and easy to perform, but, the determination of 
differences in peptide and thus protein levels is not as precise as intensity-based methods, 
especially when analyzing rather small differences (16). More fundamentally, spectral counting 
ignores a large part of the information that is available in high-precision mass spectra. Further, 
dynamic exclusion during LC-MS/MS analysis, meant to increase the overall number of 
peptides that are analyzed, can worsen the linear dynamic range of these methods (17). Also, 
any changes in the MS/MS sampling conditions will prevent comparisons between runs. 
Intensity-based methods are more sensitive than spectral counting (18). Among intensity-
based methods, quantification on the MS-level is somewhat more accurate than summarizing 
the MS/MS-level feature intensities (19). Therefore, we further focus on improving data 
analysis methods for MS-level quantification. 
Typical intensity-based workflows summarize peptide intensities to protein intensities before 
assessing differences in protein abundances (20). Peptide-based linear regression models 
estimate protein fold changes directly from peptide intensities and outperform summarization-
based methods by reducing bias and generating more correct precision estimates (21, 22). 
However, peptide-based linear regression models suffer from overfitting due to extreme 
observations and the unbalanced nature of proteomics data; i.e. different peptides and a 
different number of peptides are typically identified in each sample. We illustrate this using the 
CPTAC spike-in data set where 48 human UPS1 proteins were spiked at five different 
concentrations in a 60 ng protein/μl yeast lysate. Thus, when comparing different spike-in 
concentrations, only the human proteins should be flagged as differentially abundant (DA), 
whereas the yeast proteins should not be flagged as DA (null proteins). Fig. 9.1 illustrates the 
structure of missing data in label-free shotgun proteomics experiments using a representative 
DA UPS1 protein from the CPTAC spike-in study: missing peptides in the lowest spike-in 
condition tend to have rather low log2 intensity values in higher spike-in conditions compared 
to peptides that were not missing in both conditions, which supports the fact that the missing 
value problem in label-free shotgun proteomic data is largely intensity-dependent (23). 
 
Figure 9.1. Missing peptides are often low abundant. The boxplots show the log2 intensity 
distributions for each of the 33 identified peptides corresponding to the human UPS1 protein cytoplasmic 
Histidyl-tRNA synthetase (P12081) from the CPTAC dataset in conditions 6A (spike-in concentration 
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0.25 fmol UPS1 protein/μl) and 6B (spike-in concentration 0.74 fmol UPS1 protein/μl). Vertical dotted 
lines indicate peptides present in both conditions. Note, that most peptides that were not detected in 
condition 6A exhibit low log2 intensity values in condition 6B (colored in red). 
Fig. 9.2 shows the quantile normalized log2 intensity values for the peptides corresponding to 
the yeast null protein CG121 together with average log2 intensity estimates for each condition 
based on protein-level MaxLFQ intensities, as well as estimates derived from a peptide-based 
linear model. Here, three important remarks can be made:  
(1) CG121 is a yeast background protein, for which the true concentration is thus equal in 
all conditions, which appears to be monitored as such by MaxLFQ, except in conditions 6B 
and 6E (for the latter, no estimate is available). The LM estimate, however, is more reliable 
but seems to suffer from overfitting. 
(2) A lot of shotgun proteomic datasets are very sparse, causing a large sample-to-sample 
variability. Constructing a linear model based on a limited number of observations will thus 
lead to unstable variance estimates. Intuitively, a small sample drawn from a given 
population might “accidentally” show a very small variance while another small sample 
from the same population might display a very large variance just by random chance. This 
effect is clear from the sizes of the boxes. The interquartile range is twice as large in 
condition 6E compared to condition 6C. This issue leads to false positives since some 
proteins with very few observations are flagged as DA with very high statistical evidence 
solely due to their low observed variance (24). 
(3) Two observed features at log2 intensities 14.0 and 14.3 in condition 6B have a strong 
influence on the parameter estimate for this condition. Without these extreme observations, 
the 6B estimate lies closer to the estimates in the other conditions. As missingness is 
strongly intensity-dependent, these low intensity values could easily become missing 
values in subsequent experiments. More generally, a strong influence of only one or two 





Figure 9.2. Effect of outliers, variability, and sparsity of peptide intensities on abundance 
estimations. The figure shows log2 transformed quantile normalized peptide intensities for the yeast 
null protein CG121 from the CPTAC data set for spike-in conditions 6A, 6B, 6C, 6D, and 6E. Each color 
denotes a different condition. Connected crosses: average protein log2 intensity estimates for each 
condition are provided for a traditional protein level workflow where the mean of the protein-level 
MaxLFQ values was calculated (MaxLFQ, blue), the estimates of the peptide-based regression model 
fitted with ordinary least squares (LM, black) and the estimates of the peptide based ordinary least 
squares fit after omitting the two lowest observations in condition 6B (LM-extremes, orange). In condition 
6E there were not enough data points to provide a MaxLFQ protein-level estimate. Boxes denote the 
interquartile range (IQR) of the log2 transformed quantile normalized peptide intensities in each condition 
with the median indicated as a thick horizontal line inside each box. Whiskers extend to the most extreme 
data point that lies no more than 1.5 times the IQR from the box. Points lying beyond the whiskers are 
generally considered as outliers. Note, that the presence of two low-intensity peptide observations in 
concentration 6B has a strong effect on the estimates for both MaxLFQ and LM. 
These issues illustrate that state-of-the-art analysis methods experience difficulties in coping 
with peptide imbalances that are inherent to DDA LFQ proteomics data. We here propose 
three modular improvements to deal with the problems of overfitting, sample-to-sample 
variability and outliers:  
(1) Ridge regression, which penalizes the size of the model parameters. Shrinkage 
estimators can strongly improve reproducibility and overall performance as they have a 
lower overall mean squared error compared to ordinary least squares estimators (25–27). 
(2) Empirical Bayes variance estimation, which shrinks the individual protein variances 
toward a common prior variance, hence stabilizing the variance estimation. 
(3) M-estimation with Huber weights, which will make the estimators more robust toward 
outliers (28). 
We illustrate our method on the CPTAC Study 6 spike-in data and a published ArgP knock-out 
Francisella tularensis proteomics experiment and show that our method provides more stable 
log2 FC estimates and a better DA ranking than competing methods. 
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9.1.4. Experimental procedures 
 
CPTAC Spike-in Data Set  
The publicly available Study 6 of the Clinical Proteomic Technology Assessment for Cancer 
(29) is used to evaluate the performance of our method. Raw data can be accessed at 
https://cptac-data-portal.georgetown.edu/cptac/public?scope=Phase+I. In this study, the 
Sigma Universal Protein Standard mixture 1 (UPS1, Sigma-Aldrich, St. Louis, MO) containing 
48 different human proteins was spiked into a 60 ng protein/μl Saccharomyces cerevisiae 
strain BY4741 (MATa, leu2Δ0, met15Δ0, ura3Δ0, his3Δ1) lysate in five different concentrations 
(6A: 0.25 fmol UPS1 proteins/μl; 6B: 0.74 fmol UPS1 proteins/μl; 6C: 2.22 fmol UPS1 
proteins/μl; 6D: 6.67 fmol UPS1 proteins/μl; and 6E: 20 fmol UPS1 proteins/μl). These samples 
were sent to five independent laboratories and analyzed on seven different instruments. For 
convenience, we limited ourselves to the data originating from the LTQ-Orbitrap at site 86, 
LTQ-Orbitrap O at site 65 and LTQ-Orbitrap W at site 56. Samples were run three times on 
each instrument. The used dataset thus features five different samples, each analyzed in 
threefold on three different instruments. Raw data files were searched using MaxQuant version 
1.5.2.8 (30) with the following settings. As variable modifications we allowed acetylation 
(protein N terminus), methionine oxidation (to methionine-sulfoxide) and N-terminal glutamine 
to pyroglutamate conversion. As a fixed modification, we selected carbamidomethylation on 
cysteine residues as all samples were treated with iodoacetamide. We used the enzymatic rule 
of trypsin/P with a maximum of 2 missed cleavages and allowed MaxQuant to perform 
matching between runs with a match time window of 0.7 min and an alignment time window of 
20 min. The main search peptide tolerance was set to 4.5 ppm and the ion trap MS/MS match 
tolerance was set to 0.5 Da. Peptide-to-spectrum match level was set at 1% FDR with an 
additional minimal Andromeda score of 40 for modified peptides as these settings are most 
commonly used by researchers. Protein FDR was set at 1% and estimated by using the 
reversed search sequences. We performed label-free quantitation with MaxQuant's standard 
settings. The maximal number of modifications per peptide was set to 5. As a search FASTA 
file we used the 6718 reviewed proteins present in the Saccharomyces cerevisiae (strain ATCC 
204508/S288c) proteome downloaded from Uniprot at March 27, 2015 supplemented with the 
48 human UPS1 protein sequences. Potential contaminants present in the contaminants.fasta 
file that comes with MaxQuant were automatically added to the search space by the software. 
For protein quantification in the proteinGroups.txt file, we used unique and razor peptides and 
allowed all modifications as all samples originate in essence from the same yeast lysate and 
the same UPS1 spike-in sample. 
Francisella tularensis Data Set  
The data of Ramond et al. (31) is used to illustrate our method on a real biological experiment. 
Both raw and processed data are publicly available and can be found in the PRIDE repository 
at http://www.ebi.ac.uk/pride/archive/projects/PXD001584. The authors explored changes in 
the proteome of the facultative intracellular pathogenic coccobacillus Francisella tularensis 
after gene deletion of a newly identified arginine transporter, ArgP. Both wild-type and ArgP 
mutants were grown in biological triplicate. Each biological replicate was analyzed in technical 
triplicate via label-free LC-MS/MS. Data were processed with MaxQuant version 1.4.1.2 and 
potential contaminants and reverse sequences were removed. In addition, only proteins 
present with at least two peptides in at least 9 out of the 18 replicates were retained. 
Subsequent data analysis via t-tests on imputed LFQ intensities was performed. 
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Summarization-based Analysis  
MaxLFQ+Perseus  
This is a standard summarization-based analysis pipeline that is available in the popular 
MaxQuant-Persues software package (21). Briefly, the MaxQuant ProteinGroups.txt file was 
loaded into Perseus version 1.5.1.6, potential contaminants that did not correspond to any 
UPS1 protein as well as reversed sequences and proteins that were only identified by site 
(thus only by a peptide carrying a modified residue) were removed from the data set. MaxLFQ 
intensities (32) were log2 transformed and pairwise comparisons between conditions were 
done via t-tests. 
MaxLFQ+limma  
The MaxQuant ProteinGroups.txt file is used as input for R version 3.1.2 (Pumpkin Helmet) 
(33). Potential contaminants and reversed sequences (see above) were removed from the 
data set. The MaxLFQ intensities were log2 transformed and analyzed in limma, an 
R/Bioconductor package for the analysis of microarray and next-generation sequencing data 
(34). Limma makes use of posterior variance estimators to stabilize the naive variance 
estimator by borrowing strength across proteins (see also below). 
Peptide-based Model Analysis  
Data Preprocessing  
MaxQuant's peptides.txt file was read into R version 3.1.2, the peptide intensities were log2 
transformed and quantile normalized (35, 36). Many other normalization approaches do exist, 
however, comparing them is beyond the scope of this paper (24, 36–38). Reversed sequences 
and potential contaminants were removed from the data. For the CPTAC dataset, we only 
removed potential contaminants that did not map to any UPS1 protein. MaxQuant assigns 
proteins to protein groups using an Occam's razor approach. However, to avoid the added 
complexity of proteins mapped to multiple protein groups, we discarded peptides belonging to 
protein groups that contained one or more proteins that were also present in a smaller protein 
group. Next, peptides were grouped per protein group in a data frame. Finally, values 
belonging to peptide sequences that appeared only once were removed as the model 
parameter for the peptide effect for these sequences is unidentifiable. For notational 
convenience, a unique protein or protein group is referred to as a protein in the remainder of 
this article. 
Benchmark Peptide-based Model  
We start from the peptide-based linear regression models as proposed by Daly et al. (39) 
Clough et al. (22) and Karpievitch et al. (40), of which we have independently proven their 
superior performance compared to summarization-based workflows (21). In general, the 
following model is proposed:  
𝑦𝑖𝑗𝑘𝑙𝑚𝑛 =  𝛽𝑖𝑗𝑡𝑟𝑒𝑎𝑡 + 𝛽𝑖𝑘
𝑝𝑒𝑝 + 𝛽𝑖𝑙
𝑏𝑖𝑜𝑟𝑒𝑝 + 𝛽𝑖𝑚
𝑡𝑒𝑐ℎ𝑟𝑒𝑝 + 𝜀𝑖𝑗𝑘𝑙𝑚𝑛  
(Eq. 1) 
with yijklmn the nth log2-transformed normalized feature intensity for the ith protein under the jth 
treatment (treat), the kth peptide sequence (pep), the lth biological repeat (biorep) and the mth 
technical repeat (techrep) and εijklmn a normally distributed error term with mean zero and 
protein specific variance σi2. The 𝛽's denote the effect sizes for treat, pep, biorep and techrep 
for the ith protein. 
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Robust Ridge Model  
Our novel approach improves the estimation of the model parameters in (Eq. 1) via three 
extensions: (1) ridge regression, which leads to shrunken yet more stable log2 fold change 
(FC) estimates, (2) Empirical Bayes estimation of the variance, which further stabilizes 
variance estimators, and (3) M-estimation with Huber weights, which reduces the impact of 
outlying peptide intensities. For the robust ridge model, degrees of freedom are calculated 
using the trace of the hat matrix. 
1. Ridge Regression  
The ordinary least squares (OLS) estimates for protein i are defined as the parameter 
estimates that minimize the following loss function:  
∑ 𝑒𝑖𝑗𝑘𝑙𝑚𝑛2
𝑗𝑘𝑙𝑚𝑛








With eijklmn the residual errors and Xijklmn the row of the design matrix corresponding to 
observation yijklmn. 
Ridge regression shrinks the regression parameters by imposing a penalty on their magnitude. 


















With each 𝜆 a ridge penalty for the parameter estimator ?̂? corresponding to an effect in Eq. 1. 
When the 𝜆s are larger than zero, the ridge estimators for ?̂? will be shrunken toward 0. This 
introduces some bias but reduces the variability of the parameter estimator, which makes 
shrinkage estimators theoretically more stable and more accurate (i.e. they tend to have a 
lower root mean squared error (RMSE) compared to the OLS estimator) (25–27). On the one 
hand, ?̂?'s estimated by only a few observations will experience a strong correction toward 0, 
protecting against overfitting. On the other hand, ?̂?'s that can be estimated based on many 
observations will exhibit a negligible bias because the ridge penalty will be dominated by the 
sum of the squared errors, which reflects that these ?̂?'s can be estimated more reliably. We 
choose to tune each 𝜆 separately because the variability on the peptide effect seems generally 
much larger than the variability on the other effect terms. 𝜆 penalties can be tuned via cross-
validation, but in this work, we exploit the link between mixed models and ridge regression (41) 
and estimate the penalties by implementing ridge regression within the lme4 package (42) in 




2  with ?̂?𝑖 the estimated residual variance and ?̂?𝛽𝑡𝑟𝑒𝑎𝑡,𝑖
2  the estimated 
variance captured by the treatment effect for peptide intensities from protein i (Chapter 5, 41). 
The standard errors of the parameter estimators and contrasts of interest are based on the 
bias-adjusted variance estimator (Chapter 6, 41). 
2. Empirical Bayes Variance Estimations  
In the introduction we argued that data sparsity can lead to unstable variance estimates. In 
order to stabilize the residual variance estimation, we shrink the estimated protein specific 
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variances toward a pooled estimate over all proteins using an empirical Bayesian approach 
(43) implemented in the limma R/Bioconductor-package (44). In that way, the information 
contained in all proteins is borrowed to stabilize the variance estimates of proteins with few 
observations. Hence, the small variances will increase, while large variances will decrease. 
This avoids that proteins that exhibit a small FC and a tiny variance will appear highly 
significantly. Also, the number of degrees of freedom for all these so-called moderated t-tests 
will increase compared to normal t-tests. 
3. M-estimation With Huber Weights  
As we have shown in the introduction (see Fig. 9.2), outlying peptides might have a severe 
impact on the parameter estimates, especially in conditions with few identified features. We 
therefore propose to adopt M-estimation with Huber weights to diminish the impact of outlying 
observations. Combining ridge regression with M-estimation leads to the following penalized 




















Herein, wijklmn is a Huber weight that weighs down observations with high residuals. 
False Discovery Rate  
For both peptide-based models and MaxLFQ+limma, p values are adjusted for multiple testing 
with the Benjamini-Hochberg FDR procedure (45). Perseus uses a permutation-based FDR 
that turns out to be very close to the Benjamini-Hochberg procedure. The FDR is controlled at 
the 5% level in all analyses. 
9.1.5. Results 
We decided to compare our method to three competing methods using data from the CPTAC 
spike-in benchmark study. Additionally, its advantages are demonstrated in a case study that 
was originally analyzed with a standard summarization-based approach. For peptide-based 
models the use of MaxQuant's peptides.txt file, which contains summed up peptide level data, 
slightly increased the discriminative power as compared to analyses using the MaxQuant's 
evidence.txt file, which contains individual intensities for each identified feature (supplemental 
Fig. S7, File S1). Therefore, all peptide-based models are based on the peptides.txt file. 
1. Evaluation Using Data From a Spike-in Benchmark Study  
The performances of the different methods are assessed by comparing different spike-in 
concentrations in the CPTAC Study 6 data set. This data set consists of identical samples 
containing a trypsin-digested Saccharomyces cerevisiae proteome spiked with different 
concentrations (0.25, 0.74, 2.22, 6.67, and 20 fmol/μl) of a trypsin-digested UPS1 mix 
containing 48 human proteins. As the high spike-in concentrations are known to suffer from 
ionization competition effects (18, 21), we focus mainly on comparing 6B-6A, 6C-6A and 6C-
6B, which have the lowest spike-in concentrations. 
We compared our robust ridge approach to three competing approaches: (1) MaxLFQ-
Perseus, (2) MaxLFQ-limma, and (3) a petide based linear model (LM). (1) MaxLFQ-Perseus 
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is a standard summarization-based approach where MaxLFQ normalized log2 protein 
intensities are compared between conditions by FDR-corrected t-tests. (2) MaxLFQ-limma is 
a summarization-based approach in which MaxLFQ protein level data are analyzed via limma 
(34), an R/Bioconductor package that can stabilize variance estimation by borrowing 
information across proteins via an empirical Bayesian approach. (3) The linear model (LM) is 
a peptide-based linear regression model (Eq. 1) that is known to outperform summarization-
based approaches (21). This model contains a treatment effect, a peptide effect and an 
instrument effect, and its structure is motivated in supplemental File S1. Note, that our robust 
ridge method (RR) is an improvement of the LM approach by implementing ridge regression, 
empirical Bayes variance estimation and M-estimation with Huber weights. We compared the 
results of the four methods in terms of precision and accuracy of the log2 fold change estimates, 
as well as sensitivity and specificity. 
Precision and Accuracy  
Log2 fold change (FC) estimates using our robust ridge model for yeast null proteins are clearly 
more precise compared to the other methods; the interquartile range of the log2 FC estimates 
is on average three times smaller compared to the LM fit and 4.5 times smaller for comparison 
6B-6A; Fig. 9.3). The accuracy is also increased as most DA estimates for yeast null proteins 
are estimated very close to zero. This is due to an effect of the ridge penalty, which strongly 
shrinks the estimates for null proteins identified by a few peptides toward zero. Fig. 9.3 also 
shows a general trend for each method: as spike-in concentration differences increase, a 
negative bias of the log2 FC estimates appears. This likely reflects ionization suppression 
effects (18, 21). Note that for our method, the log2 FC distributions in all comparisons (including 
6B versus 6A) in Fig. 9.3 are skewed toward negative fold changes and that the skewness 
increases with higher spike-in concentrations, suggesting that ionization suppression effects 
already occur at very low spike-in concentrations. 
 
Figure 9.3. Precision and accuracy of fold change (FC) estimates for null proteins in the CPTAC 
study. The boxplots show the distributions of the FC estimates of the null yeast proteins for each of the 
ten comparisons for 4 different approaches. Outliers (here defined as data points that lie more than 1.5 
times the interquartile range from the box) are not shown. The horizontal dotted green line denotes the 
true log2 fold change for the yeast proteins (log2 FC = 0). Blue (MaxLFQ+Perseus): protein-level analysis 
consisting of MaxLFQ normalization followed by t-tests in Perseus, yellow (MaxLFQ+limma): protein-
level analysis consisting of MaxLFQ normalization followed by limma analysis, black (LM): peptide-
based linear regression model containing treatment, peptide and instrument effects, purple (RR): 
peptide-based ridge regression model containing treatment, peptide and instrument effects with 
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empirical Bayes variance estimator and M-estimation with Huber weights. An identical figure with outliers 
is provided in supplemental Fig. S12, File S1. 
When assessing the DA UPS1 proteins (Fig. 9.4), the log2 FC estimates for the summarization-
based approaches MaxLFQ-Perseus and MaxLFQ-limma are always more biased and more 
variable compared to the LM and RR methods, except in condition 6B-6A, where MaxLFQ-
limma has the lowest bias of all approaches. Median log2 FC estimates for UPS proteins are 
very comparable between our RR and the LM method. For eight out of ten comparisons, the 
RR estimates are even closer to the true log2 FC. The interquartile range of the log2 FC 
estimates of the DA proteins for RR is on average 1.2 times smaller compared to those of the 
LM model. Thus, shrinkage estimation does not negatively affect estimates for proteins with a 
strong evidence for DA. 
 
Figure 9.4. Precision and accuracy of fold change (FC) estimates for differential abundant 
proteins in the CPTAC study. The boxplots show the distributions of the FC estimates of the spiked-
in UPS1 proteins for each of the ten comparisons for four different approaches. Outliers (here defined 
as data points that lie more than 1.5 times the interquartile range from the box) are not shown. The 
horizontal dotted green lines denote the true log2 FC for the UPS1 proteins in each comparison. Blue 
(MaxLFQ+Perseus): protein-level analysis consisting of MaxLFQ normalization followed by t-tests in 
Perseus, yellow (MaxLFQ+limma): protein-level analysis consisting of MaxLFQ normalization followed 
by limma analysis, black (LM): peptide-based linear regression model containing treatment, peptide and 
instrument effects, purple (RR): peptide-based ridge regression model containing treatment, peptide 
and instrument effects with empirical Bayes variance estimator and M-estimation with Huber weights. 
An identical figure with outliers is provided in supplemental Fig. S13, File S1. 
Sensitivity and Specificity  
The sensitivity and specificity of the different methods are assessed using receiver operator 
characteristics (ROC) curves (Fig. 9.5, Tables 9.1 and 9.2). For the summarization-based 
approaches, it turns out that MaxLFQ+limma outperforms MaxLFQ+Perseus. This is not 
surprising, as it has been shown that limma outperforms standard t-tests, also in proteomics 
data sets (46). As we have shown before, both peptide-based regression models outperform 
the summarization-based approaches (21). Our RR method further improves on the LM model 
in comparison 6B-6A, in which the detection of DA is most challenging since it involves the two 
lowest spike-in concentrations. For all other comparisons LM and RR have a similar 
performance (Table 9.2), which was expected because the ROC curves of the LM method for 




Figure 9.5. Comparison of sensitivity and specificity. Receiver operator characteristic (ROC) curves 
show the superior performance of our robust ridge approach compared to other standard data analysis 
techniques for comparisons of conditions 6B-6A, 6C-6A, and 6C-6B in the CPTAC spike in study. Stars 
denote the cut-offs at an estimated 5% FDR level. Blue (MaxLFQ+Perseus): protein-level analysis 
consisting of MaxLFQ normalization followed by t-tests in Perseus, yellow (MaxLFQ+limma): protein-
level analysis consisting of MaxLFQ normalization followed by limma analysis, black (LM): peptide-
based linear regression model containing treatment, peptide and instrument effects, purple (RR): 
peptide-based ridge regression model containing treatment, peptide and instrument effects with 
empirical Bayes variance estimator and M-estimation with Huber weights. 
 
Table 9.1. Total areas under the curve (AUC) for three standard approaches and our robust ridge 
method for comparisons 6B-6A, 6C-6A and 6C-6B in the CPTAC spike-in study. MaxLFQ+Perseus: 
protein-level analysis consisting of MaxLFQ normalization followed by t-tests in Perseus, 
MaxLFQ+limma: protein-level analysis consisting of MaxLFQ normalization followed by limma analysis, 
LM: peptide-based linear regression model containing treatment, peptide and instrument effects, RR: 
peptide-based ridge regression model containing treatment, peptide and instrument effects with 
empirical Bayes variance estimator and M-estimation with Huber weights. 
Comparison MaxLFQ+Perseus MaxLFQ+limma LM RR 
6B-6A 0.536 0.634 0.817 0.862 
6C-6A 0.583 0.672 0.877 0.869 
6D-6A 0.583 0.680 0.880 0.878 
6E-6A 0.564 0.660 0.883 0.880 
6C-6B 0.607 0.655 0.860 0.861 
6D-6B 0.618 0.657 0.858 0.859 
6E-6B 0.601 0.644 0.863 0.863 
6D-6C 0.654 0.680 0.856 0.860 
6E-6C 0.663 0.678 0.864 0.864 









Table 9.2. Partial areas under the curve (pAUC) for a false positive rate (FPR) < 0.1 for three standard 
approaches and our robust ridge method by comparing conditions 6B-6A, 6C-6A and 6C-6B in the 
CPTAC spike-in study. MaxLFQ+Perseus: protein-level analysis consisting of MaxLFQ normalization 
followed by t-tests in Perseus, MaxLFQ+limma: protein-level analysis consisting of MaxLFQ 
normalization followed by limma analysis, LM: peptide-based linear regression model containing 
treatment, peptide and instrument effects, RR: peptide-based ridge regression model containing 
treatment, peptide and instrument effects with empirical Bayes variance estimator and M-estimation with 
Huber weights. 
Comparison MaxLFQ+Perseus MaxLFQ+limma LM RR 
6B-6A 0.061 0.075 0.083 0.091 
6C-6A 0.076 0.088 0.096 0.097 
6D-6A 0.077 0.089 0.098 0.097 
6E-6A 0.076 0.089 0.097 0.097 
6C-6B 0.081 0.086 0.096 0.097 
6D-6B 0.082 0.086 0.096 0.096 
6E-6B 0.081 0.087 0.096 0.096 
6D-6C 0.076 0.083 0.094 0.095 
6E-6C 0.088 0.090 0.095 0.095 
6E-6D 0.090 0.092 0.092 0.093 
 
FDR Control  
None of the adopted methods are able to control the true FDR at the nominal 5% level in the 
majority of the comparisons (Table 9.3). MaxLFQ+Perseus can only control the FDR at the 5% 
level in comparisons 6C-6A and 6C-6B. MaxLFQ+limma only controls the FDR accurately in 
comparison 6C-6B and both LM and RR can control the FDR only in comparisons 6B-6A and 
6C-6B. When comparing RR and LM, RR does a better job in controlling the FDR in 
















Table 9.3. Observed FDR when using a 5% FDR cut-off level for each of the three standard approaches 
and our robust ridge method for all pairwise comparisons between conditions 6A, 6B, 6C, 6D and 6E. 
MaxLFQ+Perseus: protein-level analysis consisting of MaxLFQ normalization followed by t-tests in 
Perseus, MaxLFQ+limma: protein-level analysis consisting of MaxLFQ normalization followed by limma 
analysis, LM: peptide-based linear regression model containing treatment, peptide and instrument 
effects, RR: peptide-based ridge regression model containing treatment, peptide and instrument effects 
with empirical Bayes variance estimator and M-estimation with Huber weights. This table shows that 
most methods are unable to control the FDR at 5%, especially for comparisons involving higher spike-
in concentrations (e.g. 6D and 6E). 
Comparison MaxLFQ+Perseus MaxLFQ+limma LM RR 
6B-6A 0.071 0.048 0.034 0.030 
6C-6A 0.040 0.083 0.095 0.050 
6D-6A 0.456 0.794 0.466 0.050 
6E-6A 0.917 0.922 0.870 0.883 
6C-6B 0.037 0 0 0.024 
6D-6B 0.640 0.879 0.528 0.494 
6E-6B 0.918 0.924 0.863 0.870 
6D-6C 0.429 0.799 0.481 0.434 
6E-6C 0.886 0.906 0.842 0.848 
6E-6D 0.321 0.584 0.386 0.561 
 
2. Case Study  
We further illustrate the performance of our novel method on true biological data in which a 
single trigger was expected to have an impact on several tightly regulated, but highly 
interconnected pathways. Thus, contrary to a spike-in data set where differential abundance 
typically heads in one direction (either up or down-regulated) and stays limited to the spiked-
in proteins, a biological dataset consists of a plethora of both strongly as well as weakly 
differentially regulated proteins. Moreover, in the CPTAC data set, the same sample was 
always used to spike in different amounts of UPS1 proteins in the same yeast background 
instead of isolating a new yeast proteome each time. Hence, variability in biological repeats 
will be much larger compared to the spike-in data set. Although detection of differential 
abundance in real biological data is the ultimate goal, there is no known ground truth available 
for these data sets and our evaluation is based on visual inspection of selected findings. 
We made use of the publicly available data published by Ramond et al. (31) in which the 
authors compared the proteome of Francisella tularensis mutant for the arginine transporter 
ArgP to wild-type (WT) bacteria in biological triplicate. For each biological repeat, three 
technical replicates were also available. We compared the authors' results with the results of 
our RR method based on the authors-supplied peptides.txt instead of re-searching the raw 
spectra. In their study, Ramond et al. (31) performed the analysis at the protein level using 
intensities of at least two different peptides and keeping those proteins with at least 9 out of 18 
valid values, and as such analyzed 842 proteins in total. With our approach—analysis at the 
peptide level and filtering out peptides that appeared only once in the data set—we were able 
to analyze a total of 989 proteins. Both the results of our ranking as well as the ranking from 
the original Francisella article can be found in supplemental File S2. When we compared the 
top 100 proteins with the lowest p values in both methods, only 52 proteins overlapped. 
Ramond et al. (31) found 309 DA proteins at the 5% FDR level, whereas we only found 159 




We evaluated the differential abundance of the ten proteins that were present in the RR DA 
list, but not in the original DA list, as well as the ten highest ranked proteins from the original 
DA list missing in our list. The ten proteins that were only discovered with our method were all 
lost during the preprocessing procedure of Ramond et al. (31). Among those proteins, six are 
more highly abundant in the mutant: exodeoxyribonuclease V subunit gamma and ABC 
transporter membrane protein, as well as four hypothetical proteins (the membrane protein 
FTN_0835, an AAA+ superfamily member FTN_0274, an alpha/beta hydrolase FTN_0721 and 
FTN_1244). Four out of the ten proteins that were only discovered by our method have a lower 
abundance in the mutant. These proteins are Radical SAM superfamily protein, DNA helicase 
II, C32 tRNA thiolase and the hypothetical protein FTN_0400. Log2 intensity plots of the 
individual peptide intensities suggest a differential abundance for most of these proteins 
(supplemental Figs. S14-S23, File S1). 
Eight out of the ten highest-ranked proteins in the original DA list all seem to be highly abundant 
gauged by the number of peptides identified (supplemental Figs. S24-S33, File S1). Further 
inspection reveals that most of these proteins do not appear to bear strong evidence for DA 
between WT and mutant. Except for the hypothetical protein FTN_1397 and the Mur ligase 
family protein, all variance estimates are smaller than 0.01, which leads to extreme T statistics. 
Empirical Bayesian variance estimation does increase these small variances, but not enough 
to make them insignificant at the 5% significance level. There seems to be a relatively clear 
effect for hypothetical protein FTN_1397 (supplemental Fig. S31, File S1), which in our method 
just did not pass the 5% FDR level (p value of 9.4*10−3 and FDR adjusted p value 0.057). The 
Mur ligase family protein shows no strong visual DA (supplemental Fig. S32, File S1), but 
combines a moderate DA estimate (-0.34) with a small variance (0.01). The two other proteins 
only present in the list of Ramond et al. (31) are rather low-abundant. DNA-binding protein HU-
beta (supplemental Fig. S30, File S1) shows no visual evidence for DA at all, but hypothetical 
protein FTN_1199 (supplemental Fig. S33, File S1) might possess weak evidence for DA. 
Ramond et al. (31) also noted that several protein modules had an increased enrichment in 
DA proteins. In fact, all ribosomal proteins and all proteins involved in branched-chain amino 
acid (BCAA) synthesis were either unchanged (as the p value did not reach the 5% FDR cut-
off) or present in lower amounts in the mutant. Based on their data, one could also suspect an 
up-regulation of several tricarboxylic acid (TCA) cycle proteins (nine out of 12) in the mutant. 
Ribosomal Proteins  
It is known that a global down-regulation of ribosome synthesis is a common response to 
nutrient starvation in Bacteria and Eukarya (47, 48). One might thus expect a similar drop in 
abundance in the arginine transporter-mutated F. tularensis as its delay in phagosomal escape 
can be fully restored by supplementation of the medium with excess arginine (31). When 
considering all 30S and 50S ribosomal proteins (both significant and insignificant in terms of 
DA), both our method and the original article report log2 FC estimates for 49 ribosomal proteins. 
As expected, all log2 FC estimates from our method pointed toward down-regulation in the 
mutant. Contrary, in the analysis of Ramond et al. (31), two proteins, ribosomal protein L7/L12 
and 30S ribosomal protein S18 showed, although deemed insignificant, quite large log2 FCs 
(0.12 resp. 0.54) in favor of up-regulation in the mutant. This again suggest a more stable log2 
FC estimation by our method (supplemental Fig. S34, File S1). 
BCAA Synthesis Proteins  
Based on KEGG, we could only identify nine proteins as BCAA synthesis proteins although 
the authors report on 12 BCAA synthesis proteins. As we were unable to find the remaining 3 
proteins in this pathway, we further focus on nine proteins only. Supplemental Fig. S35, File 
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S1 shows the distribution of the log2 FC estimates for both the methodology of Ramond et al. 
(31) and our method. Here, one insignificant protein, dihydroxy-acid dehydratase shows a log2 
FC of 0.22. Using our method, all log2 FCs indicate either down-regulation in the mutant (i.e. 
log2 FCs smaller than 0) or no change at all (log2 FCs smaller than 1*10−17). On average, log2 
FC estimates for BCAA synthesis proteins are more negative in our method. Thus, our method 
provides stronger evidence for down-regulation of some BCAA synthesis proteins in the mutant 
compared to the method of the original article. 
TCA Cycle Proteins  
Based on KEGG, we identified 13 TCA cycle proteins, while Ramond et al. (31) reported 12 
proteins. When assessing the log2 FC estimates of these authors for the 13 proteins, 10 TCA 
cycle proteins appear to be up-regulated in the mutant (supplemental Fig. S36, File S1), 8 of 
which are declared significant. Contrary, in our method, only 1 protein of the TCA cycle (2-
oxoglutarate dehydrogenase complex, E2 component, dihydrolipoyltranssuccinase) is found 
significant. Strikingly, 8 out of 13 TCA cycle proteins even show log2 FC estimates that are in 
absolute value smaller than 1× 10−9. We therefore zoomed in onthe individual log2 FC 
estimates of the peptides mapping to these proteins (supplemental Figs. S37-S50, File S1). 
2-oxoglutarate dehydrogenase complex, E2 component, dihydrolipoyltranssuccinase 
(supplemental Fig. S37, File S1) is the only TCA cycle protein that is found at significantly 
different levels by our analysis. It is also denoted as significant in the original paper's 
methodology. Nonetheless, the evidence does not seem to be very strong. 2-oxoglutarate 
dehydrogenase E1 component, dihydrolipoamide acetyltransferase and succinate 
dehydrogenase iron-sulfur subunit are also denoted as significant in the original analysis with 
p values of 5.3 × 10−10, 8.1 × 10−4 and 1.1 × 10−3 respectively, although the spectral evidence 
also appears quite weak (supplemental Figs. S38, S40, and S41, File S1). In our opinion, any 
visual evidence for differential abundance for malate dehydrogenase, aconitate hydratase, 
succinyl-CoA synthetase, alpha subunit and isocitrate dehydrogenase is negligible. 
Nonetheless, p values corresponding to DA for these proteins are estimated at 7.4 × 10−4, 3.6 
× 10−3, 0.02 and 0.02 respectively in the paper of Ramond et al. (31) (supplemental Figs. S42, 
S43, and S47, File S1). 
9.1.6. Discussion 
In this work, we introduced three extensions to existing peptide-based linear models that 
significantly improve stability and precision of fold change estimates. These extensions include 
minimizing a penalized least squares loss function (ridge regression), weighing down outliers 
via M-estimation with Huber weights and variance stabilization via empirical Bayes. Our 
estimation approach is inevitably computationally more complex than the linear regression 
model, albeit much faster than fully Bayesian approaches that have to be fitted by 
computationally intensive Markov chain Monte Carlo algorithms (49). In this contribution, we 
normalized log2 transformed peptide intensities using quantile normalization. Many other types 
of transformation and normalization exist and can be adopted prior to applying our method. 
Our focus however, is on robust estimation procedures for peptide-based linear models. 
Therefore, a thorough comparison of preprocessing methods is beyond the scope of this paper. 
We compared our novel estimation method to three other methods: a standard protein-level 
summarization followed by t-tests (MaxLFQ+Perseus), a standard protein-level summarization 
followed by limma (MaxLFQ+limma) and a peptide-based linear regression model. Evaluation 
was done based on the CPTAC Study 6 data set, where the ground truth is known as well as 
on a biological data set, where ArgP mutated versus wild-type Francisella tularensis proteomes 
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are compared. For the CPTAC dataset, we found our method to give more precise and more 
stable log2 FC estimates for both the yeast null proteins and the spiked-in UPS1 proteins. Thus, 
our method sufficiently shrinks abundance estimates that are driven by data sparsity in the null 
proteins, while retaining good DA estimates when sufficient evidence is present (such as for 
most UPS1 proteins in the CPTAC spike-in study). These findings are supported by theory as 
ridge regression shrinkage indeed reduces the variability of the estimator and generates 
overall more precise FC estimates (lower overall RMSE compared to ordinary least squares 
estimators) (25–27). Furthermore, empirical Bayes variance estimation squeezes the 
individual residual variances of all models toward a pooled variance which stabilizes the 
variance estimation. Finally, M-estimation with Huber weights weakens the impact of individual 
outliers. 
The systematic underestimation of the log2 FC estimates provided by our method, even in 
comparison 6B-6A (Fig. 3), suggests that ionization competition effects can already come into 
play at spike-in concentration levels of 0.74 fmol/μl (condition 6B). These effects might partly 
explain why none of the considered methods performs well in controlling the FDR at the 
nominal 5% level. When analyzing the Francisella dataset, RR is more conservative than the 
method used by Ramond et al. (31), which might suggest a better protection against false 
positives. Indeed, ionization competition effects are also relevant for true biological data sets 
as an increase in a number of highly abundant proteins in a certain condition might generate 
a downwards bias in peptide intensities corresponding to non-DA proteins in this condition. 
Researchers should thus carefully reflect whether a low log2 fold change is truly biologically 
relevant, as ionization suppression effects already seem to appear at low differences in 
concentration. Indeed, even when disregarding these effects, the abundance of a protein 
typically has to differ by a reasonable amount to be of interest to a researcher. Therefore, we 
suggest testing against a minimal log2 FC value that is biologically interesting in a particular 
experiment; e.g. 0.5 or 1 (50). A similar approach can be easily adopted within our framework, 
but we have chosen to test against an FC of 0 to make our results comparable with the analysis 
of Ramond et al. (31). 
In practice, only a handful of true positives will typically be selected for further experimental 
validation. Therefore, the ranking that is produced by a method is more important than its 
capability to accurately control the FDR at the 5% level. Here, RR produces superior ranking 
lists compared to all other methods except in comparisons 6D-6A, 6E-6A and 6E-6B, where 
large ionization suppression effects are expected due to huge spike-in concentration 
differences. Hence, it will be very difficult to discern the ionization bias from real DA for these 
comparisons. Each component of our model contributes to an improvement in performance. 
ROC curves in supplemental Fig. S4, File S1 show that empirical Bayesian variance estimation 
slightly but consistently improves the performance of the LM model, while M-estimation seems 
to cause the largest gain (supplemental Fig. S5, File S1). Ridge regression clearly improves 
the LM model, EB variance estimation slightly improves the ridge regression model while M-
estimation again seems to deliver the largest gain in performance. Corresponding AUC and 
pAUC values can be found in (supplemental Tables S7-S10, File S1). 
In the CPTAC case study, we also confirmed that a peptide-based model starting from summed 
up intensities over different charge states and modifications but corresponding to identical 
peptide sequences in the same sample (peptides.txt file) tends to have a higher discriminative 
ability than a model starting from the individual feature intensities (evidence.txt file, see 
supplemental Fig. S7, File S1). Others have also shown that analysis on the lowest level of 
summarization does not automatically lead to the best performance (18). 
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We also applied our method on a biological dataset and compared our results to the 
performance of the MaxLFQ summarization-based method used in the original publication 
(31). Proteins identified as DA by our method that were missed in the original publication were 
all filtered out because too few peptides were identified. Most of these proteins contain 
relatively strong evidence for DA based on visual inspection of the individual quantile 
normalized peptide intensities, illustrating that our method can reliably discover DA in proteins 
that suffer considerably from missing peptides across samples. Proteins which were denoted 
as DA in the original article but not by our method were typically identified by a lot of peptides 
but with a weak visual evidence for DA. Indeed, when a lot of peptide intensities are present, 
modeling at the peptide level does not contribute much to stabilize the overall log2 FC estimate. 
Mostly though, these small fold changes are not biologically relevant. However, when one 
seeks DA in sparse data, as is the case in most experiments, our method clearly outperforms 
classical approaches. We indeed identify possibly interesting effects in low abundant proteins 
without overfitting, omitting the need for extensive a priori data filtering (e.g. dropping proteins 
with less than two peptides present in at least nine out of 18 samples as done by Ramond et 
al. (31)). Consequently, our ability to detect DA in low abundant proteins combined with 
robustness against irrelevant changes in high abundant proteins is a favorable property. 
We also showed that our fold change estimates are more stable for both the ribosomal and the 
BCAA synthesis modules, which are denoted as DA by Ramond et al. (31). For TCA cycle 
proteins, nine out of 12 were described as significantly more abundant in the mutant by these 
authors, while in our method, eight out of 13 TCA cycle proteins have log2 FC estimates that 
are in absolute value smaller than 1 × 10−9. Upon visual inspection, most of these proteins 
indeed contain very limited evidence for DA. Our method thus appears to provide more reliable 
data for follow-up analysis, thereby aiding researchers in drawing more correct conclusions. 
The fact that almost 82% of the proteins in our DA list of Francisella proteins indeed contain 
less peptides in the condition with the lowest abundance of this protein, advocates the inclusion 
of imputation or censoring approaches, or even the combination of our method with estimates 
derived from spectral counting, which could be used as a rough but very simple validation 
technique. For example, hypothetical protein FTN_0400 could be a false positive because 
more peptides are identified in the mutant, although it appears to be less abundant 
(supplemental Fig. S18, File S1). This could be an indication of intensity-dependent censoring 
in the WT. Just like the peptide-based linear regression model, our RR model can handle 
missing values. The models we presented here assume missingness completely at random, 
an assumption that is flawed when analyzing shotgun proteomics data. Note, however, that 
peptide-based models partially correct for this by incorporating peptide-specific effects. 
Moreover, our strategies to improve robustness of the estimators can be easily plugged into 
censored regression methods or estimation approaches that adopt advanced imputation 
techniques for handling missing data (40). 
Another interesting outlook is to model all proteins together by incorporating pathway or 
module level effects in the model in order to make stronger inferences on individual proteins 
belonging to a certain pathway. Finally, we want to stress the importance of data exploration. 
Plots of log2 peptide intensities for proteins that are flagged as differential abundant are very 
useful for assessing the biological relevance and the degree of belief one can have in the DA 
proteins that are returned by a method. 
We are currently preparing an R/Bioconductor package for our method. Meanwhile, all code 
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9.1.9. Appendix 
Ridge regression 
The untransformed, preprocessed intensities for each peptide 𝑝 in each run 𝑟 are assumed to 
follow a log-normal distribution. After log-transformation, these intensities become normally 
distributed. In all generality, for each protein, we propose the following peptide-based 
regression model that has also been proposed by Daly et al. (2008) [1]: 
𝑦𝑝𝑟 =  𝒙𝑝𝑟𝜷 + 𝛽𝑝
peptide + 𝑢𝑟run + 𝜀𝑝𝑟 
Herein, 𝒙𝑝𝑟 is a row matrix with the covariate pattern related to peptide 𝑝 in run 𝑟, 𝜷 =
[𝛽0, 𝛽11 … , 𝛽𝑚1
1 … , 𝛽𝑀1
1 , … , 𝛽𝑚𝑔
𝑔 ,… , 𝛽𝑀𝑔
𝑔 , … , 𝛽𝑀𝐺
𝐺 ]
T
 is a vector with 1 + 𝑀 = 1 + ∑ 𝑀𝑔𝐺𝑔=1  
parameters denoting the effects of 𝑀 predictors corresponding to 𝐺 covariates. 𝛽𝑝
peptide is a 
peptide-specific effect for peptide 𝑝, 𝑢𝑟run a random run effect to account for within-run 
correlation, with 𝑢𝑟run~N(0, 𝜎𝑢2). 𝜀𝑝𝑟~N(0, 𝜎2) is a random error term. 
We now want to introduce an extra penalization on the fixed effects beta by exploiting the link 
between ridge regression and mixed models (see section 4.2.4). Except for a fixed intercept 
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𝛽0, we penalize the parameters corresponding to each covariate group 𝑔 by assuming: 
𝛽𝑚𝑔
𝑔 ~N(0, 𝜎2 𝜆𝑔⁄ ) for 𝑚𝑔 = 1,… ,𝑀𝑔. Herein, 𝑔 refers to the 𝑔th covariate and accounts for 
the fact that certain covariates are modeled with more than one parameter. For example, a 
treatment effect with three levels will be modeled with three dummy parameters 𝛽1treatment, 
𝛽2treatment, and 𝛽3treatment whereby 𝛽1treatment + 𝛽2treatment + 𝛽3treatment = 0. We also assume 
𝛽𝑝











































































peptide is a row vector of dummies, for 
which the 𝑝th element is equal to 1 and all other elements equal to 0. 𝒙𝑟run is a row vector of 
dummies with the 𝑟th element equal to 1 and all other elements equal to 0. 𝑩 is an (1 + 𝑀 +
𝑃 + 𝑅) × (1 + 𝑀 + 𝑃 + 𝑅) diagonal matrix with diagonal elements [0  𝒈 𝒑 𝒓], with 𝒈 a vector of 
length 𝑀 containing the 𝜆𝑔 that corresponds to each parameter estimate ?̂?𝑚𝑔
𝑔  for 𝑚𝑔 = 1,… ,𝑀𝑔 
and 𝑔 = 1,… , 𝐺, 𝒑 a vector of length 𝑃 containing the 𝜆peptide that corresponds to each 
parameter estimate ?̂?𝑝




corresponds to each parameter estimate ?̂?𝑟run for 𝑟 = 1,… , 𝑅. 
Robust regression with M estimation 
To robustify our procedure against outliers, we use a weighted maximum likelihood method 




l(𝑦𝑗, 𝜷, 𝒖), 
with 𝑗 = 1,… , 𝐽 an indicator for observation. This weighted log-likelihood is solved iteratively. 
The mixed model is fitted while the weights are kept constant. Then, the weights are 
recomputed using Huber’s weight function on the residuals scaled with the residual standard 
deviation. This procedure is repeated until convergence. After convergence, the weighted 





] = (𝑪T𝑾𝑪 + 𝑩)−1𝑪T𝑾𝒚, 
with 𝑾 = [𝑤1 …𝑤𝑗 …𝑤𝐽]𝑰𝐽×𝐽 and 𝑤1 to 𝑤𝐽 the weights corresponding to these observations and 
𝑰𝐽×𝐽 a 𝐽 × 𝐽 unity matrix. Zhou (2009) [2] showed that the weighted BLUP estimator is better 
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than the unweighted one in terms of bias and efficiency when the data contains some outliers 
but provides the same asymptotic efficiency when the model is correctly specified. Robust M 
estimation with Huber weights has also been used to robustify the negative binomial model in 
the popular RNA sequencing R package EdgeR [3]. 
Empirical Bayes variance estimation 
Finally, we robustify our inference with limma’s empirical Bayes variance estimation (see 
section 4.2.2). In brief, limma assumes the following prior distribution on the error variance 𝜎𝑖2 








with 𝜎02 a prior variance and 𝜒𝑑0
2  a 𝜒2 distribution with 𝑑0 degrees of freedom. A maximum a 





We then plug in this posterior residual standard deviation in the estimator for the standard 
deviation of the model parameter of interest, ?̂?𝑚𝑔
𝑔  (suppressing the indicator 𝑖 for notational 
convenience): 
?̃??̂?𝑚𝑔
𝑔 = ?̃?√(𝑪T𝑾𝑪 + 𝑩)𝑚𝑔,𝑚𝑔
−1  
Herein, 𝑚𝑔,𝑚𝑔 denotes the 𝑚𝑔th diagonal element of the matrix. This enables statistical 







Herein, 𝑑𝑖 is calculated as 𝐽 − 𝑡𝑟(𝑯), with 𝐽 the total number of observations and 𝑯 the hat 
matrix, which is calculated as follows: 
𝑯 = 𝑪(𝑪T𝑾𝑪 + 𝑩)−1𝑪T𝑾 
Implementation 
MSqRob builds on the lme4 R package for parameter estimation and statistical inference [4]. 
Shrinkage on fixed effect parameters is obtained by encoding them as random effects. To 
allow for robust M-estimation, a loop is placed around the model fitting procedure: after model 
fitting, Huber weights are calculated on the residuals scaled with the residual standard 
deviation. These weights are provided as arguments to the lmer function of the lme4 package, 
which allows to estimate the parameters via weighted log-likelihood. This procedure is 
repeated until convergence.  
References for the Appendix 
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9.2. Experimental design and data-analysis in label-free quantitative 
LC/MS proteomics: A tutorial with MSqRob 
Goeminne L.J.E., Gevaert K. and Clement L. (2018). Experimental design and data-
analysis in label-free quantitative LC/MS proteomics: A tutorial with MSqRob. Journal of 
Proteomics. 171(Supplement C), 23-36 
9.2.1. Highlights 
• Complex experiments and lack of convenient software makes MS-based label-free 
proteomics data analysis challenging 
 
• We provide key experimental design concepts and data analysis guidelines 
 
• The MSqRob package combines legitimate statistical modeling for relative protein 
quantification from peptide-level data with an easy-to-use graphical interface 
 
• We show hands-on with two worked examples how to use the MSqRob graphical user 
interface 
 
• Scripts to run MSqRob in bash mode are provided at 
https://github.com/statOmics/MSqRob 
9.2.2. Abstract 
Label-free shotgun proteomics is routinely used to assess proteomes. However, extracting 
relevant information from the massive amounts of generated data remains difficult. This tutorial 
provides a strong foundation on analysis of quantitative proteomics data. We provide key 
statistical concepts that help researchers to design proteomics experiments and we showcase 
how to analyze quantitative proteomics data using our recent free and open-source R package 
MSqRob, which was developed to implement the peptide-level robust ridge regression method 
for relative protein quantification described by Goeminne et al. MSqRob can handle virtually 
any experimental proteomics design and outputs proteins ordered by statistical significance. 
Moreover, its graphical user interface and interactive diagnostic plots provide easy inspection 
and also detection of anomalies in the data and flaws in the data analysis, allowing deeper 
assessment of the validity of results and a critical review of the experimental design. Our 
tutorial discusses interactive preprocessing, data analysis and visualization of label-free MS-
based quantitative proteomics experiments with simple and more complex designs. We 
provide well-documented scripts to run analyses in bash mode on GitHub, enabling the 
integration of MSqRob in automated pipelines on cluster environments 
(https://github.com/statOmics/MSqRob). 
9.2.3. Significance 
The concepts outlined in this tutorial aid in designing better experiments and analyzing the 
resulting data more appropriately. The two case studies using the MSqRob graphical user 
interface will contribute to a wider adaptation of advanced peptide-based models, resulting in 
higher quality data analysis workflows and more reproducible results in the proteomics 
community. We also provide well-documented scripts for experienced users that aim at 
automating MSqRob on cluster environments. 
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9.2.4. Graphical abstract 
 
9.2.5. Keywords 
Differential protein abundance; Biostatistics; Label-free quantification; Tandem mass 
spectrometry; Experimental design; Peptide-based linear model 
9.2.6. Historical background 
Proteomics was revolutionized with the rise of biological mass spectrometry, genome 
sequencing and bioinformatics [1]. In a typical workflow for comprehensive proteome analysis, 
proteins are digested with specific proteases such as trypsin. The resulting peptide mixtures 
are then separated by high performance liquid chromatography (HPLC). Subsequently, a mass 
spectrometer coupled to the HPLC instrument is used to analyze the eluting peptides and the 
generated (tandem) mass spectra are mapped to theoretical spectra generated based on 
protein sequences stored in databases. 
In early days, MS-based proteomics was used to just identify proteins. As technology matured, 
quantitative information was extracted from proteome samples. Efforts have been made to 
determine absolute protein amounts based on mass spectra. These can be very sensitive in a 
targeted proteomics context [2], [3], [4] but current methods for proteome-wide absolute 
quantification remain rather crude due to massive ionization efficiency differences between 
peptides [5]. 
In this tutorial the focus is on relative quantification; i.e. the abundance of a given protein is 
compared over different samples. One of the first relative quantification technologies was 
based on isotope-coded affinity tags (ICAT) [6]. Later, metabolic labeling with stable isotopes, 
e.g. 15N and SILAC, emerged, where some samples were grown in medium made from the 
most abundant natural isotopes, and other samples in medium containing stable heavy 
isotopes [7], [8], [9]. Note that metabolic labeling can be rather expensive and is mainly 
performed on in vitro cell cultures. In cases where metabolic labeling is not possible, post-
metabolic isobaric multiplex labeling such as iTRAQ [10] and tandem mass tags (TMT) [11] 
can be used. However, post- or non-metabolic labeling may be incomplete, leading to higher 
sample-to-sample variability compared to metabolic labeling. More information on 
quantification with isobaric labeling can be found in Rauniyar and Yates [12]. Labeling has the 
intrinsic advantages that both the analytical time as well as the run-to-run variation are reduced 
as because it enables sample multiplexing in one MS-run as two or more peaks can be 
measured in the same MS- or MS/MS-spectrum. 
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Nowadays, label-free methods are becoming more and more standard. Such methods scale 
very well, have no real upper limit on the number of samples that can be compared (even in 
retrospect) and bypass the labor-intensive and often expensive sample labeling steps. 
Moreover, up to 60% more proteins can be identified, and this at a higher dynamic range 
because the mass spectrometer does not have to fragment each labeled form of the same 
peptide [13], [14]. A disadvantage of label-free quantification is that a peptide selected for 
fragmentation in one run might not be selected for fragmentation or result in a poorer quality 
MS2 spectrum in another run, leading to missing values. “Match between runs” algorithms, 
where unidentified MS1 peaks are matched to identified peaks using a tight retention time and 
mass/charge window, significantly improve the number of identified peaks [15]. In the 
remainder of the manuscript we will focus on data-dependent label-free MS-based 
quantification. 
In data-dependent acquisition (DDA), a software identifies multiply charged peptide precursor 
ions with the highest intensities from deconvoluted MS (or MS1) spectra. In a next step, such 
peptide ions are individually selected and further fragmented, typically by collision-induced 
dissociation, whereby MS/MS (or MS2) spectra are recorded. The frequency by which peptide 
ions are fragmented depends on both the LC resolution and the scanning speed of the mass 
spectrometer, with increasingly faster instruments now mapping larger fractions of the 
expressed proteome than ever before [16], [17]. Fig. 9.6 gives an overview of a contemporary 
label-free mass spectrometry-based proteomics workflow. 
 
Figure 9.1. A typical DDA shotgun proteomics workflow using a quadrupole Orbitrap instrument. 
Extracted proteins are enzymatically digested to peptides, using a specific protease such as trypsin [18]. 
Peptides are then separated over a reverse-phase column and eluting peptides are transformed to gas-
phase ions by electrospray ionization (ESI) [19]. At discrete time points, the eluting set of ionized 
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peptides are sent through the mass spectrometer and an MS spectrum is taken. Peak intensities in the 
MS spectrum are a proxy for peptide abundance. Upon deconvoluting the spectrum, the software 
identifies the highest peaks. For the next set of ionized peptides, only one peptide family present at the 
mass-to-charge ratio corresponding to one of the highest peaks in the MS spectrum will be separated 
from the rest in the quadrupole. This peptide is further fragmented in a collision-induced dissociation 
(CID) [20] or higher-energy collisional dissociation (HCD) [21] cell and an MS2 spectrum of its fragments 
is taken. MS2 spectra for other peptides with high MS spectral intensities are also recorded. After 
recording a pre-specified number of MS2 spectra, the eluate composition will have changed, and a new 
MS spectrum is taken, followed by new MS2 spectra, and so on. 
Protein identification is a first important step in the data-analysis workflow. As technology 
advanced, manual inspection of the sheer number of MS2 spectra became practically 
impossible (the newest generation of machines identify around 25,000 peptides from their MS2 
spectra in a given run, but do note that this number depends on machine settings and sample 
complexity). Bioinformatics software was introduced that is capable of identifying a peptide 
from its fragmentation spectrum given a database in which protein sequences are stored. The 
first one was PeptideProphet [22], using the SEQUEST algorithm [23]. The Mascot search 
engine introduced probability-based scoring, giving researchers a way to remove unreliable 
identifications at a predefined false discovery rate level [24]. Other search algorithms can be 
easily executed using SearchGUI [25], a graphical user interface that allows for searches with 
X!Tandem [26], MS-GF + [27], MS Amanda [28], MyriMatch [29], Comet [30], Tide (a fast 
implementation of the SEQUEST algorithm) [31], Andromeda [32], OMSSA [33], Novor [34] 
and DirecTag [35]. Further, tools such as PeptideShaker [36] can be used to combine results 
of different search engines to boost identifications. The MaxQuant search engine, which uses 
the Andromeda algorithm, is very popular nowadays thanks to its user-friendly graphical user 
interface [37]. As soon as it became possible to automatically search spectra for peptides in a 
database, the need for data storage, processing and visualization software also emerged [38]. 
Upon identification, a subsequent protein quantification step is required, which remains a 
tedious task for several reasons. First, sample preparation needs to be tightly controlled in 
order to reduce variability in protein extraction and digestion [39]. Second, the actual protein 
sequence surrounding the protease recognition site as well as protein modifications influence 
a protease's cleavage efficiency, thus possibly yielding peptides at varying levels [40]. Third, 
some peptides from a given protein ionize poorly, while others give very strong signals, 
depending on the peptide sequence and its modification status [41]. Fourth, some peptides, 
so-called razor peptides, cannot be uniquely attributed to a single protein and should thus 
either be used with extreme care when quantifying a protein or excluded altogether. Fifth, mass 
spectrometers are stochastic, thus sampling of MS1 spectra is inherently discrete, whereas 
peptides continuously elute from the column; hence, the observed peptide peak intensities 
may vary between samples. Sixth, competition for ionization between co-eluting peptides 
causes extra variability [42], [43], [44]. And, finally, co-eluting peptides with similar mass-to-
charge ratios may be co-fragmented, resulting in chimeric spectra and biased quantifications 
[45], [46], [47]. 
Relative quantification can be done either through spectral counting or through intensity-
based methods (see Blein-Nicolas and Zivy [48] for a complete overview), although a few 
methods, like ProPCA [49], combine both approaches. Spectral counting consists of 
comparing the number of peptide-to-spectrum matches (PSMs; this includes all redundant 
peptide identifications due to modifications, charge states and expiration of dynamic exclusion) 
for a protein across samples as a proxy for protein abundance [50]. While this technique has 
the advantage of its simplicity and is able to quantify proteins for which no peptides are found 
in one condition, it has become rather obsolete for MS-based quantification as precision can 
be an issue, especially when comparing small differences in abundance [51]. Also, dynamic 
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exclusion settings of the mass spectrometer (i.e. the same MS peak is fragmented only once 
in order to boost the number of identifications) might obscure the relationship between the 
number of counts and protein abundance [51], [52], [53]. Further, when machine settings are 
changed, runs become incomparable. 
Intensity-based methods make use of the more accurate information present in spectral 
intensities or areas under the peaks in either MS or MS/MS spectra, which causes intensity-
based methods to be more sensitive [54]. Such methods can be subdivided into MS2 and MS1 
intensity-based methods. MS2 methods are less accurate as peptide fragmentation does not 
always occur at the maximum of the elution peak [55]. Within MS1 intensity-based methods, 
there are broadly two approaches, which we refer to as summarization-based methods and 
peptide-based models. 
Summarization-based methods comprise all methods that summarize observed peptide 
intensities at the protein-level before performing a statistical analysis on protein abundance 
[56], often in an ad hoc manner [57]. Examples include, but are not limited to summing up 
peptide intensities [58], [59], (weighted or trimmed) mean summarization [60], [61], (weighted 
or trimmed) median summarization [62] and summarization based on peptide ratios (e.g. the 
method developed by Dost et al. [63] and maxLFQ [64]). All but the most efficient of these 
(such as the ratio-based approaches and ProPCA) ignore the fact that peptide ionization 
efficiency strongly influences the finally reported protein intensity, which leads to a bias due to 
different peptides that are missing in different samples. Also, none of these methods account 
for the fact that for the same protein, a different number of peptides might be identified in each 
sample, leading to differences in precision of the summarized protein expression value. The 
strong correlation between a peptide's intensity and its identification probability further 
exacerbates these issues. 
Peptide-based models estimate protein fold changes (FC) directly from peptide intensities 
within the framework of a statistical (linear) regression model. Examples include linear mixed 
effect models such as presented in Daly et al. [65] and Clough et al. [57] (implemented in the 
MSStats package [66]), but also non-linear models [67], models handling peptides that are 
shared between protein groups, such as the method developed by Blein-Nicolas et al. [68] and 
SCAMPI [69] (implemented in the protiq R package) as well as censored regression models 
for missing peptides such as SALPS [70] and the method developed by Karpievitch et al. [71] 
(implemented in the DanteR R package [72]). We and others have shown that peptide-based 
models outperform summarization-based methods by reducing bias and increasing sensitivity, 
specificity, accuracy and precision [57], [73]. However, traditional peptide-based models still 
suffer from (1) overfitting, (2) unstable variances and (3) outliers. Our proteomics quantification 
package MSqRob tackles these issues by building upon (1) ridge regression, (2) borrowing 
information across proteins and (3) down-weighing outliers, all of which were discussed in 
Goeminne et al. [74]. In this tutorial paper, we focus on the integration of peptide-based models 
from the MSqRob framework in current quantitative proteomics workflows. 
9.2.7. Basic concepts 
The actual design of an experiment strongly impacts the data analysis and its power to discover 
differentially abundant proteins. Therefore, we first cover some basic concepts on experimental 
design. Next, we provide a general step-by-step overview of a typical quantitative proteomics 





Basic concepts on experimental design 
The monthly column “Points of significance” in Nature Methods is a useful primer on statistical 
design for researchers in life sciences to which we extensively refer in this section 
(http://www.nature.com/collections/qghhqm/pointsofsignificance). 
For proteomics experiments it is important to differentiate between experimental units and 
observational units. Experimental units are the subjects/objects on which one applies a given 
treatment, often also denoted as biological repeats. In a proteomics experiment, the number 
of experimental units is typically rather limited (e.g. three biological repeats of a knockout and 
a wild-type sample). The measurements, however, are applied on the observational units. In a 
shotgun proteomics experiment, these are the individual peptide intensities. For many proteins, 
there are thus multiple observations/peptide intensities for each experimental unit, which can 
be considered as technical replicates or pseudo-replicates [75]. Hence, one can make very 
precise estimates on the technical variability of the intensity measurements; i.e. how strongly 
intensity measurements fluctuate for a particular protein in a particular sample. However, the 
power to generalize the effects observed in the sample to the whole population remains limited 
as most biological experiments typically only have a limited number of biological repeats [76]. 
We thus strongly advise researchers to think upfront about their experimental design and to 
maximize the number of biological repeats as much as feasible (we suggest at least three, and 
preferably more). 
Another important concept is that of blocking [77], which randomizes the different treatments 
to experimental units that are arranged within groups/blocks (e.g. batches, time periods) that 
are similar to each other. Due to practical constraints, it is often impossible to perform all 
experiments on the same day, or even on the same HPLC column or mass spectrometer, 
leading to unwanted sources of technical variation. In other experiments, researchers might 
test the treatment in multiple cultures or in big experiments that involve multiple labs. A good 
experimental design aims to mitigate unwanted sources of variability by including all or as 
many treatments as possible within each block. That way, variability between blocks can be 
factored out from the analysis when assessing treatment effects (Fig. 9.7). 
 
 
Figure 9.2. Example of a good (A) and a bad (B) design. In design A, both the green and orange 
treatments are divided equally within each block. That way, the treatment effect can be estimated within 
a block. In design B, each block contains only one treatment, so the treatment effect is entirely 
confounded with the blocking effect and it is thus impossible to draw meaningful conclusions on the 
treatment (unless one would be willing to assume that the blocking effect is negligible, which is a very 
strong assumption that cannot be verified based on the design). 
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Finally, it is important to correctly account for the degree of pseudo-replication within each 
block so as to provide final FC estimates with correct standard errors. Note that pseudo-
replication always occurs in peptide-based linear models because the peptides from the same 
protein in the same sample can be considered as technical replicates for protein expression. 
A general label-free quantitative proteomics data analysis workflow 
A first crucial step is the identification of peptides from mass spectra. Peptide identification has 
already been touched upon in the historical background section. Methods for peptide 
identification are constantly being developed and improved. Providing a complete review on 
the strengths and limitations of popular search engines is outside the scope of this tutorial. 
Once peptides are identified and their spectral intensities are determined, the identified 
peptide-to-spectrum matches need to be assigned to the correct protein to perform 
quantification at the protein level. Often, this is trivial, but some peptides can originate from 
multiple proteins (so-called razor peptides). How to handle razor peptides is a matter of 
debate [78], but as their intensities might represent a combined intensity, it might be safer to 
remove them from the data altogether. When two or more proteins are very similar in their 
amino acid sequence, it can be more convenient to group them together into a “protein 
group”. MaxQuant does this automatically [15]. For the remainder of this text, the term 
“protein” encompasses both “proteins” and “protein groups”, unless explicitly stated otherwise. 
Before proteins can be quantified, the intensities of identified peptides need to be 
preprocessed. Raw (summarized) peptide intensities found in MaxQuant's peptides.txt file 
indeed show a distribution that is strongly skewed to the right. Common preprocessing steps 
therefore include log2-transformation to render the intensities more symmetric, and 
normalization to reduce systematic technical variation while retaining the underlying biological 
signal [79]. Other steps might include removal of common contaminant proteins (such as 
keratin from the operator's skin and hair, or leftover trypsin from digestion) [80] or bad quality 
peptides from the list of identified proteins [71]. 
Below, we illustrate how the robust peptide-based linear model from the MSqRob framework 
can be incorporated in a state-of-the-art label-free proteomics data analysis workflow. In a 
typical shotgun proteomics experiment, one would like to estimate the average log2 intensity 
per treatment for each protein. However, one also wants to correct for effects of the peptide 
sequence (which can be rather large, as explained in the historical background), pseudo-
replication at the level of biological and technical repeats (i.e. MS runs) and other potential 
blocking factors. For each protein, a statistical peptide-based model is constructed in which 
one models all observed log2-transformed peptide intensities as a function of the effects in our 
model. A typical peptide-based model is formulated below: 
𝑦𝑖𝑗𝑘𝑙𝑚𝑛 =  𝛽𝑖𝑗𝑡𝑟𝑒𝑎𝑡 +  𝛽𝑖𝑘
𝑝𝑒𝑝 + 𝛽𝑖𝑙
𝑏𝑖𝑜𝑟𝑒𝑝 + 𝛽𝑖𝑚
𝑡𝑒𝑐ℎ𝑟𝑒𝑝 + 𝜀𝑖𝑗𝑘𝑙𝑚𝑛, 
with 𝑦𝑖𝑗𝑘𝑙𝑚𝑛 the nth preprocessed peptide intensity for the ith protein, j is the index for 
treatment (treat), k the index for peptide sequence (pep), l the index for biological repeat 
(biorep) and the m the index for technical repeat (techrep). 𝜀𝑖𝑗𝑘𝑙𝑚𝑛 is a normally distributed 
error term with mean zero and protein-specific variance 𝜎𝑖2. yijklmn is also referred to as the 
response variable; and treat, pep, biorep and techrep as the predictor variables. The 𝛽's 
are the effects of each predictor on the peptide intensities of the ith protein. More information 
about linear regression models can be found in Altman and Krzywinski [81]. 
When working with the MSqRob package, one needs to discriminate between fixed and 
random effects [82], as MSqRob handles them differently. Fixed effects are those effects for 
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which all levels of interest are included in the experiment. They are generally controlled for by 
the experimenter and are typically the effects of interest. Examples include genotype (when 
comparing specific genetic constitutions), treatment, gender (only two levels), … Random 
effects are those effects for which not all levels are included in the experiment and the levels 
that are included can be considered to be drawn at random from a broader, near-infinite 
population. Experimenters are generally not interested in the observed random effect sizes, 
but they can be used to address issues with pseudo-replication, i.e. we merely incorporate 
them so that the covariance is correctly accounted for as to enable valid inference on the fixed 
effects of interest. Random effects are never under the control of the experimenter. Examples 
of random effects are MS run, biological replicate, technical replicate, animal effect, patient 
effect, etc. Note that the effect of the biological repeat (subjects/animals) only has to be 
incorporated if multiple observations are available per repeat. Sometimes, the number of 
observed levels also determines whether an effect is incorporated as fixed or random. E.g. if 
one performs an experiment with two different cell types, there are not enough levels to 
estimate the random effect variance, so it should be included as a fixed effect and the 
experimenter can only draw conclusions on the two specific cell types studied. In many cases 
blocking factors, such as effects of HPLC column or instrument, are also considered as fixed. 
They often have a limited number of levels and the variability between blocks can be factored 
out of the analysis in good experimental designs, i.e. when all effects of interest are included 
within each block. MSqRob also exploits the link between mixed models and ridge regression, 
which puts a penalty on the size of the fixed effects, preventing overfitting. The peptide effects 
often overwhelm the remaining effects in the experiment and specifying the sequence effect 
as a separate random effect allows the remaining fixed effects of interested to be penalized 
independently of the peptide effect. 
Upon fitting a linear regression model, contrasts of the model parameters are assessed in 
statistical tests to answer the research question; e.g. one could test whether there is on 
average a difference between the effects of two treatments. Since the effects are modeled on 
a log-scale, differences can be interpreted in terms of log2 fold changes. Another option is to 
perform an ANOVA test to assess multiple contrasts simultaneously or the omnibus null 
hypothesis that none of the treatments have an effect. 
Since we infer on the research question for each protein, it is necessary to correct for multiple 
testing [83], [84]. In high-throughput experiments we generally use the false discovery rate 
(FDR) for this purpose. Researchers often tolerate a few false positives in their top hits, as 
long as there are not too many. Controlling the FDR at 5% means that one expects on average 
5% false positive proteins amongst all proteins that are returned as differentially abundant. In 
MSqRob, we correct for multiple testing using the Benjamini-Hochberg FDR procedure [85]. 
9.2.8. How is MSqRob used in research? 
MSqRob can be used in two ways: either as an R package or with the “Shiny” graphical user 
interface. Info on how to use the latest version of MSqRob in R can be found in the MSqRob 
vignette or in the installation instructions on the MSqRob github repository. MSqRob offers 
custom functions for importing data, preprocessing data, fitting models and testing research 
hypotheses (“statistical contrasts”). As long as peptide-level data can be provided in either long 
or wide tabular format, MSqRob can be used after searching the data with any search engine. 
As MaxQuant is one of the most popular free quantitative proteomics software packages, we 
developed a graphical user interface for statistical analysis of differential protein abundance 
based on MaxQuant output. It allows to (1) directly import MaxQuant search results, (2) 
preprocess and visualize the data, and (3) save the output to Excel without any programming 
164 
 
knowledge required. Moreover, MSqRob is capable of handling virtually any experimental 
design. 
Our MSqRob Shiny App has three different tabs: an input, a preprocessing and a results tab. 
In the input tab, the user provides the name of the project, the location where the output needs 
to be saved, MaxQuant's peptides.txt file and an experimental annotation file. In the 
preprocessing tab, options are provided to log2-transform peptide intensities, normalize 
intensities, remove overlapping protein groups, remove contaminants and reverse sequences, 
remove all proteins that are only identified by modified peptides and remove all peptides that 
are identified by less than a specified number in the dataset. Its right panel shows diagnostic 
plots that can be used to evaluate the preprocessing step. Ultimately, the quantification tab 
allows the user to select the grouping factor, remove superfluous columns, select fixed and 
random effects and specify contrasts. When pressing the “Go” button, MSqRob will execute 
the analysis. After the analysis, the right panel of the quantification tab will show a volcano plot 
in which proteins can be selected for further inspection with a detail plot. This panel will also 
show the results table. The results table can be saved automatically to allow further inspection 
and visualization. 
9.2.9. Case studies 
Prerequisites 
R [86] and RStudio [87] have to be installed on a computer. MSqRob can be freely downloaded 
from https://github.com/statOmics/MSqRob. Installation instructions and up-to-date guidelines 
are provided in the README.md file on the website. 
MSqRob is an R package with a Shiny App that provides a graphical user interface to MSqRob 
for MaxQuant data. In the tutorial we focus on hands-on examples in the MSqRob Shiny App. 
The examples can also be coded in plain R, which can be useful for incorporating MSqRob in 
data analysis pipelines. R-markdown files with R Code and instructions are also provided for 
the examples at https://github.com/statOmics/MSqRob/blob/master/vignettes/MSqRob.Rmd. 
Upon installation, the Shiny App can be launched by copy-pasting the following command in 
the command window of RStudio: 
shiny::runApp(system.file('App-MSqRob', package = 'MSqRob')) 
Here, we provide step-by-step tutorials for two case studies with the MSqRob Shiny 
application. Our first example is a case study based on the experiment of Ramond et al. [88]. 
We use a subset of the experiment with a simple wild-type vs. knock-out design. It is a design 
with pseudo-replication at different levels. Our second example consists of a spike-in study of 
the Clinical Proteomic Technology Assessment for Cancer Network (CPTAC) in which 48 
human proteins were spiked in five different concentrations in a yeast background proteome. 
Here, the ground truth is known [89] and the experiment is set up as a randomized complete 
block design. We have already used this particular study to evaluate the performance of our 
method [74]. 
The Francisella example 
Experimental set-up 
The study on the facultative pathogen Francisella tularensis was conceived by Ramond et al. 
[88]. F. tularensis enters the cells of its host by phagocytosis. The authors showed that F. 
tularensis must import arginine from the host cell via a novel arginine transporter, ArgP, in 
order to efficiently escape from the phagosome and reach the cytosolic compartment, where 
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it can actively multiply. In their study, they compared the proteome of wild type F. tularensis 
(WT) to ArgP-gene deleted F. tularensis (knock-out, KO). For this experiment, bacterial 
cultures were grown in biological triplicate and each sample was run three times on a 
nanoRSLC-Q Exactive PLUS instrument. Hence, pseudo-replication occurs on different levels 
of the experiment, i.e. multiple peptides for the same protein in each MS-run (technical repeat) 
and 3 technical repeats for each biological repeat. The data were searched with MaxQuant 
version 1.4.1.2. Below, we give an overview on how to process the data with the MSqRob 
Shiny App. 
The input tab (Fig. 9.8) 
First, we choose an appropriate name for the project. This name, appended with a timestamp, 
will be used to generate an output folder for the MSqRob model and results. Here, we use the 
name “project_Francisella”. Select an appropriate file location where the MSqRob output 
should be saved by clicking on “Browse…”. Next, upload the peptides.txt file, which contains 
the MaxQuant peptide-level intensities that are found by default in the 
“path_to_raw_files/combined/txt/” folder from the MaxQuant output, with “path_to_raw_files” 
the folder where raw files were saved. 
 
Figure 9.3. Overview of MSqRob's input tab. 
Similarly, upload the experimental annotation file. This file should be a tab-delimited file or 
an Office Open XML spreadsheet file (“.xlsx” file). If needed, this file can be made based on 
Fig. 9.9. If the file location was already specified and the peptides.txt file was uploaded, one 
can generate the “run” column of this file automatically by clicking the “Create annotation file” 
button. The other columns need to be filled in manually based on the experimental design. 




free_Francisella_annotation.xlsx. One column (the “run” column in Fig. 4) of the experimental 
annotation file should contain the names of the MS runs; i.e. the names given in the 
“experiment names” column when searching the data with MaxQuant. These names should 
be unique. Other columns indicate other variables of interest related to the design that can 
affect protein expression; e.g. genotype: WT vs. KO and biological repeats (“biorep”). 
 
Figure 9.4. Experimental annotation file for the Francisella dataset. 
At this stage, everything is set for preprocessing and data exploration, which are implemented 
in the preprocessing tab. 
The preprocessing tab (Fig. 9.10) 
Left panel 
The preprocessing tab features different preprocessing options, many of which can be safely 




Figure 9.5. Overview of MSqRob's preprocessing tab. 
MS-based proteomic intensity distributions are nearly always strongly skewed to the right. 
Therefore, a log-transformation is highly recommended. We suggest to log-transform the 
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data with base 2. This has the added advantage that the model estimates will be interpreted 
as log2 FC. For the remainder of this work, we assume that intensities have been log2-
transformed. 
We provide different normalization approaches. As a default, we suggest quantile 
normalization [79], [90]. Quantile normalization imposes the same empirical intensity 
distribution on all runs. More information on other normalization methods that are implemented 
can be found in the documentation of the ‘normalise’ function in the R package MSnbase [91]. 
The effect of quantile normalization on the distribution of the log2-transformed peptide 
intensities is shown in Fig. 9.11. 
 
Figure 9.6. Overview of the log2-transformed peptide intensities for the Francisella dataset before and 
after preprocessing. Left: log2-transformed peptide intensities before preprocessing, center: log2-
transformed peptide intensities after preprocessing. Note that the densities are forced onto the same 
distribution. Right: MDS plot that clusters similar MS runs together. 
The option “Remove proteins that are only identified by modified peptides” allows for 
removing proteins that are only identified by peptides that carry one or more modified amino 
acids. Identification of such peptides in the background of non-modified peptides is often less 
reliable, and proteins only identified by such peptides are therefore removed in a typical 
MaxQuant-Perseus workflow. We offer the option to do a similar filtering in MSqRob. The 
MaxQuant's proteinGroups.txt file is needed for this purpose and can be found in the 
“combined/txt/” folder. 
Razor peptides are peptides that cannot be uniquely attributed to a single protein or protein 
group. As we are uncertain from which protein group these peptides originate and their 
intensities might even be a combined value from multiple protein groups, we opt to remove 
these peptides by default. The option “Remove protein groups for which any of its member 
proteins is present in a smaller protein group” deals with peptides that are shared between 
protein groups. This option removes all peptides in protein groups for which any of its peptides 
map to a protein that is also present in another smaller protein group. 
“Minimal number of times a peptide sequence should be identified” indicates a threshold T for 
how many times a certain peptide sequence should be present in the data before being 
retained in the final analysis. Peptides that are identified at least T times are retained; other 
peptides are removed from the data. This value defaults to 2 and there is a very practical 
reason for this. Indeed, we need a parameter in the model for each peptide sequence. Adding 
a parameter for a single observation leads to perfect confounding in the model as there is no 
way to discern between the peptide-specific effect and the other effects for this observation. 
Note that this is not the same as applying the so-called “two-peptide rule” [92]. A protein 
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identified by only one peptide can contribute to the estimation provided that the peptide is 
identified in multiple samples, say t with t ≥ T. 
One can further filter out reverse sequences and potential contaminants, made possible by 
providing the column names of the peptides.txt file that indicate these sequences in the “Also 
filter based on these columns” field. 
Right panel 
In the right panel, the number of peptides before any kind of preprocessing is done, and a plot 
of the densities of the (log-transformed) peptide intensities in each MS run are displayed. For 
the Francisella dataset, there were 10,693 identified peptides before preprocessing. 
The effect of preprocessing can be assessed by ticking the “Evaluate preprocessing” box. 
A plot will be generated that shows the densities of the (log-transformed) peptide intensities 
after full preprocessing (i.e. after normalization and filtering) (Fig. 9.11). A multidimensional 
scaling (MDS) plot will also be produced, which shows a dot for each MS run such that the 
distance between two dots is equal to the root-mean-square deviation for the top 500 peptides 
that distinguish the two corresponding runs. Options are provided to show only dots, only labels 
or both. It is also possible to zoom in on a particular part of the plot by dragging the mouse to 
select a particular area on the plot and then double-click to zoom in. 
One can color the density lines and MDS points by any factor provided in the experimental 
annotation file. Upon filtering, log2-transformation and normalization, 7772 peptides remained 
in the dataset. 
The quantification tab (Fig. 9.12) 
Left panel 
“Select the grouping factor (mostly the “Proteins” column)” allows selecting on which 
level the statistical inference is performed. Here, we were interested in proteins of which the 
abundance differed between the two genotypes. We thus selected the “Proteins” column. 
“Select additional annotation columns you want to keep” allows retaining extra annotation 
columns that one might have added to the peptides.txt file. Here, we selected “Protein names” 




Figure 9.7. Overview of MSqRob's quantification tab. 
Next, the fixed effects need to be specified. Fixed effects are effects that remain constant 
when repeating the experiment. For factor variables (e.g. genotype), the number of levels are 
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typically small. “genotype” should be entered as a fixed effect, as there are only 2 genotypes 
in our study. Effects of interest are nearly always fixed effects. On the contrary, “Sequence”, 
“biorep” and “run” are added as random effects. The effect of a single biological repeat will 
differ each time one would re-perform an experiment. The biological repeat also has to be 
included in the model because peptide intensities from a protein from the same biological 
repeat are more similar than those from the same protein across biological repeats. Similarly, 
each MS run will be different and peptides from the same protein in the same run are correlated 
because they originate from the same protein pool. Hence, the pseudo-replication of peptides 
within technical repeats as well as the technical repeats within each biological repeat will be 
properly addressed. Assigning “Sequence” as a random effect is debatable, but we noticed 
that the sequence effect overwhelms other effects in typical proteomics experiments. MSqRob 
also exploits the link between ridge regression and mixed models [74]. Ridge regression is 
implemented to prevent overfitting. Therefore, we strongly suggest specifying the “Sequence” 
effect as a random effect, which will allow penalizing this effect separately from the remaining 
fixed effects. 
With “Save/load options”, there are three options: 
1. “Save the models” will generate a file with an “.rDatas” extension that contains R objects 
with the data and the fitted models. It is useful to store these objects as they enable the 
user to upload and redo the statistical inference without having to perform the time-
consuming preprocessing and model fitting steps. 
 
2. “Load existing models” allows the user to upload an rDatas object from a previous analysis. 
Note that all input except the type of analysis and the contrast options will become disabled 
as the model is already fitted to the data. A new rDatas object will also be created with the 
output. This option is also useful for evaluating the output of MSqRob upon running it in 
bash mode. 
 
3. “Don't save the models”: no rDatas object will be stored. 
“Number of contrasts you want to test” indicates how many contrasts (research 
hypotheses) one would like to test. For the Francisella dataset, we were only interested in the 
difference between wild-type and knock-out strains, therefore we performed statistical 
inference on the average difference in log2 protein intensity between both genotypes. This 
difference corresponds to a log2 FC. We specify this contrast as by typing “− 1” under genoWT 
and “1” under genoKO. 
Check all settings and press the “Go” button in the left panel of the output tab. 
Right panel 
When the analysis is finished, MSqRob prints “DONE!” at the top of the right panel. In this case 
study we only evaluated one contrast (KO vs. WT). If multiple contrasts are specified, one can 
select the contrast one would like to explore further. The “Volcano plot” shows − log10(p-
values) as a function of the “estimate” (i.e., here the log2 FC between KO and WT for the 
Francisella example). One can select an area on this plot using the computer mouse and 
double clicking zooms in on this area. Upon selecting such an area, one can add all points in 
the area to a selection or remove all points in this area from a selection using their respective 
buttons. By clicking on a dot, one selects/deselects it. When only one protein is selected, a 
“Detail plot” is made for this protein, which shows the preprocessed peptide intensities as a 
function of a predictor variable from the model. Boxplots show the median preprocessed 
peptide intensity as a thick black line, the box itself comprises the interquartile range (IQR) and 
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whiskers extend to the most extreme data point that lies within 1.5 times the IQR on each side 
[93]. Each peptide intensity in the Detail plot can be given a color and a shape value according 
to any model parameter. Fig. 9.13 shows a detail plot for the most significant protein in the 
study, WP_003040894 or 3-isopropylmalate dehydratase large subunit, an enzyme required 
for the biosynthesis of leucine. Note that all identified enzymes required for the synthesis of 
branched chain amino acids were found either unchanged or downregulated in the ArgP 
mutant. Here, we specified “genotype” as independent variable, “run” as color variable and 
“Sequence” as shape variable. 
 
Figure 9.8. Example of a detail plot for the most significant protein in the study performed: 3-
isopropylmalate dehydratase large subunit. 
One may also specify the “Significance level (alpha)”. Its default value is at 5%, but it can 
be changed on the fly. Proteins with a false discovery rate (FDR) below α will be colored red 
in the Volcano plot if unselected, and purple if selected. Proteins with an FDR above α will be 
colored black if unselected, and grey if selected. In the Francisella case study, we found 162 
significant proteins at a 5% FDR threshold. 154 of those overlap with the proteins reported in 
Goeminne et al. [74]. This difference is due to subtle changes in our algorithm (e.g. all fixed 
effects except peptide sequence now all get the same shrinkage penalty). The 8 new significant 
proteins are proteins for which our old implementation could not estimate a fold change, while 
the 5 proteins that are not flagged anymore in our new implementation have an FDR value that 
is close to the 5% cut-off. 
The “Results table” shows all proteins, by default sorted from smallest to largest p value. 
When selecting/deselecting a row in the table, the corresponding dot in the Volcano plot is also 
(de)selected and vice versa. When zoomed in on the Volcano plot, the Results table only 
shows the proteins corresponding to the dots in the plot window. The Search box allows 
searching for particular proteins in the table. When only one protein is selected, the detail plot 
is also displayed. 
Note that in the file location one provided in the input tab, a folder is created, which is named 
“project_Francisella_[date and time of analysis]”. In this folder, one finds the 
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project_Francisella_models.rDatas file, which contains the data and the fitted model object as 
discussed above. The “project_Francisella_results.xlsx” contains the same information as the 
“Results” table. The first column is the protein accession. “Protein.names” and “GI.number” 
are the columns, which were indicated as “additional columns we want to keep”. “estimate” 
is the estimate of the contrast, which here is the log2 FC between the proteomes of wild-type 
and knock-out Francisella tularensis. “se” is the standard error on the contrast, “df” indicates 
the degrees of freedom, “Tval” is the T value, “pval” is the p value, “qval” is the q value, i.e. 
the minimal FDR level at which this protein will be called significant. “signif” indicates whether 
the protein is significant at the default 5% FDR threshold. 
The same analysis can also be performed in bash mode. Details are given at 
https://github.com/statOmics/MSqRob. 
The CPTAC example 
The 6th study of the Clinical Proteomic Technology Assessment for Cancer (CPTAC) is an 
experiment in which the authors spiked the Sigma Universal Protein Standard mixture 1 
(UPS1) containing 48 different human proteins in a protein background of 60 ng/μL 
Saccharomyces cerevisiae strain BY4741 (MATa, leu2Δ0, met15Δ0, ura3Δ0, his3Δ1). Five 
different spike-in concentrations were used: 6A (0.25 fmol UPS1 proteins/μL), 6B 
(0.74 fmol UPS1 proteins/μL), 6C (2.22 fmol UPS1 proteins/μL), 6D 
(6.67 fmol UPS1 proteins/μL) and 6E (20 fmol UPS1 proteins/μL) [89]. The raw data files can 
be downloaded from https://cptac-data-portal.georgetown.edu/cptac/public?scope=Phase+I 
(Study 6). We limited ourselves to the data of LTQ-Orbitrap at site 86, LTQ-Orbitrap O at site 
65 and LTQ-Orbitrap W at site 56. The data were searched with MaxQuant version 1.5.2.8, 
and detailed search settings were described in Goeminne et al. [74]. The experiment is 
conceived as a randomized complete block design with lab as a blocking factor. For every lab, 
3 replicates are available for each concentration. 
At high spike-in concentrations of human proteins, especially in conditions 6D and 6E, 
ionization suppression of yeast proteins has been reported [54], [73], [74]. Therefore, we focus 
on differences between condition 6B–6A, 6C–6A, and 6C–6B. 
The input tab 
Again, an appropriate name is chosen for the project. Here, use “project_CPTAC”, select the 
file location where the output has to be saved. Next, the location of the experimental 
annotation file and the peptides.txt file is specified, and MaxQuant's peptides.txt file is 
imported. An example of the experimental annotation for the CPTAC dataset is given in Fig. 






Figure 9.9. Top 30 rows of the annotation file for the CPTAC dataset. 
The preprocessing part is analogous as for the Francisella example. 
The quantification tab 
We again grouped by “Proteins”, but now there is no interest in additional columns. We 
selected “condition” as a fixed effect, because it is the main effect of interest and it has a fixed 
number of levels, being one for each spike-in concentration. The “lab” effect can be considered 
fixed, as it is a typical example of a so-called block effect. If one would redo the experiment, it 
will probably be in the same three labs, although it is also possible to argue for “lab” as a 
random effect (when one considers “lab” as a random draw from a huge number of possible 
labs). However, for the analysis of the treatment effect this should not matter as all treatment 
effects are observed within a lab and one can thus factor out the lab-to-lab variability from the 
analysis [77]. “Sequence” and “run” are again specified as random effects. 
In this example, we assessed three contrasts of interest; thus, set “Number of contrasts you 
want to test” to 3. For the first contrast, set condition 6A to − 1 and condition 6B to 1, for the 
second contrast, set condition 6A to − 1 and condition 6C to 1 and for the third contrast, set 
condition 6B to − 1 and condition 6C to 1 for comparisons 6B–6A, 6C–6B and 6C–6A, 
respectively. Then press the “Go” button and wait for the analysis to complete. 
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Upon comparing condition 6B to condition 6A on the Volcano plot, we noticed that most hits 
have positive FC estimates. These red circles on the right of “0” are indeed the UPS1 spike-in 
proteins and their levels in condition 6B are higher than in condition 6A. There appear to be 
two false positive hits (red circle left of “0” and the selected purple circle in Fig. 9.15). The 
selected yeast protein sp | P53115 | INO80_YEAST exhibits a strong negative log2 FC 
estimate of − 2.09 on the Volcano plot (Fig. 9.15). Upon inspecting this protein in the Detail 
plot, we found that this protein was only identified by two different peptides with very different 
intensity patterns (NAPSEGVMASLLNVEK: square and VSTTPLLK: circle). The intensities of 
the former peptide remain basically unchanged over the different spike-in concentrations, while 
those of the latter show a clear upwards trend with increasing spike-in concentration. Based 
on its intensity pattern, this latter peptide is very likely an incorrectly annotated UPS1 peptide. 
Indeed, our model assumes that all peptides behave in a similar way when comparing over 
samples. Here, the effect of the VSTTPLLK peptide is on average lower in condition 6B 
compared to the rest of the dataset, pulling the estimated average log2-intensity in this 
condition down. This effect is not at play for condition 6A, as this peptide was not identified, 
and therefore, the difference between 6B and 6A will be strongly negative (− 2.09). This 
example clearly demonstrates the added value of using Detail plots, as these enable detecting 
aberrations in the data that would otherwise go unnoticed, preventing researchers from 
drawing wrong conclusions. 
 
Figure 9.10. Use of the MSqRob output plots to find peculiar proteins. Protein 
sp | P53115 | INO80_YEAST has a log2 FC of − 2.09 and is identified by two different peptides, one of 
which is likely mis-annotated. In the Detail plot, points are colored by lab, while a different shape denotes 
a different peptide sequence. 
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9.2.10. Current limitations and useful working limits 
A major limitation of current proteomics workflows is the sequencing depth. The workflow we 
described here concerns so-called data-dependent acquisition (DDA). This means that 
identification is data-driven: only the most abundant peptide precursor ions are identified 
following MS2. As a consequence, not all peptides in a sample are identified, which gives rise 
to missing values. Missingness in proteomics datasets is a combination of missingness 
completely at random (MCAR) (e.g. a misidentified peptide can either be identified by aligning 
its elution profile with an already identified peptide or this alignment can be missed) or not at 
random (MNAR) (e.g. more abundant peptides simply have a higher chance of getting 
fragmented and thus being identified) [94]. This is even exacerbated as the probability is also 
context-dependent: when co-eluting with many other highly intense peptides, a certain peptide 
will have a smaller chance of getting identified than if these other peptides would be absent or 
lower in numbers and/or abundance. Imputing missing peptide values was suggested in the 
proteomics literature, but imputation should always be used with caution. When nothing is 
known about the nature of the missing values, recent reviews suggest the use of MCAR 
imputation approaches based on local similarity, as these perform well on average [94]. It has 
to be noted, however, that the performance of an imputation approach is highly dataset-
dependent [73], [94], [95]. Due to these peculiarities, we have chosen to omit imputation in the 
standard MSqRob workflow. Of course, when using non-imputed datasets, differential 
abundance cannot be estimated when all peptides are absent in all replicates of a particular 
condition. However, researchers have the option to impute peptide intensities before feeding 
these into MSqRob. Another solution to the presence-absence problem would be to perform 
an easy-to-implement spectral count approach to detect these proteins before continuing with 
a more sensitive intensity-based method [48]. So-called data-independent acquisition (DIA) 
workflows fragment all peptides, typically within a given m/z-window. With DIA, challenges lie 
in de-convoluting the highly complicated mixed spectra [96]. In this context missingness is due 
to the inability to resolve a spectrum but is expected to be less intensity-dependent. 
Another major issue in proteomics bioinformatics is data standardization [97]. As MS-based 
proteomics becomes more and more affordable to a wider community of researchers, the 
number of customized and multidimensional experiments (i.e. experiments in which more than 
one protein property, such as abundance, modifications, turnover, localization, etc. is analyzed 
simultaneously) is expected to rise [98], [99]. Such experiments require customized workflows, 
however, many proteomics tools work with software-specific or even proprietary data formats. 
This makes it difficult to connect different tools in a customized workflow. Therefore, open data 
formats for storing proteomics data have been developed by HUPO. Examples of these are 
mzML for raw mass spectrometer output [100] and mzQuantML [101] for quantified peptides 
and proteins. Future adaptation of these formats will allow for more interconnectivity between 
applications and massively improve the feasibility of setting up custom workflows. 
9.2.11. Future developments 
On a short term, we intend to adapt MSqRob to be able to handle DIA and isobaric labeling, 
and to enable the input of other search engines and open data formats. 
A constant theme in improvements of mass spectrometry instruments has been their increase 
in analysis speed and proteome coverage. We expect this trend to continue, which could, in 
the long run, reduce or even eliminate intensity-dependent missingness. Faster machines will 
also allow biologists to analyze an increasing number of biological repeats, which will boost 
the power of their experiments and allow them to detect small, but sometimes very relevant 
perturbations with greater confidence. Thanks to such increasing coverage, each generation 
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of machines allows us to dive deeper into the proteome than ever before. As machine duty 
cycles continue to increase, DIA and DDA are expected to come closer together as DIA 
windows will become smaller and smaller [102], while the analysis depth in DDA will continue 
to increase, so that one day, they might merge into a single technique that is capable of 
identifying all peptides in a sample. When that happens, the need to handle missing data in 
DDA will become obsolete. 
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9.2.15. Appendix 
We propose the same peptide-based regression model as in section 9.1: 
𝑦𝑝𝑟 =  𝒙𝑝𝑟𝜷 + 𝛽𝑝
peptide + 𝑢𝑟run + 𝜀𝑝𝑟 
Herein, 𝒙𝑝𝑟 is a row matrix with the covariate pattern related to peptide 𝑝 in run 𝑟, 𝜷 =
[𝛽0, 𝛽11 … , 𝛽𝑚1
1 … , 𝛽𝑀1
1 , … , 𝛽𝑚𝑔
𝑔 , … , 𝛽𝑀𝑔
𝑔 , … , 𝛽𝑀𝐺
𝐺 ]
T
 is a vector with 1 + 𝑀 = 1 + ∑ 𝑀𝑔𝐺𝑔=1  
parameters denoting the effects of 𝑀 predictors corresponding to 𝐺 covariates. 𝛽𝑝
peptide is a 
peptide-specific effect for peptide 𝑝, 𝑢𝑟run a random run effect to account for within-run 
correlation, with 𝑢𝑟run~N(0, 𝜎𝑢2). 𝜀𝑝𝑟~N(0, 𝜎2) is a random error term. 
The new version of MSqRob allows the user to put the same ridge penalty on multiple 
covariates because traditional ridge regression has a single ridge penalty 𝜆 that is equal for all 
fixed effects instead of separate ridge penalties for each covariate. We thus assume all ridge 
parameters to originate from the same distribution: 𝛽𝑚𝑔
𝑔 ~N(0, 𝜎2 𝜆⁄ ) for 𝑚 = 1, … , 𝑀𝑔 and 𝑔 =
1, … , 𝐺. Note that we still require a separate ridge penalty for the peptide effects 
𝛽𝑝
peptide~N(0, 𝜎2 𝜆peptide⁄ ) because of their large effect sizes. 
When naively imposing a single ridge penalty on multiple covariates, the amount of shrinkage 
is influenced by the scale of the predictors and the model’s parameterization (e.g. the choice 
of the reference class can impact on the ridge penalty). To ensure that the size of the ridge 
penalty is independent of the model’s parameterization, we perform a QR-decomposition on 
the part of the design matrix that corresponds to the fixed effect covariates, 𝑿fixed. 
𝑿fixed = 𝑸𝑹 
Herein, the 𝑸-matrix is an orthogonal matrix and can be used as a rescaled version of the 
original design matrix 𝑿fixed. The 𝑹-matrix is an upper triangular matrix. 
Subsequently, 𝑿fixed is replaced by the 𝑸-matrix prior to the lme4 mixed model fitting. During 
statistical inference, the part of the design matrix corresponding to the fixed effects is post-




The lme4 R package does not allow to impose a single ridge penalty over a group of multiple 
covariates. Therefore, we set up an lme4 model with a mock random effect that has the same 
number of levels as there are levels for the fixed effects that are shrunken together: 
parsedFormula <- lFormula(y~1+(1|ridgeGroup)+…) 
Then, we construct the part of the design matrix that corresponds to the shrunken fixed effects 
and perform QR-decomposition 
XridgeGroup <- model.matrix(…) 
QridgeGroup <- qr.Q(qr(XridgeGroup)) 
RridgeGroup <- qr.R(qr(XridgeGroup)) 
Next, we change the part of the design matrix in the parsedFormula that corresponds to the 
shrunken fixed effects: 
parsedFormula$reTrms <- within(parsedFormula$reTrms, 
{Zt[ridgeGroupindices,] <- t(QridgeGroup)}) 
And finally fit the model: 
devianceFunction <- do.call(mkLmerDevfun, parsedFormula) 
optimizerOutput <- optimizeLmer(devianceFunction) 
mRidge <- mkMerMod( 
                   rho = environment(devianceFunction), 
                   opt = optimizerOutput, 
                   reTrms = parsedFormula$reTrms, 
                   fr = parsedFormula$fr) 
When doing inference, the part of the design matrix that was replaced with QridgeGroup, is post-
multiplied with RridgeGroup. A similar procedure to create a single ridge penalty for multiple 
covariates in lm4 models has also exploited by the gamm4 R package [1]. 
Reference for the Appendix 





10. MSQROB TAKES THE MISSING HURDLE: UNITING 
INTENSITY- AND COUNT-BASED PROTEOMICS 
In chapter 10, we describe unpublished work. The motivation for this work is the high degree 
of missing data in label-free quantitative shotgun proteomics. Current solutions to the missing 
data problem, including those implemented by Perseus or MSstats, rely on imputation, which 
is often highly biased by assumptions that oversimplify reality.  
Our manuscript proposes a novel approach to address this important issue of missing data, by 
defining a hurdle model for the peptide intensities. The hurdle model is a mixture of a binary 
component that distinguishes between log-transformed peptide intensities that are missing 
and observed, and a normal component to model the magnitude of the log2-transformed 
peptide intensities passing the detection hurdle. The components of the hurdle model 
naturally combine the strength of count-based and intensity-based workflows for differential 
analysis in quantitative label-free MS-based proteomics within one model framework. In our 
manuscript, we first illustrate that imputation assumptions used in leading tools (i.e., Perseus 
and MSstats) often have a detrimental effect on the quantification of proteins with missing data. 
We then show that our novel hurdle approach rescues this situation without needing to rely on 
these unrealistic imputation assumptions. Importantly, we demonstrate that our method 
outcompetes existing approaches, and continues to provide reliable quantification for proteins 
where peptides are absent in one (or more) conditions. For this manuscript, I designed and 
performed analyses, set up the GitHub repository and wrote the paper together with my co-
authors. 
Ludger J.E. Goeminne, Adriaan Sticker, Lennart Martens, Kris Gevaert, and Lieven Clement 
10.1. Abstract 
Missing values present a major issue in quantitative data-dependent mass spectrometry-
based proteomics. We therefore present an innovative solution to this key issue by 
introducing a hurdle model, which is a mixture between a binomial peptide count and a 
peptide intensity-based model component. It enables dramatically enhanced quantification 
of proteins with many missing values without having to resort to harmful assumptions for 
missingness. We demonstrate the superior performance of our method by comparing it with 
state-of-the-art methods in the field. 
10.2. Introduction 
Label-free data-dependent quantitative mass spectrometry (MS) is the preferred method for 
deep and high-throughput identification and quantification of thousands of proteins in a 
single analysis [1]. However, this approach suffers from many missing values, which 
strongly reduce the amount of quantifiable proteins [2, 3]. There are three common causes 
for this missingness: (1) true absence of signal, or signal below detection limit in the MS1 
spectrum; (2) lack of fragmentation and hence missed identification of the MS1 peak; and 
(3) failed identification of the acquired fragmentation spectrum. As a result, missingness is 
more likely to occur for low-abundant proteins and/or poorly ionizing peptides. However, 
missingness may also extend to mid- and even high-range intensities, e.g. when co-eluting 
peptides suppress an MS1 signal or when poor quality of an MS2 spectrum interferes with 
correct identification. Missingness due to lack of fragmentation can be mitigated by 
“matching between runs”, where unidentified MS1 peaks in one run are aligned to identified 
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peaks in another run in narrow retention time and mass-over-charge (m/z) windows [4]. 
Nevertheless, missing values remain widespread; a survey of 73 recent public proteomics 
data sets from the PRIDE database demonstrates an average of 44% missing values (Fig. 
1 a, Supplementary Table 1). 
 
Figure 1. The impact of missing values and the superior performance of the hurdle model. (a) Missing 
values are highly prevalent in recent proteomics data. The histogram shows the distribution of the 
percentage of missing values in 96 peptides.txt files from 73 PRIDE projects with a PRIDE publication 
date in 2017 that applied shotgun proteomics to full or partial proteomes. Missingness ranges from 16 
to 82%, with an average of 44% missing values. (b) Perseus imputation fails when too many missing 
values are present: the frequency distribution of the log2-transformed LFQ intensities in the CPTAC 
dataset becomes bimodal after Perseus imputation due to the many imputed values, as exemplified by 
run A5. Observed values (978 LFQ intensities) are colored in blue, imputed values (484 LFQ intensities) 
are colored in red. Similar results for the other runs can be seen in Supplementary Fig. 1. (c, d) In the 
CPTAC dataset (38 UPS1 and 1,343 yeast proteins), the hurdle model outperforms other methods. The 
fraction of true positive UPS1 proteins flagged as DA in conditions C vs. A and B vs. A is plotted as a 
function of the fraction of false positive yeast proteins in the total number of DA proteins. 
A common solution for missingness is to impute the missing values. But, this comes at the 
expense of additional assumptions, e.g. k-nearest neighbors (kNN) assumes intensity-
independent missingness, and the popular software packages Perseus [5] (“Perseus 
imputation”, PI) and MSstats [6] assume missingness by low intensity. In reality, however, 
missing values originate from a mix of intensity-dependent and -independent mechanisms, 
which can moreover be strongly data set-specific [3, 7]. As a result, state-of-the-art 
imputation profoundly changes the distribution of protein-level intensities as it typically 
produces a second mode due to many imputed values, (shown for MaxQuant/Perseus in 
Fig. 1 b and Supplementary Fig. 1 – 2; and for kNN in Supplementary Fig. 3 – 4). This can 
have a deep impact on the downstream differential analysis. We demonstrate these effects 
on the widely studied CPTAC dataset [8], where more than 47% of peptide data are missing. 
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Because the spike-in concentrations in this dataset cover a wide range, the perils of 
imputation can be clearly shown. Indeed, while our MSqRob [9] quantification algorithm 
shows very good performance when combined with PI for comparison C (high spike-in 
concentration: 2.2 fmol/µL) vs. A (lowest spike in concentration: 0.25 fmol/µL) (Fig. 1 c), 
MSqRob with PI performs very poorly for comparisons B (intermediate amount of spike-in: 
0.74 fmol/µL) vs. A (Fig. 1 d) and C vs. B, where the differences in spike-in concentration 
are smaller (Supplementary Fig. 5, 6), thus rapidly accumulating false positives. MSqRob 
therefore omits imputation by default to avoid a severe backlash in performance [10]. 
However, without imputation, intensity-based methods cannot cope with complete 
missingness in one condition as it is impossible to calculate a fold change (FC) relative to a 
missing value. Thus, potentially interesting cases such as strong protein 
synthesis/stabilization or protein degradation remain undetected. 
Conversely, peptide counting approaches naturally handle missing peptides in a run by a 
zero count. Yet relative quantification by peptide counting generally performs very poorly 
(pink line in Fig. 1 c, d). This because counting disregards the inherent abundance-intensity 
relationship (within a given dynamic range) for each peptide [11, 12]. However, differentially 
abundant (DA) proteins for which no FC can be estimated due to missingness do differ in 
peptide counts (Supplementary Fig. 7) and proteins with a higher concentration have on 
average both higher peptide ion intensities and higher peptide counts, as it is more likely 
that even their poorly ionizing peptides are detected. 
Combining intensity-based methods with counting-based methods to exploit this 
complementary information therefore seems promising. Webb-Robertson et al. combine 
intensity- and count-based statistics to filter out peptides prior to differential analysis [13]. 
ProPCA uses principal components to summarize intensities and spectral counts into one 
value [14] and IDPQuantify uses Fisher’s method to combine the p-values from a two-
sample t-test with those of a quasipoisson regression on spectral counts [15]. However, 
ProPCA’s combined metric lacks an intuitive interpretation, and does not include any 
downstream statistical analysis. Like Perseus, IDPQuantify only handles simple pairwise 
comparisons without any possibility to correct for confounding effects. Moreover, none of 
these methods is able to pinpoint whether the statistical significance is driven by the count 
component, the intensity component, or both, thus making it impossible to interpret the 
results in terms of FCs. 
10.3. Results and discussion 
Here, we introduce a hurdle model that unites the advantages of MSqRob with the 
complementary information present in peptide counts, that avoids unrealistic imputation 
assumptions, and that provides interpretable results. This hurdle model takes peptide-level 
information as input and consists of a mixture model of two components: (1) a binary 
component that distinguishes between log2-transformed peptide intensities that are either 
missing or observed; and (2) an MSqRob-based component to model the magnitude of log2 
peptide intensities passing the detection hurdle. Inference on the parameters of both model 
components has an intuitive interpretation: the binary component can be used to assess 
differential detection (DD) and returns log odds ratios (log ORs), while the MSqRob 
component allows to test for differential abundance (DA) of a protein and returns log2 fold 
changes (log2 FCs). When peptides are completely missing in one condition, the hurdle 
model reduces to a binomial model. However, when peptides are present in both conditions, 
the hurdle approach allows to combine information in the OR and FC test statistics, and can 
be used to infer on DD, DA, or both in a post-hoc analysis. Note, that the peptide counts 
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can be over- or underdispersed, which is why the variance component is estimated via 
quasi-likelihood and the model is termed a quasibinomial model.  
We use the CPTAC study 6 dataset [8] to compare our hurdle approach to the quasibinomial 
model alone, to MSqRob alone, to Perseus (with and without imputation), and to MSstats. 
Fig. 1 c, d demonstrates the superior performance of the hurdle model: it consistently 
outperforms the other algorithms. Moreover, the hurdle model also always outperforms 
MSqRob with imputation under a low abundance assumption such as PI (Supplementary 
Fig. 5, 6). In the lowest spike-in condition, A, missing values in the UPS1 proteins are mainly 
caused by low abundance, allowing the count-component of the hurdle model to add to the 
strength of the intensity-component. In comparison C vs. B, the UPS1 spike-in 
concentrations are higher, reducing the difference in peptide counts between both 
conditions, and mainly driving significance of the hurdle model by the difference in average 
intensities. In this case, the hurdle model performs on par with MSqRob without imputation, 
as is expected, while PI approaches still perform poorly (Supplementary Fig. 5, 6). 
Next, we assess the human heart dataset of Doll et al. (2017) [16]. For the 7,822 gene 
identifiers in common after preprocessing, we assessed the overlap between the 1,500 most 
significantly regulated identifiers in the Doll et al., hurdle, and MSqRob comparisons 
between the atrial to the ventricular proteome (Fig. 2 a, Supplementary Table 2). The 652 
identifiers shared between all methods correspond to proteins with a strong DA and many 
identified peptides (Supplementary Fig. 8). The 209 identifiers shared between Perseus and 
hurdle mostly have strong DD and only few peptides in one of the heart chambers 
(Supplementary Fig. 9). The 204 identifiers unique to hurdle differ strongly in peptide counts, 
but the log2 FCs are close to one. (Supplementary Fig. 10). The 543 identifiers unique to 
Perseus often show very few peptide identifications or very small FCs, making these results 
more questionable (Supplementary Fig. 11). Indeed, the imputation strategy again has a 
profound impact on the results: there is a 22% non-overlap between Perseus with and 
without the PI strategy. Moreover, because of the stochastic nature of the PI imputation,  on 
average 4.5% of the first 1,500 proteins declared DA did not overlap between two repeated 
PI analyses. The 96 identifiers shared between MSqRob and Perseus, finally, mainly have 
many peptides, but a relatively small FC (Supplementary Fig. 12). These are not included 
in the top 1,500 differential proteins by the hurdle model as their place in the ranking is 
taken by identifiers with a strong DD. A similar analysis for the 500 and 1,000 most 
differential proteins for each method is given in Supplementary Fig. 13. 
For our novel approach we also observe a strong association between the OR and FC 
estimates (Fig. 2 b). Out of the 1,496 hurdle identifiers that are significant at the 1% FDR 
level, 466 were significantly DD, 499 significantly DA, 297 both significantly DD and DA, 
and 234 could not be attributed to either DA or DD in our post hoc analysis. All 297 identifiers 





Figure 2. The hurdle model detects both DD and DA proteins. (a) The Venn diagram shows the overlaps 
in the 1,500 most significant proteins when contrasting atrial (average of left atrium, LA; right atrium, 
RA; atrial septum, SepA) to ventricular regions (average of left ventricle, LV; right ventricle, RV; 
ventricular septum, SepV) in the HEART dataset between hurdle, MSqRob without prior imputation, and 
Perseus with imputation and SAM as implemented by Doll et al. (b) Proteins that are significant with the 
hurdle model often display a strong positive association between FC and OR. Here, log2 FCs are plotted 
as a function of log2 ORs in the atrial vs. ventricular comparison for all 6,489 proteins with an FC 
estimate. Proteins are colored by p-value. Common FDR cut-offs are indicated on the color bar. 
As in the original publication, comparing the left to the right ventricle did not render any 
significant proteins. However, when comparing the left to the right atrium, we found twelve 
significant proteins compared to only three in the original publication (Supplementary Table 
3). The higher abundance of the muscle contraction protein myotilin [17] in the left atrium 
was confirmed by both methods, but the hurdle model additionally indicates several heavy 
and light myosin chains such as MYH7 and MYL3 as DA. Moreover, the hurdle model also 
flags the voltage-dependent calcium channel CACNA2D2 and BMP10, an essential factor 
for embryonal cardiac development [18]. Finally, SERINC3 and PNMA1, which were 
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declared DA by Doll et al. actually come with very limited evidence for DA and their 
significance is likely driven by the inherent randomness of PI (Supplementary Table 4). 
In summary, we demonstrated the negative impact of imputation in protein quantification, 
and the potential flaws it induces in the downstream analysis when imputation assumptions 
are violated. We therefore propose a hurdle approach that can handle missingness without 
having to resort to imputation and its associated assumptions by leveraging both an 
intensity-based approach (MSqRob) and a count-based quasibinomial approach. Our hurdle 
approach outcompetes state-of-the-art methods with and without imputation in the presence 
of both strong missingness as well as when missingness is limited. Moreover, our hurdle 
method continues to provide valid inference when peptides are absent in one condition. It 
is therefore a highly promising approach to detect the sudden appearance of post-
translationally modified peptides in protein regulation alongside more traditional differential 
protein expression. 
10.4. Methods 
In this section, we first demonstrate how we analyzed the frequency of missing values in recent 
PRIDE projects. Then, we discuss the nature and the origin of the CPTAC and the HEART 
datasets, followed by an overview of how these datasets were preprocessed and imputed with 
different strategies. We then introduce the Perseus, MSstats, MSqRob, the quasibinomial 
model and the hurdle model as methods for statistical inference. Finally, we refer to our GitHub 
page which enables to reproduce all the analyses in this publication.  
10.4.1. Missing values in recent PRIDE projects 
For our analysis of the frequency of missing values of recent datasets in PRIDE, we 
downloaded 96 peptides.txt files corresponding to 73 PRIDE projects that adhere to the 
following conditions: 
- label-free shotgun proteomics,  
- full proteomes or enriched subsets of the proteome (i.e. no projects where there was an 
enrichment step for a chemical modification and no projects investigating protein-protein 
interactions),  
- published in PRIDE in 2017 and  
- searched with MaxQuant and peptides.txt file available from PRIDE. 
An overview of the projects and peptides.txt files with their number of missing values, 
number of observed values and percentage of missing values is given in Supplementary 
Table 1. 
10.4.2. Data availability 
We made use of two example datasets. 
1. In the benchmark CPTAC study 6, which can be downloaded from https://cptac-data-
portal.georgetown.edu/cptac/dataPublic/list?currentPath=%2FPhase_I_Data%2FStudy6&
nonav=true, the human UPS1 standard is spiked in 5 different concentrations in a yeast 
proteome background [8]. This allows to make comparisons for which the ground truth is 
known: when comparing two different spike-in conditions, only the UPS1 proteins are truly 
differentially abundant (DA), while the yeast proteins are not. 
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The three lowest spike-in conditions (A, B and C) from LTQ-Orbitrap at site 86, LTQ-Orbitrap 
O at site 65 and LTQ-Orbitrap W at site 56 were searched with MaxQuant 1.6.1.0 against a 
database containing 6,718 reviewed Saccharomyces cerevisiae (strain ATCC 
204508/S288c) proteins downloaded from UniProt on September 14, 2017, supplemented 
with the 48 human UPS1 protein sequences provided by Sigma Aldrich. 
Carbamidomethylcysteine was set as a fixed modification and methionine oxidation, protein 
N-terminal acetylation and N-terminal glutamine to pyroglutamate conversion were set as 
variable modifications. Detailed search settings are described in Supplementary Material. 
We only performed pairwise comparisons between the 3 lowest spike-in concentrations 
because of the huge ionization competition effects in the higher spike-in concentrations, as 
described earlier [9]. 
2. The HEART dataset originates from a large-scale proteomics study of the human heart, 
where 16 different regions and 3 different cell types from three healthy human adult hearts 
were studied [16]. 
For our analysis, we made use of the peptides.txt and proteinGroups.txt files made available 
by Doll et al. in ProteomeXchange via the PRIDE Archive repository under the identifier 
PXD006675. Here, we limited ourselves to the data from 6 regions: the atrial and ventricular 
septa (SepA and SepV), the left and right atrium (LA and RA) and the left and right ventricle 
(LV and RV). We compare the atrial regions (LA, RA and SepA) to the ventricular regions 
(LV, RV and SepV), as well as LA vs. RA and LV vs. RV. 
10.4.3. Preprocessing for MSqRob and the quasibinomial model 
Peptide intensities obtained from MaxQuant’s peptides.txt file were log2-transformed and 
quantile normalized. Next, potential contaminants, reverse sequences and proteins that 
were only identified by peptides carrying a modification were removed from the data. Finally, 
proteins identified by only a single peptide were also removed. 
10.4.4. Imputation methods 
Missing values were either not imputed or imputed with kNN or Perseus imputation. 
No imputation 
For MSqRob without imputation, we additionally removed peptides that are only identified 
in a single run. Indeed, MSqRob directly models peptide intensities and the peptide-specific 
effect for peptides with one identification cannot be estimated because no replicates are 
available. This additional filtering step is not required for MSqRob with imputation, because 
missing values in the peptide intensity matrix are imputed first. 
kNN imputation 
k-nearest neighbors (kNN) imputation calculates a Euclidean distance metric on all peptide 
intensities to find the k most similar peptides and imputes the missing value with the average 
of the corresponding values from the k neighbors [19]. We used the default value of k = 10 
neighbors. 
Perseus imputation 
We call “Perseus imputation (PI)” the standard imputation approach from the popular 
proteomics computational platform Perseus [5]. The imputation is achieved by using the 
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“Replace missing values from normal distribution” function in Perseus 1.0.6.7. We applied 
PI on peptide intensities for MSqRob with PI and on LFQ intensities for Perseus with PI.  
PI first constructs a rescaled normal distribution with: (1) a downshifted mean equal to the 
average of all the observed data minus 𝑑 times the standard deviation of the observed data 
and (2) a standard deviation equal to 𝑤 times the standard deviation of the observed data. 
Missing values are then imputed with random draws from this rescaled distribution. We 
adopt Perseus’ default values for 𝑤 (0.3) and 𝑑 (1.8). 
10.4.5. Statistical inference 
In this subsection, we discuss differential protein analysis with Perseus and MSstats, followed 
by MSqRob, the quasi-binomial model and our hurdle model. All methods mentioned below 
model the data protein by protein. To improve readability, we will suppress the protein 
indicator in the remainder of this section. 
Perseus 
For the CPTAC dataset, LFQ intensities were imported into Perseus 1.6.0.7. Potential 
contaminants, reversed sequences and proteins only identified by peptides carrying 
modification sites were removed from the data. Next, empty columns were removed and via 
“Categorical annotation rows”, runs were sorted according to their spike-in conditions (A, B 
or C). Data were either imputed with PI (“Perseus with imputation”) or not (“Perseus without 
imputation”). Finally, we performed two-sample t-tests for each of the three comparisons.  
For the atrial vs. ventricular comparison in the HEART dataset, Doll et al. provided the 




MSqRob has been described in detail in Goeminne et al. (2016) [9]. Briefly, for each protein, 
the log2-transformed peptide intensities 𝑦𝑝𝑟 for peptide 𝑝 = 1, … , 𝑃 in run 𝑟 = 1, … , 𝑅 are 
modeled as follows: 
𝑦𝑝𝑟 = 𝛽0 + 𝒙𝒑𝒓T 𝜷 + 𝛽𝑝
peptide + 𝑢𝑟run + 𝜀𝑝𝑟,                                                                                        (Eq. 10.1) 
where 𝛽0 is the intercept, 𝛽𝑝
peptide is the fixed effect of the individual peptide sequence 𝑝, 
𝑢𝑟run is a random run effect (𝑢𝑟run~N(0, 𝜎𝑢2)) that accounts for the correlation of peptide 
intensities 𝑦𝑗𝑟 and 𝑦𝑘𝑟 from the same protein within the same run 𝑟, 𝒙𝒑𝒓T = (𝑥1,𝑝𝑟, … , 𝑥𝑚,𝑝𝑟)
T 
is a vector with the covariate pattern of the 𝑚 remaining predictors, 𝜷 = [𝛽1, … , 𝛽𝑚]T is a 
vector of parameters modeling the effect of each predictor on the peptide intensity 
conditionally on the remaining covariates, and 𝜀𝑝𝑟 is the error term that is assumed to be 
normally distributed (𝜀𝑝𝑟~N(0, 𝜎2)). 
For the CPTAC and HEART datasets, the MSqRob model can be written as follows: 







peptide + 𝑢𝑟run + 𝜀𝑝𝑟,                                 (Eq. 10.2) 
where 𝛽0 is the intercept, 𝛽𝑡treat is the effect of interest (𝑡 = 1 to 3 corresponding to spike-in 
conditions A, B, C for CPTAC, 𝑡 = 1 to 6 for the six cardiac regions in the HEART dataset), 
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𝛽𝑏block is a blocking factor (lab 𝑏 = 1 to 3 for CPTAC, patient 𝑏 = 1 to 3 for HEART), 
𝑥𝑡,𝑝𝑟treat and 𝑥𝑏,𝑝𝑟block are dummy variables which are equal to 1 if run 𝑟 corresponds to treatment 
𝑡 or block 𝑏, respectively, and 0 otherwise. 𝛽𝑝
peptide is the effect of the individual peptide 
sequence 𝑝, 𝑢𝑟run is a random effect that accounts for the fact that peptides within each run 
𝑟 are correlated. Due to the parameterization of the model, the following restrictions apply: 
∑ ?̂?𝑡treat𝑇𝑡=1 = 0, ∑ ?̂?𝑏block = 0𝐵𝑏=1 , ∑ ?̂?𝑝
peptide = 0𝑃𝑝=1  and ∑ ?̂?𝑟run = 0𝑅𝑟=1 . 
The effect sizes 𝛽(.)
(.) (except for the intercept) are estimated using penalized regression. 
Distinct ridge penalties are used for the treatment, block and peptide parameters, 
respectively and the ridge penalties are tuned by exploiting the link between ridge 
regression and mixed models (see e.g. Ruppert et al. (2003), chapter 4 [20]). Outliers are 
accounted for using M-estimation with Huber weights. Protein-wise degrees of freedom are 
now calculated in a less liberal way as: 𝑅 − (1 + (𝑇 − 1) + (𝐵 − 1)). Variances are stabilized 
by borrowing information over proteins using limma’s empirical Bayes approach which 
results in a moderated t-test. Scripts to run MSqRob are provided on our GitHub page (see 
below under “Code availability”). 
MSstats 
MSstats has been described by Choi et al. (2014) [6]. For our analysis, we used the default 
settings of MSstats version 3.12.2. During preprocessing, feature intensities are log 2-
transformed and normalized by equalizing the run medians. Then, missing values are 
imputed with the default MSstats settings. Features are summarized to the protein level with 
Tukey’s median polish method. Treatment effects are specified as “Condition” and blocking 
factors as “BioReplicate” in the MSstats workflow.  
Quasi-binomial model 
When assuming that the number of observed peptides 𝑛𝑟
peptide in each run 𝑟 (after 
preprocessing) for a protein are binomially distributed 
𝑛𝑟
peptide|𝒙𝑟~Binomial(𝑃, 𝜋𝑟),                                                                                                                (Eq. 10.3) 
with 𝑃 the total number of unique peptides observed over all runs 𝑟 = 1, … , 𝑅 for this protein, 
and 𝜋𝑟 the probability to identify a peptide for this protein; the peptide counts can be 
modeled using logistic regression. However, they are often under- or over-dispersed with 
respect to the binomial distribution. We therefore adopt quasi-binomial regression 
(McCullagh and Nelder (1989), section 4.5 [21]) where we model the first two moments 
(mean E[𝑛𝑟
𝑝𝑒𝑝𝑡𝑖𝑑𝑒] and variance Var[𝑛𝑟
𝑝𝑒𝑝𝑡𝑖𝑑𝑒]) as follows:  
E[𝑛𝑟
𝑝𝑒𝑝𝑡𝑖𝑑𝑒] = 𝑃𝜋𝑟,                                                                                                                                    (Eq. 10.4) 
logit(𝜋𝑟) = log (
𝜋𝑟
1 − 𝜋𝑟
) = 𝒙𝒓T𝜷,                                                                                                          (Eq. 10.5) 
Var[𝑛𝑟
𝑝𝑒𝑝𝑡𝑖𝑑𝑒] = 𝜑𝑃𝜋𝑟(1 − 𝜋𝑟),                                                                                                            (Eq. 10.6) 
with 𝜑 a dispersion parameter accommodating for a more flexible variance function than 
that of the binomial regression model. Note that the quasibinomial approach models the log 
odds, i.e. the logarithm of the probability that a peptide is detected divided by the probability 
that a peptide is not detected, i.e. the odds on detection. Hence, the model will return log 
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ORs when contrasting different treatments to each other, which can be used to infer on 
differential peptide detection for a specific protein. 
Hurdle model 
The normalized intensities for each peptide 𝑝 in each run 𝑟 are typically assumed to follow 
a log-normal distribution. Upon log2-transformation, missing (zero) intensities are set at −∞ 
and cannot be modeled with intensity-based methods such as Perseus, MSstats and 
MSqRob. Missing values are therefore either omitted or imputed. 
Here, we consider a hurdle model that consists of two parts: a binary component 𝑧𝑝𝑟 that 
distinguishes between peptide intensities in run 𝑟 that are missing (𝑧𝑝𝑟 = 0) or observed 
(𝑧𝑝𝑟 = 1) with detection probability  𝜋𝑟; and a normal component 𝑦𝑝𝑟 with mean 𝜇𝑝𝑟 and 
variance 𝜎2 to model log2 peptide intensities passing the detection hurdle. Note, that the 
detection probability 𝜋𝑟 and the mean 𝜇𝑝𝑟 can be further parameterized using peptide 
specific effects, a random run effect 𝑢𝑟run, and additional covariates 𝒙𝑝𝑟. More formally, the 
hurdle model for log2-transformed intensities 𝑦𝑝𝑟 for peptide 𝑝 = 1, … , 𝑃 in run 𝑟 = 1, … , 𝑅 can 
be specified as follows: 
𝑧𝑝𝑟|𝒙𝑝𝑟 ~ Bernoulli(𝜋𝑟)                                                                                                                          (Eq. 10.7) 
𝑦𝑝𝑟|𝑧𝑝𝑟 = 1, 𝒙𝑝𝑟, 𝑢𝑟run ~ N(𝜇𝑝𝑟, 𝜎2)                                                                                                     (Eq. 10.8) 
The log-likelihood for 𝝅 = [𝜋1, … , 𝜋𝑅]T, 𝝁 = [𝜇11, … , 𝜇𝑃𝑅]T and  𝜎2 given 𝒚 = [𝑦11, … , 𝑦𝑃𝑅]T, 𝒛 =
[𝑧11, … , 𝑧𝑃𝑅]T ,  𝒖𝑟𝑢𝑛 = [𝑢1, … , 𝑢𝑅]T,   and 𝑿 the matrix with rows 𝒙𝑝𝑟T  can then be written as: 






Note, that the log-likelihood implies an estimation orthogonality between 𝜋𝑟 and 𝜇𝑝𝑟 and that 
the first two terms in the equation are equivalent to the log-likelihood of a Bernoulli process. 
Further, we omit a peptide-specific effect for the parameterization of 𝜋𝑟 because this leads 
to complete separation for too many proteins. The detection probability is thus considered 
constant for all peptides of a particular protein in run 𝑟. When summing over the peptides 
𝑝 = 1, … , 𝑃, peptide counts 𝑛𝑟
peptide = ∑ 𝑧𝑝𝑟𝑝  are obtained and it is computationally more 
efficient to estimate 𝜋𝑟 using a binomial model for the peptide counts. To account for under- 
and/or over-dispersion in the counts, we will again estimate the detection probability 𝜋𝑟 
using quasi-binomial regression with Model (Eq. 10.4 − 10.6). The last term in the log-
likelihood corresponds to a normal log-likelihood and we propose to estimate 𝜇𝑝𝑟 and 𝜎2 
using the MSqRob Model (Eq. 10.2). 
Both model components model their means using the same covariate pattern 𝒙𝑝𝑟 and they 
will allow us to assess the same contrast of interest to infer on the log OR on detection and 
a log2 FC between conditions, respectively.  Assuming independence between both 
statistics under the null hypothesis (see section 10.7. Appendix), the hurdle model allows to 
assess the omnibus null hypothesis of no differential detection and no differential expression 
by combining the p-values of MSqRob without imputation and of the quasi-binomial model 




𝜒hurdle2 = 𝑧MSqRob2 + 𝑧quasi−binomial2                                                                                                   (Eq. 10.10) 
If an MSqRob log2 FC can be estimated the chi-square statistic follows a chi-square 
distribution with 2 degrees of freedom under the omnibus null hypothesis, otherwise the 
corresponding p-value is equivalent to that of the quasi-binomial model. 
Two-stage inference 
We used stageR version 1.3.29 to implement a two-stage inference procedure [22]. It is a 
two-stage testing paradigm that leverages power of aggregating multiple tests per protein 
(here a test for differential detection, DD and differential abundance, DA) in the screening 
stage. Upon rejection of the omnibus null hypothesis, stageR performs post-hoc tests to 
assess on DD and DA. We adopt the Benjamini-Hochberg False Discovery Rate (FDR) 
procedure on the aggregated tests in the first stage. In the post-hoc analysis, we use the 
modified Holm procedure implemented in stageR to control the Family Wise Error Rate for 
the DD and DA tests within a protein at the FDR-adjusted significance level of the first stage.  
Multiple testing correction 
All p-values for MSstats, MSqRob, the quasibinomial and the hurdle model were corrected 
for multiple testing using the Benjamini-Hochberg FDR correction. Perseus uses a 
permutation-based FDR based on 250 iterations. 
10.4.6. Code availability 
All scripts to reproduce the results in this contribution and in supplementary material are 
available at https://github.com/statOmics/MSqRobHurdlePaper. 
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Under the null hypothesis of no differential abundance, the combined test statistic 𝜒hurdle2  
(Eq. 10.10) will follow a chi-squared distribution with two degrees of freedom if both z-statistics 
are independent. To assess this assumption, we performed a mock analysis on the repeats of 
the spike-in conditions within each lab. We also included the combination of spike-in condition 
and lab as a blocking factor in the analysis (see Table 10.1). This set-up ensures that none of 
the proteins are differentially abundant. 
Table 10.1. Overview of the mock treatment levels and the condition-lab combinations for each MS run 
in the mock analysis. 
Condition:lab Mock treatment 
 One Two Three 
6A_Orbitrap_86 6A1 6A2 6A3 
6A_Orbitrap_65 6A4 6A5 6A6 
6A_Orbitrap_56 6A7 6A8 6A9 
6B_Orbitrap_86 6B1 6B2 6B3 
… … … … 
 
The results of the three pairwise comparisons, both for the MSqRob and for the quasi-binomial 
model compontent of the hurdle model are shown in Fig. 10.3. and confirm that the estimates 




Figure 10.3. There seems to be no correlation between the estimates from the MSqRob and quasi-
binomial model component. The scatter plots show the log2 FC estimates on the horizontal axis and log 
OR estimates on the vertical axis of the hurdle model for all proteins in the CPTAC dataset for which a 
log2 FC could be estimated in all three comparisons of the mock analysis (UPS1 proteins are indicated 






























In recent years, enormous progress has been made in MS instrumentation and quantitative 
proteome analysis protocols, not only on how experiments are planned and executed, but also 
on how the data are analyzed. Given the quite large costs of a proteomics experiment, it is 
important to extract the maximum out of the obtained data. Nonetheless, because of historical 
reasons, the number of statisticians studying proteomics data is limited compared to the 
number of statisticians in the transcriptomics field. Indeed, proteomics initially only aimed for 
protein identification and not quantification, and the low duty cycles rendered proteomic 
analyses laborious, time-consuming and costly. Therefore, biological repeats were often not 
included in these early studies, which made it impossible for statisticians to infer the results of 
these studies towards the population (see 4.2.1). The enormous technological advances in 
instrumentation over the latest 10 years led to a massive increase in throughput and 
reproducibility. This enabled the adoption of experimental designs that include proper 
biological replication, which is now required by all major proteomics journals. This evolution 
towards more statistical rigor occurred much earlier in the transcriptomics field, and most 
statisticians who used to work on microarray data migrated towards RNA-Seq data as they 
were used to these types of designs. 
Given the importance of quantitative proteomics in the study of diseases, it is unacceptable 
that biologically relevant proteins go unnoticed because of suboptimal protein quantification 
strategies [1]. Therefore, I focused in my PhD project on understanding and improving 
quantification in label-free shotgun proteomics. Nowadays, large and complex experimental 
designs are being analyzed more and more routinely and many different methods to quantify 
proteomes have emerged of which the performances differ widely. For a non-expert, the choice 
of different methods presented in the literature seems overwhelming. In this discussion, I do 
not aim at giving a complete overview of every single method that is available now, as new 
approaches are emerging every other day. Alternatively, I present my view on why certain 
approaches work better than others in order to provide experimentalists with basic tools to 
critically reflect on new methods and select that workflow that is the most adapted to their 
needs. Hopefully, this work will not only help researchers in getting the most out of their data, 
but also inspire data scientists to improve existing methods. 
11.1. Comparing performances 
An optimal differential analysis method can discern truly differentially abundant proteins (true 
positives) from non-differentially abundant proteins (false positives) as good as possible. 
Therefore, the most important performance metric is the protein ranking: truly differentially 
abundant proteins should appear near the top of the ranking, while proteins with very little 
evidence for differential abundance should be found near the bottom of the ranking. Once a 
ranking is obtained, a threshold should be set above which all proteins are deemed significantly 
differentially abundant at a certain FDR level. In practice, only a few proteins that are deemed 
differentially abundant with a high certainty will be selected for further experimental validation. 
Setting the boundary straight between differentially abundant and non-differentially abundant 
proteins is therefore of secondary importance compared to generating a useable ranking in the 
first place. 
High variabilities in peptide intensities relative to protein fold changes are characteristics of 




(e.g. due to differences in ionization efficiencies), and methods that fail to appropriately model 
the different sources of variability in the data are doomed to return many false positives. 
Indeed, the high variability in observed peptide intensities might sometimes lead to large 
apparent fold changes with low apparent uncertainties, especially when very few peptides are 
identified for the corresponding protein. Such false positives will however fail to pass the 
validation stage in follow-up experiments, which results in a waste of valuable resources and 
contributes to the replication crisis in life sciences. 
Not all methods are easy to include in a comparative study as some published data analysis 
methods do not provide scripts, let alone user-friendly interfaces. Other tools function like a 
black box: they do not provide any insight in how protein level fold changes are calculated, nor 
do they give any indication on the certainty of the quantification. Finally, many scripts and tools 
have been abandoned because the scientist that introduced them has moved on to another 
project. Luckily, the usage of such methods is expected to diminish strongly, as the proteomics 
field is undergoing a rapid transition towards more transparent and reproducible ways of data 
analysis. 
Benchmark datasets, in which the ground truth is known, are necessary to compare methods. 
There are three main ways of generating benchmark datasets: computationally simulating a 
dataset, computationally introducing differences in a biological dataset, and generating a 
spike-in dataset in the lab.  
Simulated datasets are entirely computer-generated and therefore easy to create. However, 
simulation studies often fail to capture all sources of variability in a biological dataset. For 
example, ionization competition effects are rarely considered in simulation studies, and there 
are many other known and unknown influences on peptide intensity that interact amongst each 
other in complex ways, that are very difficult to predict. Moreover, it is often tempting to 
simulate the data under assumptions that are very close to those of the model under study or 
even use this model to generate the data, therefore artificially boosting its performance.  
Artificial differences between different treatments can also be generated by computational 
manipulation of an existing dataset. The intensities of all peptides mapping to a group of 
proteins can for example be computationally decreased or increased in half of the samples 
from the control arm of an existing case-control experiment. Although such datasets have a 
representative data structure for non-differentially abundant proteins, differential effects of e.g. 
enzymatic digestion or ionization are generally ignored for the differentially abundant proteins. 
Furthermore, if all peptide intensities for each differentially abundant protein are changed by a 
fixed amount, the variability in the peptide intensities might be underestimated compared to a 
biological dataset, which makes it easier to detect the differentially abundant proteins in the 
artificial dataset. 
In spike-in studies such as the CPTAC study 6, different amounts of proteins are spiked into a 
background proteome and analyzed on the HPLC-MS system. Although the generation of such 
datasets requires setting up an actual MS experiment, well-executed spike-in studies capture 
the data structure of biological datasets. When setting up a spike-in study, it is important to 
incorporate biological repeats. Unfortunately, many spike-in studies, such as CPTAC, spike 
the samples only once and repeatedly analyze the same samples. The variability in such 





In chapter 8, we used the CPTAC dataset to rigorously compare summarization-based 
methods to peptide-based methods. We provided an objective comparison and showed that 
methods starting from normalized peptide intensity data are superior to methods using a 
summary step, and this in terms of sensitivity, specificity, accuracy and precision. A crucial 
element of that study is that we provided clarity on the different mechanisms causing the 
differences in performance. This insight is extremely important, both for practitioners who need 
to understand why certain methods outperform others, and for data scientists who want to 
develop new quantification methods.  
Naive summarization methods such as mean and median summarization produce biased fold 
change estimates because their protein abundance summaries are based on different peptides 
in each run without properly controlling for peptide-specific effects. MaxLFQ summaries are 
theoretically unbiased, but its protein summaries are inefficiently estimated as MaxLFQ only 
uses the PSM intensities that are shared between each pair of runs. This unstable estimation 
of the MaxLFQ summaries is particularly apparent in the samples with low spike-in 
concentrations, where very few peptides are found due to intensity-dependent missingness 
and hence very few ratios are used to calculate the MaxLFQ estimates. Furthermore, 
summarization-based methods cannot propagate the differences in uncertainty on the 
summary estimates to the downstream analysis because they ignore the fact that the standard 
errors on the summaries are dependent on the number of peptides used in each summary. 
Peptide-based models, on the contrary, can naturally incorporate a peptide effect, hence 
avoiding bias and accounting for the fact that estimates based on many peptides are more 
precise than those based on only a few peptides. 
When constructing a peptide-based model, it is important to correctly model different sources 
of variability as failure to correctly take the data structure into account might lead to imprecise 
or biased results. Indeed, the treatment of interest is not the only source of variability and 
variability due to different peptides and sample-to-sample variability should also accounted for. 
Do note however, that including too many parameters in a model will lead to over-
parameterization, the phenomenon whereby a model is too complex for the dataset at hand 
(i.e. it has too many parameters compared to the amount of data). Models for proteins with 
very sparse peptide evidence are particularly at risk for over-parameterization. An over-
parameterized model will be tuned too well to the data: part of the random residual variability 
will be absorbed by the model’s parameter estimates as if that variability reflects meaningful 
variation that can be explained by the model. As a result, the model’s parameter estimates will 
be extremely imprecise.  
In chapter 8, we also showed that including a fixed sample effect leads to over-
parameterization for most proteins in the CPTAC dataset. This is not surprising as most 
proteins are identified with only a few peptides per sample. Hence, fold change estimates and 
variance components for proteins with very few peptides will be unstable. More importantly, 
estimating a sample effect removes the between-sample variability from the analysis. Ignoring 
this between-sample variability causes a vast underestimation of the standard errors on the 
fold changes and will thus lead to an increase the number of false positives. This is the reason 
why the peptide-based model without sample-effect was shown to be more accurate and more 
precise. Indeed, not only is this model less prone to over-fitting, the standard error on the fold 
change estimates is also more correctly estimated as both the within- and between-sample 
variances are lumped together in the model’s error term. However, a model without a sample 
effect does not account for the fact that peptides within the same sample are correlated with 




solution as random effects allow to model the correlation structure in the data in a natural way 
by correctly taking the between-sample variance into account while still acknowledging the 
within-sample correlation. This explains the slightly better performance of the mixed model 
compared to the peptide-based model without a sample effect. 
We observed that the performance gain of the mixed model compared to the peptide-based 
model without a sample effect is very limited in the CPTAC dataset. This is likely because the 
CPTAC dataset is highly artificial as UPS1 proteins were spiked into a yeast background in 
five different concentrations and these samples were repeatedly analyzed in multiple labs. 
Hence, the dataset only contains technical variability. In a biological experiment, one expects 
the differences between the individual samples to be bigger because of the additional biological 
variability between samples. Consequently, the within-sample correlations will be stronger and 
the contribution of the sample effects to the total variability in the data will be larger. 
11.2. The impact of MSqRob 
The fact that peptide-based models outperform naive summarization-based models and that 
mixed models have a theoretical advantage for dealing with hierarchical data inspired us to 
develop MSqRob. This was motivated by the observation that state-of-the-art peptide-based 
mixed models declare many proteins as differentially abundant for which there is in reality very 
little evidence as based on visual inspection of the data. These false positives were often 
proteins for which very little peptides were identified. Sometimes, only one or two peptides 
seemed to drive the differential abundance estimate, but more often, the fold change estimates 
of such proteins were relatively small. Closer inspection of these models revealed that their 
residual variances and those of the sample-effects were very close to zero. In other words, 
these models were clearly over-fitted. MSqRob tackles these issues with three modular 
extensions: ridge regression, empirical Bayes variance estimation and M-estimation with 
Huber weights. 
Ridge regression imposes a penalty on the magnitude of a parameter by which the parameter 
estimate is shrunk towards zero. This will introduce a small bias compared to an ordinary least-
squares estimation, but causes a large gain in stability, which protects against over-fitting. In 
the literature, it has been shown that shrinkage estimators outperform ordinary least squares 
estimators in terms of root mean squared error [2-4]. 
To estimate our parameters, we make use of the link between ridge regression and mixed 
modeling. The best linear unbiased predictions of random effects in a mixed model can indeed 
be considered as shrinkage estimates where the estimated ridge penalty ?̂?𝛽 on a parameter 𝛽 
is equal to ?̂?𝛽 =
?̂?2
?̂?𝛽
2 with ?̂?2 the residual variance and ?̂?𝛽2 the estimated variance on the 
parameter 𝛽. This shrinkage estimator is equivalent to assuming a normal prior with mean 0 
on the parameter 𝛽 in the Bayesian framework. Because of this, parameter estimates for 
proteins with very few identified peptides will be strongly shrunken towards the prior (zero). 
Contrary, in protein models with many identified peptides, the parameter estimates will be 
mainly driven by the data. 
To stabilize the residual variance, we make use of empirical Bayes variance estimation, which 
relies on the fact that thousands of protein models are fitted in parallel. The data structures of 
protein models with many identified peptides might be useful templates for the model structures 
of proteins for which there are too little peptides to precisely estimate the model structure. It 




common pooled variance estimate. Similar to ridge, the squeezing of the variances will be 
done in such a way that the residual variances for protein models with very sparse peptide 
evidence will be strongly shrunken towards the common variance, while the shrinkage effect 
will be smaller for proteins with many identified peptides. Moreover, the resulting moderated t-
statistic will follow a t-distribution with increased degrees of freedom. Implemented in the 
popular R package limma, empirical Bayes variance estimation is routinely performed on 
microarray data [5], but has also demonstrated its use in the proteomics field [6]. limma is 
executed after the model fitting since only the residual variances and the degrees of freedom 
for each model are required as input. The limma procedure is extremely fast and provides a 
noticeable boost in performance: proteins that would otherwise be very significant due to 
seemingly small variances originating from sparse peptide evidence are much less significant 
with the moderated t-test. 
Down-weighing outliers with robust M-estimation with Huber weights, finally, reduces the 
impact of outlying peptides, which is especially important for proteins with sparse peptide 
evidence. Such outliers correspond for example to peptides with differential modification 
statuses, misidentified peptides or even peptides with ionization efficiencies that are drastically 
different from the bulk of the peptides. A disadvantage of this procedure is that it markedly 
increases MSqRob’s run time as each model needs to be refitted until convergence of the 
weights. In our most recent implementation of MSqRob, we did some optimizations to increase 
the speed of the M-estimation procedure. First of all, we ensured that the models were 
iteratively updated instead of letting R build a completely new model object with each iteration. 
Second, we increased the tolerance level of the loop and reduced the maximum number of 
iterations since we noticed that most models already reached convergence after one or two 
iterations. 
An important remark is that MSqRob’s major boost in performance truly originates from the 
combined effects of these three improvements: ridge regression, empirical Bayes variance 
estimation and M-estimation with Huber weights. Indeed, irrespective of the order in which 
these improvements are added to the mixed model, the first two additions only cause slight 
gains in performance. However, the third addition generates a large performance boost, 
irrespective of whether it is ridge regression, empirical Bayes variance estimation or M-
estimation. An important advantage of MSqRob is that it reduces the need for filtering out 
sparse proteins. Indeed, fold changes and variance estimates for proteins with sparse peptide 
evidence are automatically shrunken unless there is enough evidence for differential 
abundance in the data. 
A superior performance is not at all a guarantee for a new tool to gain wide adoption by a 
scientific community. Hence, we made MSqRob available as a Shiny App. Our Shiny App is 
an important asset as it provides an easy-to-use point-and-click interface to users who are not 
proficient in R scripting. In my opinion, such an interface is essential for the wider adoption of 
any data analysis method. This is one of the reasons for the huge success of the MaxQuant-
Perseus workflow in the proteomics field which allows users to perform the whole data analysis 
workflow from raw files to quantification in a single, intuitive point-and-click environment. 
However, we need to note that the Perseus workflow is clearly outcompeted by peptide-based 
models because the MaxLFQ summaries are inefficient and Perseus cannot handle the 
blocking effect for lab. 
MSqRob’s graphical user interface needs a proper preprocessing pipeline. Therefore, we offer 
the most commonly-used preprocessing algorithms. Alternatively, a user can import 




MSqRob GUI compatible with MaxQuant, the open mzTab data standard [7], Progenesis QI 
for proteomics (Nonlinear Dynamics, Newcastle, UK), and our own moFF tool [8]. Furthermore, 
I included the automatic generation of density plots before and after preprocessing and a 
multidimensional scaling (MDS) plot after preprocessing. Such diagnostic plots are extremely 
important for exploratory analyses, in which the data quality and the quality of the 
preprocessing workflow are evaluated. Density plots might for example reveal that the peptide 
intensities in some runs deviate strongly from those in other runs, which might point to runs of 
inferior quality (Fig. 11.1). MDS plots are useful as they clearly show the major sources of 
variability and might even reveal sources of variability that were unaccounted for. This might 
probe the data analysist to re-discuss the experimental protocol and experimental design with 
the experimenters to assess if e.g. a blocking factor might have been forgotten in the analysis. 
 
Figure 11.1. Left: density plots of the log2-transformed peptide intensities in the CPTAC dataset [9] after 
artificial introduction of noise and missing values in the first three runs from lab 1 (purple). The other 
runs are colored according to the lab that generated the data (red: orbitrap at site 56, yellow: orbitrap at 
site 65 and blue: orbitrap at site 86). Such a pattern is typical for MS runs in which something went 
wrong during the analysis (e.g. with the HPLC flow or during peptide ionization). When some runs 
deviate strongly from others, it is always advised to inspect the raw data (e.g. are there much more 
missing values) and to try to find out what exactly went wrong during the analysis. It is generally 
advisable to remove runs of poor quality from the analysis. Right: MDS plot after quantile normalization. 
As demonstrated in the introduction, runs cluster together according to the lab that generated the data. 
This demonstrates the usefulness of the blocked design. The poor-quality runs clearly deviate from the 
other runs in lab 1 but are still closer to those runs than to the runs in labs 2 and 3. 
Volcano plots show the -log10-transformed p-values as a function of the log2 fold change 
estimates for all fitted proteins. This gives a general idea of the number of up- and down-
regulated proteins in the comparison of interest as well as of the factors contributing to 
statistical significance for each protein. Indeed, proteins with relatively high p-values and large 
fold changes can be expected to be highly variable and/or identified by very little peptides. 
Conversely, the significance of proteins with extremely low p-values and relatively small fold 
changes are either driven by a relatively large number of peptides of which the intensities are 
relatively stable, or by lower numbers of peptides for which the variance was underestimated 




Clicking on a dot or a protein in the protein list reveals a detail plot that shows the underlying 
preprocessed log2-transformed intensities for all peptides in all samples for that particular 
protein. This is very useful information as it allows to visually inspect the underlying data that 
determine each protein’s significance. Therefore, users can focus on validating proteins for 
which there is the most visual evidence for differential abundance (i.e. a clear difference in 
abundance and enough identified peptides). If proteins with very weak or even negligible visual 
evidence for differential abundance would show up as differentially abundant anyway, this 
might be an indication for experimental flaws or flaws in the data analysis prior to differential 
analysis (e.g. erroneous protein inference for one or more peptides). If several of such proteins 
share some characteristics in their data structure35, this can provide a first clue about why 
MSqRob fails in those particular instances. This information is very useful for statisticians who 
aspire to improve MSqRob’s quantification algorithm. Alternatively, the detail plot can help 
users to uncover potentially interesting biological phenomena such as one or more peptides 
that behave differently from the other peptides in a protein. Such peptides might indicate 
differential modification statuses or changes in protein splicing resulting from the treatment. 
When I started my PhD in September 2013, the majority of the proteomics data analysis 
pipelines consisted of preprocessing pipelines that were often borrowed from the microarray 
context followed by summarization-based methods. Apart from a few exceptions, these 
pipelines were often constructed ad hoc without any statistical rationale. Some Bayesian 
methods existed, but these are slow and therefore not routinely used in practice [10]. MSstats 
had just been published as a peptide-based model and gained a considerable user base over 
the years [11]. However, such peptide-based models suffer from over-fitting (chapter 8). 
MSqRob provides a statistically sound data analysis pipeline that copes better with proteins 
with sparse peptide evidence. This should result in an improved ability to detect differential 
abundance, which will in turn lead to improved biological insights. To facilitate the adoption of 
MSqRob by experimenters, we provide a GUI next to our R package. Since the publication of 
our tutorial paper in 2018, MSqRob is gaining some traction. Indeed, MSqRob has already 
been used in a paper by other groups on carbon fixation in Arthrospira platensis cells [12] and 
in a multi-omics study that discovered potential therapeutic drug targets for diffuse large B-cell 
lymphoma [13]. We also demonstrated MSqRob ourselves in a recent study in which we 
demonstrated Immune-responsive gene 1 to be a target of A20 [14]. Here, many A20 targets 
could not be quantified with Perseus as they had very sparse peptide evidence and were 
therefore filtered out. MSqRob was however sensitive enough to quantify such low-abundant 
proteins. Finally, the impact of MSqRob reaches beyond academia. Indeed, the development 
and dissemination of more efficient and user-friendly data analysis methods and software for 
differential proteomics is also immediately relevant for other research and development in 
sectors where high-throughput proteomics profiling is used, such as the clinical, biomedical 
and pharmaceutical sectors. 
11.3. The impact of the hurdle model 
We expect our hurdle model to have a major impact on the field. Indeed, missing values have 
many causes and can be seen as a dataset-dependent mix of missingness completely at 
random and not at random. In reality, the precise mechanisms behind missing values remain 
unknown and imputation is often used to avoid having to remove too much information from 
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one or more outlying peptide intensities that drive the fold change, or their fold changes might be driven by the 




datasets. In chapter 8, we demonstrated the unpredictable consequences of imputation. 
Imputation under the missing completely at random assumption cause an upwards 
quantification bias for low-abundant proteins, while imputation based on missingness by low 
abundance might lead to a downwards bias for highly-abundant proteins. 
MSqRob does not impute missing values by default to avoid drawing conclusions based on 
unrealistic imputation assumptions. The hurdle model combines the power of MSqRob with 
complementary information that is available from peptide counts. Indeed, count-based 
approaches can naturally handle missing values as zero counts. Moreover, the hurdle model’s 
fold change and odds ratio estimates have meaningful interpretations in terms of differential 
abundance and differential detection probability, respectively. This strongly expands the range 
of proteins that can be quantified as it is now possible to provide accurate statistical inference 
on proteins for which all peptides are missing in one condition. 
The hurdle model is also highly promising to detect differential modification states in 
proteomics datasets. Indeed, many biological treatments cause changes in protein signaling 
cascades that result in changes in protein modifications. Such modifications are often 
completely absent before (or after) the treatment. Since most post-translational protein 
modifications are very low abundant and hence not easily detected in a typical shotgun 
proteomics experiment, this application of the hurdle model will be mainly suitable for studies 
that enrich for certain post-translational modifications. 
11.4. Controlling the false discovery rate 
I noticed that MSqRob is often rather liberal in its false discovery rate cut-offs. One reason 
affects all methods and has been explained in chapter 8 as being specific for the CPTAC 
dataset: the fact that high amounts of UPS1 proteins were spiked into a yeast background 
suppresses the yeast peptide ion intensities, which makes that, if two different spike-in 
conditions are compared, yeast proteins can be found as false positives with fold changes 
opposite to that of the spiked UPS1 proteins. We therefore advise researchers not to spike too 
much of an internal calibrant, and to deplete highly abundant proteins such as albumin from 
blood samples, if possible. A reason for MSqRob being rather liberal compared to other 
methods might be that peptide-level proteomics data is highly unbalanced due to many missing 
values. This makes it impossible to assign degrees of freedom to the moderated t-test. Indeed, 
the determination of a correct null distribution for contrasts based on finite samples in 
unbalanced mixed models is a long-standing unresolved issue. It is known that the null 
distribution of each contrast is asymptotically36 normal, but with finite sample sizes, these 
distributions have fatter tails and are difficult to characterize. The Kenward-Roger [15] and 
Satterthwaite [16] approaches are well-known approximations in such cases. 
It is however reasonable to assume that the upper bound on the degrees of freedom is 
determined by counting the number of peptides and subtracting the trace of the Hat-matrix. 
The Hat matrix 𝑯 is defined as the matrix that transforms the fitted values ?̂? into the response 
values 𝑦: 
?̂? = 𝑯𝑦                                                                                                                                                         (Eq. 11.1) 
The trace (i.e. the sum of the diagonal elements) of 𝑯 provides an indication for the effective 
degrees of freedom that are lost by fitting the model. When shrinkage estimators are used, the 
                                               




loss of degrees of freedom will be lower than the number of parameters in the model. A 
reasonable lower bound on the degrees of freedom is the total number of samples minus the 
number of parameters corresponding to all effects that are unrelated to samples or peptides. 
This is the number of degrees of freedom that would be used if the data were summarized to 
the protein level and fitted with an ordinary least squares model. Initially, MSqRob used the 
total number of peptides minus the trace of the Hat matrix to calculate the degrees of freedom. 
However, for the hurdle model (chapter 10), we changed the degrees of freedom used for 
statistical inference to the lower bound, which makes MSqRob slightly less liberal. For 
example, in the HEART dataset, the difference between both approaches is 1946 significant 
proteins versus 1527 significant proteins at a 5% FDR cut-off level when comparing the atrial 
versus the ventricular regions. The difference is 74 vs. 12 significant proteins at 5% FDR when 
comparing the left vs. the right atrium and 45 vs. 0 when comparing the left vs. the right 
ventricle. 
A second reason for MSqRob’s perceived liberal performance on certain datasets is the fact 
that the models are often over-parameterized, especially for proteins with sparse peptide 
evidence. With shrinkage estimation, over-parameterization in the strict sense is not an issue, 
since inestimable model parameters will be shrunken to values very close to zero. However, 
due to the shrinkage of MS run effects and other potential batch effects towards values very 
close to 0, their contribution in the overall model variability will be grossly underestimated. This 
results in underestimated random effect variances and therefore too liberal results. Indeed, in 
the CPTAC dataset, the within-sample correlations are expected to be small because each run 
is a pure technical repeat: the same sample is measured over and over again. 
11.5. MSqRob compared to other methods 
MSqRob is not the only method that is used for differential protein abundance analysis. 
Competitors such as Perseus and MSstats were already widely used when MSqRob was first 
published in 2015, and over the years, new approaches for differential protein abundance 
analysis have emerged. In this section, I will give a brief overview of MSqRob’s performance 
and user friendliness as compared to its main competitors and some new emerging 
approaches (summarized in table 11.1). 
Table 11.1. Overview of the advantages and disadvantages of MSqRob’s main competitors and some 
newly-published approaches. 
Method name Advantages Disadvantages 
Perseus [17] User-friendly, comprehensive 
GUI 
Inefficient summarization, only 
pairwise comparisons, arbitrary, 
arbitrary fudge factor 
MSstats [18] User-friendly, comprehensive R 
package, data-driven censoring 
threshold, GUI 
No correct modeling of complex 
hierarchical designs, no 
continuous covariates 
DanteR [19] data-driven censoring 
threshold, GUI 
Windows only  
Koopmans et al. [20] approach Data-driven censoring 
threshold, shared prior 
distributions: borrow strength 
across proteins 
Not implemented, only pairwise 
comparisons, requires Markov 
Chain Monte Carlo (MCMC) 
sampling and is therefore likely 
rather slow 
ProteoSign [21] Convenient web application Not methodologically innovative 




Proteus [22] Convenient R package Not methodologically innovative 
in terms of differential analysis 
Diffacto [23] Down-weighing or removal of 
incoherent peptides 
Data structure not taken into 
account 
MS-EmpiRe [24] Relies on empirical distributions Data structure not taken into 
account 
CSNorm [25] Non-parametric Data structure not taken into 
account, incorrect permutation 
strategy, low power, too liberal 
FDR 
DAPAR (pepa.test function) 
[26] 
Includes shared peptides Only pairwise comparisons 
BayesENproteomics [27] Includes peptide-treatment 
interactions, elastic net 
penalization, combines MCAR 
and MNAR imputation, weighs 
peptides by scores, pathway-
level inference 
Relies on Markov Chain Monte 
Carlo sampling and therefore 
likely rather slow 
 
Perseus is widely used, but its appeal cannot be contributed to the performance of its default 
workflow, but rather to its versatility, user-friendliness to the non-expert and its seamless 
integration with the output of the popular, free search engine MaxQuant. Part its popularity 
might also be due to “inbreeding effects”, whereby a protocol or data analysis procedure is 
repeated simply because it worked in the past or because it is the default approach and not 
because it provides the best possible results. This also applies for seemingly abandoned tools 
and home-brew scripts that are still used locally. 
The default Perseus workflow is based on MaxLFQ summarization and although MaxLFQ does 
account for peptide-specific effects, it seems to perform slightly suboptimal compared to 
MSqRobSum summarization. More fundamentally, Perseus only allows pairwise t-tests, but 
no regression modeling. Compared to pairwise t-tests, regression models benefit from an 
increased power to estimate the residual variance because their variance estimate is based 
on all the observations in the model. This includes those observations that are not directly 
involved in the comparison at hand. Moreover, t-tests are unable to model additional sources 
of variability such as block effects. Finally, SAM is Perseus’ only possibility to stabilize the t-
tests’ variance estimates. And, although the effects of SAM in Perseus are quite similar to 
those of limma’s empirical Bayes variance estimation, SAM requires the user to set an arbitrary 
fudge factor s0 which is added to the denominator of the t-test statistic [28], while limma’s 
moderated t-test statistics are data-driven. This makes the SAM approach very arbitrary. The 
most recent Perseus version (1.6.2.3) allows two-way ANOVAs with post-hoc testing, which 
allows to take a blocking factor such as lab into account. However, Perseus’ post-hoc tests are 
only capable of determining whether a protein passes a certain pre-specified significance 
threshold but fail to return any p-values. It is therefore impossible to produce rankings based 
on this analysis. For all these reasons, MSqRob shows a large and consistently superior 
performance compared to Perseus. 
The R/Bioconductor proteomics quantification package MSstats can be seen as our most 
direct competitor. MSstats provides options for data visualization, statistical modeling and 
inference. MSstats’ current workflow imputes missing values with an accelerated failure time 
model, summarizes the data to the protein level with Tukey’s Median Polish and fits a linear 
mixed model to the summarized data [29]. However, imputation can also be omitted, and 




to specify one treatment effect (“Condition”) and one effect for biological replicates 
(“BioReplicate”). If multiple treatments were used, each treatment combination should be 
assigned to a different level of the “Condition” variable. Similarly, multiple blocking effects can 
be modeled in MSstats by assigning a different level to each combination of blocking factors 
in the “BioReplicate” input. However, this approach does not allow fitting additive models 
because it automatically assumes interaction effects. Moreover, due to the constraint of a 
single treatment and a single blocking effect, it is not possible to correctly model hierarchical 
effects in MSstats. Also, contrary to MSqRob, MSstats can only model discrete, but not 
continuous covariates. MSqRob’s ability to model both makes it much more flexible as it can 
correct for continuous covariates such as age. Furthermore, MSqRob outcompetes MSstats in 
terms of sensitivity and specificity because MSstats does not include ridge regression, 
empirical Bayes variance estimation and M-estimation. Indeed, we demonstrated the superior 
performance of MSqRob compared to the old MSstats mixed model in section 9.1 and to the 
current default MSstats pipeline in chapter 10. 
Some papers seem to only discuss parts of MSqRob’s improvements. The Bioconductor 
package PECA, for instance, uses moderated t-tests with limma’s empirical Bayes procedure 
to estimate differential abundance of each peptide. Protein-level fold changes are then 
calculated by averaging over the fold changes of all peptides corresponding to a protein [30]. 
The censored regression approach of Karpievitch et al. (2009) [31] is a fruitful approach to deal 
with missing values because it assumes a combination of missingness completely at random 
and missingness due to low abundance. These authors developed the R package DanteR, 
where they use the Karpievitch et al. censored regression model for imputation [19]. They also 
suggested to summarize the data based on a peptide-based model, which should in principle 
result in unbiased summaries [32]. The development of DanteR has now been frozen and 
superseded by the InfernoRDN package, which has a GUI that can be installed on Windows 
systems. 
Similarly, Koopmans et al. [20] proposed an "empirical Bayesian random censoring model" 
that assumes a censoring threshold for every protein. This model uses all protein data to 
estimate the different variance components in the model. However, separate models are fitted 
for each pairwise comparison. This approach is less powerful than modeling the data from all 
treatments together in a single model because residual variance estimate will be based on less 
data and will therefore be less stable. Furthermore, the model assumes a missing-by-low-
abundance mechanism but does not account for missingness completely at random. Fitting 
the model is also computationally intensive because it requires Markov Chain Monte Carlo 
(MCMC) sampling. 
Do note that lack of computational speed might not always an issue, especially considered in 
the light of a complete proteomics study, that can easily span over twelve months. For large 
studies, even very complex models can be run on high-performance computers within 
reasonable timeframes. Nevertheless, users often need some time to get used to new software 
and this process goes much easier if the analysis can be done in a short timeframe on their 
own computers. For simple routine analyses, users will therefore often prefer faster methods 
over slower ones. 
Some other novel approaches do not seem to be methodologically innovative. For example, 
the workflow of the ProteoSign web application only provides model fitting and empirical Bayes 
variance estimation with limma on summarized protein values [21]. Similarly, the R package 




approaches might contribute to user comfort, they seem rather redundant as the first 
application of limma on summarized protein values already dates back to 2009 [6]. Indeed, as 
shown in Fig. 9.5, differential protein abundance analysis with limma based on MaxLFQ values 
performs better compared to simple t-tests but does not attain the performance of peptide-
based linear regression models. This stresses the importance of explaining why certain 
approaches perform better than others so that researchers can focus their efforts on improving 
the state-of-the-art rather than on reinventing the wheel. 
The Python workflow Diffacto weighs down or removes peptides with signals that are 
incoherent with other peptides of a protein, under the assumption that these peptides have a 
high probability of being misidentified [23]. This might also be relevant to dampen the impact 
of differential modification statuses on protein quantification. Diffacto calculates protein fold 
changes as the sums of weighted peptide ratios between treatments. This enables factoring 
out the peptide effects. Protein significance is determined via an F-test whereby the 
assignments of the samples are permuted between treatments to generate a null distribution. 
However, Diffacto does not allow users to correct for additional covariates and does not 
account for within-sample correlation, which will result in biased quantifications. Inference is 
limited to ANOVA-like research hypotheses, i.e. testing whether the average protein 
abundance in at least one treatment is different from the average protein abundance in the 
other treatments. Furthermore, there should be enough samples per treatment to allow a 
sufficiently powerful permutation analysis. Indeed, the authors note that for pairwise 
comparisons, they require at least five samples in each condition to allow proper FDR control 
on the random permutation test. Therefore, Diffacto will likely perform poorly compared to 
MSqRob. Nonetheless, the exclusion of peptides that are deemed unreliable is a novelty that 
might increase its performance. 
The MS-EmpiRe R package, which has only very recently been made available on bioRxiv, 
uses MSqRob as a state-of-the-art benchmark [24]. Its normalization approach uses single 
linkage clustering: runs are added one-by-one to a cluster whereby the log-transformed 
peptide intensities in each run undergo a shift in median relative to the runs that are already in 
the cluster. Hence, this normalization approach does not take distributional changes into 
account. However, their approach to protein quantification is very innovative. It is known that 
even after log2-transformation, there is often still a mean-variance relationship in the data. 
Therefore, MS-Empire assigns each peptide to a discrete bin based on its average log2-
transformed intensity over all samples and treatments. For each bin, an empirical distribution 
of the peptide log2-fold changes for each pairwise sample combination within, but not across 
treatments is constructed. When comparing two treatments, the log2-fold change between 
those treatments for each peptide is compared to the empirical distribution of its corresponding 
bin to calculate a peptide-level z-value quantile. After correcting for outlying z-values, peptide-
level z-values are summed to obtain protein-level z-values. These protein-level z-values are 
compared to a standard normal distribution to obtain protein-level p-values.  
Based on a recently-published spike-in study [33], it was shown that MS-EmpiRe outperforms 
MSqRob in terms of sensitivity and specificity. Reasons for this superior performance might be 
that inference based on linear regression models like MSqRob rely on assumptions which we 
know to be rather questionable based on data exploration. Indeed, the residuals are not always 
normally distributed and since a small mean-variance structure can often be detected even 
after log-transformation, the homoscedasticity (i.e. equality of variances) assumption is also 
violated. MS-EmpiRe makes use of empirical fold change distributions to determine 




also performs rather well because its variability estimates for the log2 fold changes are based 
on many peptides. Since many proteins have very sparse peptide evidence, MS-EmpiRe relies 
on the assumption that peptides in the same bin behave alike, which is a way of borrowing 
strength across proteins. These authors also noted that MSqRob seems over-optimistic when 
scoring proteins with few peptide identifications, which might be an indication that our filtering 
is not stringent enough or that we need to improve our shrinkage estimation. Furthermore, it 
was noticed that MSqRob has difficulties in controlling the FDR, but, as the authors used a 
spike-in dataset without biological variability, this issue might be less severe in practice for 
reasons already outlined in section 11.1. MS-EmpiRe also has some shortcomings. Indeed, 
like Diffacto, MS-EmpiRe does not correct for within-sample correlation and it cannot correctly 
analyze complex designs as it does not allow the inclusion of additional covariates. Moreover, 
MS-EmpiRe only provides inference for pairwise comparisons.  
CSNorm is new approach that uses non-parametric statistics to assess differential protein 
abundance [25]. In brief, each peptide’s raw intensity is rescaled in a range from 0 to 1 and 
missing values are set to 0. For each protein, these values are summed per treatment over all 
its peptides in all replicates. The test statistic for differential abundance between two 
treatments is then the difference of these summed values. p-values are determined based on 
permutations of the treatment labels over the different peptides. Although CSNorm does not 
rely on any distributional assumption and therefore does not suffer from any deviations from 
normality or homoscedasticity, its permutation strategy is incorrect as it breaks the correlation 
structure of the peptides within a protein. Furthermore, by permuting the peptides without 
taking the within-run correlation into account, their results will be way too liberal. On top of that, 
CSNorm’s true power will be rather low, especially for proteins with sparse peptide evidence, 
because it does not use any distributional information. From a practical point of view, methods 
to increase stability such as borrowing information across proteins are difficult to combine with 
a non-parametric method. CSNorm is also less favorable in terms of interpretability because 
its score is a computed value that is no longer linked to a protein’s fold change. The authors 
used a spike-in experiment to compare their method to MSstats, amongst others. MSstats 
performed poorly on low spike-in concentrations because it cannot deal with missingness in 
one condition. For higher spike-in concentrations, however, MSstats outperformed CSNorm. 
This demonstrates that MSqRob will likely outperform CSNorm as well, especially when the 
hurdle extension is taken into account. Finally, it is remarkable to notice that all methods 
investigated by the authors have difficulties at controlling the FDR on the spike-in dataset, 
especially at high spike-in concentrations. This is again most likely due to ionization 
suppression of the background yeast proteins. 
The pepa.test function in the DAPAR Bioconductor R package aims to improve protein 
quantification by including shared peptides [26]. Here, a single regression model was 
constructed that includes peptide effects and protein effects whereby peptides can map to 
multiple proteins. Protein significance is determined via likelihood ratio tests for each protein 
for the model under the assumption that a protein would be differentially abundant versus the 
assumption that a protein would not be differentially abundant. The residual variances are 
estimated with a shrinkage estimator and their likelihood ratio test statistic is proven to be 
asymptotically chi-squared distributed. To demonstrate superiority, pepa.test was compared 
to MSqRob and some other approaches by making use of two datasets. The first dataset is a 
simulation study with varying amounts of shared peptides. The second dataset is a spike-in 
dataset to which varying amounts of shared peptides were artificially added. The rationale for 
adding shared peptides is that it has been claimed that up to 50% of all peptides can be shared 




datasets that were engineered to contain many shared peptides, as this is exactly the problem 
the authors tried to address. However, MSqRob also seems to show a somewhat poorer 
performance (in terms of precision vs. recall) on the simulated and spike-in datasets to which 
no shared peptides were added. This might be due to the fact that DAPAR also makes use of 
a shrinkage estimator for its likelihood ratio test statistic. However, as the pepa.test function 
can only test protein significance in pairwise comparisons, the authors only used datasets with 
two experimental conditions. Therefore, MSqRob cannot demonstrate the superior 
performance of linear regression models by estimating the residual variance based on many 
runs. Blocking effects or additional hierarchical levels are also not issues in these designs. 
Finally, the pepa.test function can also not be used to estimate protein fold changes. 
BayesENproteomics is a Bayesian method that expands upon the ideas introduced by 
MSqRob [27]. It includes interactions of peptide effects with treatment effects to account for 
peptides that behave differently from other peptides mapping to the same protein. This 
theoretically allows the detection of differential modification statuses or splice variants. To cope 
with the increased model complexity, BayesENproteomics makes use of elastic net 
penalization instead of ridge regression. Elastic net is a combination of ridge with LASSO 
(Least Absolute Shrinkage and Selection Operator) [35]. The LASSO shrinkage penalty is 
proportional to the L1 norm ‖𝜷‖1 of the model parameters. The LASSO component allows 
parameters to be set exactly to 0. Such an automatic model selection will help to avoid too 
complex model structures. However, a disadvantage of LASSO compared to ridge is that it is 
less stable: other variables might be selected if the data is slightly perturbed. Elastic net 
regularization combines the “model selection property” of LASSO with the stability of ridge 
regression.  
BayesENproteomics also assigns weights to peptides, thereby disfavoring not only outlying 
peptides (a similar goal as the M-estimation in MSqRob), but also peptides with low 
identification scores. BayesENproteomics imputes missing values with a multiple imputation 
strategy under the assumption of a combination of missingness completely at random and 
missingness not at random. In brief, BayesENproteomics constructs a logistic regression 
model for each protein that contains peptide and treatment effects to determine which missing 
values are missing completely at random versus not at random. Missing values that are 
deemed completely at random are imputed from multivariate normal distribution. Missing 
values that are deemed not at random are imputed from a truncated normal distribution with 
an upper limit equal to the percentile of the observed values corresponding to the fraction of 
values that were determined missing not at random by the logistic regression model. This 
imputation procedure is repeated with each iteration of the Gibbs sampler. 
BayesENproteomics also provides a linear regression model for pathway analysis which can 
be fit after the main analysis: 
𝑦𝑖𝑡 = 𝛽0 + 𝛽𝑡treatment + 𝛽𝑖
protein + 𝜀𝑖𝑡                                                                                                (Eq. 11.2) 
Herein, 𝑦𝑖𝑡 is the log2 fold change of protein 𝑖 in treatment 𝑡, 𝛽0 the intercept that represents 
the pathway-level effect, 𝛽𝑡treatment the effect of treatment 𝑡, 𝛽𝑖
protein the effect of protein 𝑖 and 
𝜀𝑖𝑡 a random error term. The advantage of this approach over traditional enrichment strategies 
is that there is no arbitrary cut-off between differentially regulated and background pathways. 
Moreover, their approach includes information on the magnitudes and the directions of fold 




BayesENproteomics outcompetes an ordinary least squares model and a robust ridge 
regression with Huber weights that was re-implemented in MatLab but did not include empirical 
Bayes variance estimation. For these models, the data were imputed with Perseus imputation, 
which assumes missingness due to low abundance. However, I would not be too surprised if 
this method would perform more or less on par or even outcompete the full MSqRob 
implementation with empirical Bayes variance estimation because of the shrinkage provided 
by the elastic net and the down-weighing of peptides with low identification FDRs. Moreover, 
the addition to detect peptides that deviate from their corresponding protein’s fold change is 
definitely an asset. This again demonstrates the enormous potential of Bayesian methods to 
model extremely complex model structures. However, like all Bayesian methods, 
BayesENproteomics is computationally intensive and therefore slow. Running the model on a 
desktop computer took the researchers several hours for a dataset with only a few 100’s of 
proteins. Present-day high-throughput shotgun mass spectrometric experiments typically 
contain however several thousands of proteins. Moreover, BayesENproteomics was 
demonstrated on a simple benchmark dataset with only three spike-in conditions. For more 
complex experimental designs, BayesENproteomics will be even much slower. 
All of this demonstrates that MSqRob is rapidly becoming accepted as a valid method for 
differential protein analysis in the field. MSqRob is being challenged and used as a benchmark 
by several research groups and several of these new approaches are very promising. I 
personally see a bright future for Bayesian approaches. Indeed, even though MCMC sampling 
might currently still be somewhat too slow for routine high-throughput analyses, approaches 
such as plugging in a maximum a posteriori estimator, Bayes factors and variational Bayes 
make Bayesian approaches feasible as they are much faster than classic MCMC sampling. 
11.6. The impact of technological and algorithmic innovations 
The proteomics field is currently evolving extremely rapidly, and technical improvements are 
constantly pushing the boundaries of proteome coverage. In a future where mass 
spectrometers might one day be able to identify each and every peptide, one could question 
the usefulness of developing methods that deal with unbalancedness and missing data for 
proteome quantification. However, as this moment might still lie quite some years ahead, it is 
still important to strive for the best-possible analysis pipeline for data that is acquired with 
present-day technology (1). Moreover, even when these advancements would finally arrive, 
there would be massive amounts of historical public data containing a wealth of information 
ready to be queried (2). 
Concerning point (1), technical improvements have indeed been massive over the years. 
Consider for example data-independent acquisition (DIA). Contrary to data-dependent 
acquisition (DDA), DIA fragments the complete range of the MS spectrum, often in sequential 
m/z windows. The main advantage of this method is that every peptide ion gets fragmented, 
so that at least in theory, every single peptide can be quantified, as long as it can be identified. 
At the start of my PhD in 2013, DIA was, although very promising, still considered a niche 
application as the quantification depth of DIA was rather limited due to the difficulties in 
deconvoluting the highly multiplexed MS² spectra. Nowadays, DIA is reported to detect more 
than twice the number of peptides of a comparable DDA run [36]. Modern DIA approaches 
also showed only 1 – 2% missing values compared to 51% in a DDA shotgun proteomics with 
a similar quantitation depth [37]. However, at present, it is still not completely clear how the 
protein discovery FDR should be controlled in DIA analyses. Moreover, DIA still needs one or 




libraries that can be used to identify peptides. Therefore, DIA is generally more suited for e.g. 
clinical proteomics and less for “hit-and-run” discovery analyses, although the Gevaert lab is 
currently experimenting with in silico-generated spectral libraries generated by the 
CompOmics lab, which would obviate the need for prior DDA runs. As the latest mass 
spectrometers can record over 40 spectra per second [38] and increases in machine speed 
allow DIA acquisition windows to become smaller and smaller [39], I expect DDA and DIA to 
converge more and more towards each other in the future. 
Other new techniques such as differential ion mobility separation are also finding their way into 
practice. Thanks to differential ion mobility separation, co-eluting peptides can be separated, 
which drastically reduces the occurrence of chimeric spectra [40].  
Moreover, protein identification methods are also becoming more advanced. For instance, the 
strong increase in analysis depth now allows the sporadic registration of some low-abundant 
or poorly detectable protein modifications in regular shotgun proteomics workflows. Such sub-
stoichiometric modifications would be responsible for at least a third of all unassigned spectra 
[41]. This fact spurred the development of open modification search engines, which are 
capable of detecting mass shifts due to modifications that were not a priori specified [42, 43]. 
Dr. Sven Degroeve from the CompOmics lab at VIB-Ghent University recently developed 
Ionbot, an MS2PIP-based open modification search engine that is also capable of detecting 
amino acid substitutions [44, 45]. Furthermore, the ever increasing MS resolutions allow a 
higher MS² fragment ion coverage, which slowly paves the way for de novo peptide 
sequencing, the direct identification of peptides based on the MS² spectra without the need for 
a protein database, although these algorithms are still not accurate enough to compete with 
database searching [46]. 
However, despite all these exciting technical and algorithmic improvements that are brimming 
on the horizon, current routine DDA MS workflows still suffer from all the issues described in 
the introduction and even DIA data are not completely free from missing values. Moreover, in 
the coming years, technologies such as single cell proteomics are expected to start emerging 
[47]. Like current single-cell genomic sequencing technologies [48], such datasets can be 
expected to be plagued by many missing values. Therefore, the work that I have done is not 
only useful for present-day research but will also lay the foundations for future work on similar 
data types that will arise from new technologies. Naturally, one day, MSqRob in its current 
implementation will become obsolete for label-free proteomics. Thus, to remain a competitive 
method for protein quantification, we will need to keep innovating and improving (see chapter 
12). 
Concerning point (2), there is indeed a wealth of data available in public repositories, of which 
the potential is grossly underused. Many biological research questions could indeed be 
answered by re-analyzing existing publicly available datasets. Sharing data is extremely 
important for science as it allows others to uncover interesting biology that was not the primary 
focus of the original research group [49]. In a 2016 editorial in the New England Journal of 
Medicine, researchers who re-use public data have been termed “research parasites” [50], a 
derogatory term that has now been reappropriated, e.g. with the introduction of “The Parasites 
Awards” [51]. MSqRob can have an important contribution in the reanalysis of public data since 
it is much more sensitive than most of the tools that were used to quantify these datasets 
initially, yet fast enough to be used for high-throughput analyses. Important in this respect is 
interoperability between the output of proteomics search engines and MSqRob. Unfortunately, 
almost every search engine uses its own different file format. The Proteomics Standards 




standards, such as mzTab, which can be used, amongst others, to store peptide-level 
intensities [7]. However, the mzTab standard has not yet been widely adopted in the field. 
Therefore, we currently also provide support input from MaxQuant and moFF, as well as some 
basic support for Progenesis output. 
Finally, I would like to stress that MSqRob will not be abandoned when I will leave StatOmics 
and the Gevaert groups. Indeed, other colleagues are actively working on MSqRob and I also 










12. FUTURE RESEARCH PERSPECTIVES 
MSqRob’s extremely versatile regression framework provides ample opportunities for 
methodological improvements. Furthermore, future research should also be directed towards 
increasing MSqRob’s computational performance and making it more broadly available to 
make sure that MSqRob remains competitive in the field. 
As discussed, MSqRob might have too liberal FDR cut-offs (see section 11.4). However, part 
of the reason for too liberal FDR cut-offs in certain spike-in studies could be caused by the fact 
that the fold changes of the spiked proteins only go in one direction. Indeed, since the total 
amount of peptides (in µg) that is loaded onto the mass spectrometer is constant in each run, 
a higher abundance of a certain (spiked) protein in a first sample compared to a second sample 
must theoretically be compensated by a lower abundance of one or more (unspiked) proteins 
in the latter. However, the same holds true when a biological treatment results, for example, in 
an increase in the abundance of mitochondrial proteins. Such an increase in mitochondrial 
proteins will indeed imply loading a lower amount of all other proteins onto the mass 
spectrometer. Therefore, there is a need for better normalization methods that account for ion 
suppression effects. 
Too liberal FDR cut-offs might also be particularly prevalent for datasets where biological 
variability is rather small or absent (e.g. classical spike-in studies such as CPTAC) because 
the MS run effects for proteins with sparse peptide evidence are shrunken to zero. This effect 
might be tempered in experimental datasets wherein true biological variability is included. Due 
to the much larger variability between biological replicates, it might be that MSqRob is capable 
of more correctly estimating the within-sample correlations in an experimental dataset with a 
biological research purpose. For this reason, it would be interesting if a spike-in dataset could 
be created that mimics this biological variability. This could for example be done by growing 
multiple human cultures under similar conditions and spiking each of them with yeast proteins 
and E. coli proteins obtained from cell cultures that were independently grown (i.e. creating 
biological repeats of the experiment proposed by Navarro et al. (2016) [52]). Spiking in low 
amounts of yeast and E. coli proteins would ensure that only the most abundant of these 
proteins would be detected, thus avoiding the rather unrealistic scenario of a whole proteome 
being differentially abundant. Moreover, spiking in low amounts would avoid a strong increase 
in sample complexity and prevent large ion suppression effects. By spiking in two different 
proteomes, it would be possible to mimic a realistic scenario where some proteins are more 
and others are less differentially abundant. 
In terms of speed, MSqRob is computationally more demanding than ordinary least squares 
models as mixed models need to be fitted with an iterative procedure (the penalized least 
squares algorithm implemented in the lme4 package in R) [53]. These models then need to be 
iteratively updated during the M-estimation procedure. Also, as MSqRob is a peptide-based 
model, it does not provide protein-level summaries for each MS run by default. Such 
summaries are needed to obtain meaningful information at the protein level and are often used 
by experimenters, e.g. to create protein heat maps. And, although these summaries can be 
calculated based on MSqRob’s parameter estimates, they are not meaningful if the MS run 
effects are shrunken to zero. This results in identical protein summaries for each run of the 
same treatment. Finally, MSqRob’s relatively complicated model structure might be relatively 




To avoid issues with degrees of freedom and too liberal FDRs, we are developing a 
summarization-based approach for MSqRob, MSqRobSum. Indeed, it has been shown that 
mixed models can also be fitted with a two-stage approach [54]. For the first stage, we propose 
the following regression model: 
𝑦𝑖𝑝𝑡𝑟 = 𝛽𝑖𝑝
peptide + 𝛽𝑖𝑡𝑟run + 𝜀𝑖𝑝𝑡𝑟                                                                                                             (Eq. 12.1) 
Here, 𝑦𝑖𝑝𝑟 is the log2-transformed intensity for peptide 𝑝 corresponding to protein 𝑖 in MS run 
𝑟. 𝛽𝑖𝑝
peptide and 𝛽𝑖𝑡𝑟run are the peptide and run effect, respectively and 𝜀𝑖𝑝𝑡𝑟 is a random error 
term. 𝑡 is an indicator for treatment whereby each treatment spans multiple runs. In such a 
model, 𝛽𝑖𝑡𝑟run corresponds to the average intensity for protein 𝑖 in run 𝑟 after correcting for the 
peptide effects and can thus be used as a protein-level summary. We then proceed to model 
the protein-level summaries 𝛽𝑖𝑡𝑟run as follows: 
𝛽𝑖𝑡𝑟run = 𝛽𝑖0 + 𝛽𝑖𝑡treatment + 𝜀𝑖𝑡                                                                                                                 (Eq. 12.2) 
Herein, 𝛽𝑖0 is the intercept, which corresponds to the average effect of a certain reference 
treatment, 𝛽𝑖𝑡treatment is the effect of the 𝑡th treatment relative to the reference treatment and 𝜀𝑖𝑡 
is a random error term. Both stages are fitted with ridge regression and M-estimation, although 
convergence in the second stage already seems to occur after a single iteration. Due to the 
simpler model structures in both stages, MSqRobSum is much faster than MSqRob. Moreover, 
the summarization step can be performed automatically “under the hood”, allowing the user to 
concentrate only on the stage 2 model specification. 
However, MSqRobSum’s performance is inevitably somewhat lower compared to MSqRob 
because information on the accuracy of each protein-level summary 𝛽𝑖𝑡𝑟𝑟𝑢𝑛 is lost. Indeed, 
MSqRobSum can no longer take the peptide-level correlation structure into account. However, 
the bias that plagues many other summarization-based methods due to the summarization of 
different types of peptides is avoided because the peptide-level effects are corrected for in the 
first stage. MSqRobSum thus trades a small drop in performance for a gain in simplicity, 
modularity and computational speed. 
Measures to further improve variance stabilization have a strong potential to improve 
MSqRob’s performance. A logical methodological improvement might be to extend the limma 
empirical Bayesian variance estimation to the random run effects in the model. Indeed, since 
MSqRob’s mixed model encodes the run effects as random, their variance components can 
be estimated. It should therefore also be possible to borrow information across proteins with 
more abundant peptide evidence to improve random effect estimates for proteins with sparse 
peptide evidence. 
In the future, MSqRob might take the step towards becoming fully Bayesian. Such an evolution 
would be natural because MSqRob’s current implementation already contains quite some 
Bayesian flavors. Indeed, ridge regression is methodologically equivalent with assuming a 
normal prior, and the limma implementation uses a maximum a posteriori estimator after 
assuming a chi-squared prior on the inverse of the residual variances. As noted in section 11.5, 
plugging in a maximum a posteriori estimator, Bayes factors and variational Bayes are 
computationally fast, and we are currently looking into such approaches in collaboration with 
Mark Van de Wiel (Amsterdam University Medical Center). The main advantage of the 
Bayesian framework is its flexibility. Bayesian approaches would for example provide endless 




behavior. A disadvantage of the Bayesian framework is that inference becomes more 
complicated. Bayes factors, for instance, require fitting a complex and a simpler model for each 
contrast as the difference in parameterization between both models must correspond to each 
contrast. 
In recent years, the focus in proteomics has shifted from pairwise comparisons to protein 
dynamics [55]. The Gevaert Lab also has various time series experiments [56] and many 
researchers are interested in how the abundances of proteins change over time, for example 
after a specific treatment. With classical algorithms it is only possible to make inferences about 
differences between discrete time points or linear changes over time [57, 58]. Such linear 
relationships can already be modeled with MSqRob but not with MSstats. However, linear 
relationships between treatment variables and protein abundances are very rare in practice, 
e.g. because of saturation effects. Moreover, relationships between treatment and protein 
abundance can often be non-linear in nature. For example, proteins related to the circadian 
rhythm have been shown to follow a sinusoidal abundance pattern [59]. Some authors have 
already applied non-linear regression models to proteomics data, for example to determine 
turnover rates [60], but these methods are limited by their prior assumptions. Additionally, 
state-of-the-art methods are not suitable for the analysis of longitudinal clustered data because 
they cannot correctly handle correlation structures. 
Given the current version of MSqRob based on the mixed model framework, random effects 
can easily be added. This allows to exploit the link between penalization, splines and mixed 
models (see e.g. Wood (2004) [61]) for modeling non-linear trends in abundance patterns. In 
concrete terms, the method of Storey et al. (2005) [62] can easily be generalized from a spline-
based analysis of microarray time series to the proteomics context. 
Another possibility for expansion is the broadening of MSqRob’s applicability. Until now, 
MSqRob has been promoted as a method for differential protein abundance analysis in label-
free shotgun proteomics. However, MSqRob should be applicable on DIA data without any 
change in algorithm. If DIA features are identified and mapped to proteins prior to 
quantification, MSqRob can be applied as-is because the DIA data structure is then exactly 
the same as for label-free DDA data. If the goal is to quantify unidentified features, the analysis 
becomes simpler because the protein-level hierarchy is omitted. In that case, MSqRob’s model 
structure can be simplified as follows: 
𝑦𝑓𝑡𝑏 =  𝛽𝑓0 + 𝛽𝑓𝑡treatment + 𝛽𝑓𝑏block + 𝜀𝑓𝑡𝑏                                                                                              (Eq. 12.3) 
Here, 𝑦𝑓𝑡𝑏 is the log2-transformed intensity of feature 𝑓, 𝛽𝑓0 the intercept, 𝛽𝑓𝑡treatment the effect 
of treatment 𝑡, 𝛽𝑓𝑏block the effect of block 𝑏 (if present) and 𝜀𝑓𝑡𝑏 a random error term. Since 
DIA data has much fewer missing values, the count component of the hurdle model is likely 
superfluous. 
MSqRob could also be expanded towards labeled data. The only important addition to the 
model would be an extra term to group differentially labeled peptides in the same run together, 
irrespective of whether peptides are quantified in the MS (e.g. SILAC labeling) or MS² spectrum 
(isobaric labeling). MSqRob’s model would then appear as follows: 
𝑦𝑖𝑡𝑔 =  𝛽𝑖0 + 𝛽𝑖𝑡treatment + 𝛽𝑖𝑔




In this model, 𝛽𝑖0 is the intercept, the average log2-transformed intensity of protein 𝑖 for the 
reference treatment in the reference group. 𝛽𝑖𝑡treatment is the effect of the 𝑡th treatment 
relative to the reference after correction for group and 𝛽𝑖𝑔
group the effect of group 𝑘 relative to 
the reference after correction for treatment. 𝛽𝑖𝑔
group models the 𝑔 + 1 blocks of two or three 
(for duplex or triplex labeling, respectively) identical peptides sequences that are 
differentially labeled within the same run. Note that block effects and run effects are no longer 
explicitly included in the model because the inclusion of 𝛽𝑖𝑔
group guarantees the correction for 
all effects higher up in the hierarchy. Furthermore, an interaction between treatment and 
group effect can be added to account for differential fold changes for different peptides.  It is 
already possible to encode such a model structure with MSqRob’s current implementation, 
both in an R script as with the MSqRob Shiny App. 
MSqRob can also be used for targeted proteomics data (e.g. SRM) or data from protein-protein 
interaction experiments. Difficulties here are more related to normalization. Indeed, both 
targeted proteomics experiments and interaction studies will mainly detect proteins that are 
differentially abundant. However, since most normalization methods assume that the bulk of 
the protein abundances remains unchanged, finding a correct normalization approach might 
be difficult for these types of experiments. Such experiments are sometimes normalized 
against cell counts, total amounts of proteins (determined by e.g. bicinchoninic acid (BCA) 
assay) or “housekeeping” proteins. However, such approaches are very crude and might 
sometimes even deteriorate the accuracy of the quantification [63]. Furthermore, testing 
MSqRob and the hurdle model on future single cell proteomics experiments will also be very 
exciting due to the many missing values that can be expected in those kinds of experiments 
[47]. 
Quantification in metabolomics is very similar to proteomics quantification [64]. It would 
therefore be straightforward to apply MSqRob to metabolomics data as well. Similar to the 
analysis of unidentified features in DIA data, metabolomics data has one less hierarchical level 
compared to label-free DDA data. Indeed, each metabolic peak typically corresponds to a 
single metabolite (or metabolic degradation product). Therefore, MSqRob’s model can be 
simplified as follows: 
𝑦𝑖𝑡𝑏 =  𝛽𝑖0 + 𝛽𝑖𝑡treatment + 𝛽𝑖𝑏block + 𝜀𝑖𝑡𝑏                                                                                               (Eq. 12.5) 
Here, 𝑦𝑖𝑡𝑏 is the log2-transformed intensity of metabolite 𝑖, 𝛽𝑖0 the intercept, 𝛽𝑖𝑡treatment the 
effect of treatment 𝑡, 𝛽𝑖𝑏block the effect of block 𝑏 (if present) and 𝜀𝑖𝑡𝑏 a random error term. 
It will also be interesting to implement the ideas set forth by Mallikarjun et al. (2018) [27] in 
MSqRob, many of which we were already considering of implementing in the near future. 
However, since MSqRob does not make use of MCMC sampling, it will be much faster than 
BayesENproteomics. The idea of using elastic net regularization can indeed also be 
implemented in a frequentist context, although it remains to be seen if this will grant a boost in 
performance to MSqRob that is large enough for the added computational complexity. An 
elastic net penalty might mainly be interesting for the treatment parameters as elastic net can 
shrink treatment parameters exactly to zero, thus eliminating them from the model if there is 
not enough evidence in the data to justify inclusion in the model. 
Note that MSqRob currently shrinks parameters towards zero. However, when two model 




penalized. Therefore, it would be interesting to explore fusion penalties, whereby the treatment 
parameters are shrunken towards each other, thus effectively penalizing the log2 fold changes 
[65]. 
It would also be interesting to integrate the uncertainty on the peptide identification into 
MSqRob’s framework, or at least to pass on an uncertainty measurement (such as the peptide 
identification FDR) from the identification to the quantification step. I already briefly tried this in 
a very simple setting in the past, by comparing MSqRob without M-estimation to MSqRob with 
MaxQuant’s posterior error probabilities (PEP) as weights, but this did not improve the 
performance on the CPTAC dataset. However, the heuristic of Mallikarjun et al. to combine 
peptide confidence scores with down-weighing outliers might be worthwhile to pursue in 
MSqRob as well. 
Another obvious extension of MSqRob would be to increase its hierarchical levels. A first way 
to do this would be to start from the PSM level instead of from the peptide level. However, 
analysis on the lowest level of summarization does not guarantee a better performance if 
correlation is not considered [66]. Therefore, the peptide-level hierarchy should not be omitted 
because PSMs that map onto the same peptide are correlated to each other. Nonetheless, I 
suspect that the gain of modeling at the PSM level compared to the peptide level will be 
relatively small because most of the variation seems to manifest at the peptide level. 
It is also possible to increase the hierarchy by adding a pathway level to the model. Indeed, in 
order to better understand the effects of a certain treatment, it is important to derive a functional 
interpretation from the proteomics data. This is not trivial since each of the thousands of 
detected proteins is part of a complex network of protein-protein interactions and thus can 
participate in multiple, related or unrelated pathways [67]. By introducing an extra hierarchy for 
the pathway level, correlations between proteins can be taken into account. The Kyoto 
Encyclopedia of Genes and Genomes (KEGG) [68] and Gene Ontology (GO) [69] are 
commonly used databases that assign proteins to different pathways. The main effect for mean 
differential abundance over all proteins will allow to prioritize modules with proteins that show 
differential abundance in the same direction. Using F-tests for protein-treatment interactions 
will allow to enrich for pathways with proteins that show differential abundance in a different 
direction, because the interaction term allows the differential abundance to be protein-
dependent. Such a hierarchical approach has the advantage that effects that are too weak to 
be detected at the individual protein level can still be picked up at the pathway level on the 
basis of the abundance patterns of other proteins in the pathway. 
Another option is modeling all proteins together in one big model, with or without an extra 
pathway-level hierarchy. This would make the inference even more powerful because 
pathways are also interconnected with each other. Moreover, modeling all proteins together 
could also enable MSqRob to take shared peptides into account. However, fitting such a big 
model would be computationally very demanding and therefore strongly decrease MSqRob’s 
speed. Accounting for differential peptide usage is also a very promising road to explore. This 
would allow the detection of e.g. differential modification statuses or the production of 
alternative splice variants. For this purpose, some authors have proposed a peptide-centric 
approach (i.e. modeling each peptide separately) [70]. However, a much more powerful 
approach is to keep modeling the data at the protein level and adding a treatment-peptide 
interaction parameter to the model [27]. If the evidence is strong enough, this interaction effect 
will not be shrunken to zero. This interaction effect can be interpreted as the log2 fold change 
of a particular peptide after correction for a possible change in protein abundance and would 




would be helpful to detect splice variants or changes in a protein’s modification status due to 
the treatment. Note that the hurdle model already provides a useful framework for detecting 
the complete presence or absence of (modified) peptides in shotgun proteomics datasets, as 
already discussed in section 11.3.  
Together with my colleague Adriaan Sticker, I rewrote MSqRob’s code to make it leaner and 
more performant. We also intend to work towards the publication of MSqRob as a Bioconductor 
software package. In addition, the inclusion of the tool in open source software suites for the 
analysis of MS-based proteomics will enable academics and companies to easily use state-of-
the-art data analysis methods for differential proteomics in their daily research and 
development activities. To this aim, MSqRob will also be developed into a Perseus plug-in. 
Moreover, we will allow the MSqRob Shiny App to output the results of its differential analysis 
in a tab-delimited output format so that MSqRob’s results can seamlessly be imported into 
Perseus. 
Finally, the integration with moFF is also a very important point. MSqRob is already able to 
input moFF data. With the development of Ionbot by the CompOmics group, it will become 
possible to create an Ionbot – moFF – MSqRob workflow that handles all the data analysis 
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